**Confidential** 



### **Paroxetine**

### 29060

# A Double-blind, Multicentre Placebo Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression

377

### Final Clinical Report

SB Document Number: BRL-029060/RSD-100TNP/2

Issue Date: 19th November 1998 Amended: 8th December 1998

# Signature Page

**Report Title:** A Double-blind, Multicentre Placebo Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.



# **Report Synopsis**

## **Study Title**

A Double-blind, Multicentre Placebo Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression

## Investigator(s) and Center(s)

The study was carried out in 33 centres in Belgium, Italy, Spain, United Kingdom, Holland, Canada, South Africa, United Arab Emirates, Argentina and Mexico.

### **Publication**

None published as of August 1998.

## **Study Dates**

26th April 1995 to 15th May 1998.

# Objective(s)

The primary objective of the study was to compare the efficacy of paroxetine and placebo in the treatment of adolescents with unipolar, major depression.

The secondary objective of this study was to assess the safety and tolerability of paroxetine in adolescents with unipolar, major depression.

# **Study Design**

This was a multicentre, double-blind, randomised, parallel group, placebo controlled study to compare the efficacy and safety of paroxetine (20-40mg daily, flexible dose) and placebo in the treatment of adolescents with unipolar, major depression as defined by DSM-IV criteria. After Screening patients entered a 2 week, single-blind, placebo run-in period. Eligible patients were then randomised to receive paroxetine (20-40mg daily, flexible dose) or placebo (2:1 randomisation) for a period of 12 weeks. Patients returned to the clinic at the end

of Weeks 1, 2, 3, 4, 6, 8 and 12 for assessments of efficacy, safety, concomitant medications and general compliance with study procedures. Patients withdrawing prematurely from the study received 2 week run out medication. At the end of the study all patients were down-titrated off study medication over a period of 2 weeks and returned to the clinic for a last assessment of safety at the end of Week 14.

### **Study Population**

Male or female patients aged between 13 years and 18 years 11 months at Screening, with a current diagnosis of unipolar, major depression as defined by DSM IV criteria, a C-GAS score <69 and a MADRS score ≥16 were eligible to enter the study.

### **Treatment and Administration**

Study medication was formulated as capsules for oral administration twice a day. Batch numbers: paroxetine 10mg – M94002 and M96328; paroxetine 15mg – M94003; paroxetine 20mg – M94004, M95004 and M96330; placebo – CT2/4301 and M96332

### **Evaluation Criteria**

### **Efficacy Parameters**

The primary efficacy parameters were the proportion of patients with a 50% or greater reduction in MADRS score between baseline and study endpoint, and the change from baseline to study endpoint in K-SADS-L depression subscale. The secondary efficacy variables were: change from baseline in MADRS total score; change from baseline in CGI severity of illness score; CGI global improvement score; change from baseline in BDI and change from baseline in MFQ. All primary and secondary variables were analysed at Weeks 6, 8 and study endpoint. Please note: the protocol states analysis of the secondary variables at week 6 and endpoint only. An amendment to the reporting and analysis plan prior to database freeze added week 8 as a time point for analysis, this should have been reflected in the protocol as a protocol modification.

### **Safety Parameters**

Safety parameters consisted of adverse experiences and assessment of vital signs and laboratory data.

### Statistical Methods

The proportion of patients responding ( $\geq$ 50% reduction in MADRS total score) was analysed using logistic regression (PROC LOGISTIC of SAS). The model included treatment group, country group, and covariates of age and baseline score. Odds ratios and 95% confidence intervals were presented. The effect of adding treatment by country group interaction into the model was assessed with the above terms in the model. If the treatment by country group interaction was not statistically significant ( $p\geq0.1$ ), it was dropped from the model. Treatment by covariate and covariate by covariate interactions were assessed in a similar way.

The mean change from baseline in K-SADS-L depression subscale score, MADRS, BDI and MFQ total scores were analysed using analysis of covariance (PROC GLM of SAS) with factors treatment, country group, age and baseline score. Least squares means were compared at the 5% level and 95% confidence intervals presented for treatment differences. The effect of adding treatment by country group interaction into the model was assessed with the above terms in the model. If the treatment by country group interaction was not statistically significant ( $p \ge 0.1$ ), it was dropped from the model. Treatment by covariate and covariate by covariate interactions were assessed in a similar way.

The changes from baseline in the CGI severity of illness (an ordered categorical rating scale) were analysed non parametrically using the Wilcoxon Rank Sum test (PROC NPAR1WAY of SAS). No adjustment was made for country grouping or covariates. The CGI global improvement scores were compared using Cochran-Mantel-Haenszel chi-square tests (stratifying by country group) at the 5% level using PROC FREQ of SAS.

# Patient Disposition and Key Demographic Data

Patient disposition and key demographic data are shown below.

	Treatment group		Total
_	Paroxetine	Placebo	
Number of patients:			
Screened	-	-	324
Randomized	187	99	286
ITT populations	182	93	275
Per-protocol population	130	68	198
Completed the study (ITT)	127	69	196
Demography (ITT population)			
Females: number (%)	122 (67.0)	61 (65.6)	-
Mean age (sd): years	15.5 (1.6)	15.8 (1.6)	-
Age range: years	*12 - 19	13 - 18	-
Caucasian: number (%)	126 (69.2)	61 (65.6)	-

<sup>\*</sup> Patients 377.026.00200, 377.029.00040, and 377.057.00532 were 12 years old when recruited into the study and were excluded from the per-protocol population as protocol violators.

A total of 324 patients were screened and 286 patients were randomised to study medication, 187 to paroxetine and 99 to placebo. The treatment groups were well matched for all demographic parameters. Eleven patients were not eligible to be included in the ITT population, 5 in the paroxetine group (2 due to AEs, 1 protocol violator, 1 lost to follow-up and 1 centre 007 patient) and 6 in the placebo group (2 centre 007 patients, 1 protocol violator, 1 lost to follow-up, 1 due to lack of efficacy and 1 for another reason). Of all randomised patients, similar numbers of patients withdrew during the study, 60 out of 187 in the paroxetine group (32.1%) and 30 out of 99 in the placebo group (30.3%), 55 (30.2%) and 24 (25.8%) respectively in the ITT population. Slightly more patients withdrew due to adverse experiences in the paroxetine group, 11.8% compared with 7.1% in the placebo group (11.0% and 7.5% respectively in the ITT population).

Please note that the data from the centre 007 patients was not included in the efficacy analyses due to clinical concerns over the validity of the data from this centre. The decision to exclude this data in the efficacy analysis was made prospectively, prior to database freeze.

### **Efficacy Results**

#### **Data Sets**

Two sets of efficacy data were used, observed cases (OC) and last observation carried forward (LOCF). The OC dataset consisted of each patient's observations at each visit. The LOCF dataset was generated from the OC dataset whereby missing data were estimated by extending forward the data from the previous visit. The primary analysis population for the study was the intention-to-treat population using the LOCF dataset with the primary timepoint of interest being the Week 12 LOCF timepoint. A confirmatory analysis based on the per-protocol analysis was carried out on the primary efficacy variables.

### **Primary Efficacy Variable(s)**

No clinically or statistically significant differences were detected between paroxetine and placebo in either of the primary efficacy variables.

The results are summarised below:-

# Proportion of patients with a 50% or greater reduction from baseline in MADRS total score

Dataset	Tr	eatmen	t group:	S			
Timepoint	Paroxetino	e	Placebo	)	Adjusted Odds Ratio	95% CI (Paroxetine/ Placebo	P- value
	n/N	%	n/N	%			
LOCF dataset							
Week 12	107/177	60.45	53/91	58.24	1.109	(0.653, 1.884)	0.702
OC dataset							
Week 12	94/126	74.60	47/66	71.21	1.161	(0.590,	0.666
						2.285)	

No statistically significant treatment differences were observed at any time point. At the week 12 endpoint in the ITT LOCF population, 60.5% of the paroxetine patients and 58.2% of the placebo patients had responded. These findings were confirmed by the OC dataset and in the per protocol population.

The only statistically significant interaction found was treatment by age (p=0.002). The results from re-analysis of the dataset split by age group ( $\leq$  16 and > 16 years old) showed that in the younger group the proportion of responders was

higher in the placebo group, although this was not statistically significant. In the older age group, the proportion of responders was higher in the paroxetine group.

# Proportion of Patients with a $\geq 50\%$ reduction in MADRS Total Score by Age Group at Week 12:

Age Group ≤ 16 years Old

rige Grou	p = 10 years or	u			
Dataset	Paroxetine	Placebo	Adjusted	95% CI	P-value
	Responders	Responders	Odds Ratio	(Paroxetine	
				/Placebo)	
LOCF	65/118	37/57	0.609	(0.309,1.201)	0.153
	(55.08%)	(64.91%)			
OC	56/80	33/45	0.815	(0.355, 1.870)	0.629
	(70.00%)	(73.33%)			

Age Group > 16 years Old

1150 0100	<b>p</b> 10 <b>Jun</b> 20 1	<del>-</del>			
Dataset	Paroxetine	Placebo	Adjusted	95% CI	P-value
	Responders	Responders	Odds Ratio	(Paroxetine	
	_	_		/Placebo)	
LOCF	42/59	16/34	-	-	-
	(71.19%)	(47.06%)			
OC	38/46	14/21	-	-	-
	(82.61%)	(66.67%)			

NB – Model could not be fitted due to lack of responders per treatment group.country group combination.

The odds ratios, confidence intervals and p-values were obtained using logistic regression adjusting for country group, baseline MADRS total score and age (in years).

The per-protocol population confirmed the ITT LOCF results i.e. that there was no overall evidence of treatment differences. However, the statistically significant treatment by age interaction confirmed that there appeared to be differences between treatment groups depending on the patients age.

**Kiddie-SADS-Lifetime Schedule depression subscale Score at Week 12:** 

Dataset	Treatmen	nt groups			
	Paroxetine N, adjusted mean, (S.E.)	Placebo N, adjusted mean, (S.E.)	Difference in Adjusted Means	95% CI (Paroxetine/ Placebo	P- value
LOCF	171, -9.330 (0.54)	88, -8.923 (0.70)	-0.408	(-2.007,1.192)	0.616
OC	126, -10.824 (0.49)	66, -10.167 (0.63)	-0.657	(-2.126,0.812)	0.379

The P-values were obtained using analysis of covariance adjusting for country group, baseline K-SADS-L depression subscale score and age (in years). The confidence intervals were obtained using adjusted means.

At Endpoint, the difference between the treatment groups in the adjusted means (see appendix I) of –0.41 in the ITT LOCF population did not achieve clinical or statistical significance. This was confirmed by the ITT OC dataset and the per protocol population.

Again, the only statistically significant interaction found was treatment by age (p=0.020 ITT LOCF). The dataset was re-analysed, split by age group. As with the other primary parameter, although there was no evidence of overall treatment differences, in the older age group, the mean change from baseline was larger in the paroxetine group.

# Change from Baseline in K-SADS-L Depression Subscale Score by Age Group at Week 12:

Age Group ≤ 16 years Old

Dataset	Paroxetine	Placebo	Difference	95% CI	P-
	N, Adjusted	N, Adjusted	in Adjusted	(Paroxetine	value
	Mean (S.E.)	Mean (S.E.)	Means	/Placebo)	
LOCF	113, -8.416	55, -9.384	0.968	(-0.954, 2.891)	0.321
	(0.61)	(0.83)			
OC	80, -10.081	45 -9.797	-0.285	(-2.141, 1.571)	0.762
	(0.61)	(0.77)			

Age Group	) > 16 years Old	1			
Dataset	Paroxetine	Placebo	Difference	95% CI	P-
	N, Adjusted	N, Adjusted	in Adjusted	(Paroxetine	value
	Mean (S.E.)	Mean (S.E.)	Means	/Placebo)	
LOCF	58, -11.163	33, -8.438	-2.725	(-5.641,0.192)	0.067
	(1.25)	(1.47)			
OC	46, -12.060	21, -10.899	-1.161	(-3.681, 1.358)	0.360
	(0.93)	(1.20)			

Age Group > 16 years Old

The p-values were obtained using analysis of covariance adjusting for country group, baseline K-SADS-L depression subscale score and age (in years). The confidence intervals were obtained using adjusted means.

Results from the per protocol analyses confirmed those obtained from the ITT population.

### **Secondary Efficacy Variable(s)**

No overall treatment differences between paroxetine and placebo were detected for any of the secondary efficacy variables. However, there did appear to be some evidence of treatment by age interactions as seen for the primary efficacy variables (See Appendix I), and hence for consistency all variables were additionally analysed by age group.

# **Safety Results**

### **Adverse Experiences**

Similar proportions of patients from both treatment groups experienced adverse events (65.4% of paroxetine patients compared with 59.1% of placebo patients; ITT population).

### **Serious Adverse Experiences**

Twenty two (12.1%) patients in the paroxetine group and 6 (6.5%) patients in the placebo group experienced serious emergent adverse events in the ITT population. None of the SAEs were fatal.

### Withdrawals Due to Adverse Experiences

For all randomised patients, 22 out of 187 (11.8%) patients in the paroxetine group withdrew due to adverse experiences compared to 7 out of 99 (7.1%) in the placebo group. This difference was not statistically significant.

### Vital Signs

Changes in mean vital signs values between baseline and week 12 were small for both treatment groups and of no clinical concern, and there were no differences between the treatment groups regarding vital signs values meeting sponsor-defined clinical concern criteria.

### **Laboratory Tests**

Similar proportions of patients in the two treatment groups had one or more laboratory value meeting sponsor-defined clinical concern criteria (paroxetine 29.1%, placebo 33.3%).

# Conclusion(s)

The results failed to show any superiority for paroxetine over placebo in the treatment of adolescent depression. A significant age by treatment interaction was detected in both of the primary efficacy variables and most of the secondary, indicating evidence of a different treatment effect dependent on age. Therefore conclusions drawn on the data presented overall should be treated with caution.

Paroxetine was well tolerated with no unexpected finding regarding adverse experiences, vital signs or laboratory values.

# **Table of Contents**

Report Synopsis	000003
List of Tables	000015
List of Figures	000017
List of Appendices	000018
List of Abbreviations & Definitions	000019
1 Introduction	000022
2 Objectives	000024
2.1 Primary Objective	000024
2.2 Secondary Objective	000024
3 Methodology	000025
3.1 Study Design	000025
3.1.1 Protocol Amendment/Modification	000025
3.2 Investigators	000026
3.3 Ethics	000026
3.4 Eligibility Criteria	000027
3.4.1 Inclusion Criteria	000027
3.4.2 Exclusion Criteria	000027
3.5 Study Medication and Administration	000029
3.5.1 Study Medication	000029
3.5.2 Dosage and Administration	000031
3.5.3 Method of Blinding	000032
3.6 Compliance with Study Medication	000032
3.7 Prior and Concomitant Medication	000032
3.7.1 Prior Medication	000032
3.7.2 Prohibited Medication	000033
3.7.3 Allowed Medication	000033
3.8 Study Procedures	000033
3.8.1 Schedule of Assessments	000033
3.8.2 Prestudy Screening and Enrollment	000035
3.8.3 Baseline Phase	000036
3.8.4 Treatment Phases	000037
3.8.5 Reasons for Concluding Study	000038
3.9 Efficacy Assessments	000040
3.9.1 Primary Efficacy Parameters	000040
3.9.2 Secondary Efficacy Parameters	000040
3.10 Safety Assessments	000042
3.10.1 Adverse Experiences	000042

3.10.2 Vital Signs 3.10.3 Laboratory Monitoring 3.10.4 Medical, Personal, Psychiatric History and Physical Examination 3.10.4 Medical, Personal, Psychiatric History and Physical Examination 3.10.5 ECG 3.000044 3.11 Pharmacoeconomic Assessments 3.12 Data Quality Assurance 3.13 Statistical Evaluation 3.13 Statistical Evaluation 3.13.1 Target Sample Size 3.13.2 Method of Randomization 3.13.3 Planned Efficacy Evaluations 3.13.4 Methods of Analysis 3.13.5 Populations/Data Sets to be Evaluated 3.13.6 Safety Evaluations 3.13.7 Other Evaluations 3.13.7 Other Evaluations 3.13.7 Other Evaluations 4.1 Study Population 3.1.1 Study Dates 4.2 Patient Disposition 4.2.1 Number and Distribution of Patients 4.2.2 Number of Patients Present at Each Visit 4.2.3 Withdrawal Reasons 4.2.4 Demographic and Baseline Characteristics 4.4.1 Demographic Characteristics 4.4.1 Demographic Characteristics 4.5 Heorical Previous Psychiatric History 4.6 Baseline Characteristics 4.7 Prior and Concomitant Medications 5 Efficacy Results 5.1 Hoat Sets Analysed 5.2 Primary Efficacy Parameters 5.2.1 Montgomery Asberg Depression Rating Scale (MADRS) 5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale 5.2.3 Secondary Efficacy Parameters. 5.2.1 Montgomery Asberg Depression Rating Scale (MADRS) 5.3 Secondary Efficacy Parameters. 5.2000073			
3.10.4 Medical, Personal, Psychiatric History and Physical Examination		3.10.2 Vital Signs	000043
Examination		3.10.3 Laboratory Monitoring	000043
3.10.5 ECG		3.10.4 Medical, Personal, Psychiatric History and Physical	
3.11 Pharmacoeconomic Assessments       000044         3.12 Data Quality Assurance       000044         3.13 Statistical Evaluation       000045         3.13.1 Target Sample Size       000045         3.13.2 Method of Randomization       000046         3.13.3 Planned Efficacy Evaluations       000047         3.13.4 Methods of Analysis       000047         3.13.5 Populations/Data Sets to be Evaluated       000049         3.13.6 Safety Evaluations       000051         3.13.7 Other Evaluations       000052         4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000053         4.2.3 Withdrawal Reasons       000053         4.3 Protocol Violations       000054         4.4 Demographic and Baseline Characteristics       000054         4.4.1 Demographic Characteristics       000054         4.4.2 Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.5.2 Previous Psychiatric History       000060         4.5.2 Previous Psychiatric History       000060         4.6 Baseli		Examination	000044
3.12 Data Quality Assurance       000044         3.13 Statistical Evaluation       000045         3.13.1 Target Sample Size       000045         3.13.2 Method of Randomization       000046         3.13.3 Planned Efficacy Evaluations       000047         3.13.4 Methods of Analysis       000047         3.13.5 Populations/Data Sets to be Evaluated       000049         3.13.6 Safety Evaluations       000051         3.13.7 Other Evaluations       000052         4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.4 Demographic and Baseline Characteristics       000057         4.4.1 Demographic Characteristics       000058         4.4.2 Baseline Characteristics       000058         4.5 Presenting Conditions and Medical History       000060         4.5.1 Medical/Surgical History and Physical Examination at Baseline       000060         4.5 Previous Psychiatric History       000060         4.5 Previous Psychiatric History       000060 <td></td> <td>3.10.5 ECG</td> <td>000044</td>		3.10.5 ECG	000044
3.13 Statistical Evaluation.       000045         3.13.1 Target Sample Size.       000045         3.13.2 Method of Randomization       000046         3.13.3 Planned Efficacy Evaluations.       000047         3.13.4 Methods of Analysis.       000047         3.13.5 Populations/Data Sets to be Evaluated.       000049         3.13.6 Safety Evaluations.       000051         3.13.7 Other Evaluations.       000052         4 Study Population.       000053         4.1 Study Dates.       000053         4.2 Patient Disposition.       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit.       000054         4.2.3 Withdrawal Reasons.       000053         4.3 Protocol Violations.       000057         4.4 Demographic and Baseline Characteristics.       000057         4.4.1 Demographic Characteristics.       000058         4.4.2 Baseline Characteristics.       000058         4.5 Presenting Conditions and Medical History.       000058         4.5 Presenting Conditions and Medical History.       000060         4.5.2 Previous Psychiatric History.       000060         4.5 Previous Psychiatric History.       000060         4.6 Baseline Signs and Symptoms.       0000		3.11 Pharmacoeconomic Assessments	000044
3.13.1 Target Sample Size       000045         3.13.2 Method of Randomization       000046         3.13.3 Planned Efficacy Evaluations       000047         3.13.4 Methods of Analysis       000047         3.13.5 Populations/Data Sets to be Evaluated       000049         3.13.6 Safety Evaluations       000051         3.13.7 Other Evaluations       000052         4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3 Protocol Violations Excluded from the Per Protocol Analyses       000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.5 Presenting Conditions and Medical History       000058         4.5.1 Medical/Surgical History and Physical Examination at Baseline       000060         4.5 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000064         5.1 Effica		3.12 Data Quality Assurance.	000044
3.13.2 Method of Randomization       000046         3.13.3 Planned Efficacy Evaluations       000047         3.13.4 Methods of Analysis       000047         3.13.5 Populations/Data Sets to be Evaluated       000049         3.13.6 Safety Evaluations       000051         3.13.7 Other Evaluations       000052         4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3 Protocol Violations Excluded from the Per Protocol Analyses       000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.5 Presenting Conditions and Medical History       000058         4.5.1 Medical/Surgical History and Physical Examination at Baseline       000060         4.5 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000064         5.1 Data Se		3.13 Statistical Evaluation	000045
3.13.3 Planned Efficacy Evaluations       000046         3.13.4 Methods of Analysis       000047         3.13.5 Populations/Data Sets to be Evaluated       000049         3.13.6 Safety Evaluations       000051         3.13.7 Other Evaluations       000053         4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.4.2 Baseline Characteristics       000058         4.5 Presenting Conditions and Medical History       000060         4.5 Presenting Conditions and Medical History       000060         4.5.2 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Data Sets Analysed       000064         <		3.13.1 Target Sample Size	000045
3.13.4 Methods of Analysis.       000047         3.13.5 Populations/Data Sets to be Evaluated       000049         3.13.6 Safety Evaluations       000051         3.13.7 Other Evaluations       000052         4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.5 Presenting Conditions and Medical History       000060         4.5 Presenting Conditions and Medical History       000060         4.5 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Data Sets Analysed       000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       0		3.13.2 Method of Randomization	000046
3.13.5 Populations/Data Sets to be Evaluated       000049         3.13.6 Safety Evaluations       000051         3.13.7 Other Evaluations       000052         4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.4.2 Baseline Characteristics       000058         4.5 Presenting Conditions and Medical History       000060         4.5.1 Medical/Surgical History and Physical Examination at Baseline       000060         4.5.2 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Efficacy Evaluation       000064         5.2.1 Montgomery Asberg Depression Rating		3.13.3 Planned Efficacy Evaluations	000046
3.13.6 Safety Evaluations       000051         3.13.7 Other Evaluations       000052         4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.4.2 Baseline Characteristics       000058         4.5 Presenting Conditions and Medical History       000060         4.5.1 Medical/Surgical History and Physical Examination at Baseline       000060         4.5.2 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Efficacy Evaluation       000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       000064         5.2.2 Kiddie-SADS-Lifetime (K-S		3.13.4 Methods of Analysis	000047
3.13.7 Other Evaluations       000052         4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.4.2 Baseline Characteristics       000059         4.5 Presenting Conditions and Medical History       000060         4.5.1 Medical/Surgical History and Physical Examination at Baseline       000060         4.5.2 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Efficacy Evaluation       000064         5.2 Primary Efficacy Parameters       000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       000064         5.2.2 Kiddie-SADS-Lifetim		3.13.5 Populations/Data Sets to be Evaluated	000049
4 Study Population       000053         4.1 Study Dates       000053         4.2 Patient Disposition       000053         4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.5 Presenting Conditions and Medical History       000069         4.5 Presenting Conditions and Medical History       000060         4.5.2 Previous Psychiatric History       000060         4.5 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Efficacy Evaluation       000064         5.2 Primary Efficacy Parameters       000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       000069		3.13.6 Safety Evaluations	000051
4.1 Study Dates       .000053         4.2 Patient Disposition       .000053         4.2.1 Number and Distribution of Patients       .000053         4.2.2 Number of Patients Present at Each Visit       .000054         4.2.3 Withdrawal Reasons       .000055         4.3 Protocol Violations       .000057         4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       .000058         4.4.1 Demographic Characteristics       .000058         4.5 Presenting Conditions and Medical History       .000059         4.5 Presenting Conditions and Medical History       .000060         4.5.1 Medical/Surgical History and Physical Examination at Baseline       .000060         4.5.2 Previous Psychiatric History       .000060         4.6 Baseline Signs and Symptoms       .000061         4.7 Prior and Concomitant Medications       .000061         4.8 Treatment Compliance       .000063         5 Efficacy Results       .000064         5.1 Efficacy Evaluation       .000064         5.2 Primary Efficacy Parameters       .000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       .000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       .000069		3.13.7 Other Evaluations	000052
4.2 Patient Disposition       .000053         4.2.1 Number and Distribution of Patients       .000053         4.2.2 Number of Patients Present at Each Visit       .000054         4.2.3 Withdrawal Reasons       .000055         4.3 Protocol Violations       .000057         4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       .000058         4.4.1 Demographic Characteristics       .000059         4.5 Presenting Conditions and Medical History       .000059         4.5.1 Medical/Surgical History and Physical Examination at Baseline       .000060         4.5.2 Previous Psychiatric History       .000060         4.6 Baseline Signs and Symptoms       .000061         4.7 Prior and Concomitant Medications       .000061         4.8 Treatment Compliance       .000063         5 Efficacy Results       .000064         5.1 Efficacy Evaluation       .000064         5.2 Primary Efficacy Parameters       .000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       .000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       .000069	4	Study Population	000053
4.2.1 Number and Distribution of Patients       000053         4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.4.2 Baseline Characteristics       000059         4.5 Presenting Conditions and Medical History       000060         4.5.1 Medical/Surgical History and Physical Examination at Baseline       000060         4.5 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Efficacy Evaluation       000064         5.2 Primary Efficacy Parameters       000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       000069		4.1 Study Dates	000053
4.2.2 Number of Patients Present at Each Visit       000054         4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.4.2 Baseline Characteristics       000059         4.5 Presenting Conditions and Medical History       000060         4.5.1 Medical/Surgical History and Physical Examination at Baseline       000060         4.5 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Efficacy Evaluation       000064         5.2 Primary Efficacy Parameters       000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       000069		4.2 Patient Disposition	000053
4.2.3 Withdrawal Reasons       000055         4.3 Protocol Violations       000057         4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057         4.4 Demographic and Baseline Characteristics       000058         4.4.1 Demographic Characteristics       000058         4.4.2 Baseline Characteristics       000059         4.5 Presenting Conditions and Medical History       000060         4.5.1 Medical/Surgical History and Physical Examination at Baseline       000060         4.5.2 Previous Psychiatric History       000060         4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Efficacy Evaluation       000064         5.2 Primary Efficacy Parameters       000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       000069		4.2.1 Number and Distribution of Patients	000053
4.3 Protocol Violations		4.2.2 Number of Patients Present at Each Visit	000054
4.3.1 Protocol Violations Excluded from the Per Protocol Analyses 000057 4.4 Demographic and Baseline Characteristics		4.2.3 Withdrawal Reasons	000055
4.4 Demographic and Baseline Characteristics		4.3 Protocol Violations	000057
4.4 Demographic and Baseline Characteristics		4.3.1 Protocol Violations Excluded from the Per Protocol Analyses	000057
4.4.2 Baseline Characteristics0000594.5 Presenting Conditions and Medical History0000604.5.1 Medical/Surgical History and Physical Examination at Baseline0000604.5.2 Previous Psychiatric History0000604.6 Baseline Signs and Symptoms0000614.7 Prior and Concomitant Medications0000614.8 Treatment Compliance0000635 Efficacy Results0000645.1 Efficacy Evaluation0000645.2 Primary Efficacy Parameters0000645.2.1 Montgomery Asberg Depression Rating Scale (MADRS)0000645.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale000069		-	
4.4.2 Baseline Characteristics0000594.5 Presenting Conditions and Medical History0000604.5.1 Medical/Surgical History and Physical Examination at Baseline0000604.5.2 Previous Psychiatric History0000604.6 Baseline Signs and Symptoms0000614.7 Prior and Concomitant Medications0000614.8 Treatment Compliance0000635 Efficacy Results0000645.1 Efficacy Evaluation0000645.2 Primary Efficacy Parameters0000645.2.1 Montgomery Asberg Depression Rating Scale (MADRS)0000645.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale000069		4.4.1 Demographic Characteristics	000058
4.5.1 Medical/Surgical History and Physical Examination at Baseline			
Baseline       .000060         4.5.2 Previous Psychiatric History       .000060         4.6 Baseline Signs and Symptoms       .000061         4.7 Prior and Concomitant Medications       .000061         4.8 Treatment Compliance       .000063         5 Efficacy Results       .000064         5.1 Efficacy Evaluation       .000064         5.1.1 Data Sets Analysed       .000064         5.2 Primary Efficacy Parameters       .000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       .000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       .000069		4.5 Presenting Conditions and Medical History	000060
Baseline       .000060         4.5.2 Previous Psychiatric History       .000060         4.6 Baseline Signs and Symptoms       .000061         4.7 Prior and Concomitant Medications       .000061         4.8 Treatment Compliance       .000063         5 Efficacy Results       .000064         5.1 Efficacy Evaluation       .000064         5.1.1 Data Sets Analysed       .000064         5.2 Primary Efficacy Parameters       .000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       .000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       .000069		4.5.1 Medical/Surgical History and Physical Examination at	
4.6 Baseline Signs and Symptoms       000061         4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Efficacy Evaluation       000064         5.1.1 Data Sets Analysed       000064         5.2 Primary Efficacy Parameters       000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       000069		Baseline	000060
4.7 Prior and Concomitant Medications       000061         4.8 Treatment Compliance       000063         5 Efficacy Results       000064         5.1 Efficacy Evaluation       000064         5.1.1 Data Sets Analysed       000064         5.2 Primary Efficacy Parameters       000064         5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)       000064         5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale       000069		4.5.2 Previous Psychiatric History	000060
4.8 Treatment Compliance0000635 Efficacy Results0000645.1 Efficacy Evaluation0000645.1.1 Data Sets Analysed0000645.2 Primary Efficacy Parameters0000645.2.1 Montgomery Asberg Depression Rating Scale (MADRS)0000645.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale000069		4.6 Baseline Signs and Symptoms	000061
5 Efficacy Results		4.7 Prior and Concomitant Medications	000061
5.1 Efficacy Evaluation0000645.1.1 Data Sets Analysed0000645.2 Primary Efficacy Parameters0000645.2.1 Montgomery Asberg Depression Rating Scale (MADRS)0000645.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale000069		4.8 Treatment Compliance	000063
5.1.1 Data Sets Analysed	5	Efficacy Results	000064
5.2 Primary Efficacy Parameters		5.1 Efficacy Evaluation	000064
5.2.1 Montgomery Asberg Depression Rating Scale (MADRS) 000064 5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale 000069		5.1.1 Data Sets Analysed	000064
5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale 000069		5.2 Primary Efficacy Parameters	000064
		5.2.1 Montgomery Asberg Depression Rating Scale (MADRS)	000064
		5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale	000069

5.3.1 MADRS	. 000073
5.3.2 Clinical Global Impression (CGI)	. 000075
5.3.3 Beck Depression Inventory (BDI)	. 000078
5.3.4 Mood and Feelings Questionnaire (MFQ)	. 000080
5.4 Pharmacoeconomic Variables	. 000082
5.4.1 Nottingham Health Profile (NHP)	. 000082
5.4.2 Euroqol	
5.4.3 Socio-Economic Questionnaire	. 000083
5.5 Psychotherapy Evaluation	. 000083
5.6 Child Global Assessment Scale	. 000083
6 Safety Results	. 000084
6.1 Extent of Exposure	. 000084
6.2 Adverse Experiences	. 000085
6.2.1 Adverse Experiences by Severity	. 000087
6.2.2 Adverse Experiences Thought to be Drug-related	. 000088
6.3 Dose Reduction for Adverse Experiences	. 000089
6.4 Adverse Experiences Requiring Corrective Treatment	. 000090
6.5 Deaths	. 000090
6.6 Serious Adverse Experiences	. 000090
6.7 Withdrawals Due to Adverse Experiences	. 000096
6.8 Vital Signs	. 000099
6.9 Electrocardiograph Data	. 000102
6.10 Laboratory Tests	. 000102
6.10.1 Laboratory Values Meeting Sponsor-defined Clinical	
Concern Criteria	
7 Discussion	
8 Conclusions	
9 References	
10 Source Tables: Study Population	
11 Source Tables: Efficacy Results	
12 Source Tables: Safety Results	
13 Source Tables: Safety Narratives	
14 Source Tables: Safety Narratives	
Appendices	. 000495

# **List of Tables**

Table 1 Appearance, Formulation and Dosage Strength of Drugs used with Batch Numbers	000029
Table 2 Outline of Study Assessments	000034
Table 3 Criteria for Assessment of Vital Signs	
Table 4 The Number of Patients Screened, Randomized Into the Study and the Number Who Completed the Study	
Table 5 The Number of Patients who were Randomised (R) to each Treatment Group by Centre, as well as those who Completed (C) the Study	000054
Table 6 The Number (%) of ITT Patients Present at each Visit	
Table 7 The Number (%) of Patients in the ITT population who Completed the Study or were Withdrawn by the Reason for Study	
	000056
Table 8 The Cumulative Percentage Patients Withdrawn During the Study by the Reason for Withdrawal, ITT population	000057
Table 9 Randomised Patients Excluded from the Per-protocol Analyses by Protocol Violation. Number (%) of Patients	000058
Table 10 Demographic Data for the ITT and Per Protocol Populations	000059
Table 11 Psychiatric History. Number (%) of Patients	000060
Table 12 Prior and Concomitant Medications used by 3 or More Patients in Either Treatment Group. Number (%) of Patients	
Table 13 The Proportions of Patients with >=50% Reduction from Baseline in Total MADRS Score at Study Endpoint (ITT and Per-protocol Populations)	000065
Table 14 Proportion of Patients with a $\geq$ 50% reduction in MADRS	000066
Table 15 Change from Baseline to Study Endpoint in K-SADS-L Depression Subscale (ITT and Per Protocol Populations)	000070
Table 16 Change from Baseline in K-SADS-L Depression Subscale Score by Age Group, ITT LOCF Population	
Table 17 Change from Baseline in K-SADS-L Depression Subscale Score by Age Group, ITT OC Population	
Table 18 Proportion of Patients with a 50% or Greater Reduction in MADRS Total Score at Weeks 6 and 8, ITT LOCF Population	
Table 19 Change from Baseline in MADRS Total Score at Weeks 6, 8 and Study Endpoint (ITT Population)	
Table 20 Change from Baseline in MADRS Total Score by Age Group, ITT LOCF Population	
Table 21 Change from Baseline in CGI Severity of Illness Score, ITT LOCF Population	
	0000/0

Table 22 Change from Baseline in CGI Severity of Illness Score by Age Group, ITT LOCF Population	00077
Table 23 CGI Global Improvement Score, ITT LOCF Population	
Table 24 Change from Baseline in BDI Score at Weeks 6, 8 and Study Endpoint (ITT LOCF Population)	000079
Table 25 Change from Baseline in MFQ Score at Weeks 6, 8 and Study Endpoint (ITT LOCF Population)	000080
Table 26 Change from Baseline in MFQ Total Score by Age Group, ITT LOCF Population	000081
Table 27 Extent of Exposure to Study Drug	000084
Table 28 The Number (%) of Patients with the Most Frequent (i.e. at least 3%) Reported Treatment Emergent Adverse Experiences (AEs) During Active Treatment Regardless of Treatment Attribution in Descending Order for Paroxetine	000086
Table 29 The Distribution of the Most Common Severe Adverse  Experiences for each Treatment Group. Number (%) of Patients (	
Table 30 The Number (%) of Patients with Serious Adverse  Experiences Occurring in More than One Patient	)00091
Table 31 The Number (%) of Patients Withdrawn for At Least One AE Occurring in More Than One Patient in the ITT population	000097
Table 32 Mean (s.d.) Vital Signs at Baseline and Week 12	)00100
Table 33 The Number (%) of Patients with Vital Signs Values Meeting Sponsor-defined Clinical Concern Criteria During the Study	000101
Table 34 Laboratory Values of Potential Clinical Concern	000103
Table 35 Number (%) of Patients with Laboratory Values Meeting Sponsor-defined Clinical Concern Criteria During the Study	000104

# **List of Figures**

Figure 1 Proportion of patients responding (achieving $\geq 50\%$ reduction	Ĺ
in MADRS total score) (ITT)	000067
Figure 2 Proportion of patients responding age <= 16 (achieving >= 50% reduction in MADRS total score) (ITT)	000068
Figure 3 Proportion of patients responding age >16 (achieving >= 50% reduction in MADRS total score) (ITT)	000069

# **List of Appendices**

Appendix A: Protocol(s) including Amendments, Sample Blank CRFs,	
Randomisation Code, Investigator Affiliation List, Curriculum Vitae	
of Investigators, Audited Investigator Sites, Certificates of Analysis	
and Publications	000496
Appendix B: Listings of Demographic Data, Medical History and	
Baseline Signs and Symptoms	001392
Appendix C: Listings of Efficacy	001393
Appendix D: Listings of Adverse Experiences	001395
Appendix E: Listings of Vital Signs	001396
Appendix F: Listings of Laboratory Values	001397
Appendix G: Annotated CRFs	001398
Appendix H: Case Report Form Tabulations	001399
Appendix I: Statistical Appendix	001400

# **List of Abbreviations & Definitions**

Abbreviation	Unabridged Term(s)						
AE	adverse experience						
ALT (SGPT)	alanine aminotransferase						
AST (SGOT)	aspartate aminotransferase						
BDI	Beck Depression Inventory						
BP	blood pressure						
bpm	beats per minute						
BUN	blood urea nitrogen						
CATMOD	Categorical Modeling						
C-GAS	Child Global Assessment Scale						
CGI	Clinical Global Impression						
CI	confidence interval						
CNS	Central Nervous System						
CRF	Case Report Form						
DBP	diastolic blood pressure						
DSM-IV	Diagnostic and Statistical Manual of Mental Disorders-IV						
ECG	electrocardiogram						
ECT	electroconvulsive therapy						
EEG	electroencephalogram						
ERC	Ethics Review Committee						
Euroqol	European Quality of Life Scale						

**FDA** Food and Drug Administration

**GLM** General Linear Modeling

**HR** heart rate

**ITT** intention-to-treat

**K-SADS-L** Kiddie-SADS-L; Schedule for affective disorders and

schizophrenia for school age children (Lifetime)

**LOCF** Last Observation Carried Forward

MADRS Montgomery Asberg Depression Rating Scale

**MAO** monoamine oxidase

**MAO(I)** monoamine oxidase (inhibitor)

**MFQ** Mood and Feelings Questionnaire

NA not applicable

**NHP** Nottingham Health Profile

OC Observed Cases

**OCD** Obsessive Compulsive Disorder

**PID** patient identification

**RBC** red blood cell

**SAE** Serious Adverse Experience

SB SmithKline Beecham Pharmaceuticals

**SBP** systolic blood pressure

**SD (sd)** standard deviation

**SE (se)** standard error

**SEM** standard error of the mean

**SSRI** selective serotonin re-uptake inhibitor

**WHO** World Health Organisation

**WBC** white blood cell

adverse experience An adverse experience includes any noxious, pathological

or unintended change in anatomical, physiological or metabolic functions as indicated by physical signs, symptoms and/or laboratory changes occurring in any phase of the clinical study whether associated with the study drug or placebo and whether or not considered drug related. This includes an exacerbation of pre-existing conditions or events, intercurrent illnesses, drug interaction or the significant worsening of the disease under investigation that is not recorded elsewhere in the case record form under specific efficacy assessments.

**Baseline** The last available value before administration of active

study treatment.

serious adverse A serious adverse experience is any event which is fatal, experience life threatening, disabling or incapacitating or results in

hospitalisation, prolongs a hospital stay or is associated with congenital abnormality, cancer or overdose (either accidental or intentional). In addition any experience which the investigator regards as serious or which would suggest any significant hazard, contraindication, side effect or precaution that may be associated with the use

of the drug was to be documented as a serious event.

### 1 Introduction

Depression in children and adolescents can be a chronic, debilitating condition with major impact on family, social and intrapsychic life. Early detection facilitates early treatment; a key to preserving a child's continued growth and development.

Similarities between adolescent and adult depression in symptomatology, family history and prospective course provide a compelling rationale for investigating the efficacy of antidepressant drug therapy in young patients with depression. However, the evidence from trials in adolescents does not support drug efficacy [1], [2], [3], although existing studies have collectively evaluated fewer than 200 patients.

This difference in response between adults and younger patients has been the subject of several reviews [4], [5], [6] and three main reasons have been suggested: (a) deficiencies in study design, methodology and conduct; (b) the adequacy of diagnostic criteria and various nosological problems; and (c) developmental issues in that children and adolescents who suffer from adult-like depression may respond in a pharmacologically different manner due to quantitative and/or qualitative developmental differences in neurotransmitter/receptor systems.

Paroxetine is a novel phenylpiperidine derivative developed by SB as an antidepressant. It belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class of antidepressants and registration approval for this indication has been granted in over 80 markets worldwide.

Pharmacological and biochemical studies *in vitro* and *in vivo* have shown that paroxetine, unlike conventional tricyclic antidepressants, exhibits a high degree of selectivity and potency for serotonin re-uptake processes with little affinity for catecholamine mechanisms.

Paroxetine is well tolerated, with nausea, headache, sweating and somnolence being the most commonly reported adverse effects, which are generally mild and transient in nature and rarely lead to discontinuation of therapy. Paroxetine is associated with significantly fewer anticholinergic effects than the tricyclic antidepressants and produces no clinically significant effects on the EEG or ECG in volunteers or in patients with depression [7].

Paroxetine has been studied in clinical trials in over 6000 adult patients with major depressive illness, but has not been systematically studied in adolescent depression in well controlled studies. The present study examines paroxetine therapy in adolescents with unipolar major depression and attempts to avoid the perceived flaws of previous studies.

# 2 Objectives

# 2.1 Primary Objective

To compare the efficacy of paroxetine and placebo in the treatment of adolescents with unipolar, major depression.

# 2.2 Secondary Objective

To assess the safety and tolerability of paroxetine in adolescents with unipolar, major depression.

# 3 Methodology

### 3.1 Study Design

This was a multicentre, double-blind, randomised, parallel group, placebo controlled study to compare the efficacy and safety of paroxetine (20-40mg daily, flexible dose) and placebo in the treatment of adolescents with unipolar, major depression as defined by DSM-IV criteria<sup>1</sup>.

Patients who met the inclusion and exclusion criteria were enrolled into a 2 week, single-blind, placebo run-in period. Eligible patients were then randomised to receive paroxetine (20-40mg daily, flexible dose) or placebo (2:1 randomisation) for a period of 12 weeks. Patients returned to the clinic at the end of Weeks 1, 2, 3, 4, 6, 8 and 12 for assessments of efficacy, safety, concomitant medications and general compliance with study procedures. Patients withdrawing prematurely from the study received 2 weeks of run out medication. At the end of the study all patients were down-titrated off study medication over a period of 2 weeks and returned to the clinic for a last assessment of safety at the end of Week 14.

#### 3.1.1 Protocol Amendment/Modification

The original protocol was approved on 6 February 1995. This was followed by one protocol amendment and one protocol modification<sup>2</sup>.

### Protocol Amendment

The protocol amendment, which applied to all centres, was approved on 16 January 1996 and was incorporated into the protocol.

Initial recruitment into the study was slow and this amendment was made to increase the rate of enrollment. Changes consisted of a small increase in the maximum allowed age of patients from 17 years 11 months to 18 years 11 months, limiting the wash-out period for psychotropic medication to two weeks, and allowing the K-SADS-L scale to be completed over Visits 2 and 3.

<sup>&</sup>lt;sup>1</sup> Appendix A contains the protocol and sample case report forms.

<sup>&</sup>lt;sup>2</sup> Appendix A contains the protocol amendments/modifications

### **Protocol Modification**

This modification, which applied to all centres, was approved on 21st April 1997.

The modification related to the Socio-Economic questionnaire data being collected as part of this study. Problems were arising because some questions were being asked at each visit but different answers were being recorded (e.g. Question 1 "Where does the patient live?"), and there were also inconsistencies between the information collected in different questions (eg. Questions 2 and 3). As a result it was decided to modify some of the questions and data collected.

# 3.2 Investigators

The study was carried out in 33 centres in Belgium, Italy, Spain, United Kingdom, Holland, Canada, South Africa, United Arab Emirates, Argentina and Mexico (only 32 centres randomised patients to study medication). A list of investigators with their affiliations is shown in Appendix A. The investigators were chosen for their interest in the study and their ability to enter eligible patients<sup>3</sup>. The centres in Argentina, Mexico and the United Arab Emirates became involved approximately one year after study start in order to aid recruitment.

It was prospectively decided prior to database freeze not to include the data from centre 007 in the efficacy analyses due to concerns over the validity of the data from this centre. The CRFs for 3 of the patients could not be recovered from the site and this has resulted in the safety data from the patients not being reported. The data anomalies are explained in footnotes to the relevant tables where necessary.

### 3.3 Ethics

The study was conducted in accordance with Good Clinical Practices<sup>4</sup> and the Declaration of Helsinki as amended in Hong Kong in 1989. The protocol and statement of informed consent were approved by an Institutional Review Board (or Ethics Committee) prior to each center's initiation. Written informed consent<sup>5</sup>

<sup>&</sup>lt;sup>3</sup> Appendix A contains the CVs of the principal investigators.

<sup>&</sup>lt;sup>4</sup> as stated in EU CPMP for European multi-national studies and 21 CFR for studies filed to the US IND.

<sup>&</sup>lt;sup>5</sup> Appendix A contains the protocol and the sample informed consent is an appendix to the protocol.

was obtained from each patient and their legal guardian prior to entry into the study. Case report forms were provided for each patient's data to be recorded.

## 3.4 Eligibility Criteria

#### 3.4.1 Inclusion Criteria

Patients had to fulfil the following criteria to be eligible to enter the study:

- 1 Male or female hospital outpatients aged between 13 years and 18 years 11 months at the time of Screening. "Day patients" or patients staying overnight to complete all study assessments for practical purposes e.g. traveling long distances, were permitted.
- 2 Current diagnosis of unipolar, major depression as defined by DSM IV criteria.
- 3 A score of under 69 on the C-GAS.
- 4 MADRS score of 16 or more.
- 5 Patients must have given written informed consent to participate in the study, and written informed consent was also to have been obtained from the patient's legal guardian.
- 6 A negative pregnancy test for female patients if required by the local Ethical Committee or law.

### 3.4.2 Exclusion Criteria

Patients were excluded from the study for the following reasons:

- 1 Patients who had not yet, in the opinion of the investigator, entered puberty.
- 2 Patients with the following diagnosis;
  - Persistent conduct disorder in childhood, i.e. as the primary disorder, or a history of non-compliance.
  - Autism or pervasive mental disorder.
  - Current organic psychiatric disorder including schizophrenia and epilepsy.

- Serious suicidal ideation. Patients with a history of suicide attempt but who were not considered a significant risk now, could be included.
- OCD, panic, social phobia or post traumatic stress disorder which had preceded the diagnosis of depression. i.e. depression was to be the primary diagnosis and not a subsequent occurrence to any of the above conditions.
- 3 Patients with medical illness which, in the opinion of the investigator, contraindicated the use of paroxetine e.g. uncontrolled diabetes, severe cardiovascular, renal, hepatic, gastrointestinal, metabolic (hyper- and hypothyroidism), neurological or autoimmune disease.
- 4 Patients who had previously responded to psychotherapy as treatment for depression.
- 5 Patients who were scheduled to undergo long-term, individualised, formal psychotherapy during the study period. Routine short-term supportive psychotherapy or family supportive therapy was permitted.
- 6 Patients who had received ECT in the previous 3 months or who were scheduled to receive ECT during the study period.
- 7 Patients who were currently dependent on illicit drugs or alcohol or with a history of dependency in the previous 6 months.
- 8 Patients who received psychotropics as from the date of the Screening visit, e.g. anticonvulsants, anxiolytics, neuroleptics, lithium or psychostimulants. Concomitant use of psychotropics was not permitted.
- 9 Current treatment with sumatriptan, oral anticoagulants or type 1C antiarrythmics, i.e. encainide, flecainide, lorcainide and propafenone.
- 10 Patients with long-term use of any other drug with CNS activity e.g. thyroxine, corticosteroids. Such medications used for short periods e.g. antihistamines, were to be avoided or used for the minimum length of time, at the discretion of the investigator, consistent with good medical care.
- 11 Patients who had received MAOIs within a 2 week period before Screening. Concurrent use of MAOIs was not permitted.
- 12 Patients who had previously received paroxetine.

- 13 Patients with a known sensitivity to SSRIs.
- 14 Patients who received SSRIs as from the date of the Screening visit.

  Concomitant use of other SSRIs during the study period was not permitted.
- 15 Sexually active females who were not using reliable contraception.
- 16 Patients who were pregnant or lactating. Patients who became pregnant while on the study were withdrawn.
- 17 Use of an investigational drug within 30 days or 5 half-lives of entering the study (the longer period applied). Use of an investigational drug during the study period was not permitted.

## 3.5 Study Medication and Administration

### 3.5.1 Study Medication

Details of study medication are shown below (see Table 1 Appearance, Formulation and Dosage Strength of Drugs used with Batch Numbers, page 21).

Table 1 Appearance, Formulation and Dosage Strength of Drugs used with Batch Numbers

Study drug	Appearance	Formulation	Dose	Batch numbers
Paroxetine	Blue	Size 1 capsule	10mg	M94002, M96328
Paroxetine	Blue	Size 1 capsule	15mg	M94003
Paroxetine	Blue	Size 1 capsule	20mg	M94004, M95004, M96330
Placebo	Blue	Size 1 capsule	NA	CT2/4301, M96332

Data source: Appendix A contains the batch numbers and certificates of analysis for all doses of paroxetine and placebo

All study medication was provided in white opaque high density polyethylene (HDPE) bottles and sealed with tamper evident clic-loc closures. Both the active treatment phase and the run-out medication were presented in an outer box which comprised the patient pack. The active treatment medication and the run-out medication were separated by a fixed partition within the outer box. Bottles for the placebo run-in, active treatment phase and run-out medication were labelled with the following information:

- Protocol Number
- Patient Number (except run-in phase)
- Patient Initials (run-in phase only)
- Treatment Period

Day Number: (run-in phase and active treatment phase)

Week: (run-out phase)

- Batch Number
- Use By Date
- "Please return all unused medication at the next visit" (if appropriate)
- Dosing Instructions
- Dose Level (except run-in phase)
- Storage Instructions
- "Keep out of the reach of children under 12 years"
- Address

The study medication was to be stored at room temperature (below 25°C) under secure conditions.

### Placebo Run-in Phase Medication

Medication for the single-blind placebo run-in phase was supplied in one 60ml bottle containing 18 days medication. The placebo run-in phase medication was packed separately from the patient pack.

### Active Treatment Phase and Run-out Phase Medication

Active treatment phase and run-out phase medication was contained in a patient pack. Each patient pack contained the entire study medication for all dose levels for one patient.

#### **Active Treatment Phase Medication**

The active treatment medication consisted of a total of 18 bottles. The bottles were labelled with plain white labels incorporating a white tear-off portion which indicated the dose level. The medication for the treatment period Day No. 1-56 was supplied in 60ml bottles and the medication for treatment period Day No. 57-84 was supplied in 120ml bottles.

Depending on the visit sequence, patients were supplied with one, two or four weeks of active treatment medication. An extra two days medication was supplied for every seven days of treatment.

The bottles were assembled in the patient pack with each treatment period in sequence from the top of the box to the fixed partition, and each dose level in sequence from left to right.

#### **Run-out Phase Medication**

Run-out medication comprised of one small box for each dose level. Each small box contained 2 x 60ml bottles of medication. The box was labelled with a white label incorporating a tear-off portion which indicated the dose level. The bottles were labelled with a plain white label and indicated the treatment period. Each bottle contained medication for an exact seven days.

### 3.5.2 Dosage and Administration

Patients were instructed to take 2 capsules each morning, with food, throughout the study. All patients received a 2 week period of placebo medication during the run-in phase of the study. After the placebo run-in period, patients who were randomly allocated to receive placebo continued to receive placebo during the whole phase of the study.

Patients who were randomly allocated to the paroxetine group started at dose level one. The dose could be uptitrated at weekly intervals (10 mg per week maximum) at the discretion of the investigator, according to clinical response and tolerability.

The dosage of paroxetine in the active phase of the study was identified by the following dose levels:

Dose level	Paroxetine dose	Study medication
1	20mg	2 x 10mg capsules
2	30mg	2 x 15mg capsules
3	40mg	2 x 20mg capsules

At the end of the study treatment period patients were down-titrated off study medication with a 2 week pack of "run-out" medication (blinded treatment). This was used in the following way:

Dose level at the end	Treatment during "run-out"				
of treatment	Week 1	Week 2			
Placebo	Placebo	Placebo			
1 = 20 mg	Placebo	Placebo			
2 = 30 mg	20mg	Placebo			
3 = 40 mg	30mg	20mg			

### 3.5.3 Method of Blinding

Paroxetine and placebo capsules were identical in appearance and all packaging maintained the double-blind nature of the study.

Only in the event of a serious adverse experience which the investigator felt could not be adequately treated without knowing the identity of the study medication, was the medication code to be broken for a particular subject. Every effort was to be made to contact an SB Medical Monitor prior to breaking the code. If this was not possible and the situation was an emergency the investigator could break the code and contact the Medical Monitor as soon as possible thereafter.

# 3.6 Compliance with Study Medication

Every effort was to be made to encourage patient compliance with the dosage regimen as per protocol. All patients were instructed to return their medication pack, with any unused drug, to the investigator at their next visit. A record of the supplies dispensed, taken and returned was made in the CRF at each visit.

If there were any significant irregularities in compliance, the patient was to be withdrawn from the study. The investigator's judgement of compliance was accepted by SB (as a guideline, non-compliance is usually defined as less than 80% or more than 120% of the scheduled dose at each of 2 consecutive visits).

### 3.7 Prior and Concomitant Medication

All concomitant medication taken during the study was to be recorded in the CRF with indication, daily dose, and dates of administration.

### 3.7.1 Prior Medication

Patients were excluded from the study if they had previously responded to psychotherapy as treatment for depression, if they had received ECT in the previous 3 months, if they were receiving long-term treatment with CNS active drugs such as thyroxine or corticosteroids (short term use could be permitted, see below), if they had received MAOIs within a 2 week period before Screening, if they had previously received paroxetine, if they had received an investigational drug within 30 days or 5 half-lives of entering the study (the longer period applied) or if they received psychotropics, (e.g. anticonvulsants, anxiolytics, neuroleptics, lithium or psychostimulants) or SSRIs from the date of the Screening visit.

### 3.7.2 Prohibited Medication

Patients were not permitted to receive concomitant therapy with sumatriptan, oral anticoagulants or type 1C antiarrythmics (i.e. encainide, flecainide, lorcainide and propafenone), psychotropics (e.g. anticonvulsants, anxiolytics, neuroleptics, lithium or psychostimulants) or SSRIs. Patients were also not to receive ECT or long-term, individualised, formal psychotherapy during the study period. Routine short-term supportive psychotherapy or family supportive therapy was permitted.

### 3.7.3 Allowed Medication

Whilst short-term use of drugs with CNS activity was to be avoided some medications e.g. antihistamines, could be used for the minimum length of time, at the discretion of the investigator, consistent with good medical care.

### 3.8 Study Procedures

### 3.8.1 Schedule of Assessments

The timing of the study visits, and the procedures to be carried out at each visit, are shown below (see Table 2 Outline of Study Assessments, page 26).

**Table 2 Outline of Study Assessments** 

	Placebo Run-in Active			ctive Trea	tment Pha	se		Down Titration		EWD	
	Screen Day –14	Base Day 0	Wk 1 Day 7	Wk 2 Day 14	Wk 3 Day 21	Wk 4 Day 28	Wk 6 Day 42	Wk 8 Day 56	Wk 12 Day 84	Wk 14 Day 98	
Assessments	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	
Demographic data & ECG	X										
Med/Pers/Psychiatric history	X										
DSM IV criteria & Informed consent	X										
Incl./Exclusion criteria	X	X*									
Physical examination	X								X		X
Psychotherapy evaluation	X	X	X	X	X	X	X	X	X		
Dispense study medication	Placebo	X	X	X	X	X	X	X	Run-out		Run-out
Assess compliance		X	X	X	X	X	X	X	X	X	X
C-GAS	X								X		X
MADRS & BDI	X**	X	X	X	X	X	X	X	X		X
CGI (parts 1 & 2)		Χ#		X		X	X	X	X		X
MFQ		X		X		X	X	X	X		X
K-SADS-L depression subscale		X##		X		X	X	X	X		X
Vital signs & AEs	X	X	X	X	X	X	X	X	X	X	X
Laboratory assessments	X	Χ\$							X		X
Concomitant medication	X+	X	X	X	X	X	X	X	X	X	X
Euroqol		X							X		X
NHP (part I) & Socio-Economic ques		X				X		X	X		X

Data Source: Study Protocol in Appendix A of this report

EWD = Early withdrawal; Screen = Screening; Base = Baseline; Wk = Week; Med = Medical; Pers = Personal; Incl = Inclusion; ques = questionnaire

- \* Secondary inclusion criteria
- # Part 1 only
- + Prior and concomitant medications

- \*\* MADRS only ## Full K-SADS-L
- \$ Only if abnormal at screening

### 3.8.2 Prestudy Screening and Enrollment

Adolescent patients presenting with unipolar major depression were assessed as suitable candidates for this study against the inclusion and exclusion criteria (see Sections 3.4.1 and 3.4.2). A log was kept of all patients considered for the study but not entered in the trial. Reasons for excluding these patients were recorded.

The following assessments were performed at the initial Screening visit and recorded in the CRF. Written informed consent was obtained from all patients before any study specific procedures were carried out:

- Informed consent
- Demographic data
- Medical and psychiatric history
- Inclusion/exclusion criteria
- Psychotherapy evaluation
- Vital Signs (sitting and standing blood pressure and pulse, height and weight)
- Standard 12 lead ECG
- Physical examination
- Baseline adverse experiences
- Laboratory evaluation including haematology, clinical chemistry and urinalysis (abnormal values were checked by repeat testing before randomisation)
- Concomitant medication and medication discontinued in the month prior to Screening
- DSM IV criteria for unipolar major depression
- C-GAS
- MADRS

Patients who complied with the inclusion and exclusion criteria entered a single-blind run-in period of 2 weeks (± 4 days) during which they received placebo medication.

#### 3.8.3 Baseline Phase

At the end of the run-in period, evaluations were conducted to determine eligibility to enter the treatment phase as follows:

- Secondary inclusion criteria
- Psychotherapy evaluation
- Check compliance with run-in medication
- Vital signs (sitting and standing blood pressure and pulse)
- Check the laboratory results of the Screening visit for abnormal findings
- Concomitant medication
- Assessment of adverse experiences
- MADRS
- CGI (part 1)

Patients who were still eligible for the study according to the secondary inclusion criteria i.e. fulfil MADRS >16, received no formal psychotherapy, had no clinically significant abnormal laboratory values and a negative pregnancy test continued in the study. The following Baseline assessments were then conducted:

- Full K-SADS-L (could also partly be completed at Visit 3, except for the depression subscale, which had to be completed at Visit 2)
- Beck Depression Inventory
- Mood and Feelings Questionnaire
- NHP (part I)
- Euroqol
- Socio-Economic questionnaire

#### 3.8.4 Treatment Phases

Patients attended the clinic after 7, 14, 21, 28, 42, 56, 84 and 98 days of study medication when the following assessments were performed:

At every visit (except Day 98)

- Psychotherapy evaluation
- Dispense study medication
- Compliance with study medication
- MADRS
- Beck Depression Inventory
- Vital signs (sitting and standing blood pressure and pulse)
- Adverse experiences
- Concomitant medication

On Days 14 and 42

- CGI (parts 1 & 2)
- MFQ
- K-SADS-L depression subscale

On Days 28, 56

- CGI (parts 1 & 2)
- MFQ
- K-SADS-L depression subscale
- NHP (part I)
- Socio-Economic questionnaire

## On Day 84

- CGI (parts 1 & 2)
- MFQ
- K-SADS-L depression subscale
- C-GAS
- Laboratory assessments
- Weight
- Physical examination
- Euroqol
- NHP (part I)
- Socio-Economic questionnaire

## On Day 98

- Compliance with study medication
- Vital signs (sitting and standing blood pressure and pulse)
- Adverse experiences
- Concomitant medication

## 3.8.5 Reasons for Concluding Study

A patient was considered to have completed the study upon completion of 98 days (±4 days to allow for flexibility in scheduling of assessments) of dosing with active medication.

A patient could withdraw, or be withdrawn, from the study prematurely for the following reasons:

- 1 Adverse experience (Adverse experience section of the CRF was to be completed)
- 2 Lack of efficacy

- 3 Deviation from protocol
- 4 Lost to follow-up
- 5 Termination of the study by SB
- 6 Other

The primary reason for patient withdrawal was to be recorded in the CRF.

Every attempt was to be made to carry out the following assessments at the patient's last visit:

- Dispense run-out medication
- Compliance with study medication
- Concomitant medication
- Vital Signs (sitting and standing blood pressure and pulse)
- Physical examination
- Adverse experiences
- Laboratory assessments
- MADRS
- CGI (parts 1 & 2)
- Beck Depression Inventory
- Mood and Feelings Questionnaire
- K-SADS-L depression subscale
- C-GAS
- Euroqol
- NHP (part I)
- Socio-Economic questionnaire

# 3.9 Efficacy Assessments

## 3.9.1 Primary Efficacy Parameters

The primary efficacy parameters for this study were the proportion of patients with ≥50% reduction between baseline and endpoint in the Montgomery Asberg Depression Rating Scale (MADRS) and the change from baseline at endpoint in the Kiddie-Schedule for affective disorders and schizophrenia for school age children-Lifetime depression subscale (K-SADS-L).

#### **MADRS**

The MADRS scale consists of 10 items covering apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts, each of which is scored between 0 and 6 in defined steps. MADRS was assessed at every visit except at the end of the down titration phase (week 14, visit 10).

#### K-SADS-L Depression Subscale

The K-SADS-L questionnaire consists of 56 questions in 30 subsections relating to various aspects of the patients mood, self image, attitude to life, psychomotor agitation/retardation, sleep problems, appetite/weight loss/weight gain and suicidal ideation over the previous 2 weeks. The K-SADS-L Depression Subscale consists of 9 of these questions. Most questions are scored between 0 and a maximum of 4 to 7 in defined steps but some questions also have additional specific answers. K-SADS-L depression subscale was assessed at Baseline (full K-SADS-L scale), weeks 2, 4, 6, 8 12 and early withdrawal.

# 3.9.2 Secondary Efficacy Parameters

Secondary efficacy parameters were the proportion of patients with a ≥50% reduction in their baseline MADRS score at week 6 and 8, change from baseline in the MADRS score at week 6, week 8 and week 12, change from baseline in the K-SADS-L at week 6, 8 and 12, Clinical Global Impression (CGI) - severity of illness change from baseline at week 6, week 8 and week 12 and global improvement total score, Beck Depression Inventory (BDI) change from baseline at week 6, week 8 and week 12 and Mood and Feelings Questionnaire (MFQ) change from baseline at week 6, week 8 and week 12. Please note that the protocol states analysis of the secondary efficacy variables at week 6 and endpoint only. An amendment to the reporting and analysis plan prior to database freeze added week 8 as a timepoint for analysis for all the secondary efficacy variables

and added change from baseline in the K-SADS-L at weeks 6 and 8. This alteration should have been reflected in the protocol as a protocol modification.

#### **MADRS**

For details of MADRS see section above.

#### **CGI**

The CGI scale is composed of two parts:

• severity of illness, assessed on a 7-point scale and scored as follows:

1	Normal not at all ill	5	Markedly ill
2	Borderline mentally ill	6	Severely ill
3	Mildly ill	7	Among the most extremely ill
4	Moderately ill		patients

CGI severity of illness was assessed at Baseline, weeks 2, 4, 6, 8, 12 and at early withdrawal.

• global improvement, assessed on a 7-point scale and scored as follows:

1	Very Much Improved	5	Minimally Worse
2	Much Improved	6	Much Worse
3	Minimally Improved	7	Very Much Worse
1	No Change		

4 No Change

CGI global improvement was assessed at weeks 2, 4, 6, 8, 12 and at early withdrawal.

## BDI

The BDI scale consists of 21 items each of which is scored between 0 and 3 in defined steps. The scale is completed by the patient and relates to how they have been feeling during the past week including the day of completing the questionnaire. BDI was assessed at Baseline, weeks 1, 2, 3, 4, 6, 8, 12 and at early withdrawal.

## **MFQ**

The MFQ consists of 34 questions which are answered by the patient by ticking boxes as true (scored as 2), sometimes (scored as 1) and not true (scored as 0). The questions relate to how they have been feeling or acting within the last 2 weeks. The MFQ was assessed at Baseline, weeks 2, 4, 6, 8, 12 and at early withdrawal.

# 3.10 Safety Assessments

## 3.10.1 Adverse Experiences

Adverse experiences (AEs) were elicited by the investigator asking the patient a non-leading question such as "Do you feel different in any way since the last visit?" If the patient responded "Yes", details of the treatment emergent AE and its severity including any change in study drug administration, investigator attribution to study drug, any corrective therapy given and outcome status were documented on the case report form. Attribution or relationship to study drug was judged by the investigator to be unrelated, probably unrelated, possibly related or related. All adverse experiences were coded from the verbatim term according to the WHO Adverse Reaction Terminology (ART) dictionary by body system and preferred term. Any patients who withdrew prematurely or completed the study with an ongoing AE or out of range labortory values, where scheduled to return for a follow-up visit 14 days after their last visit.

#### Serious Adverse Experiences

A serious adverse experience was defined as any event which was fatal, life threatening, disabling/incapacitating or resulted in hospitalisation, prolonged a hospital stay or was associated with congenital abnormality, cancer or overdose (either accidental or intentional). In addition any experience which the investigator regarded as serious or which would suggest any significant hazard, contraindication, side effect or precaution that may be associated with the use of the drug was to be documented as a serious event.

Any serious adverse experiences which occurred at any time during the clinical study or within 30 days (or five half lives, whichever was the longer) of receiving the last dose of study medication, whether or not related to the study drug, were to be reported by the investigator to the study monitor by telephone within 24 hours.

Investigators were not to wait to receive additional information to fully document the event before notifying SmithKline Beecham of a serious adverse experience. The telephone report was to be followed by a full written summary detailing relevant aspects of the adverse experiences in question. Where applicable, information from relevant hospital case records and autopsy reports was to be obtained.

Instances of death, cancer or congenital abnormality if brought to the attention of the Investigator at any time after cessation of study medication and linked by the investigator to the clinical trial, were to be reported to the study monitor.

Any instance of overdosage (suspected or confirmed) was to be communicated to SmithKline Beecham within 24 hours and be fully documented as a serious adverse experience. Details of any signs or symptoms and their management were to be recorded including details of any antidote(s) administered.

Patients who became pregnant during the study were to discontinue the study immediately. Patients were instructed to notify the investigator if it was determined after completion of the study that they became pregnant either during the treatment phase of the study or within 30 days or five half lives after the treatment period, whichever was longer. Whenever possible a pregnancy was to be followed to term, any premature terminations reported, and the status of the mother and child reported to SmithKline Beecham after delivery.

#### 3.10.2 Vital Signs

Sitting and standing blood pressure (systolic and diastolic) and pulse rate were measured at each clinic visit. Body weight were measured at Screening and at Week 12.

#### 3.10.3 Laboratory Monitoring

Blood and urine samples were taken for laboratory tests (haematology, clinical chemistry and urinalysis) at Screening, Baseline (only if abnormal at screening), Week 12 and early withdrawal.

The haematology variables measured were haemoglobin, haematocrit (PCV), red blood cell counts, total and differential white blood cell counts and platelets. The clinical chemistry variables measured were urea, creatinine, total bilirubin, alkaline phosphatase, SGPT (ALT), SGOT (AST), total protein, globulin and albumin. At the same study visits, dipstick urinalysis (blood, protein and glucose)

was to be performed, and if any results were abnormal the sample was to be sent for further analysis.

In addition a pregnancy test, where required by the local ethical committee or law, was to be performed at the Screening Visit.

Laboratory assessments were to be repeated if clinically significant abnormalities were detected and followed up until resolved or stabilised. Clinically significant abnormalities in laboratory parameters were to be recorded as adverse experiences in the patient's CRF.

#### 3.10.4 Medical, Personal, Psychiatric History and Physical Examination

A full medical, personal and psychiatric history and physical examination was to be carried out at Screening. The physical examination was to be repeated at Week 12 and, if applicable, early withdrawal. Any adverse changes in the physical examination were to be recorded in the adverse experience pages of the patient's CRF.

#### 3.10.5 ECG

A standard 12-lead ECG was to be carried out at Screening and all clinically significant abnormalities were to be identified.

## 3.11 Pharmacoeconomic Assessments

The patient completed the Euroqol at Baseline, Week 12 and, if applicable, at early withdrawal, and the NHP and Socio-Economic questionnaire at Baseline, weeks 4, 8 and 12 and, if applicable, at early withdrawal. The pharmacoeconomic data are discussed in a separate report.

# 3.12 Data Quality Assurance

To ensure that study procedures across all investigator sites were consistent, the protocol, case report from and safety reporting were reviewed with the investigator and his/her personnel responsible for the conduct of the study by the Company representative(s) at the investigator site. Investigator meetings were held on 3/4th April 1995 in Rome, Italy, 5th October 1996 in Dubai, United Arab Emirates and 17th December 1996 in Monterrey, Mexico.

Adherence to the protocol requirements and verification of data generation accuracy was achieved through monitoring visits to each investigator site. Subsequent data handling and reporting processes were subject to in-process Quality Control and this final clinical report has, in addition, been subject to an end-stage Quality Control review. All the above procedures were performed according to methodologies detailed in SmithKline Beecham Standard Operating Procedures (SOPs).

A Contract Research Organization (CRO), xxx xxxxxxxxxxxxxxxxx xxxx, was employed to perform the data management of the study according to an agreed contract. The CRO responsibilities were conducted according to their SOPs.

Independent Audit Statement:

This study was subject to audit by SmithKline Beecham's department of Worldwide Regulatory Compliance-GCP (WRC-GCP). A list of audited sites can be found in Appendix A.

#### 3.13 Statistical Evaluation

# 3.13.1 Target Sample Size

The number of patients required for comparison of the two treatment groups in the efficacy analysis was based upon the following statistical assumptions:

- Significance level ( $\alpha$ ) = 0.05
- Power  $(1-\beta) = 0.9$
- Detectable difference between paroxetine and placebo = 25%
- Response rate of paroxetine = 70%
- Response rate of placebo = 45%
- Allocation of patients (paroxetine:placebo) = 2:1

Response was defined as a decrease from baseline of 50% or greater in the MADRS score.

The number of patients completing the study period and valid for inclusion in the analysis, required under the given assumptions, was 120 paroxetine patients and 60 placebo patients, i.e. 180 patients for the entire study. Assuming an attrition

rate of 30% over the 12-week study, it was estimated that 264 patients in blocks of 6 would be randomised.

#### 3.13.2 Method of Randomization

A computer generated randomisation list (see appendix A) was used in which treatments were allocated 2:1, paroxetine:placebo. Each investigator/centre was allocated medication in blocks of 6 consecutively numbered patient packs which were to be allocated in strict sequential order.

Randomised patients were numbered 1-286. The master randomisation list was held by SB. Individual sealed code break envelopes were held by the investigator. Treatment codes for an individual patient could be broken in case of emergency, (see Section 3.5.3 of this report).

# 3.13.3 Planned Efficacy Evaluations

#### Primary Efficacy Variables

The primary efficacy variables were:

- The proportion of patients with a 50% or greater reduction in MADRS score between baseline and study endpoint
- The change from baseline to study endpoint in K-SADS-L depression subscale

#### Secondary Efficacy Variables

The secondary efficacy variables were:

- The proportion of patients with a 50% or greater reduction in MADRS score between baseline, weeks 6 and 8
- Change from baseline in KSADS depressive subscale score at week 6 and 8
- Change from baseline in MADRS total score at week 6, 8 and study endpoint
- Change from baseline in CGI severity of illness score at week 6, 8 and study endpoint
- CGI global improvement score at week 6, 8 and study endpoint
- Change from baseline in BDI at week 6, 8 and study endpoint

• Change from baseline in MFQ at week 6, 8 and study endpoint

## 3.13.4 Methods of Analysis

#### Statistical Analyses

For MADRS, BDI and MFQ where any of the items were not scored, provided at least 60% were answered, the total score was calculated as follows:

score = Number of items in the scale X Score for items answered

Number of items answered

The proportion of patients responding ( $\geq$ 50% reduction in MADRS total score) was analysed using logistic regression (PROC LOGISTIC of SAS). The model included treatment group, country group, and covariates of age and baseline score. Odds ratios and 95% confidence intervals were presented. The effect of adding treatment by country group interaction into the model was assessed with the above terms in the model. If the treatment by country group interaction was not statistically significant ( $p\geq0.1$ ), it was dropped from the model. Treatment by covariate and covariate by covariate interactions were assessed in a similar way.

The mean change from baseline in K-SADS-L depression subscale score, MADRS, BDI and MFQ total scores were analysed using analysis of covariance (PROC GLM of SAS) with factors treatment, country group, age and baseline score. Least squares means were compared at the 5% level and 95% confidence intervals presented for treatment differences. The effect of adding treatment by country group interaction into the model was assessed with the above terms in the model. If the treatment by country group interaction was not statistically significant ( $p \ge 0.1$ ), it was dropped from the model. Treatment by covariate and covariate by covariate interactions were assessed in a similar way.

The changes from baseline in the CGI severity of illness (an ordered categorical rating scale) were analysed non parametrically using the Wilcoxon Rank Sum test (PROC NPAR1WAY of SAS). No adjustment was made for country grouping or covariates. The CGI global improvement scores were compared using Cochran-Mantel-Haenszel chi-square tests (stratifying by country group) at the 5% level using PROC FREQ of SAS.

#### Visit windows

Visit days were defined by visit windows for reporting purposes. Day 0 was defined as the day on which the randomised medication was started. Assessments

taken at every visit (Vitals, MADRS, Psychotherapy evaluation, BDI) were included in the analyses at a particular timepoint if they occurred within the following visit windows relative to Day 0 (NOTE: Assessments made at baseline and Week 12 (or early withdrawal) only i.e Euroqol and CGAS scales, were also slotted as below for the purposes of listings. However, only Week 12 was tabulated)

```
Pre-treatment = < day -3
Baseline
          = days -3 to 0
Week 1
            = days 1 to 10
Week 2
            = days 11 to 17
Week 3
            = days 18 to 24
Week 4
            = days 25 to 35
Week 6
            = days 36 to 49
Week 8
            = days 50 to 70
Week 12
            = days 71 to 91
>Week 12
            = > day 91
```

Assessments taken fortnightly initially, then monthly (CGI, KSADS, MFQ) were included in the analyses at a particular timepoint if they occurred within the following visit windows relative to Day 0:

```
Pre-treatment = < day -3

Baseline = days -3 to 0

Week 2 = days 1 to 21

Week 4 = days 22 to 35

Week 6 = days 36 to 49

Week 8 = days 50 to 70

Week 12 = days 71 to 91

> Week 12 = > day 91
```

Assessments taken monthly (Socioeconomic questionnaire, NHP) were included in the analyses at a particular timepoint if they occurred within the following visit windows relative to Day 0:

```
Pre-treatment = < day -3
Baseline = days -3 to 0
Week 4 = days 1 to 49
Week 8 = days 50 to 70
Week 12 = days 71 to 91
```

> Week 12 = > day 91

If multiple observations for a patient fell into one visit window, then the last (furthest from the start of the study) observation was used to represent the patient's visit for that time period in the tabulations and analyses; however, all values are presented in the data listings. If a patient had an assessment falling into the pretreatment window but none into the baseline window, then the pre-treatment value was used as the baseline.

Efficacy assessments performed more than 7 days after the last dose of randomised medication and safety assessments performed more than 14 days after the last dose of randomised medication were excluded from the tabulations and analyses but are presented in the data listings.

## 3.13.5 Populations/Data Sets to be Evaluated

#### **Patient Populations**

Two patient populations, intention to treat (ITT) and per protocol, were defined as follows. The intention to treat population was the primary population in the analysis.

#### **Intention to Treat**

All patients who were randomised and received at least one dose of double-blind study medication and for whom at least one on-treatment assessment was available were included in the intention to treat population.

#### Per Protocol

Those intent to treat patients who met the criteria below were included in the per protocol population. The identification of patients thus excluded was done blind to treatment allocation. The per protocol population was only analysed with respect to the primary efficacy variables.

The criteria for inclusion in the per protocol population were:

- a No major protocol violations exist with respect to inclusion and exclusion criteria
- b Duration of active treatment was at least 6 weeks (36 days) (please note: an amendment to the reporting and analysis plan on 26th June 1996 prior to

database freeze lengthened the duration of active treatment from 3 weeks to 6 weeks, this should have been incorporated into the protocol as a protocol modification)

- c There was no concomitant use during the study of the following medications:
  - MAO inhibitors
  - Psychotropics e.g. anticonvulsants, anxiolytics, neuroleptics, lithium, psychostimulants
  - Long-term use of other drugs with CNS activity e.g. thyroxine
  - Short-term use of such drugs e.g. antihistamines, should be avoided or used, at the discretion of the investigator, with the minimum length of time consistent with good medical care
  - Other SSRIs
  - Hypnotics
  - Investigational drug i.e. without a product licence
- d Patient was compliant (non-compliance was defined as less than 80% or more than 120% of the scheduled dose at each of 2 consecutive visits)

#### Datasets

Two datasets were considered in the analysis of the efficacy data - the OC dataset and the LOCF dataset. The primary analysis was performed on the ITT LOCF dataset with the LOCF Week 12 timepoint being the primary timepoint of interest. A confirmatory analysis based on the per protocol analysis was carried out on the primary efficacy variables.

The OC dataset consisted of each patient's observations at each visit (Observed Cases). The LOCF dataset was generated from the OC dataset whereby missing data were estimated by extending forward the data from the previous visit (Last Observation Carried Forward). If the first visit on active treatment was missing then the baseline visit was not used to extend forward.

#### 3.13.6 Safety Evaluations

#### Adverse Experiences

Adverse experiences (AEs) were coded using the ADECS (COSTART based) classification to give a body system and preferred term for each event. Proportions of patients with emergent adverse events are presented by treatment group. An emergent event was defined as one with a start date on or after the first day of randomised medication.

Experiences are categorised according to onset day as follows:

- onset during active treatment phase (and prior to start of down titration phase)
- onset during the down titration phase

Gender specific AEs contain a correction for gender in the calculation of percentages for the preferred term tables.

Numbers of patients with serious adverse experiences (for definition see Section 6.10.1), patients who died, patients with emergent events rated severe by the investigator, patients with events thought to be drug related by the investigator and patients withdrawn from the study due to adverse experiences were recorded.

## Vital Signs

Mean changes from baseline in blood pressure, pulse rate and weight have been tabulated. In addition, abnormalities were flagged using normal ranges and changes from Baseline (Day 0) as shown below (see Table 3 Criteria for Assessment of Vital Signs, page 44).

**Table 3 Criteria for Assessment of Vital Signs** 

Parameter	Normal	Pre-determined change from baseline		
	range	Decrease	Increase	
Systolic BP (mmHg)	90-180	≥30	≥40	
Diastolic BP (mmHg)	50-105	≥20	≥30	
Pulse rate (bpm)	50-120	≥30	≥30	
Weight	NA	≥7%	≥7%	

## Laboratory evaluations

Abnormal values were flagged using the limits detailed in Section 6.10.1 and counts made by treatment group of the flagged values.

#### 3.13.7 Other Evaluations

The following pharmacoeconomic data were summarised. No statistical analysis was carried out.

## **Euroqol**

Total and change from baseline in Euroqol score.

## Nottingham Health Profile (NHP)

Change from baseline in the (unweighted) domain scores: energy, pain, emotional reactions, sleep, social isolation, physical mobility.

# Socio-Economic Questionnaire

Socio-economic data including living arrangements, employment status, school attendance and freetime activity were summarised by treatment group.

# **4 Study Population**

# 4.1 Study Dates

The study started on 26th April 1995 and the last study visit was on 15th May 1998.

# 4.2 Patient Disposition

#### 4.2.1 Number and Distribution of Patients

A total of 324 patients entered the study at 33 centres in Belgium, Italy, Spain, UK, Holland, Canada, South Africa, United Arab Emirates, Argentina and Mexico. Of these, 286 patients were randomized, 187 to receive paroxetine and 99 to receive placebo. 38 patients were not randomised due to protocol violations, improvement on placebo, withdrawal of consent, lost to follow-up and 1 case of an adverse experience. 11 patients were not eligible to be included in the ITT population making 182 patients in the paroxetine group and 93 in the placebo group. The reasons for patient exclusion from the per-protocol population are discussed in Section 4.3 (Protocol Violations). Further details for the patients in the study are summarised in the tables below (see Table 4 The Number of Patients Screened, Randomized Into the Study and the Number Who Completed the Study, page 46) (see Table 5 The Number of Patients who were Randomised (R) to each Treatment Group by Centre, as well as those who Completed (C) the Study, page 47).

Table 4 The Number of Patients Screened, Randomized Into the Study and the Number Who Completed the Study

Number of patients	Treatmer	Total	
	Paroxetine	Placebo	
Screened	-	-	324
Randomized	187	99	286
ITT populations*	182	93	275
Per-protocol populations	130	68	198
Completed the study ITT	127	69	196

Data Source: Tables 13.01 and 13.13b in Section 10; Appendices 13.1 and 13.13 in Appendix B \* 377.

Table 5 The Number of Patients who were Randomised (R) to each Treatment Group by Centre, as well as those who Completed (C) the Study

		<b>Number of Patients</b>					
Centre	Investigator	Paro	xetine	Plac	cebo		
No.	Last Name	R	C	R	C		
002	XXXX	0	0	1	1		
005	XXXXXXX	8	4	3	2		
007	XXXXXXX	5	2	4	2		
008	XXXXXXX	2	2	1	1		
009	XXXXXXX	11	9	6	2		
010	XXXXXXXX	4	4	2	1		
011	XXXXXXXXX	4	3	1	0		
014	XXXXXXX	4	4	2	2		
015	XXXXXXX	4	4	2	2		
022	XXXXXXX	0	0	0	0		
023	XXXX	3	2	1	0		
024	XXXXXX	2	2	1	1		
026	XXXXXXX	1	1	0	0		
029	XXXXXXX	32	16	15	10		
030	XXXXXX	5	1	2	0		
033	XXXXXX	0	0	1	1		
038	XXXXX	2	2	1	1		
040	XXXXXXXXX	2	1	2	2		
041	XXXXXXX	4	3	2	2		
042	XXXXXXX	24	10	13	9		
044	XXXXXXXX	1	1	1	0		
045	XXXXXXXX	6	13	8	8		
046	XXXXXXX	0	0	1	0		
047	XXXXXXX	5	4	3	3		
049	XXXXXXXX	15	12	8	6		
050	XXXXXXXXXXX	4	3	3	2		
052	XXXXXXX	1	1	0	0		
053	XXXXX	2	1	1	1		
054	XXXXXX	1	1	1	0		
056	XXX	10	10	4	3		
057	XXXXX	8	6	5	4		
058	XXXXXXXX	5	3	2	1		
059	XXXXXX	2	2	2	2		

Data source: Table 13.02 and Table 13.13b in Section 10; Appendix 13.13 in Appendix B

#### 4.2.2 Number of Patients Present at Each Visit

The numbers of patients in the ITT population who were present at each visit during the study are shown below (see Table 6 The Number (%) of ITT Patients Present at each Visit, page 48).

Table 6 The Number (%) of ITT Patients Present at each Visit

Study Visit	Treatment group			
	Paroxetine n=182	Placebo n=93		
Week 1	182 (100)	93 (100)		
Week 2	176 (96.7)	91 (97.8)		
Week 3	166 (91.2)	88 (94.6)		
Week 4	164 (90.1)	84 (90.3)		
Week 6	155 (85.2)	81 (87.1)		
Week 8	149 (81.9)	78 (83.9)		
Week 12	136 (74.7)	73 (78.5)		
Completed	127 (69.8)	69 (74.2)		

Data Source: Table 13.13b in Section 10; Appendix 13.13 in Appendix B

The proportion of patients remaining at each visit was similar for both treatment groups.

## 4.2.3 Withdrawal Reasons

In the ITT population, 55 (30.2%) patients in the paroxetine group and 24 (25.8%) patients in the placebo group, withdrew during the study. The reasons for withdrawal in each group are summarised below (see Table 7 The Number (%) of Patients in the ITT population who Completed the Study or were Withdrawn by the Reason for Study Withdrawal, page 49).

Table 7 The Number (%) of Patients in the ITT population who Completed the Study or were Withdrawn by the Reason for Study Withdrawal

	Treatment Group			
Study Conclusion Reason	Paroxetine n=182	Placebo n=93		
COMPLETED STUDY	127 (69.8)	69 (74.2)		
Withdrawal Reason				
Adverse Experiences	20 (11.0)\$	7 (7.5)*		
Lack of efficacy	9 (4.9)	6 (6.5)		
Protocol Violation	7 (3.8)	4 (4.3)*		
Lost to Follow-up	13 (7.1)	6 (6.5)		
Other	6 (3.3)	1 (1.1)		
TOTAL WITHDRAWN	55 (30.2)	24 (25.8)		

Data Source: Table 13.13b Section 10; Appendix 13.13 in Appendix B

PID 041.00289 withdrew due to AE of kidney pain during down titration period. This patient is not included in appendix 13.13

The most common reason for withdrawal in the paroxetine group was due to adverse experiences (11.0%). The patients withdrawing from the placebo group were evenly distributed across the categories.

Data Anomalies: Table 13.13b in Section 10 and Appendix 13.13 in Appendix B detailing patient withdrawals by reason for withdrawal in the ITT population states 20 patients withdrawing from the paroxetine group and 6 patients withdrawing from the placebo group due to adverse experiences. Table 15.061b in Section 12 detailing the adverse experiences leading to withdrawal states 19 patients withdrawing from the paroxetine group and 7 patients withdrawing from the placebo group. Patient 023.00170 in the paroxetine group was recorded as withdrawing due to an adverse experience, however, did not have an adverse experience with an action of drug stopped recorded. As such, this patient does not appear in table 15.061b but does appear in table 13.13b. In the placebo group, patient 029.00030 had an adverse experience with an action of drug stopped, but the reason for withdrawal was recorded as protocol violation. Consequently, this patient appears in table 15.061b but is recorded in table 13.13b as withdrawing due to protocol violation, not due to an AE. In order to assume the worst case scenario, where withdrawals from the ITT population due to adverse experiences

<sup>\*</sup> Patient 377.029.00030 experienced an AE leading to withdrawal but was wrongly recorded as withdrawing due to protocol violation. To correct for this and to ensure consistency with table 15.061b, the number of patients withdrawing due to an AE has been increased to 7 and the number withdrawing due to protocol violation reduced to 4.

<sup>\$</sup> Patient 377.023.00170 in the paroxetine group was recorded as withdrawing due to an AE but did not have an AE with an action of drug stopped recorded. In order to assume the worst case scenario, the figure of withdrawal due to an AE has been left as 20 although only 19 patients have been recorded as withdrawing due to an AE in table 15.061b.

are discussed, the figures used are 20/182 patients (11.0%) in the paroxetine group and 7/93 patients (7.5%) in the placebo group.

Details of the cumulative percentage ITT population patients withdrawn by visit during the study are shown below (see Table 8 The Cumulative Percentage Patients Withdrawn During the Study by the Reason for Withdrawal, page 50).

Table 8 The Cumulative Percentage Patients Withdrawn During the Study by the Reason for Withdrawal, ITT population

		Cumulative (%) Withdrawn						
Study Visit		Paroxeti	ne n=182			Placeb	o n=93	
When Withdrawn	AE	LOE	Other	Total	AE	LOE	Other	Total
Week 1	1.6	0.5	1.1	3.3	2.2	0.0	0.0	2.2
Week 2	4.4	1.1	3.3	8.8	3.2	1.1	1.1	5.4
Week 3	4.9	1.1	3.8	9.9	3.2	2.2	4.3	9.7
Week 4	7.7	1.6	5.5	14.8	4.3	3.2	5.4	12.9
Week 6	7.7	2.7	7.7	18.1	4.3	4.3	7.5	16.1
Week 8	8.8	4.9	11.5	25.3	6.5	6.5	8.6	21.5
Week 12	11.0	4.9	14.3	30.2	7.5*	6.5	11.8*	25.8
Endpoint								

Data Source: Table 13.13b in Section 10; Appendices 13.13 in Appendix B

KEY: AE = adverse experiences; LOE = Lack of efficacy; Other = Protocol violation, lost to follow-up and other reason

#### 4.3 Protocol Violations

#### 4.3.1 Protocol Violations Excluded from the Per Protocol Analyses

See Section 3.13.5 for a definition of the per protocol population. Randomised patients excluded from the per protocol populations and their reasons for exclusion are detailed in Appendix 13.20 in Appendix B and summarised below (see Table 9 Randomised Patients Excluded from the Per-protocol Analyses by Protocol Violation. Number (%) of Patients, page 51). Fifty-seven patients in the paroxetine randomised population (30.5%) and 31 patients in the placebo randomised population (31.3%) were excluded from the per-protocol populations.

<sup>\*</sup>Patient 377.029.00030 has been added to the AE column at week 1, and removed from the other colomn (protocol violation) to ensure consistency with the other tables

Table 9 Randomised Patients Excluded from the Per-protocol Analyses by Protocol Violation. Number (%) of Patients

_	Treatment group		
	Paroxetine	Placebo	
Protocol violation	n=187	n=99	
Long term psychotherapy during study period	18 (9.6)	8 (8.1)	
Patient received psychotropic medication	3 (1.6)	0(0.0)	
Duration of active treatment less than 6 weeks*	32 (17.1)	17 (17.2)	
Concomitant use of prohibited medications	9 (4.8)	5 (5.1)	
Not compliant on two consecutive visits	3 (1.6)	3 (3.0)	
Did not fulfill inclusion criteria	5 (2.7)	0 (0.0)	
Out of range screening lab values	2(1.1)	1 (1.0)	

Data Source: Tables 13.20 in Section 10; Appendix 13.20 in Appendix B

# 4.4 Demographic and Baseline Characteristics

# 4.4.1 Demographic Characteristics

Demographic data for the ITT and per protocol populations are summarised below (see Table 10 Demographic Data for the ITT and Per Protocol Populations, page 52). The treatment groups were well matched for all demographic parameters. Tables 13.6b, 13.7b and 13.10b in Section 10 give further details of the patient population's baseline demographics.

<sup>\*</sup> reporting and analysis plan amendment lengthened duration of active treatment from 3 to 6 weeks, this should have been reflected in the protocol as a modification

Table 10 Demographic Data for the ITT and Per Protocol Populations

Demography	Treatment groups					
	IT	T	Per-protocol			
	Paroxetine n=182	Placebo n=93	Paroxetine n=130	Placebo n=68		
Sex: number (%)						
Females	122 (67.0)	61 (65.6)	92 (70.8)	43 (63.2)		
Males	60 (33.0)	32 (34.4)	38 (29.2)	25 (36.8)		
Race: number (%)						
Black	2 (1.1)	4 (4.3)	2 (1.5)	4 (5.9)		
Caucasian	126 (69.2)	61 (65.6)	88 (67.7)	41 (60.3)		
Oriental	2 (1.1)	0(0.0)	2 (1.5)	0(0.0)		
Other	52 (28.6)	28 (30.1)	38 (29.2)	23 (33.8)		
Age: years						
Mean age (sd)	15.5 (1.6)	15.8 (1.6)	15.5 (1.6)	15.7 (1.5)		
Age range	*12-19	13-18	13-18	13-18		
Height						
Mean height (sd)	163.6 (9.1)\$	164.5 (8.5)	162.7 (8.7)\$	164.2 (9.0)		
Height range	140-185	131-184	142-185	131-184		

Data source: Tables 13.2b and 13.2c in Section 10; Appendix 13.2 in Appendix B

#### 4.4.2 Baseline Characteristics

The psychiatric history of the patients is summarised in table 13.4b in Section 10. 29.1% of patients in the paroxetine treated group and 31.2% in the placebo group had had a previous episode or suspected previous episode of major depression. Table 13.5b in Section 10 summarises the family composition and shows that 50.5% of patients in the paroxetine group and 51.6% in the placebo group resided at home with both parents. The mean baseline MADRS scores for both the paroxetine group and the placebo group at baseline were 25.9 (s.e. = 0.5 and 0.6 respectively). This score indicates a moderately to severely ill population. At baseline, 33.7% of patients in the paroxetine group and 39.3% of patients in the placebo groups (ITT LOCF) were either markedly or severely ill as measured by the CGI Severity of illness item.

<sup>\*</sup> Patients 377.026.00200, 377.029.00040, and 377.057.00532 were 12 years old when recruited into the study and were excluded from the per-protocol population as protocol violators.

n = 180 and 128 for the ITT and PP populations respectively

# 4.5 Presenting Conditions and Medical History

# 4.5.1 Medical/Surgical History and Physical Examination at Baseline

Table 13.3b (Section 10) contains a summary of ITT patients medical/surgical history data at Baseline, and Appendix 13.3 in Appendix B contains the data listing by patient.

Table 13.3.2b contains a summary of ITT patients significant medical/surgical history data which were past, ongoing or past and ongoing. In the paroxetine group, 64 patients (35.2%) had a medical history compared with 37 patients (39.8%) in the placebo group. The most common condition in the paroxetine group was asthma (5.5%). In the placebo group the most common conditions were headache and nose/mouth operations, both 5.4%.

Active medical conditions on entry to the study were recorded for 45 paroxetine patients (24.7%) and 27 placebo patients (29.0%). The most common condition for paroxetine patients was asthma (4.9%). For placebo patients the most common conditions were allergic rhinitis (4.3%) and skin disorders (4.3%).

## **4.5.2 Previous Psychiatric History**

The previous psychiatric conditions for ITT patients by treatment group are summarised below (see Table 11 Psychiatric History. Number (%) of Patients, page 53).

Table 11 Psychiatric History. Number (%) of Patients

	Treatment group					
	Paro	xetine	Placebo			
Disorder	n=	182	n=	=93		
	Yes	Suspected	Yes	Suspected		
Major episode of depression	39 (21.4)	14 (7.7)	19 (20.4)	10 (10.8)		
Schizophrenia	0(0.0)	0(0.0)	0(0.0)	0(0.0)		
Alcoholism or drug/medication abuse*	4 (2.2)	0(0.0)	3 (3.2)	1 (1.1)		
Anxiety/obsessional disorder	13 (7.1)	6 (3.3)	9 (9.7)	2 (2.2)		
Personality disorder	2(1.1)	3 (1.6)	0 (0.0)	0 (0.0)		
Data Source: Tables 13.4b in Section 10: Apr	pendix 13.4 in A	ppendix B	•	-		

<sup>\*</sup> not within the previous 6 months

# 4.6 Baseline Signs and Symptoms

Baseline signs and symptoms i.e. adverse experiences that occurred prior to randomisation, were not reported for this study.

#### 4.7 Prior and Concomitant Medications

Appendix 13.11 in Appendix B details prior and concomitant medications by WHO ATC classification and generic term, and by treatment group and patient respectively, and the results are summarised for the ITT populations in Tables 13.11b (prior medications) and 13.12b (concomitant medications) in Section 10. Prior medications are those which were received prior to starting the study including those that were continued into the study. Concomitant medications are those that were initiated during the study.

In the paroxetine group, 18.7% of patients received at least one prior medication compared with 20.4% of placebo patients, and 42.9% of paroxetine patients received at least one concomitant medication compared with 41.9% of placebo patients. The most common prior and concomitant medications are presented below (see Table 12 Prior and Concomitant Medications used by 3 or More Patients in Either Treatment Group. Number (%) of Patients, page 55).

Table 12 Prior and Concomitant Medications used by 3 or More Patients in Either Treatment Group. Number (%) of Patients

Medications	Treatme	ent groups
_	Paroxetine	Placebo
	n=182	n=93
Prior medications		
Ethinylestradiol	13 (7.1)	7 (7.5)
Salbutamol	7 (3.8)	0(0.0)
Cyproterone Acetate	5 (2.7)	1 (1.1)
Paracetamol	5 (2.7)	2 (2.2)
Beclomethasone Dipropionate	4 (2.2)	0(0.0)
Gestodene	3 (1.6)	2 (2.2)
Desogestrel	2 (1.1)	3 (3.2)
<b>Concomitant Medications</b>		
Paracetamol *	31 (17.0)	20 (21.5)
Codeine Phosphate*	13 (7.1)	3 (3.2)
Acetylsalicylate Acid	11 (6.0)	6 (6.5)
Caffeine	6 (3.3)	1 (1.1)
Pseudoephedrine Hydrochloride	6 (3.3)	1 (1.1)
Ibuprofen *	6 (3.3)	9 (9.7)
Phenylephrine hydrochloride	5 (2.7)	4 (4.3)
Cyclizine Hydrochloride*	4 (2.2)	1 (1.1)
Amoxicillin	4 (2.2)	0(0.0)
Amoxicillin Trihydrate	3 (1.6)	1 (1.1)
Ampicillin	3 (1.6)	1 (1.1)
Ascorbic Acid	3 (1.6)	0(0.0)
Chlorphenamine Maleate	3 (1.6)	2 (2.2)
Dextromethorphan hydrobromide	3 (1.6)	0(0.0)
Dimenhydrinate	3 (1.6)	1 (1.1)
Ethinylestradiol	3 (1.6)	1 (1.1)
Etilefrine Hydrochloride	3 (1.6)	2 (2.2)
Guaifenesin	3 (1.6)	0 (0.0)
Levonorgestrel	3 (1.6)	0 (0.0)
Triprolidine Hydrochloride	3 (1.6)	1 (1.1)

Data source: Tables 13.11b and 13.12b in Section 10; Appendix 13.11, in Appendix B

Nine paroxetine patients and 5 placebo patients received prohibited medications (SSRIs, benzodiazepines and other psychoactive medication) after the screening date.

<sup>\*</sup> medication appears under more than 1 ATC classification so numbers have been added together

# 4.8 Treatment Compliance

Details of study medication taken during the study are shown in Appendix 13.21 in Appendix B. As a guideline, non-compliance was defined in the protocol as taking <80% or >120% of the prescribed paroxetine or placebo study medication at each of 2 consecutive visits. Three paroxetine patients (1.6% of the ITT population) and 3 placebo patients (3.2% of the ITT population) were non-compliant.

# **5 Efficacy Results**

# 5.1 Efficacy Evaluation

# 5.1.1 Data Sets Analysed

Definitions of the ITT and per-protocol efficacy populations are given in Section 3.13.5.

The primary analysis population for the study was the intention-to-treat population using the LOCF datasets, with the LOCF Week 12 timepoint being the primary timepoint of interest. In the OC dataset, efficacy data were evaluated only for the timepoint when it was collected. In the LOCF dataset, the last available on-therapy observation for a patient was used to estimate missing data points (last observation carried forward, or LOCF). A confirmatory analysis based on the per protocol analysis was carried out on the primary efficacy variables.

Fifty-two paroxetine patients and 25 placebo patients were excluded from the respective ITT populations to make the per-protocol population (see Section 4.3.1 for details of reasons for exclusion).

# 5.2 Primary Efficacy Parameters

#### **5.2.1** Montgomery Asberg Depression Rating Scale (MADRS)

Full details of the MADRS results are given in Appendix 14.01 in Appendix C and summaries of MADRS scores are shown in Tables 14.01b, c, d and e; 14.02b, c, d and e; 14.03b and d; 14.05b and d; 14.06b and d and 14.07b and d in Section 11. Appendix 14.01.01 contains the details of the MADRS scores from the patients recruited in centre 007 only. These patients were excluded from the efficacy analyses for all efficacy parameters.

One of the primary efficacy parameters for this study was the proportion of ITT patients with a 50% or greater reduction in MADRS score between baseline and study endpoint. The results for the ITT and per-protocol populations are shown below (see Table 13 The Proportions of Patients with ≥50% Reduction from Baseline in Total MADRS Score at Study Endpoint (ITT and Per-protocol Populations), page 58)

Table 13 The Proportions of Patients with ≥50% Reduction from Baseline in Total MADRS Score at Study Endpoint (ITT and Per-protocol Populations)

Dataset	Treatmen				
	Paroxetine Proportion of responders n/N	Placebo Proportion of responders n/N	Adjusted Odds Ratio	95% CI (Paroxetine/ Placebo	P- value
ITT					
LOCF	107/177 (60.45%)	53/91 (58.24%)	1.109	(0.653, 1.884)	0.702
OC	94/126 (74.60%)	47/66 (71.21%)	1.161	(0.590, 2.285)	0.666
Per-Protocol					
LOCF	91/130 (70.00%)	45/68 (66.18%)	1.171	(0.613, 2.237)	0.633
OC	82/108 (75.93%)	40/56 (71.43%)	1.195	(0.567, 2.516)	0.639
Data Source: Tables 1	4.01b, c,d and e in Section	on 11; Appendix 14.0	1 in Appendix	x C; Appendix I	
•	ts with ≥50 reduction in 1		y endpoint		
N = Total number of j	patients in the treatment g	group at that time			

Despite a 60.5% response rate in the ITT LOCF paroxetine treated group, 58.2% of placebo treated patients also achieved a 50% reduction in their baseline MADRS score and as such paroxetine was not statistically or clinically superior to placebo. These results were confirmed by the per protocol LOCF analysis where 70.0% of the paroxetine group responded and 66.2% of the placebo treated patients (See Appendix I).

The following assessment of interactions were performed; treatment by country group, treatment by baseline score, treatment by age, age by country group, age by baseline score and baseline score by country group. The only statistically significant interaction found was treatment by age (p=0.002; ITT LOCF). When this was analysed further by splitting the data by prospectively defined age groups (≤ 16 and > 16 years old) it appears that in the younger age group, the proportion of responders was higher in the placebo group than in the paroxetine group at each visit, although these differences were not statistically significant. However in the older age group, the proportion of responders was higher in the paroxetine group at each visit, although the numbers of patients were too low for a formal statistical analysis using the final model. This was confirmed in the OC dataset and in the per-protocol population. Details of all the covariate analyses can be found in the Statistical Appendix in Appendix I.

Table14 Proportion of Patients with a >= 50% reduction in MADRS Total Score by Age Group at Week 12

Age Group ≤ 16 years Old						
Dataset	Paroxetine	Placebo	Adjusted	95% CI	P-value	
	Proportion of	Proportion of	Odds	(Paroxetine		
	Responders	Responders	Ratio	/Placebo)		
LOCF	65/118 (55.08%)	37/57 (64.91%)	0.609	(0.309,1.201)	0.153	
OC	56/80 (70.00%)	33/45 (75.33%)	0.815	(0.355, 1.870)	0.629	
Age Group > 16 years Old						
Dataset	Paroxetine	Placebo	Adjusted	95% CI	P-value	
	Proportion of	Proportion of	Odds	(Paroxetine		
	Responders	Responders	Ratio	/Placebo)		
LOCF	42/59 (71.19%)	16/34 (47.06%)	-	-	-	
OC	38/46 (82.61%)	14/21 (66.67%)	-	-	-	

 $NB-Model\ could\ not\ be\ fitted\ due\ to\ lack\ of\ responders\ per\ treatment\ group/country\ combination.$ 

The odds ratios, confidence intervals and p-values were obtained using logistic regression adjusting for country group, baseline MADRS total score and age (in years).

To further understand the data and the age by treatment interaction observed, the response data were plotted by country group. Figure 1 represents the proportion of patients responding by treatment and country group and it can be seen that the proportion of patients responding is higher in the paroxetine group in all country groups except Africa, where the proportion is higher on placebo (See Appendix I).




Figure 1 Proportion of patients responding (achieving >= 50% reduction in MADRS total score) (ITT)

In contrast, when analysing the proportion of younger patients (<=16 years) responding by treatment group and country group (see Figure 2) it can be seen that the proportion of younger patients responding is higher in the placebo group in all country groups except the Middle East, where the proportion remains higher on paroxetine (See Appendix I).




Figure 2 Proportion of patients responding age <= 16 (achieving >= 50% reduction in MADRS total score) (ITT)

However, in the older age group (see Figure 3) the proportion of patients responding is higher in the paroxetine group in Europe/Canada and South America, but in Africa, the proportion of older patients responding remains higher on placebo. In the Middle East, all the patients responded although caution should be exercised when interpreting results from this country group due to the low numbers, particularly in the placebo group (See Appendix I).




Figure 3 Proportion of patients responding age >16 (achieving >= 50% reduction in MADRS total score) (ITT)

Although no country by treatment group interaction was detected, these figures show the considerable variability in the response pattern observed within different country groups and age groups.

## 5.2.2 Kiddie-SADS-Lifetime (K-SADS-L) Depression Subscale

Full details of the K-SADS-L results are given in Appendix 14.04 in Appendix C and summaries of mean change from baseline in the K-SADS L depressive subscale are shown in Tables 14.04b, c, d and e; 14.08b and d; 4.09b and d and 14.010b and d in Section 11. The full details of the K-SADS-L for patients from centre 007 are given in Appendix 14.04.01 in Appendix C.

One of the primary efficacy parameters for this study was the change from baseline to study endpoint in K-SADS-L depression subscale. The results for the ITT and per-protocol populations and the Baseline K-SADS-L depression subscale scores are shown below (see Table 15 Change from Baseline to Study Endpoint in K-SADS-L Depression Subscale (ITT and Per Protocol Populations), page 63).

Table 15 Change from Baseline to Study Endpoint in K-SADS-L Depression Subscale (ITT and Per Protocol Populations)

Dataset	Treatment groups					
	Paroxetine N, adjusted mean (S.E.)	Placebo N, adjusted mean (S.E.)	Difference in Adjusted Means	95% CI (Paroxetine/ Placebo	P- value	
ITT						
LOCF	171, -9.330 (0.54)	88,-8.923 (0.70)	-0.408	(-2.007, 1.192)	0.616	
OC	126, -10.824 (0.49)	66,-10.167 (0.63)	-0.657	(-2.126,0.812)	0.379	
Per-Protocol						
LOCF	130,-9.949 (0.51)	68,-9.603 (0.68)	-0.347	(-1.952,1.259)	0.671	
OC	108,-10.600 (0.49)	56,-10.295 (0.64)	-0.304	(-1.831,1.223)	0.694	

Data source: Tables 14.04b, c,d and e in Section 11; Appendices 14.04 and 14.04.01 in Appendix C; Appendix I

The p-values were obtained using analysis of covariance adjusting for country group, baseline K-SADS-l depression subscale score and age (in years). The confidence intervals were obtained using adjusted means.

Again despite a 9.3 point drop from baseline in the K-SADS-L score in the paroxetine treated patients, the placebo group score decreased by 8.9 points (ITT LOCF). The difference in the adjusted means of –0.41 (see appendix I) was not clinically or statistically significant. This was reflected in the per-protocol population.

As with the other primary efficacy variable (see appendix I) the only statistically significant interaction found was treatment by age (p=0.020; ITT LOCF). In the older age group (>16 years of age) the mean change from baseline was larger in the paroxetine group at each visit and this was statistically significant at week 8 (p=0.019). In the younger age group (<=16 years of age), mean change from baseline was larger in the placebo group than in the paroxetine group although observed differences were not statistically significant. These results support those observed for the other primary efficacy variable.

Table 16 Change from Baseline in K-SADS-L Depression Subscale Score by Age Group, ITT LOCF Population

Age Group ≤ 16 years old						
Week	Paroxetine	Placebo	Difference	95% C.I.	P-value	
	N, adjusted	N, adjusted	in adjusted	(Paroxetine/		
	mean (S.E.)	mean (S.E.)	means	Placebo)		
6	113,-6.664	55, -7.846	1.182	(-0.621, 2.985)	0.197	
	(0.57)	(0.78)				
8	113, -7.828	55,-8.876	1.049	(-0.766, 2.863)	0.256	
	(0.57)	(0.78)				
12	113,-8.42	55,-9.38	0.968	(-0.954, 2.891)	0.321	
	(0.61)	(0.83)				
Age Group > 16 years old						
Week	Paroxetine	Placebo	Difference	95% C.I.	P-value	
	N, adjusted	N, adjusted	in adjusted	(Paroxetine –		
	mean (S.E.)	mean (S.E.)	means	Placebo)		
6	58,-9.454	33,-6.864	-2.590	(-5.266, 0.085)	0.058	
	(1.15)	(1.35)				
8	58,-10.127	33,-6.850	-3.277	(-5.997, -0.558)	0.019*	
	(1.17)	(1.37)				
12	58,-11.163	33,-8.438	-2.725	(-5.641, 0.192)	0.067	
	(1.25)	(1.47)				
Data Source: Appendix I						

Data Source: Appendix I

\* = significance at the 5% level

Table 17 Change from Baseline in K-SADS-L Depression Subscale Score by Age Group, ITT OC Population

Age Group ≤ 16 years old						
Week	Paroxetine	Placebo N,	Difference	95% C.I.	P-value	
	N, adjusted	adjusted	in adjusted	(Paroxetine		
	mean (S.E.)	mean (S.E.)	means	<ul><li>Placebo)</li></ul>		
6	97,-7.285	51,-7.930	0.645	(-1.208,	0.493	
	(0.59)	(0.78)		2.498)		
8	93,-8.796	49,-8.98	0.183	(-1.558,	0.836	
	(0.55)	(0.73)		1.923)		
12	80,-10.081	45,-9.797	-0.285	(-2.141,	0.762	
	(0.61)	(0.77)		1.571)		
Age Gro	oup > 16 years	old				
Week	Paroxetine	Placebo N,	Difference	95% C.I.	P-value	
	N, adjusted	adjusted	in adjusted	(Paroxetine		
	mean (S.E.)	mean (S.E.)	means	<ul><li>Placebo)</li></ul>		
6	49,-9.980	26,-7.974	-2.006	(-4.689,	0.140	
	(1.06)	(1.31)		0.677)		
8	50-11.148	23,-9.166	-1.983	(-4.293,	0.091	
	(0.87)	(1.13)		0.328)		
12	46,-12.060	21,-10.899	-1.161	(-3.681,	0.360	
	(0.93)	(1.20)		1.358)		

Data Source: Appendix I

The p-values were obtained using analysis of covariance adjusting for country group, baseline K-SADS-L depression subscale score and age 9in years). The confidence intervals were obtained using adjusted means.

# **5.3 Secondary Efficacy Parameters**

#### **5.3.1 MADRS**

Full details of the MADRS results are given in Appendix 14.01 in Appendix C and summaries of MADRS scores are shown in Tables 14.01b, c, d and e; 14.02b, c, d and e; 14.03b and d; 14.05b and d; 14.06b and d and 14.07b and d in Section 11. Appendix 14.01.01 contains the details of the MADRS scores from the patients recruited in centre 007 only.

#### ≥50% Reduction in MADRS Score

The proportion of patients with a 50% or greater reduction in MADRS score between baseline and weeks 6 and 8 was a secondary efficacy parameter. The results are shown below .

Table 18 Proportion of Patients with a 50% or Greater Reduction in MADRS Total Score at Weeks 6 and 8, ITT LOCF Population

(see Patient Disposition and Key Demographic Data, page 5)

Week	Paroxetine	Placebo	Adjusted	95% C.I.	P-value
	Proportion of	Proportion of	Odds	(Paroxetine/	
	responders	responders	Ratio	Placebo)	
6	73/177	33/91	1.242	(0.728, 2.119)	0.427
	(41.24%)	(36.26%)			
8	97/177	45/91	1.261	(0.750, 2.121)	0.382
	(54.80%)	(49.45%)			

Data Source: Tables 14.01b and d and 14.03b and d in Section 11; Appendix 14.01 and 14.01.01 in Appendix C; Appendix I

Again, despite 41.2% of paroxetine patients achieving a 50% reduction in their MADRS score at week 6, this was in comparison with 36.3% of patients in the placebo group. At week 8, these figures were 54.8% and 49.5% for paroxetine and placebo respectively. These differences were not statistically significant (see appendix I).

 $N = Number of patients with \ge 50 reduction in MADRS score at study endpoint$ 

n = Total number of patients in the treatment group at that time

### Change from Baseline in MADRS Score

Change from baseline in MADRS total score was analysed at weeks 6, 8 and study endpoint. Results are shown below (see (see Table 19 Change from Baseline in MADRS Total Score at Weeks 6, 8 and Study Endpoint (ITT Population), page 67)).

Table 19 Change from Baseline in MADRS Total Score at Weeks 6, 8 and Study Endpoint (ITT Population)

Week	Paroxetine	Placebo N,	Difference	95% C.I.	P-value
	N, adjusted	adjusted	in adjusted	(Paroxetine –	
	mean (S.E.)	mean (S.E.)	means	Placebo)	
6	177,-10.466	91,-9.926	-0.540	(-2.725, 1.645)	0.627
	(0.73)	(0.95)			
8	177,-12.383	91, 11.009	-1.374	(-3.773, 1.025)	0.260
	(0.80)	(1.05)			
12	177, -13.604	91, -12.796	-0.809	(-3.278, 1.661)	0.520
	(0.82)	(1.08)			

Data source: Tables 14.03b and 14.03d in Section 11; Appendices 14.01 and 14.01.01 in Appendix C; Appendix I

No overall statistically significant treatment differences were observed.

Again, a statistically significant interaction was found with the treatment by age covariate, (p=0.059; ITT LOCF), see Appendix I. As for the primary efficacy variables, an analysis by age group was performed. In the >16 years of age group, the difference in the adjusted means at week 8 of –5.870 was statistically significant in favour of paroxetine (p=0.006). In the <=16 years of age group, a similar pattern to the primary efficacy variables was observed i.e a greater mean change was observed in the placebo group than in the paroxetine group although again these differences were not statistically significant.

**Table 20 Change from Baseline in MADRS Total Score by Age Group, ITT LOCF Population** 

Age Gro	oup ≤ 16 years o	ld			
Week	Paroxetine N, adjusted	Placebo N, adjusted	Difference in	95% C.I. (Paroxetine -	P-value
	mean (S.E.)	mean (S.E.)	adjusted means	Placebo)	
6	118, -9.394 (0.86)	57, -10.252 (1.19)	0.859	(-1.894, 3.610)	0.539
8	118,-11.124 (0.92)	57, -12.411 (1.27)	1.287	(-1.649, 4.223)	0.388
12	118, -12.584 (0.95)	57, -13.50 (1.30)	0.910	(-2.108, 3.929)	0.552
Age Gro	oup > 16 years o	ld			
Week	Paroxetine N, adjusted mean (S.E.)	Placebo N, adjusted mean (S.E.)	Difference in adjusted means	95% C.I. (Paroxetine - Placebo)	P-value
6	59, -12.503 (1.60)	34, -9.755 (1.90)	-2.748	(-6.43, 0.94)	0.142
8	59, -14.351 (1.81)	34, -8.481 (2.15)	-5.870	(-10.045, - 1.696)	0.006*
12	59, -15.515 (1.93)	34, -11.788 (2.28)	-3.728	(-8.164, 0.708)	0.098
	e: Appendix I ant at the 5% level				

Results from the OC analyses confirmed those observed in the LOCF dataset. However, a treatment by age interaction was not detected for this OC dataset but to maintain consistency, analyses by age group were performed and results can be found in the Statistical Appendix I.

### 5.3.2 Clinical Global Impression (CGI)

### Severity of Illness

Full details of the CGI severity of illness results are given in Appendices 14.10 and 14.10.01 (centre 007 only) in Appendix C and summaries of CGI severity of illness results are shown in Tables 14.10b and d and 14.11b and d in Section 11.

Change from baseline in CGI severity of illness score was analysed at weeks 6, 8 and study endpoint. The results are shown below (see Table 21 Change from Baseline in CGI Severity of Illness Score, ITT LOCF Population, page 69).

**Table 21 Change from Baseline in CGI Severity of Illness Score, ITT LOCF Population** 

Week	Paroxe	etine		Place	bo		P-value
	N	Mean	Median	N	Mean	Median	
6	172	-1.41	-1.0	89	-1.28	-1.0	0.38
8	172	-1.65	-2.0	89	-1.46	-1.0	0.35
12	172	-1.91	-2.0	89	-1.82	-2.0	0.85

Data source: Tables 14.11b and d in Section 11; Appendices 14.10 and 14.10.01 in Appendix C; Appendix I

N.B. The means and medians are based on the changes in the actual CGI Severity of Illness scores. However, the p-values were obtained using the Wilcoxon rank-sum test (i.e the analysis was performed on the ranked values)

As for the other efficacy variables, the change from baseline for the LOCF paroxetine group at week 6 (-1.4), week 8 (-1.6) and week 12 (-1.9) was not statistically significantly different from that in the placebo group (-1.3, -1.5 and – 1.8 respectively). This was also reflected in the OC dataset.

Due to the non-parametric analysis performed (see appendix I), treatment by age interaction could not be assessed for this parameter. However, to maintain consistency with the other variables, the results were also presented by age group. In the >16 age group at week 8, there was a statistical difference in favour of paroxetine (p=0.043).

**Table 22 Change from Baseline in CGI Severity of Illness Score by Age Group, ITT LOCF Population** 

Age Gro	oup ≤ 16	years old					
Week	Paroxe	etine		Place	bo		P-value
	N	Mean	Median	N	Mean	Median	
6	114	-1.32	-1.0	56	-1.29	-1.0	0.80
8	114	-1.50	-2.0	56	-1.55	-1.0	0.68
12	114	-1.78	-2.0	56	-1.93	-2.0	0.34
Age Gro	oup > 16	years old					
Week	Paroxe	etine		Place	bo		P-value
	N	Mean	Median	N	Mean	Median	
6	58	-1.60	-2.0	33	-1.27	-1.0	0.24
8	58	-1.93	-2.0	33	-1.30	-1.0	0.04*
12	58	-2.16	-2.5	33	-1.64	-1.0	0.14
Data Sourc	e: Appendi	хI					

N.B. The means and medians are based on the changes in the actual CGI Severity of Illness scores. However, the p-values were obtained using the Wilcoxon rank-sum test (i.e the analysis was performed on the ranked values)

### Global Improvement

Full details of the CGI global improvement results are given in Appendices 14.10 and 14.10.01 in Appendix C and summaries of CGI global improvement results are shown in Tables 14.12b and d and 14.13b and d in Section 11.

CGI global improvement score was analysed at weeks 6, 8 and study endpoint . The results are shown below (see Table 23 CGI Global Improvement Score, ITT LOCF Population, page 71) .

Table 23 CGI Global Improvement Score, ITT LOCF Population

Week	Category	Paroxetine	Placebo
Week 6 (p=0.279)	Very much improved Much improved Minimally improved No change Minimally worse Much worse Very much worse Total	35 (20.35%) 63 (36.63%) 38 (22.09%) 22 (12.79%) 5 (2.91%) 9 (5.23%) 0 (0.00%) 172	15 (16.85%) 29 (32.58%) 25 (28.09%) 13 (14.61%) 6 (6.74%) 1 (1.12%) 0 (0.00%) 89
Week 8 (p=0.416)	Very much improved Much improved Minimally improved No change Minimally worse Much worse Very much worse Total	52 (30.23%) 53 (30.81%) 32 (18.60%) 20 (11.63%) 5 (2.91%) 9 (5.23%) 1 (0.58%) 172	27 (30.34%) 18 (20.22%)
Week 12 (p=0.283)	Very much improved Much improved Minimally improved No change Minimally worse Much worse Very much worse Total	71 (41.28%) 48 (27.91%) 20 (11.63%) 18 (10.47%) 8 (4.65%) 6 (3.49%) 1 (0.58%) 172	32 (35.96%) 19 (21.35%) 15 (16.85%) 16 (17.98%) 6 (6.74%) 1 (1.12%) 0 (0.00%)

these p values were obtained from a Cochran Mantel-Haenszel test stratified by country group

There were no statistically significant treatment differences observed (see appendix I). Due to the non-parametric analysis performed (see appendix I), treatment by age interaction could not be assessed for this parameter. However, to maintain consistency with the other variables, the results were also presented by age group (See Appendix i).

### **5.3.3** Beck Depression Inventory (BDI)

Full details of the BDI results are given in Appendices 14.20 and 14.20.01 in Appendix C and summaries of BDI results are shown in Tables 14.20b and 14.20d in Section 11.

Change from baseline in BDI scores were analysed at week 6, 8 and study endpoint. The results are shown below (see Table 24 Change from Baseline in BDI Score at Weeks 6, 8 and Study Endpoint (ITT LOCF Population), page 72).

Table 24 Change from Baseline in BDI Score at Weeks 6, 8 and Study Endpoint (ITT LOCF Population)

Week	Paroxetine	Placebo N,	Difference	95% C.I.	P-value
	N, adjusted	adjusted	in adjusted	(Paroxetine -	
	mean (S.E.)	mean (S.E.)	means	Placebo)	
6	174, -10.179	90, -10.272	0.093	(-2.316, 2.502)	0.940
	(0.80)	(1.05)			
8	174, -11.573	90, -11.182	-0.391	(-2.864, 2.082)	0.756
	(0.82)	(1.08)			
12	174, -12.504	90, -12.074	-0.430	(-2.923, 2.062)	0.734
	(0.82)	(1.08)			

Data source: Tables 14.20b and d in Section 11; Appendices 14.20 and 14.20.01 in Appendix C; Appendix I

As for the other efficacy variables, the difference in the adjusted means (Appendix I) was not statistically significant at week 6, 8 or 12.

In the ITT LOCF dataset, a statistically significant treatment by country group interaction was observed at week 12 (p=0.094). When split by country group at week 12 it can be seen that in the African country group, the mean change from baseline was larger in the placebo group that in the paroxetine group at week 12. However, in the other country groups, the mean change from baseline was larger in the paroxetine group. This effect was also seen, to a lesser degree, in the primary parameters (see appendix I), and supports the idea of some evidence of variability across country groups. No treatment by country group interaction was observed in the OC dataset analysis.

A statistically significant baseline score by country group interaction was also observed at week 12. (p=0.064). The mean baseline score in the Middle Eastern country group was much smaller in the placebo group than in the paroxetine group but due to the low numbers of patients, particularly in the placebo group, this was not investigated further.

No significant treatment by age interaction was observed. However, to maintain consistency with other variables, results by age group can be found in the Statistical Appendix I.

#### 5.3.4 Mood and Feelings Questionnaire (MFQ)

Full details of the MFQ results are given in Appendices 14.30 and 14.30.01 (centre 007 only) in Appendix C and summaries of MFQ results are shown in Tables 14.30b and 14.30d in Section 11.

Change from baseline in MFQ score at weeks 6, 8 and study endpoint was analysed. The results are shown below (see Table 25 Change from Baseline in MFQ Score at Weeks 6, 8 and Study Endpoint (ITT LOCF Population), page 73).

Table 25 Change from Baseline in MFQ Score at Weeks 6, 8 and Study Endpoint (ITT LOCF Population)

Week	Paroxetine	Placebo N,	Difference	95% C.I.	P-value
	N, adjusted	adjusted	in adjusted	(Paroxetine/	
	mean (S.E.)	mean (S.E.)	means	Placebo)	
6	169, -12.777	88, 12.185	-0.592	(-3.893, 2.708)	0.724
	(1.10)	(1.44)			
8	169, -15.240	88, -15.257	0.018	(-3.573, 3.608)	0.992
	(1.20)	(1.56)			
12	169, -16.416	88, -15.678	-0.738	(-4.271, 2.794)	0.681
	(1.18)	(1.54)			

Data source: Tables 14.30b and d in Section 11; Appendices 14.30 and 14.30.01 in Appendix C; Appendix I

As for the other efficacy variables, the difference in the adjusted means at week 12 ITT LOCF of -0.74, was not statistically significant.

A statistically significant baseline score by country group interaction was observed at week 12 (p=0.054). As for the previous efficacy parameter, the mean baseline score in the Middle Eastern country group was much smaller in the placebo group than in the paroxetine group but for the reasons discussed earlier, this imbalance was not investigated further.

As for the primary efficacy variables, a statistically significant treatment by age interaction was observed (p=0.055) at week 12 LOCF. As before, analyses were repeated by age group and similar patterns of response to the primary efficacy

parameters were observed i.e in the older age group, the mean change from baseline was larger in the paroxetine group at each visit although these differences from baseline were not statistically significant, and in the younger age group, the mean change from baseline was larger in the placebo group This interaction was not observed in the OC dataset.

A statistically significant baseline score by country group interaction was observed at week 12 (p=0.054). As for the analysis of BDI scores, an imbalance of baseline scores in the Middle East country group appeared to be the cause of this observed interaction. This interaction was not investigated further due to low numbers (particularly in the placebo group)

**Table 26 Change from Baseline in MFQ Total Score by Age Group, ITT LOCF Population** 

Age Gro	oup ≤ 16 years o	ld			
Week	Paroxetine N, adjusted mean (S.E.)	Placebo N, adjusted mean (S.E.)	Difference in adjusted means	95% C.I. (Paroxetine – Placebo)	P-value
6	112, -11.385 (1.31)	56, -12.503 (1.77)	1.118	(-3.014, 5.249)	0.594
8	112, -13.478 (1.47)	56, -16.361 (1.98)	2.882	(-1.749, 7.514)	0.221
12	112, -15.121 (1.38)	56, -16.609 (1.87)	1.489	(-2.885, 5.862)	0.502

Age Gro	up > 16 years o	ld			
Week	Paroxetine N, adjusted	Placebo N, adjusted	Difference in adjusted	95% C.I. (Paroxetine –	P-value
	mean (S.E.)	mean (S.E.)	means	Placebo)	
6	57, -15.268	32, -12.186	-3.082	(-8.717, 2.553)	0.280
	(2.37)	(2.85)			
8	57, -18.502	32, -13.660	-4.842	(-10.616,	0.099
	(2.43)	(2.92)		0.931)	
12	57, -19.116	32, -15.009	-4.107	(-10.276,	0.189
	(2.60)	(3.12)		2.062)	
Data source:	Appendix I				

### 5.4 Pharmacoeconomic Variables

### **5.4.1** Nottingham Health Profile (NHP)

Full details of the NHP are given in Appendices 14.41, 14.42 and 14.43 (14.41.01, 14.42.02 and 14.43.01 give details for the centre 007 patients only) in Appendix C and summaries of NHP results are shown in tables 14.50b and d, 14.51b and d, 14.52b and d, 14.53b and d, 14.54b and d, 14.55b and d and 14.56b and d in section 11.

The mean change (s.e.) from baseline at endpoint in the total scores was -0.17 (0.02) for paroxetine compared with -0.19 (0.02) for placebo in the ITT LOCF dataset. This result was mirrored in all the separate domains of the scale, with no difference being found between paroxetine and placebo in the energy, emotional reaction, pain, physical mobility, sleep or social isolation domains. No statistical analyses were performed on this data.

#### 5.4.2 Eurogol

Full details of the Euroqol are given in Appendices 14.60 and 14.60.01 (details for centre 007 patients only) in Appendix C and summaries of Euroqol results are shown in tables 14.60b and 14.61b in Section 11.

The Euroqol data was collected at baseline and Week 12 only, hence no LOCF dataset was constructed for this variable. In the paroxetine group there was a mean increase (improvement) from baseline of 22.1 points at Week 12 versus a mean increase of 24.0 points in the placebo group. There was no clinically relevant difference between paroxetine and placebo.

#### **5.4.3** Socio-Economic Questionnaire

Appendices 14.70 to 14.75 in Appendix C give full details of the socio-economic questionnaire and summaries can be found in Tables 14.70b, 14.71b, 14.72b, 14.73b, 14.74b, 14.75b and 14.76b in Section 11. The two treatment groups were well matched at baseline.

Again, both groups were well matched at baseline with respect to the patients current employment status. Slightly more patients in the paroxetine group than the placebo group were attending school and slightly more patients in the placebo group than the paroxetine group attending college or further education. These differences were not clinically significant. No differences between the groups were detected at endpoint.

# 5.5 Psychotherapy Evaluation

Appendices 14.81, 14.81.01, 14.82 and 14.82.01 give full details of the psychotherapy evaluation and summaries of the ITT population can be found in Tables 14.81b and 14.82b. At baseline, no clinically significant differences were seen between the groups in either the number of patients receiving professional involvement or in the therapy that they were receiving. At week 12, the proportion of patients receiving psychotherapy had reduced in both groups to 1.5%.

### 5.6 Child Global Assessment Scale

Appendices 14.90 and 14.9.1 give full details of the child global assessment scale and summaries of the ITT population can be seen in Table 14.90b. At week 12, the mean score in both groups had decreased, by 52.1% in the paroxetine group and 55.5% in the placbo groups. There was difference between the groups either at baseline or at week 12.

# 6 Safety Results

Throughout this section, results for the ITT population have been presented (see section 3.13.5 Populations/Data sets to have Evaluated). Table 13.00 in Section 10 lists the patients for whom narratives have been written, which include non-fatal serious adverse experiences and withdrawals due to adverse experiences. There were no deaths on study.

# **6.1 Extent of Exposure**

Details of study medication data are shown in Appendix 13.14 in Appendix B. The doses and summary statistics of dose levels during the study are summarised in Tables 13.14b, 13.15b, 13.16b, 13.17b, 13.18b in Section 10 and shown below (see Table 27 Extent of Exposure to Study Drug, page 77).

**Table 27 Extent of Exposure to Study Drug** 

			Treatmen	it group		
	Paro	xetine n=1	81*	P	acebo n=9	93
Maximum dose	20mg	30mg	40mg	1	2	3
level						
n (%)	103 (56%)	46 (25%)	32 (17%)	52 (55%)	18 (19%)	23 (24%)
Mean (SD)	2	26.1mg (7.7)				
Mean dose on active	2	23.9mg (5.2)				
treatment (SD)						
	• 0	•	40	4	_	
Dose level at	20mg	30mg	40mg	1	2	3
endpoint	107 (500/)	42 (220/)	21 (170/)	56 (600/)	17 (100/)	20 (210/)
n (%)	107 (59%)	43 (23%)	31 (17%)	56 (60%)	17 (18%)	20 (21%)
Mean (SD)	. 2	25.8mg (7.7)				

Data source: Tables 13.14b, 13.15b, 13.16b, 13.17b, 13.18b in Section 10 ; Appendix 13.14 in Appendix B

More than half the patients (56%) remained on the lowest dose of paroxetine, and the mean maximum daily dose was 26.1mg. Only 17% had dose increases to the maximum dose of 40mg. At the end point 59% were on the lowest dose of 20mg. Patient 005.00232 had a dose reduction from 40mg to 30mg. Patients 009.00226, 029.00022, 030.00185 and 056.00520 had dosage reductions of 30mg to 20mg.

<sup>\*</sup> Patient 377.023.000170 was included in the ITT population in error. This patient did not take any active medication and as such is not included in the above table

These reductions were at some point during the study period, not necessarily at endpoint.

The numbers of patients at the different dose levels in the placebo group were very similar to those of the paroxetine group.

### **6.2** Adverse Experiences

Treatment emergent adverse experiences are detailed in Appendices 15.1 in Appendix D. These emergent adverse experiences are summarised by body system in Table 15.01B in Section 12

In the paroxetine group, 120 patients (65.9%) experienced at least one emergent adverse experience during the active treatment phase compared with 55 (59.1%) patients in the placebo group. The most commonly occurring adverse experiences in both treatment groups were in the digestive system (paroxetine 35.2%; placebo 22.6%) and in the nervous system (paroxetine 35.2%; placebo 23.7%)

The most commonly occurring individual experiences (i.e. those occurring in at least 3% of patients in any group) during active treatment are shown (see Table 28 The Number (%) of Patients with the Most Frequent (i.e. at least 3%) Reported Treatment Emergent Adverse Experiences (AEs) During Active Treatment Regardless of Treatment Attribution in Descending Order for Paroxetine, page 79).

Table 28 The Number (%) of Patients with the Most Frequent (i.e. at least 3%) Reported Treatment Emergent Adverse Experiences (AEs) During Active Treatment Regardless of Treatment Attribution in Descending Order for Paroxetine

AEs by Preferred Term	Treatment group				
	Paroxetine	Placebo			
	n=182	n=93			
Patients with at least 1 AE	120 (65.9%)	55 (59.1%)			
Nausea	44 (24.2%)	14 (15.1%)			
Headache	34 (18.7%)	21 (22.6%)			
Dizziness	19 (10.4%)	7 (7.5%)			
Somnolence	17 (9.3%)	6 (6.5%)			
Decreased appetite	14 (7.7%)	3 (3.2%)			
Infection	14 (7.7%)	6 (6.5%)			
Asthenia	12 (6.6%)	9 (9.7%)			
Insomnia	9 (4.9%)	3 (3.2%)			
Emotional Lability	8 (4.4%)	3 (3.2%)			
Vomiting	7 (3.8%)	3 (3.2%)			
Abdominal pain	6 (3.3%)	9 ( 9.7%)			
Tremor	6 (3.3%)	1 (1.1%)			
Respiratory disorder	5 (2.7%)	3 (3.2%)			
Diarrhea	4 (2.2%)	3 (3.2%)			
Rhinitis	3 (1.6%)	3 (3.2%)			
Nervousness	2 (1.1%)	3 (3.2%)			
Pharyngitis	2 (1.1%)	5 (5.4%)			
Bronchitis	1 (0.5%)	3 (3.2%)			
Cystitis	1 (0.5%)	3 (3.2%)			

Data source: Table 15.011b in Section 12; Appendix 15.1 in Appendix D

The most common adverse experiences for both paroxetine and placebo patients were nausea and headache.

The number of patients with adverse experiences are shown by baseline body weight by body system on Table 15.10B and by prefered term on Table 15.101B, Section 12. Gender specific figures are given on Tables 15.102B and 15.103B in Section 12. The percentages show no clear relationship between body weight and adverse experience.

The majority of the adverse experiences in both groups had been reported within the first two weeks of active treatment. The figures are summarised in Tables

15.08B 15.081B, 15.082B and 15.083B in Section 12. Ninety patients (49.5%) in the paroxetine group and 35 (37.6%) in the placebo group had reported adverse experiences within this period (Table 15.081B; Section 12). The most common experiences early in treatment were nausea, somnolence and headache. The adverse experiences during the first two weeks of active treatment are shown by body weight and body system in Table 15.09B, and by body weight and preferred term in Table 15.091B, Section 12. The figures show no clear relationship between body weight and adverse experience.

Few adverse experiences were reported in either group during the down titration phase of treatment (Table 15.11B, Section 12). Only 19 patients in the paroxetine group (14.3%), and six patients in the placebo group (8.3%) reported adverse experiences during this phase. Adverse experiences during the down titration phase are shown by preferred term in Table 15.111B.

### **6.2.1** Adverse Experiences by Severity

The numbers of patients with emergent adverse experiences during the active treatment phase, classed as severe in each treatment group are shown in Tables 15.04B, 15.041B, 15.042B and 15.043B in Section 12. In the paroxetine group 20 patients (11.0%) had severe adverse experiences as did six placebo group patients (6.5%). The number of severe experiences in both treatment groups was low, the most common being of the nervous system with 10 patients (5.5%) in the paroxetine group and three patients (3.2%) in the placebo group reporting severe adverse experiences of the nervous system.

The distribution of the most common adverse experiences occurring in two or more patients for each treatment group is shown below (see Table 29 The Distribution of the Most Common Severe Adverse Experiences for each Treatment Group. Number (%) of Patients, page 81)

Table 29 The Distribution of the Most Common Severe Adverse Experiences for each Treatment Group. Number (%) of Patients

AEs by Preferred	Treatment group		
Term	Paroxetine n=182	Placebo n=93	
	Severe AEs	Severe AEs	
Headache	3 (1.6%)	0	
Nausea	3 (1.6%)	0	
Emotional lability	2 (1.1%)	2 (2.2%)	
Agitation	2 (1.1%)	0	
Insomnia	2 (1.1%)	0	
Somnolence	2 (1.1%)	0	

Data source: Table 15.041b in Section 12; Appendix 15.1 in Appendix D

There were few adverse experiences that were classed as severe throughout the study. The majority of events were mild or moderate in severity for both treatment groups. The most common severe adverse experiences for paroxetine patients were headache and nausea and for placebo patients emotional lability, but all these only occurred in approximately 2% of the patients.

## 6.2.2 Adverse Experiences Thought to be Drug-related

In this study 31 (17.0%) patients treated with paroxetine and 4 (4.3%) patients treated with placebo experienced one or more adverse experiences which were thought to be drug-related (see Tables 15.05B, 15.051B, 15.052B and 15.053B in Section 12). In the paroxetine group the most commonly reported drug related adverse experiences were of the digestive system with 20 patients (11.0%), followed by the nervous system with 14 patients (7.7%), compared with 1 patient (1.1%) and 2 patients (2.2%) in the placebo group, respectively.

Emergent AEs considered to be related to study medication during the active treatment phase of the study are detailed in Table 15.051b. The most common drug-related adverse experiences in the paroxetine group during active treatment were nausea, (16 patients, 8.8%), somnolence (six patients, 3.3%) and headache, decreased appetite and insomnia each in four patients (2.2%). These same events during active treatment were considered drug related in the placebo group in two or fewer patients (2.2% or less).

### **6.3 Dose Reduction for Adverse Experiences**

Four patients on paroxetine and one on placebo required a dose reduction for adverse experiences (Appendix 15.1 in Appendix D).

#### Paroxetine

Patient 377.005.00232, a 15 year old Caucasian male. On day 19 the patient experienced mild dizziness and mild headache both considered possibly related to study drug. The patients dose was reduced from 40mg to 30mg. No corrective therapy was administered. On day 77 the patient experienced Myoclonus/repetitive involuntary muscle contractions of moderate intensity in the neck and arm. The AE was considered to be serious and possibly related study medication. The study medication was stopped. No corrective therapy was administered.

Patient 377.029.00022, a 17 year old Caucasian female. On day 22 the patient experienced moderate dizziness and nausea considered possibly related to study drug. The patient was on 30 mg paroxetine and a dose reduction was implemented.

Patient 377.030.000185, a 15 year old Caucasian female. On day 5 the patient felt dazed and "spaced out", a feeling which lasted six days and was considered possibly related to study drug. The dose of study drug, 30 mg, was decreased to 20mg but increased again back to 30mg one week later. On day 20 the patient felt physically tired, a feeling which lasted 19 days. The investigator considered this event to be probably unrelated to study medication, but the dose was again decreased from 30 mg back to 20mg She remained on this dose until the end of the study.

Patient 377.049.00490, a 14 year old oriental female. On day 11 the patient experienced a rash which lasted 31 days and was considered moderate in intensity and probably unrelated to study drug. The patient was on 20 mg paroxetine at the onset of the rash. A dose increase to 30 mg took place during the time she had the rash, but the dose was reduced again down to 20 mg after four days. Ten days later the dose was again increased to 30 mg. The patient remained on this dose until the down titration period of Week 12.

#### Placebo

Patient 377.041.00293, a 15 year old Caucasian female. On day 15 the patient experienced moderate somnolence considered possibly related to study drug. A dose reduction was implemented.

# 6.4 Adverse Experiences Requiring Corrective Treatment

There are no summary tables for patients who required corrective therapy. However, most of the experiences reflected the normal collection of problems in adolescents and very few were considered related or possibly related to study drug (Appendix 15.1, Appendix D).

#### 6.5 Deaths

There were no deaths during the study or within 30 days of the last dose of study drug (Table 15.12b, Section 12 and Appendix 15.12 in Appendix D).

# 6.6 Serious Adverse Experiences

A serious adverse experience was defined as any event which was fatal, life threatening, disabling or incapacitating or resulted in hospitalisation, prolonged a hospital stay or was associated with congenital abnormality, cancer or overdose (either accidental or intentional).

Tables 15.07B, 15.071B, 15.072B and 15.073B in Section 12 and Appendix 15.1 in Appendix D give details of serious adverse experiences. Twenty two (12.1%) patients in the paroxetine group, and six (6.5%) patients in the placebo group experienced serious treatment emergent adverse events, which occurred during the treatment phase.

A summary of the serious adverse experiences which started during active treatment and occurred in more than one patient are shown below (see Table 30 The Number (%) of Patients with Serious Adverse Experiences, page 84).

Table 30 The Number (%) of Patients with Serious Adverse Experiences Occurring in More than One Patient

	Treatment group		
AE Body system	Paroxetine	Placebo	
Preferred term	n=15 (8.2%)	n=4 (4.3%)	
Digestive system			
Nausea	2 (1.1%)	0	
Nervous system			
Agitation	3 (1.6%)	0	
Depression	2 (1.1%)	0	
Emotional lability	6 (3.3%)	3 (3.2%)	

Data source: Appendix 15.1 in Appendix D; Table 15.071B, Section 12.

The number of patients within a body system are not additive since a patient can have more than one withdrawal reason within a Body System

In addition, a few patients experienced serious adverse experiences either before any study drug was dispensed but after consent was given, during the placebo screening phase, or after study medication was stopped. None of the SAEs which occurred during this study was fatal.

Narratives for all patients who had a serious adverse experience are presented in Table 16 (Section 12) and brief details for all patients who experienced non-fatal serious events are given below (see tables Tables 13.2 and 13.2b and Appendices 13.2 in Appendix B and 15.1 in Appendix D). These include an additional patient in the placebo group (patient 377.041.00294) whose adverse experience was classified under Body as a Whole although she suffered also from emotional lability.

#### Paroxetine

Patient 377.005.00232, a 15 year old Caucasian male. On day 77 the patient experienced myoclonus, described by the investigator as repetitive involuntary muscle contractions in his neck and arm. The investigator considered the experience to be moderate in severity and possibly related to study medication. It lasted 14 hours. The patient was on 30 mg paroxetine when the adverse experience started. Study drug was stopped but no corrective therapy was given.

Patient 377.005.00234, a 15 year old Caucasian female. On day 32, three days post-treatment the patient experienced worsening depression which required

hospitalization and lasted 11 days. The investigator considered the experience to be severe but unrelated to study medication.

Patient 377.009.00225, a 17 year old female of other race. On day 79 the patient attempted suicide. The investigator considered the experience to be unrelated to study medication. The patient was on 20 mg paroxetine when the attempt occurred. Study drug was stopped but no other corrective therapy was given.

Patient 377.011.00061, a 17 year old Caucasian female. On day 74 the patient took an intentional overdose of drug. The investigator considered the experience to be severe and possibly related to study medication. It lasted 2 days. The patient was on 40 mg paroxetine when the adverse experience started. Study drug was stopped and appropriate therapy was given.

Patient 377.023.00170, a 16 year old Caucasian male. On day 9, and two days post-treatment, the patient became hostile and aggressive leading to assault following alcohol abuse and requiring police intervention. The patient experienced amnesia. The investigator considered the experience which lasted two days to be moderate in severity. No corrective therapy was given.

Patient 377.029.00006, a 13 year old Caucasian male. On day 67 the patient came down with tick fever lasting 10 days resulting from a tick bite. The investigator considered the event to be severe but unrelated to study medication. The patient was on 20 mg paroxetine when the adverse experience started. There was no change in study drug treatment and other appropriate therapy was given for the infection.

Patient 377.029.00015, a 13 year old Caucasian male. On day 66 the patient experienced tonic clonic convulsions The investigator considered the experience to be moderate in severity and unrelated to study medication. The convulsions lasted five minutes. The patient was on 20 mg paroxetine when the adverse experience started. Study drug was stopped but no corrective therapy was given. A second episode of convulsions occurred on Day 68, two days after study drug was stopped. This was again considered unrelated to study drug and no corrective therapy was given.

Patient 377.030.00181, a 17 year old Caucasian female. On day 56 the patient experienced emotional lability and worsening depression and was considered a suicide risk. The investigator considered the experience to be moderate in severity and unrelated to study medication. It lasted 25 days. The patient was on 40 mg paroxetine when the adverse experience started. Study drug was stopped and other corrective therapy was given.

Patient 377.040.00298, a 17 year old Caucasian female. On day 13 the patient experienced worsening depression which the investigator considered to be severe but unrelated to study medication. It lasted 22 days. The patient was on 20 mg paroxetine when the adverse experience started. The patient continued on study drug and other corrective therapy was given.

Patient 377.041.00289, a 18 year old Oriental female. On day 87, during the down titration dosing period, the patient experienced severe renal colic which lasted two days. The investigator considered the experience to be probably unrelated to study medication. The patient was on 30 mg paroxetine when the adverse experience started. Study drug was stopped and no other corrective therapy was given.

Patient 377.041.00290, a 15 year old Caucasian female. On day 83, during the down titration dosing period the patient experienced moderate anxiety which required hospitalisation because the patient was unable to cope at home. The investigator considered the experience, which lasted 106 days, to be unrelated to study medication. The patient was on 20 mg paroxetine when the adverse experience started. Study drug was continued.

Patient 377.041.00292, a 15 year old Caucasian female. On day 8 of the treatment period the patient experienced a severe fit of hysterics lasting one day, which was considered by the investigator unrelated to study medication. The patient was on 30 mg paroxetine when the adverse experience started. Study drug was stopped but no other corrective therapy was given.

Patient 377.042.00310, a 15 year old female of other race. On day 23 the patient experienced emotional lability and was parasuicidal for one day. The investigator considered the experience to be mild in severity and possibly related to study medication. The patient was on 20 mg paroxetine when the adverse experience started. Study drug was stopped but no other corrective therapy was given.

Patient 377.042.00315, a 15 year old female of other race. On day 7 the patient experienced agitation and anxiety lasting 16 days. The investigator considered the experiences to be severe and related to study medication. The patient was on 20 mg paroxetine when the adverse experience started. Study drug was stopped on Day 13, and other corrective therapy was given for insomnia, but three days later the patient experienced emotional lability leading to an intentional overdose. This was considered moderately severe and possible related to study drug. No action or other corrective therapy was given.

Patient 377.042.00317, an 18 year old female of other race. On day 9 the patient experienced mild nausea, and on day 14, one day after treatment with study medication was stopped, the patient was found to be pregnant. The investigator considered the experience to be unrelated to study medication. No corrective therapy was given.

Patient 377.042.00554, a 16 year old female of other race. On day 67 the patient took an overdose of study medication which was described as Neurosis and an Accidental Overdose. The investigator considered the experience to be mild in severity and unrelated to study medication. The patient was on 30 mg paroxetine when the adverse experience started. Study drug was continued. Other corrective therapy was given for a non-serious AE of infection.

Patient 377.042.00555, a 16 year old Caucasian female. On day 13 the patient experienced severe emotional lability in the form of agitation, accompanied by decreased appetite, moderate dizziness, severe insomnia and nausea, which continued. The investigator considered the experiences to be related to study medication. The patient was on 30 mg paroxetine when the adverse experience started. Study drug was stopped but no other corrective therapy was given.

Patient 377.042.00557, a 17 year old female of other race. The patient experienced facial angiodema during the placebo screening phase of the study. The investigator considered the experience to be related to study medication, and because the patient would have been randomised to paroxetine, this case is listed under that drug rather than placebo. Study drug was stopped and other corrective therapy was given.

Patient 377.042.00561, a 14 year old Caucasian female. On day 0 the patient experienced severe nausea and vomiting accompanied by moderate tremor and agitation all of which were considered by the investigator to be related to study medication. At the same time the patient also experienced mild blurring of vision, dry mouth and postural hypotension which were considered possibly related to study drug. The patient was on 20 mg paroxetine when the adverse experiences started. Study drug was stopped and other corrective therapy was given were appropriate.

Patient 377.049.00479, a 17 year old male of other race. On day 35 the patient experienced severe irritability and nervousness considered possibly related to study drug. This was followed on day 37 by severe emotional lability with suicidal intent, considered unrelated to study drug. The patient had been on 40 mg

paroxetine the week before the first event occurred but on Day 35 study medication was stopped. No other corrective therapy was given.

Patient 377.053.00508, a 14 year old Caucasian female. On day 53 the patient experienced mild emotional lability and made a suicide attempt. The investigator considered the experience to be unrelated to study medication. The patient was on 20 mg paroxetine when the adverse experience occurred and the investigator increased the dose of study drug.

Patient 377.057.00539, a 17 year old Caucasian female. On day 99, the day after treatment with study drug was stopped, the patient experienced acute appendicitis, considered to be unrelated to study drug. Other corrective therapy was given.

#### Placebo

Patient 377.005.00231, a 14 year old Caucasian female. On day 30 the patient experienced severe emotional lability and attempted suicide. The investigator considered the experiences to be possibly related to study medication. Study drug was stopped. No other corrective therapy was given. The following day the patient experienced moderate somnolence, considered unrelated to study drug, and on day 51 had the gastrointestinal disorder appendicitis also considered unrelated to study drug.

Patient 377.010.00068, a 14 year old Caucasian female. On day 82 the patient experienced mild emotional lability and tried to overdose on benzodiazepines. The investigator considered the experiences to be unrelated to study medication, but study drug was stopped and no other corrective therapy was given.

Patient 377.029.00024, a 16 year old Caucasian female. On day 29 the patient experienced emotional lability which was continuing and attempted self damaging acts and suicide. The investigator considered these experiences to be unrelated to study medication, but study drug was stopped and no other corrective therapy was given.

Patient 377.041.00294, a 14 year old Caucasian female. On day 86 the patient experienced moderate emotional lability and took a tentative overdose in a suicide attempt. The investigator considered the event to be possibly related to study medication. The patient continued in the study and other corrective therapy was given.

Patient 377.047.00619, a 17 year old Caucasian female. During the screening period the patient experienced moderate emotional lability and tried to overdose

on bromazepam. The relationship to study medication was not given, but the patient continued in the study. No other corrective therapy was given.

Patient 377.049.00458, an 18 year old female of other race. On day 24 the patient experienced severe irritability which was considered to be unrelated to study medication. The patient continued in the study and no other corrective therapy was given.

In addition two patients experienced serious adverse events before study medication was dispensed that lead to the patients being withdrawn from the study.

Patient 377.005.09286, a 17 year old Caucasian female, experienced severe worsening depression which lasted 12 days,

Patient 377.049.09576, a 17 year old male of other race, experienced severe psychosis. Both were given corrective therapy.

# 6.7 Withdrawals Due to Adverse Experiences

Twenty patients in the active treatment phase and 1 patient in the down titration phase in the paroxetine group (11.0%) and seven patients in the placebo group (7.5%) experienced one or more emergent adverse experiences during active treatment with study drug resulted in withdrawal from the study. In both groups the majority of these were of the nervous system; paroxetine 15 patients (8.2%) and placebo 5 patients (5.4%) (Table 15.06B; Section 12). Details of the adverse experiences which started during active treatment and resulted in the withdrawal of more than one patient from the study are shown below (see Table 31 The Number (%) of Patients Withdrawn for At Least One AE Occurring in More Than One Patient in the ITT population, page 90).

**Data anomalies:** Table 13.13b in Section 10, records 20 patients in the paroxetine group and 6 in the placebo group withdrawing from the ITT population due to an adverse experience whereas table 15.061b in Section 12 details 19 patients in the paroxetine group and 7 patients in the placebo group. For the purpose of stating the worst case scenario for paroxetine the numbers used where applicable are 20 patients in the paroxetine group and 7 patients in the placebo group withdrawing from the ITT population. Two further patients who withdrew due to an AE (377.005.00263 and 377.042.557) were randomised to receive

paroxetine but were excluded from the ITT population. Therefore, the figures for the all randomised patient population used are 22 patients in the paroxetine and 7 patients in the placebo group withdrawing due to adverse experiences .

Table 31 The Number (%) of Patients Withdrawn for At Least One AE Occurring in More Than One Patient in the ITT population

	Treatment group		
AE Body system	Paroxetine	Placebo	
Preferred term	n=20* (11.0%)	n=7 (7.5%)	
Body as a whole general			
Headache	2 (1.1%)	0	
Digestive system*			
Nausea	6 (3.3%)	1 (1.1%)	
Vomiting	2 (1.1%)	0	
Nervous system			
Agitation	3 (1.6%)	0	
Anxiety	2 (1.1%)	0	
Emotional lability	5 (2.7%)	3 (3.2%)	
Somnolence	4 (2.2%)	1 (1.1%)	

Data source: Appendix 15.1 in Appendix D; Table 15.061B, Section 12.

Narratives for 7 paroxetine patients and 4 placebo patients who were withdrawn for non-serious adverse events are included in Table 17 in Section 12 and brief details are given below. The remaining patients had also experienced serious adverse experiences as discussed above and their narratives are presented in Table 16 Section 12 (non-fatal serious adverse experiences) as shown above (see 6.6 Serious Adverse Experiences, page 83).

#### **Paroxetine**

Patient 377.029.00013, a 14 year old Caucasian male. On day 1 the patient felt tiredness which lasted 14 days, followed on day 5 by heartburn lasting ten days, with severe nausea on day 11 for three days and again on day 15 of moderate intensity, all considered related to study drug. Also on day 11 the patient had an upper respiratory tract infection, considered unrelated to study drug and did not lead to withdrawal, and dyspnoea, considered probably unrelated. By day 16 the dyspnoea was described as severe, and the patient was taken off study drug. The patient was on 20 mg study drug. Other medication was given.

patient 377.042.00317 withdrew 1 day after last dose due to unintended pregnancy, not included in above table

Patient 377.029.00016, a 15 year old Caucasian female. On day 0 the patient felt daytime sleepiness which lasted 8 days, By day 8 the daytime sedation was becoming worse and was now severe. As the effect was considered related to study drug the patient, who had been on 20 mg, was taken off study drug and withdrawn from the study.

Patient 377.029.00035, a 16 year old Caucasian male. On day 7 the patient experienced moderate nausea which lasted 13 days and was considered possibly related to study drug. The patient was on 20 mg study drug when medication was stopped and the patient withdrawn from the study.

Patient 377.029.00040, a 12 year old Caucasian male. On day 0 the patient felt moderate nausea and mild somnolence, both considered related to study drug. The patient was on 20 mg study drug when medication was stopped.

Patient 377.029.00047, a 16 year old Caucasian female. On day 11 the patient experienced moderately severe daytime sedation which lasted 24 days, was considered possibly related to study drug and lead to withdrawal. In addition the patient experienced headache on Day 17 which was mild, and again on Day 24 which was described as moderately severe. The patient was on 20 mg study drug when medication was stopped on Day 27, and the patient withdrawn from the study.

Patient 377.047.00620, an 18 year old Caucasian male. On day 0 the patient experienced moderate diarrhoea and palpitations considered possibly related to study drug. The patient had just started on 20 mg paroxetine when study drug was stopped and the patient withdrawn from study.

Patient 377.058.00195, a 17 year old Caucasian female. On day 72 the patient experienced moderately severe vomiting which was considered possibly related to study drug. The patient was on 40 mg paroxetine. Study drug was stopped and the patient withdrawn from study.

#### Placebo

Patient 377.009.00227, an 18 year old Caucasian female. On the day treatment started the patient experienced mild nervousness lasting six days considered possibly related to study drug, Study drug was stopped after two days, and the patient withdrawn from study.

Patient 377.029.00030, a 13 year old Caucasian male. On the day the patient started treatment he experienced mild nausea and stopped the treatment. This was considered to be probably unrelated to study drug and no corrective therapy was administered

Patient 377.054.00512, a 13 year old Caucasian female. On day 56 the patient had a pharyngeal abscess considered probably unrelated to study drug. Study drug was stopped and other corrective therapy given.

Patient 377.056.00518, an 18 year old Caucasian male. On day 7 the patient experienced moderate drowsiness lasting six days considered possibly related to study drug, followed the next day by severe asthenia lasting five days and considered related to study drug. Study drug was stopped, and the patient withdrawn from study.

# 6.8 Vital Signs

Appendix 15.2 (Appendix E) details vital signs values by treatment group and patient, and vital signs values meeting sponsor-defined clinical concern criteria by treatment group and parameter respectively. Table 15.22b in Section 12 summarises mean vital signs values during the study and these are further summarised by changes from baseline to Week 12 in Table 15.23b Section 12.

The table below summarises the mean vital signs at baseline and at Week 12 for both treatment groups (see Table 32 Mean (s.d.) Vital Signs at Baseline and Week 12, page 93).

Table 32 Mean (s.d.) Vital Signs at Baseline and Week 12

Vital Sign	Treatment group				
Time Period	Paroxetine			Placebo	
	n	Mean (s.d.)	n	Mean (s.d.)	
Sitting DBP (mm Hg)					
Baseline	179	70.2 ( 9.12)	92	69.3 (9.27)	
Week 12	130	69.6 (10.15)	69	67.2 (8.39)	
Standing DBP (mm Hg)					
Baseline	178	71.6 (9.91)	92	70.9 (9.21)	
Week 12	129	70.6 (9.69)	69	69.6 (8.64)	
Sitting SBP (mm Hg)					
Baseline	179	110.7 (11.52)	92	108.5 (11.43)	
Week 12	130	109.1 (12.67)	69	107.1 (11.77)	
Standing SBP (mm Hg)					
Baseline	178	109.8 (12.41)	92	108.7 (13.21)	
Week 12	129	108.5 (12.39)	69	107.2 (11.33)	
Sitting Pulse Rate (bpm)					
Baseline	178	76.6 (10.57)	91	75.5 (9.30)	
Week 12	129	77.1 (9.96)	69	76.4 (9.68)	
Standing Pulse Rate (bpm)					
Baseline	177	82.2 (12.01)	91	80.4 (10.98)	
Week 12	129	81.8 (10.31)	69	81.7 (9.87)	
Weight (kg)					
Baseline	180	57.6 (13.51)	92	58.2 (11.53)	
Week 12	118	57.8 (14.01)	62	57.6 (11.13)	

Data source: Table 15.22b in Section 12; Appendix 15.2 in Appendix E

DBP = Diastolic blood pressure; SDP = Systolic blood pressure

Changes in mean vital signs values from Baseline to Week 12 were small for both treatment groups and of no clinical concern (Table 15.23b, Section 12).

Table 15.21b in Section 12 summarises the number of patients in the treatment groups with vital signs values meeting sponsor-defined clinical concern criteria and these are shown in the table below (see Table 33 The Number (%) of Patients with Vital Signs Values Meeting Sponsor-defined Clinical Concern Criteria During the Study, page 94).

n = total number of patients assessed at that visit

Table 33 The Number (%) of Patients with Vital Signs Values Meeting Sponsordefined Clinical Concern Criteria During the Study

Vital Sign	Treatment group	
Sponsor-defined Clinical	Paroxetine	Placebo
Concern Criteria	n=182	n=93
Sitting Diastolic BP (mm Hg)		
H (>105mmHg and increase≥30mmHg)	8 (4.4%)	5 (5.4%)
L (<50mmHg and decrease≥20mmHg)	27 (14.8%)	17 (18.3%)
Standing Diastolic BP (mm Hg)		
H (>105mmHg and increase≥30mmHg)	8 (4.4%)	4 (4.3%)
L (<50mmHg and decrease≥20mmHg)	24 (13.2%)	17 (18.3%)
Sitting Systolic BP (mm Hg)		
H (>180mmHg and increase≥40mmHg)	0	0
L (<90mmHg and decrease≥30mmHg)	24 (13.2%)	17 (18.3%)
Standing Systolic BP (mm Hg)		
H (>180mmHg and increase≥40mmHg)	0	2 (2.2%)
L (<90mmHg and decrease≥30mmHg)	33 (18.1%)	16 (17.2%)
Sitting Pulse Rate (bpm)		
H (>120bpm and increase≥30bpm)	12 (6.7%)	4 (4.3%)
L (<50bpm and decrease≥30bpm)	7 (3.8%)	1 (1.1%)
Standing Pulse Rate (bpm)		
H (>120bpm and increase≥30bpm)	18 (9.9%)	10 (10.8%)
L (<50bpm and decrease≥30bpm)	9 (5.1%)	4 (4.3%)
Weight (kg)*		
H (increase≥7%)	12 (8.2%)	5 (6.8%)
L (decrease≥7%)	5 (3.4%)	4 (5.5%)

Data source: Table 15.21b in Section 12; Appendix 15.2 in Appendix E

Very few patients experienced an increase in sitting or standing blood pressure values meeting sponsor-defined clinical concern criteria. For both paroxetine and placebo groups 13 to 18% of patients showed a decrease in sitting or standing blood pressure values which met sponsor-defined clinical concern criteria. However, there were no differences between the paroxetine and placebo treatment groups. Ten percent of patients showed raised pulse rates meeting sponsor-defined clinical concern criteria, but again these were the same in both treatment groups. Similarly the flagged changes in weight during the study were similar in the two treatment groups. Paroxetine showed a similar safety profile to that of placebo in terms of vital signs of clinical concern.

<sup>\*</sup> weight changes based only on patients with both baseline and post-baseline values i.e paroxetine n=146, placebo n=73

# 6.9 Electrocardiograph Data

Table 13.31 in Section 10 and Appendix 13.31 in Appendix B detail the the number of patients with clinically significant abnormalities in their ECGs at screening. Only 1 patient (0.5%) in the paroxetine group and no patients in the placebo group were recorded as having an abnormal ECGs.

## 6.10 Laboratory Tests

# 6.10.1 Laboratory Values Meeting Sponsor-defined Clinical Concern Criteria

The table below shows the values of laboratory parameters meeting sponsor-defined clinical concern criteria that were used in the study (see Table 34 Laboratory Values of Potential Clinical Concern, page 96).

**Please note:** Due to a calibration error at the xxxxxxxxxxxxxxxxxxxxxxxx in the xx the creatinine values for 13 patients in this study were incorrectly reported as 17 micromoles/L higher than the true values. As a consequence of this, the creatinine values for 3 of these patients, placebo patients 377.042.00562 and 377.042.00397 and paroxetine patient 377.058.0589, were incorrectly reported to be in range when they should in fact have been reported as low. The correct laboratory values have been forwarded to the investigators concerned and are not considered to be of clinical significance.

**Table 34 Laboratory Values of Potential Clinical Concern** 

Laboratory		Units	Levels of potential
parameter			clinical concern
Hematology			
Hemoglobin		g%	≤9.5
Hematocrit		%	≤32
White blood cells		$x10^{9}/L$	≤2.8 or≥16
Neutrophils		%	≤15
Lymphocytes		%	≥75
Monocytes		%	≥15
Basophils		%	≥10
Eosinophils		%	≥10
Platelets		$x10^{9}/L$	≤75 or ≥700
Bands		%	≥10
Segmented neutro	phils	%	≤15
Red blood cells	males	%	≥8
	females	%	≥10
Clinical Chemistry	<b>y</b>		
Urea		mmol/L	≥10.71
Serum creatinine		μmol/L	≥176.80
Total bilirubin		mmol/L	≥34.20
SGOT (AST)		U/L	≥150
SGPT (ALT)		U/L	≥165
Alkaline phosphat	ase	U/L	≥390
Albumin		g/l	≤25.0
Calcium		mmol/l	2.05-3.00
Protein		g/l	45-100
Urine			
RBC		hpf	≥8.01
WBC		hpf	≥10.01
11 DC		np:	210.01

Data source: Appendix Lab 001 in Appendix F

As references ranges differed by age and by centre they are not included on this table, but the full listings of references ranges used in the study are in Appendix F.

The proportions of patients with laboratory values meeting sponsor-defined clinical concern criteria are summarised in Table 15.3b and 15.34B in Section 12 and are presented below for those parameters with one or more value of concern in either treatment group (see Table 35 Number (%) of Patients with Laboratory Values Meeting Sponsor-defined Clinical Concern Criteria During the Study, page 97).

Table 35 Number (%) of Patients with Laboratory Values Meeting Sponsordefined Clinical Concern Criteria During the Study

		Treatment group		
Laboratory Parameter	High/Low	Paroxetine n=182	Placebo n=93	
	IIIgii/Low	11-102	11-93	
Clinical Chemistry		44 (640)	. (2.20()	
Alkaline phosphatase	H	11 (6.1%)	2 (2.2%)	
Calcium	L	1 (0.6%)	0	
Total Bilirubin	Н	0	1 (1.1%)	
Haematology				
Haematocrit	L	3 (1.7%)	2 (2.2%)	
White blood cell count	Н	1 (0.6%)	0	
Eosinophils	Н	9 (5.0%)	4 (4.3%)	
Monocytes	Н	0	1 (1.1%)	
Neutrophils (segmented)	L	0	1 (1.2%)	
Others				
Serum BHCG pregnancy test	+ve	1 (1.1%)	0	
Urine blood	+ve	16 (19.3%)	12 (25.5%)	
Urine glucose	+ve	0	1 (2.1%)	
Urine protein	+ve	11 (13.3%)	7 (14.9%)	

Data source: Table 15.3b and 15.34B in Section 12; Appendices 15.31, 15.32, 15.33 in Appendix F

A total of 53 paroxetine patients (29.1%) had one or more laboratory values meeting sponsor-defined clinical concern criteria compared with 31 placebo patients (33.3%). The most common clinical chemistry parameter was high alkaline phosphatase levels, occurring in 11 paroxetine patients and two in the placebo group. A high eosinophil count occurred in 5% and 4.3% of patients in the paroxetine and placebo groups, respectively; this was probably due to the few patients who had concomitant infections during the study. As shown in the above table (see Table 35 Number (%) of Patients with Laboratory Values Meeting Sponsor-defined Clinical Concern Criteria During the Study, page 97) paroxetine showed as good a safety profile as placebo in terms of laboratory values of clinical concern.

# 7 Discussion

The primary objective of this study was to compare the efficacy of paroxetine with that of placebo in the treatment of adolescent depression. The secondary objective was to compare the safety of the two treatments.

The 12 week study was of double-blind, randomized, multicentre design. Two hundred and sixty four patients were to be randomised in a 2:1 ratio of paroxetine to placebo. The final ITT population consisted of 182 paroxetine patients and 93 placebo patients.

The two treatment groups were well matched for all baseline characteristics, demographic variables and medical history. From the ITT population, there was no difference between the treatment groups in the proportions of patients who withdrew during the study (30.2% on paroxetine treatment Vs 25.8% of placebo treatment).

None of the primary or secondary efficacy variables indicated any clinical or statistical significant treatment effect. A statistically significant treatment by age interaction was observed for both primary efficacy parameters and most of the secondary parameters where numerical trends indicated that for patients greater than 16 years of age, patients on paroxetine had better response rates.

Similar proportions of patients from both treatment groups experienced adverse experiences (65.9% of paroxetine treated patients Vs 59.1% of placebo patients). The proportion of patients in the ITT population with serious adverse experiences was slightly higher for the paroxetine group compared with placebo patients (12.1% paroxetine Vs 6.5% placebo). No patients died during the course of the study. The proportion patient withdrawing from the ITT population due to adverse experiences was slightly higher in the paroxetine group (11.0%) compared to placebo (7.5%) but this difference was not statistically significant.

Regarding other aspects of the safety analysis, changes in mean vital signs values from baseline to week 12 were small for both treatment groups and of no clinical concern. Similar proportions of patients in the two treatment groups had one or more laboratory value meeting sponsor defined clinical concern criteria (paroxetine 29.1% Vs placebo 33.3%).

# **8 Conclusions**

The results failed to show any superiority for paroxetine over placebo in the treatment of adolescent depression. A significant age by treatment interaction was detected in both of the primary efficacy variables and most of the secondary, indicating evidence of a different treatment effect dependent on age. Therefore conclusions drawn on the data presented overall should be treated with caution.

Paroxetine was well tolerated with no unexpected finding regarding adverse experiences, vital signs or laboratory values.

# 9 References

- KRAMER AD, FEIGUINE RJ. 1981. Clinical effects of amitriptyline in adolescent depression. A pilot study. J Am Acad Child Psychiatry, 20 (3), 36-44.
- 2. RYAN ND ET AL. 1986. Imipramine in adolescent major depression: plasma level and clinical response. *Acta Psychiatr Scand*, **73** (3), 275-288.
- 3. BOULOS C ET AL. 1991. Response to desipramine treatment in adolescent major depression. *Psychopharmacol Bull*, **27** (1), 59-65.
- 4. STROBER M ET AL. 1992. The pharmacotherapy of depressive illness in adolescence. II Effects of lithium augmentation in nonresponders to imipramine. *J Am Acad Child Adolesc Psychiatry (USA)*, **31/1**, 16-20.
- 5. CONNERS CK. 1992. Methodology of antidepressant drug trials for treating depression in adolescents. *Journal of child and adolescent psychopharmacology*, **2**/**1**,
- 6. JENSEN PS ET AL. 1992. Psychopharmacology of child and adolescent major depression: present status and future directions. *Journal of child and adolescent psychopharmacology*, **2/1**,
- 7. BOYER WF AND BLUMHARDT CL. 1991. The safety profile of paroxetine. *J Clin. Psychiatry*, **53:2 (suppl)**,

# 10 Source Tables: Study Population

Table 13.00 List of Patients Narratives	000109
Table 13.01 Summary of Patients Evaluated	000112
Table 13.02 Summary of Patients Evaluated by Country	000113
Table 13.10b Kiddie-SADS-Lifetime Diagnostic Criteria. Summary of Past and Continuing Episodes (ITT)	000124
Table 13.11b Summary of Concomitant Medication Present at Baseline and Continued (ITT)	
Table 13.12b Summary of Concomitant Medication Initiated During the Study	
Table 13.13b Patient Withdrawals (ITT)	
Table 13.14b Maximum. Daily Amount of Investigational Drug (ITT)	
Table 13.15b Summary Statistics of Maximum Daily Amount of	000111
Investigational Drug (ITT)	000142
Table 13.16b Summary of Dose Level at Endpoint (ITT)	000143
Table 13.17b Summary Statistics of Dose Level at Endpoint (ITT)	000144
Table 13.18b Summary Statistics of Mean Dose on active treatment	
(ITT)	000145
Table 13.2b Summary of Demographic Data (ITT)	000146
Table 13.2c Summary of Demographic Data (PP)	000148
Table 13.20 Number (%) of Patients by Protocol Violation. Randomised	
patients	
Table 13.21b Study Medication Compliance	000151
Table 13.3b Significant Medical/Surgical History and Physical	
Examination. Number and % of patients with Ongoing Conditions (ITT)	000152
Table 13.31 Number (%) of Patients with Clinically Significant	000132
Abnormalities of ECG at Screening. All Patients	000155
Table 13.4b Psychiatric History (ITT)	
Table 13.3.2b Significant Medical/Surgical History and Physical	
Examination Number and % of Patients With Past, Ongoing or Past	
and Ongoing Conditions (ITT)	000157
Table 13.5b Personal History - Current Situation Family Composition	0004 54
(ITT)	
Table 13.6b Personal History - Current Situation Adoptive Status (ITT)	
Table 13.7b Personal History-Current Situation Education (ITT)	000163

Confidential



# **Peroxetine**

**BRL-029060** 

**Narrative Location Table** 

377

Table 13.00

SB Document Number: BRL-029060/RSD-100WFW/1

**Table 13.00 List of Patient Narratives** 

PID	Deaths	Non-Fatal Serious AEs	AE leading to withdrawal
Paroxetine			
377.005.00232		Y	Y
377.005.00234		Y	
377.005.00263			Y
377.009.00225		Y	Y
377.011.00061		Y	Y
377.023.00170		Y	
377.029.00006		Y	
377.029.00013			Y
377.029.00015		Y	Y
377.029.00016			Y
377.029.00035			Y
377.029.00040			Y
377.029.00047			Y
377.030.00181		Y	Y
377.040.00298		Y	
377.041.00289		Y	Y
377.041.00290		Y	
377.041.00292		Y	Y
377.042.00310		Y	Y
377.042.00315		Y	Y
377.042.00317		Y	Y
377.042.00554		Y	

377.042.00555	Y	Y
377.042.00557	Y	Y
377.042.00561	Y	Y
377.047.00620		Y
377.049.00479	Y	Y
377.053.00508	Y	
377.057.00539	Y	
377.058.00195		Y
Placebo	l l	I
377.005.00231	Y	Y
377.009.00227		Y
377.010.00068	Y	Y
377.029.00024	Y	Y
377.041.00294	Y	
377.047.00619	Y	
377.049.00458	Y	
377.054.00512		Y
377.056.00518		Y
No therapy d	ispensed	
377.005.09286	Y	Y
377.049.09576	Y	Y

Table 13.01

## Summary of Patients Evaluated

	 	Treatment		 
	Paroxetine	Placebo	No Therapy Dispensed	Total
Total Patients Entered	187	99	38	324
Intention to Treat Population	182	93		275
Per Protocol Population	130	68		198

Paroxetine - Protocol: 377
Table 13.02

## Summary of Patients Evaluated by Country Groupings

				Treatment		
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				
South America	Argentina	052	Total Patients Entered	1		1
			Intention to Treat Population	1		
		Popul 	Per Protocol Population	1		
			Total Patients Entered	2	1	
			Intention to Treat Population	2	1	
		054	Per Protocol Population	2	1	
			Total Patients Entered	1	1	
			Intention to Treat Population	1	1	
			Per Protocol Population	1	1	<del> </del>

(CONTINUED)

# Summary of Patients Evaluated by Country Groupings

					Treatment	
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				
South America	Argentina	056	Total Patients Entered	10	4	2
			Intention to Treat	10	4	
			Per Protocol Population	9	3	
		057	Total Patients Entered	8	5	1
			Intention to Treat	8	5	
			Per Protocol Population	7	4	
	Mexico 049	049	Total Patients Entered	15	8	4
			Intention to Treat	15	8	
			Per Protocol Population	13	     6	

(CONTINUED)

Paroxetine - Protocol: 377

Table 13.02

Summary of Patients Evaluated by Country Groupings

				Treatment		
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				
South America	Mexico	050	Total Patients Entered	4	3	
			Intention to Treat Population	4	3	
			Per Protocol Population	3	2	
Europe / Canada	Belgium	002	Total Patients Entered		1	
			Intention to Treat		1	
			Per Protocol Population		1	<del> </del>
		005   Total Patients Entered	Patients	8	3	
			Intention to Treat	7	3	
			Per Protocol Population	5	2	<del>-</del>

(CONTINUED)

Paroxetine - Protocol: 377

Table 13.02

# Summary of Patients Evaluated by Country Groupings

			 	Treatment		
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				
Europe / Canada	Belgium	007	Total Patients Entered	5	4	
			Intention to Treat Population	4	2	
			Per Protocol Population			
		008	Total Patients Entered	2	1	
			Intention to Treat	2	1	
			Per Protocol Population			
		009	Total Patients Entered	11	6	
			Intention to Treat	11	5	
			Per Protocol Population	10	3	

(CONTINUED)

# Summary of Patients Evaluated by Country Groupings

				Treatment		
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre	ļ			
Europe / Canada	Belgium	040	Total Patients Entered	2	2	]
			Intention to Treat Population	2	2	
			Per Protocol Population	1	2	
		041	Total Patients Entered	4	2	
			Intention to Treat Population	4	2	
			Per Protocol Population	2	2	
		044	Total Patients Entered	1	1	
			Intention to Treat Population	1		
		Per Protocol Population	1		   	

(CONTINUED)

# Table 13.02

# Summary of Patients Evaluated by Country Groupings

Paroxetine - Protocol: 377

				Treatment		
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				
Europe / Canada	Belgium	047	Total Patients Entered	5	3	
			Intention to Treat Population	5	3	
			Per Protocol Population	4	3	
	Canada	030	Total Patients Entered	5	2	:
			Intention to Treat	5	2	
			Per Protocol Population	3	1	
		058	Total Patients Entered	5	2	
			Intention to Treat Population	5	2	
			Per Protocol		1	

(CONTINUED)

# Summary of Patients Evaluated by Country Groupings

			 	Treatment		
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				
Europe / Canada	Italy	010	Total Patients Entered	4	2	
			Intention to Treat Population	4	2	
		011	Per Protocol Population	2	1	
			Total Patients Entered	4	1	
			Intention to Treat Population	4	1	
			Per Protocol Population	4	1	
		014	Total Patients Entered	4	2	
			Intention to Treat	4	2	
			Per Protocol Population	4	2	

(CONTINUED)

# Summary of Patients Evaluated by Country Groupings

					Treatment	
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				
Europe / Canada	Italy	015	Total Patients Entered	4	2	
			Intention to Treat	4	2	
			Per Protocol Population	1		
		022	Total Patients Entered			2
			Intention to Treat Population			
			Per Protocol Population			
		038	Total Patients Entered	2	1	
			Intention to Treat	2	1	
			Per Protocol Population			

(CONTINUED)

# Summary of Patients Evaluated by Country Groupings

					Treatment	
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				+   
Europe / Canada	Netherlands	023	Total Patients Entered	3	1	
			Intention to Treat	3	1	
			Per Protocol Population			
		024	Total  Patients  Entered	2	1	
			Intention to Treat Population	2	1	
			Per Protocol Population	2		
		046	Total Patients Entered		1	
			Intention to Treat Population		1	
			Per Protocol Population			

(CONTINUED)

Paroxetine - Protocol: 377
Table 13.02

# Summary of Patients Evaluated by Country Groupings

					Treatment	
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				
Europe / Canada	Spain	033	Total Patients Entered		1	
			Intention to Treat Population		1	
			Per Protocol Population		1	
	United 026 Kingdom		Total Patients Entered	1		
			Intention to Treat Population	1		
			Per Protocol Population	<del>-</del>		
Africa	South  Africa	029	Total Patients Entered	32	15	16
			Intention to Treat Population	32	14	
			Per Protocol Population	25	10	

(CONTINUED)

# Summary of Patients Evaluated by Country Groupings

					Treatment	
				Paroxetine	Placebo	No Therapy Dispensed
Country Groupings	Country	Centre				
Africa	South  Africa	042	Total  Patients  Entered	24	13	7
			Intention to Treat Population	22	12	
			Per Protocol Population	9	11	
		059	Total  Patients  Entered	2	2	
			Intention to Treat Population	2	2	
			Per Protocol Population	2	2	
Middle East	United Arab  Emirates	045	Total  Patients  Entered	16	8	
			Intention to Treat Population	15	8	
			Per Protocol Population	14	8	

# Table 13.10b

## Kiddie-SADS-Lifetime Diagnostic Criteria Summary of Past and Continuing Episodes

## Intention To Treat Population

			Paroxet	ine		<u>!</u>			Place	ebo				
		Number	of Patien	ts in Gr	oup:		Number of Patients in Group:							
			182			<u>+</u>	93							
	Continu	ing	Past	<u> </u>	Both		Continu	ing	Past	;	Both			
	N	*	N	*	N	*   	N	%	N	8	N	%		
Major Depressive Episode	152	83.5	9	4.9	21	11.5	77	82.8	1	1.1	15	16.1		
Hypomanic Episode	0	0	0	0	0	0	0	0	1	1.1	0	0		
Manic Episode	0	0	0	0	0	0	0	0	0	0	0	0		
Anorexia Nervosa	1	0.5	2	1.1	0	0	0	0	2	2.2	0	0		
Bulimia Nervosa	2	1.1	1	0.5	0	0	0	0	1	1.1	0	0		
Specific Phobia	6	3.3	3	1.6	0	0	3	3.2	1	1.1	1	1.1		
Separation Anxiety Disorder	5	2.7	8	4.4	0	0	3	3.2	6	6.5	0	0		
Panic Disorder   without Agoraphobia	3	1.6	5	2.7	0	0	0	0	2	2.2	0	0		
Panic Disorder with Agoraphobia	0	0	1	0.5	0	0	0	0	1	1.1	0	0		
Agoraphobia without   History of Panic Disorder	0	0	1	0.5	0	0	0	0	1	1.1	0	0		
Social Phobia	3	1.6	1	0.5	1	0.5	4	4.3	1	1.1	0	0		

(CONTINUED)

### Table 13.10b

# Kiddie-SADS-Lifetime Diagnostic Criteria Summary of Past and Continuing Episodes

## Intention To Treat Population

 			Paroxet	ine			 		Place	ebo			
		Number	of Patier	nts in Gr	coup:		Number of Patients in Group:						
			182	2			93						
	Continu	ing	Past	:	Both	1	Continu	uing	Past	=	Both		
	N	%	N	%	N	%	N N	%	N	%	N	%	
Obsessive Compulsive	0	0	3	1.6	0	0	0	0	1	1.1	0	0	
Generalised Anxiety Disorder	13	7.1	7	3.8	0	0	4	4.3	4	4.3	1	1.1	
Post-Traumatic Stress Disorder	1	0.5	7	3.8	0	0	3	3.2	4	4.3	0	0	
Attention- Deficient/Hyperacti- vity Disorder	3	1.6	1	0.5	0	0	0	0	3	3.2	0	0	
Conduct Disorder	0	0	0	0	0	0	0	+   0	0	0	0	0	
Antisocial Personality Disorder	0	0	0	0	0	0	0	0	0	0	0	0	
Oppositional Defiant Disorder	1	0.5	1	0.5	0	0	1	1.1	0	0	0	0	
Alcohol Dependence	0	0	0	0	0	0	0	0	0	0	0	0	
Alcohol Abuse	0	0	1	0.5	0	0	0	0	2	2.2	0	0	
Substance Dependence	0	0	0	0	0	0	0	0	0	0	0	0	

(CONTINUED)

### Table 13.10b

# Kiddie-SADS-Lifetime Diagnostic Criteria Summary of Past and Continuing Episodes

 			Paroxet	ine			Placebo						
		Number	of Patier	nts in Gr	coup:		Number of Patients in Group:						
			182	2			93						
	Continu	Continuing   Past   Both							Past	:	Both	1	
	N	%	N	N   %   N   %				%	N	%	N	%	
Substance Abuse	0	0	4	2.2	0	0	1	1.1	2	2.2	0	0	
Tic Disorders	0	0	0	0	0	0	0	0	2	2.2	0	0	
Schizophrenia	0	0	0	0	0	0	0	0	0	0	0	0	
Schizoaffective Disorder	0	0	0	0	0	0	0	0	0	0	0	0	
Brief Psychotic Disorder	0	0	0	0	0	0	0	0	0	0	0	0	
Delusional Disorder	0	0	0	0	0	0	0	0	0	0	0	0	
No History	6	3.3	0	0	0	0	1	1.1	0	0	0	0	

BRL-029060/RSD-100TNP/2/CPMS-377

Paroxetine - Protocol: 377

Table 13.11b

## Summary of Concomitant Medication Present at Baseline and Continued

## Intention To Treat Population

TREATMENT GROUP		PAROXET	INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH MEDICATIONS	: :	182 34	100.0% 18.7%	93 19	100.0% 20.4%	275 53	100.0
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	%	N	%	N	%
ALIMENTARY TRACT/METAB:			2.7	5	5.4 1.1 1.1 0.0 1.1 1.1 0.0 1.1 1.1 1.1 1.1	10	3.6
ALUMINIUM HYDROXIDE		0	0.0	1	1.1	1	0.4
AMINOBENZOIC ACID		1	0.5	1	1.1	2	0.7
ASCORBIC ACID		1	0.5	0	0.0	1	0.4
BIOTIN		1	0.5	1	1.1	2	0.7
BISACODYL		0	0.0	1	1.1	1	0.4
CALCIUM PANTOTHENATE		1	0.5	0	0.0	1	0.4
CHOLINE BITARTRATE		1	0.5	1	1.1	2	0.7
CISAPRIDE		1	0.5	0	0.0	1	0.4
DIMETICONE		0	0.0	1	1.1	1	0.4
HESPERIDIN		1	0.5	1	1.1	2	0.7
INOSITOL		1	0.5	1	1.1	2	0.7
INSULIN		0	0.0	1	1.1	1	0.4
INSULIN INJECTION, ISOPHANE		0	0.0	1	1.1	1	0.4
MESALAZINE		1	0.5	0	0.0	1	0.4
METOCLOPRAMIDE HYDROCHLORIDE		0	0.0	1	1.1	1	0.4
MINERALS NOS		1	0.5	1	1 1	2	0.7
NICOTINAMIDE		1	0.5	0	0.0	1	0.4
PYRIDOXINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4
RETINOL		0	0.0	1	0.0 0.0 1.1 0.0	1	0.4
RIBOFLAVIN		1	0.5	0	0.0	1	0.4
RUTOSIDE		1	0.5	1	1.1	2	0.7
SULFASALAZINE		1	0.5	0	0.0	1	0.4
THIAMINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4
VITAMINS NOS		1	0.5	1	1.1	2	0.7
ANTIINFECTIVES, SYSTEMIC:		2	1.1	2		4	1.5
CLINDAMYCIN		1	0.5	0	0.0	1	0.4
LYMECYCLINE		1	0.5	0	0.0	1	0.4
MINOCYCLINE HYDROCHLORIDE		0	0.0	1	1.1	1	0.4

BRL-029060/RSD-100TNP/2/CPMS-377

Table 13.11b

# Summary of Concomitant Medication Present at Baseline and Continued $\qquad \qquad \text{Intention To Treat Population}$

TREATMENT GROUP					BO 		
TOTAL NUMBER OF PATIENTS PATIENTS WITH MEDICATIONS	: :	182 34	100.0% 18.7%	93 19	100.0% 20.4%	275 53	100.0% 19.3%
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	%	N	* 8	N	%
TETRACYCLINE PHOSPHATE COMPLEX		0	0.0	1	1.1	1	0.4
ANTINEOPLASTIC & IMMUNOSUP: MEDROXYPROGESTERONE ACETATE		1 1	0.5 0.5	0 0	0.0	1 1	0.4 0.4
BLOOD/BLOOD FORM ORGANS: FERROUS SULFATE		2 2	1.1	0 0	0.0	2 2	0.7 0.7
CARDIOVASCULAR: ETILEFRINE HYDROCHLORIDE		0 0	0.0	1 1	1.1 1.1	1 1	0.4 0.4
CENTRAL NERVOUS SYSTEM: ALPRAZOLAM BROMAZEPAM CAFFEINE CODEINE PHOSPHATE HYDROXYZINE HYDROCHLORIDE LORMETAZEPAM MEPROBAMATE OLSALAZINE SODIUM PARACETAMOL		8 1 0 0 0 1 1 1 0 1 5	4.4 0.5 0.0 0.0 0.5 0.5 0.5 2.7	0 1 1 0 1 1 0 2	4.3 0.0 1.1 1.1 1.1 0.0 1.1 1.1 0.0 2.2	1 1 1 1 2	0.4 0.4 0.4 0.4 0.7
DERMATOLOGICALS: DIPHENHYDRAMINE DIPHENHYDRAMINE HYDROCHLORIDE RETINOL TETRACYCLINE PHOSPHATE COMPLEX		1 1 0 0	0.5 0.5 0.0 0.0	0 1 1	2.2 0.0 1.1 1.1	1 1 1	0.4
GU SYSTEM/SEX HORMONES: CYPROTERONE ACETATE		15 5	8.2 2.7	7 1	7.5 1.1	22 6	8.0 2.2

Paroxetine - Protocol: 377

Table 13.11b

Summary of Concomitant Medication Present at Baseline and Continued  $\qquad \qquad \text{Intention To Treat Population}$ 

TREATMENT GROUP		PAROXET	INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH MEDICATIONS	:	34	18.7%	19	100.0% 20.4%	53	100.0% 19.3%
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	%	N	%	N	%
DESOGESTREL		2	1.1	3	3.2 7.5 2.2 1.1	5	1.8
ETHINYLESTRADIOL		13	7.1	7	7.5	20	7.3
GESTODENE		3	1.6	2	2.2	5	1.8
LEVONORGESTREL		2	1.1	1	1.1	3	1.1
MEDROXYPROGESTERONE ACETATE		1	0.5	0	0.0	1	0.4
NORETHISTERONE ENANTATE		1	0.5	0	0.0	1	0.4
NORGESTIMATE		1	0.5	0	0.0	1	0.4
MUSCULO-SKELETAL:		2	1.1	2	2.2	4	1.5
IBUPROFEN		0	0.0	1 1 0	1.1	1	0.4
NAPROXEN		0	0.0	1	1.1	1	0.4
PHENYLBUTAZONE		1	0.5	0	0.0	1	0.4
PIROXICAM		1	0.5	0	0.0	1 1 1 1	0.4
RESPIRATORY:		12	6.6	2	2.2	14	5.1
BECLOMETASONE DIPROPIONATE		4	2.2	0		4	
CETIRIZINE HYDROCHLORIDE		1	0.5		0.0	1	0.4
CROMOGLICATE SODIUM		0	0.0	1	1.1	1	0.4
DIMENHYDRINATE		1	0.5	0	0.0	1	0.4
DIPHENHYDRAMINE		1	0.5	0	0.0	1	0.4
DIPHENHYDRAMINE HYDROCHLORIDE		0	0.0	1	1.1	1 1	0.4
OXYMETAZOLINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4
SALBUTAMOL		7	3.8	0	0.0	7	2.5
XYLOMETAZOLINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4
SENSORY ORGANS:		2	1.1	2	2.2	4	1.5
CROMOGLICATE SODIUM		0	0.0			1	0.4
OXYMETAZOLINE HYDROCHLORIDE		1	0.5			1	
TETRACYCLINE PHOSPHATE COMPLEX		0	0.0	1	1.1	1	0.4
XYLOMETAZOLINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4

LEVOTHYROXINE SODIUM

# Paroxetine - Protocol: 377 Table 13.11b

Summary of Concomitant Medication Present at Baseline and Continued

Intention To Treat Population

\_\_\_\_\_\_ TREATMENT GROUP PAROXETINE PLACEBO TOTAL TOTAL NUMBER OF PATIENTS : 182 100.0% 93 100.0% 275 100.0% PATIENTS WITH MEDICATIONS : 34 18.7% 19 20.4% 53 19.3% ATC CLASSIFICATION LEVEL 1 : GENERIC TERM N % N % N % SYSTEMIC HORMONAL:

BRL-029060/RSD-100TNP/2/CPMS-377

Paroxetine - Protocol: 377

Table 13.12b

### Summary of Concomitant Medication Initiated During the Study

TREATMENT GROUP		PAROXET	INE	PLACE	30	TOTAI	
TOTAL NUMBER OF PATIENTS PATIENTS WITH MEDICATIONS	:	182 78	100.0% 42.9%	93 39	100.0% 41.9%	275 117	100.0% 42.5%
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	%	N	%	N	8
ALIMENTARY TRACT/METAB:					14.0 0.0 1.1 1.1 0.0		
ACETYLSALICYLIC ACID		1	0.5	0	0.0	1	0.4
ALUMINIUM HYDROXIDE		0	0.0	1	1.1	1	0.4
AMINOPENTAMIDE		ĺ	0.5	1	1.1	2	0.7
ASCORBIC ACID		3	1.6	0	0.0 1.1 1.1 1.1 0.0 2.2 1.1 0.0 0.0 1.1 0.0 0.0 1.1 1.1	3	1.1
ATTAPULGITE		1	0.5	1	1.1	2	0.7
BACILLUS SUBTILIS		0	0.0	1	1.1	1	0.4
BISMUTH SUBCARBONATE		1	0.5	1	1.1	2	0.7
CAFFEINE		1	0.5	0	0.0	1	0.4
CALCIUM CARBONATE		0	0.0	2	2.2	2	0.7
CHARCOAL, ACTIVATED		ĺ	0.5	1	1.1	2	0.7
CHLORPHENAMINE MALEATE		1	0.5	0	0.0	1	0.4
CINNARIZINE		1	0.5	0	0.0	1	0.4
CYCLIZINE HYDROCHLORIDE		4	2.2	1	1.1	5	1.8
DICYCLOVERINE		1	0.5	0	0.0	1	0.4
DOMPERIDONE		1	0.5	Ō	0.0	1	0.4
EPHEDRINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4
FENPIVERINIUM BROMIDE		1	0.5	1	1.1	2	0.7
HYOSCINE HYDROBROMIDE		0	0.0	1	1.1	1	0.4
KANAMYCIN SULFATE		1	0.5	1	1.1	2	0.7
KAOLIN		0	0.0	1	1.1	1	0.4
LEVOCARNITINE		1	0.5	0	0.0	1	0.4
LOPERAMIDE HYDROCHLORIDE		2	1.1	1	1.1	3	1.1
MAGNESIUM ASPARTATE		1	0.5	0	0.0	1	0.4
MAGNESIUM CARBONATE		0	0.0	1	1.1	1	0.4
MAGNESIUM SULFATE		1	0.5	1	1.1	2	0.7
MESALAZINE		1	0.5	0	0.0	1	0.4
METAMIZOLE SODIUM		ī	0.5	í	1.1 1.1 0.0	2	0.7
METOCLOPRAMIDE		Ō	0.0	ī	1.1 1.1 0.0 0.0	1	0.4
METOCLOPRAMIDE HYDROCHLORIDE		ĺ	0.5	1	1.1	2.	0.7
MINERALS NOS		ī	0.5	0	0.0	1	0.4
PARACETAMOL		ī	0.5	Õ	0.0	1	0.4

Paroxetine - Protocol: 377

# Table 13.12b Summary of Concomitant Medication Initiated During the Study

		======	=======	.=====	=======	======	
TREATMENT GROUP		PAROXET:	INE	PLACE	30	TOTAI	
TOTAL NUMBER OF PATIENTS PATIENTS WITH MEDICATIONS	: :	182 78	100.0% 42.9%	93 39	100.0% 41.9%	275 117	100.0% 42.5%
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	%	N	%	N	%
PECTIN		_	0.5	2	2.2 0.0	3	1.1
PHENYLEPHRINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4
PINAVERIUM BROMIDE		1	0.5	0	0.0	1	0.4
PITOFENONE HYDROCHLORIDE		1	0.5	1	1.1 0.0 0.0	2	0.7
POTASSIUM CITRATE		1	0.5	0	0.0	1	0.4
RETINOL		1	0.5	0	0.0	1	0.4
SACCHAROMYCES BOULARDII		0	0.0	1	1.1	1	0.4
SENNA FRUIT		1	0.5	0	0.0	1	0.4
TOCOPHERYL ACETATE		1	0.5	0	0.0	1	0.4
VITAMINS NOS		1	0.5	0	0.0	1	0.4
ANTIINFECTIVES, SYSTEMIC:		23	12.6	8	8.6	31	11.3
AMOXICILLIN		4	2.2	0	0.0	4	1.5
AMOXICILLIN TRIHYDRATE		3	1.6	1	1.1	4	1.5
AMPICILLIN		3	1.6	1	1.1	4	1.5
AMPICILLIN SODIUM		1	0.5	0	0.0	1	0.4
ANTIBIOTIC NOS		2	1.1	0	0.0	2	0.7
AZITHROMYCIN		1	0.5	0	1.1 1.1 0.0 0.0 0.0 1.1 0.0 1.1	1	0.4
BENZATHINE BENZYLPENICILLIN		0	0.0	1	1.1	1	0.4
CEFALEXIN MONOHYDRATE		1	0.5	0	0.0	1	0.4
CEFUROXIME AXETIL		0	0.0	1	1.1	1	0.4
CIPROFLOXACIN		1	0.5	2	2.2	3	1.1
CIPROFLOXACIN HYDROCHLORIDE		1	0.5	0	0.0	1	0.4
CLAVULANIC ACID		1	0.5	i	1.1	2	0.7
CLOXACILLIN SODIUM		1	0.5	0	0.0	1	
DOXYCYCLINE HYDROCHLORIDE		1	0.5	0	0.0 1.1 0.0 0.0	1	
ERYTHROMYCIN		ī	0.5	0	0.0	1	
MEASLES VIRUS VACCINE LIVE ATTENUATED		ī	0.5	0	0.0	1	0.4
METRONIDAZOLE		0	0.0	1	1.1	1	0.4
MINOCYCLINE		1	0.5	ī	1.1	2	0.7
PHENOXYMETHYLPENICILLIN		0	0.0	ī	1.1 1.1 1.1	1	0.4
ROXITHROMYCIN		1	0.5		0.0	1	0.4

Table 13.12b

# Summary of Concomitant Medication Initiated During the Study

	===:	======	=======	======	=======	======	======
TREATMENT GROUP		PAROXET	INE	PLACE	BO	TOTA	L
		182	100.0%	93	100.0% 41.9%	275	
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	%	N	 % 	N	%
STREPTOVARYCIN SULFAMETHOXAZOLE TETRACYCLINE TRIMETHOPRIM			0.5 1.1 0.5	0 2 0	0.0 2.2 0.0 2.2	1 4 1	0.4 1.5 0.4
BLOOD/BLOOD FORM ORGANS: FERROUS SULFATE EXSICCATED FOLIC ACID		1 1 1	0.5 0.5 0.5	0 0 0	0.0 0.0 0.0	1	0.4 0.4 0.4
CARDIOVASCULAR: AMEZINIUM METILSULFATE ETILEFRINE HYDROCHLORIDE		4 1 3	2.2 0.5 1.6	2 0 2	2.2 0.0 2.2	6 1 5	2.2 0.4 1.8
CENTRAL NERVOUS SYSTEM: ACETYLSALICYLATE CALCIUM ACETYLSALICYLIC ACID ALPRAZOLAM ASCORBIC ACID BROMISOVAL CAFFEINE CANNABIS CARBROMAL CHLORAL HYDRATE		50 2 11 0 1 6 1 1 2	27.5 1.1 6.0 0.0 0.5 0.5 0.5 0.5	0 6 1 0 0 1 1	0.0 6.5 1.1 0.0 0.0	17 1	27.3 0.7 6.2 0.4 0.4 2.5 0.7 0.4
CHLORPHENAMINE MALEATE CODEINE CODEINE PHOSPHATE DIAZEPAM DIPOTASSIUM CLORAZEPATE DOXEPIN HYDROCHLORIDE EPHEDRINE HYDROCHLORIDE FLUNITRAZEPAM FLUOXETINE		1 0 12 1 1 1 1	0.5 0.6 0.5 0.5 0.5 0.5	0 1 3 0 1	0.0 1.1 3.2 0.0 1.1	1 15 1 2	0.4 0.4 5.5 0.4 0.7

Table 13.12b

# Summary of Concomitant Medication Initiated During the Study

	=====	-=====	=======	:=====:	=======	======	=====	
TREATMENT GROUP		PAROXET	INE	PLACE	30	TOTAL		
TOTAL NUMBER OF PATIENTS PATIENTS WITH MEDICATIONS	: :	182 78	100.0% 42.9%	93	100.0% 41.9%	275	100.09	
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	%	N	 % 	N	%	
FLUVOXAMINE		1	0.5	0	0.0 0.0 3.2 0.0 0.0 0.0 1.1 0.0 2.2 0.0	1	0.4	
FLUVOXAMINE MALEATE			0.5	0	0.0	1	0.4	
IBUPROFEN		3	1.6	3	3.2	6	2.2	
LEVOCARNITINE		1	0.5	0	0.0	1	0.4	
LORAZEPAM		2	1.1	0	0.0	2	0.7	
MAGNESIUM ASPARTATE		1	0.5	0	0.0	1	0.4	
MAGNESIUM SULFATE		1	0.5	1	1.1	2	0.7	
MEPROBAMATE			0.5	0	0.0	1	0.4	
METAMIZOLE SODIUM		1	0.5	2	2.2	3	1.1	
METHYLENEDIOXYMETHAMPHETAMINE		1	0.5	0	0.0	1	0.4	
PARACETAMOL		30	16.5	19	20.4	49	17.8	
PAROXETINE		0	0.0	_		_	٠. ـ	
PHENYLEPHRINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4	
PROCHLORPERAZINE		1	0.5	0	0.0	1	0.4	
PROMETHAZINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4	
SERTRALINE		2	1.1	0	0.0 0.0 0.0	2	0.7	
TRAZODONE		1	0.5	0	0.0	1	0.4	
VENLAFAXINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4	
DERMATOLOGICALS:		12	6.6	4	4.3 1.1 1.1 0.0 0.0 0.0 0.0	16	5.8	
BENZOYL PEROXIDE		0	0.0	1	1.1	1	0.4	
BETAMETHASONE ACETATE		1	0.5	1	1.1	2	0.7	
BETAMETHASONE SODIUM PHOSPHATE		1	0.5	1	1.1	2	0.7	
BETAMETHASONE VALERATE		1	0.5	0	0.0	1	0.4	
CALAMINE		1	0.5	0	0.0	1	0.4	
CAMPHOR		1	0.5	0	0.0	1	0.4	
CHINOFORM		1	0.5	0	0.0	1	0.4	
DIPHENHYDRAMINE		2	1.1	1	1.1	3	1.1	
DIPHENHYDRAMINE HYDROCHLORIDE		2	1.1	1	1.1	3	1.1	
DOXEPIN HYDROCHLORIDE		1	0.5	0	0.0	1	0.4	
ERYTHROMYCIN		1	0.5 1.1 1.1 0.5 0.5	0	1.1 0.0 0.0	1	0.4	
FLUTICASONE PROPIONATE		1	0.5	0	0.0	1	0.4	

BRL-029060/RSD-100TNP/2/CPMS-377

Paroxetine - Protocol: 377

# ${\tt Table~13.12b}$ Summary of Concomitant Medication Initiated During the Study

	:	======	=======	=====	======	======	=====
TREATMENT GROUP		PAROXET	INE	PLACE	во	TOTA	С
					100.0% 41.9%		
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	%	N	======================================	N	%
GENTAMICIN SULFATE		1	0.5	0	0.0	1	0.4
GLYCEROL		1	0.5	0	0.0	1	
HEXAMIDINE ISETHIONATE		1	0.5	0	0.0	1	
HYDROCORTISONE		0 1	0.0	2	2.2 0.0 0.0	2 1	0.7
LEVOCABASTINE HYDROCHLORIDE METHYLPREDNISOLONE		1	0.5 0.5	0	0.0	1	0.4
MICONAZOLE NITRATE		0	0.5	0	2.2	2	0.4
NIFUROXAZIDE		1	0.5		0.0		0.7
RETINOL		1	0.5	0	0.0	1	0.4
TETRACYCLINE		1	0.5	0	0.0	1	0.4
TOLNAFTATE		1	0.5	0	0.0 0.0 0.0	1	0.4
GU SYSTEM/SEX HORMONES:		7	3.8		2.2		3.3
CIPROFLOXACIN		1	0.5	2	2.2	3	1.1
CIPROFLOXACIN HYDROCHLORIDE		1	0.5	Λ	0 0	1	0.4
CITRIC ACID		1	0.5	0	0.0	1	0.4
ETHINYLESTRADIOL		3	1.6	1	1.1	4	1.5
GESTODENE		0	0.0	1	1.1	1	0.4
LEVONORGESTREL		3	1.6	0	0.0	3	1.1
NORETHISTERONE ACETATE		1	0.5	0 1 0	0.0 1.1 0.0	1	0.4
NORFLOXACIN		0	0.0	1	1.1	1 1	0.4
SODIUM BICARBONATE		1 1	0.5	0	0.0	1	
SODIUM CITRATE		_	0.5	0	0.0		0.4
TARTARIC ACID		1	0.5	0	0.0	Τ	0.4
MUSCULO-SKELETAL:		9	4.9	7	7.5		5.8
DICLOFENAC SODIUM		2	1.1	0	0.0		0.7
FLURBIPROFEN		1	0.5		0.0		0.4
IBUPROFEN		3	1.6	6	6.5	9	3.3
MEFENAMIC ACID		0	0.0	1	1.1	1	0.4
NAPROXEN SODIUM		2	1.1	0	0.0	2	0.7
PIROXICAM		0	0.0	1	1.1	1	0.4

BRL-029060/RSD-100TNP/2/CPMS-377

0013

Table 13.12b

# Summary of Concomitant Medication Initiated During the Study

TREATMENT GROUP		PAROXET	INE 	PLACE	BO	TOTA	L 
TOTAL NUMBER OF PATIENTS PATIENTS WITH MEDICATIONS	:	182 78	100.0% 42.9%	93 39	100.0% 41.9%	275 117	100.0
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	%	N	%	N	%
SUXAMETHONIUM CHLORIDE		1	0.5	0	0.0	1	0.4
RESPIRATORY:		29	15.9	15	16.1	44	16.0
ACETYLCYSTEINE		2	1.1	1	1.1	3	1.1
ACETYLSALICYLIC ACID		1	0.5	0	0.0	1	0.4
ACONITE TINCTURE		1	0.5	0	0.0 0.0 2.2	1	0.4
AMMONIUM CHLORIDE		2	1.1	2	2.2	4	1.5
AMYLMETACRESOL		0	0.0	1	1.1 0.0 1.1 0.0	1	0.4
ARISTOLOCHIC ACID		1	0.5	0	0.0	1	0.4
ASCORBIC ACID		2	1.1	1	1.1	3	1.1
BALSAM SULPHURIS		1	0.5	0	0.0	1	0.4
BECLOMETASONE DIPROPIONATE		1	0.5	0	0.0		0.4
BROMHEXINE HYDROCHLORIDE		1	0.5	1	1.1	2	0.7
BROMPHENIRAMINE MALEATE		1	0.5	1	1.1	2	0.7
BUCHU		1	0.5	0	0.0	1	0.4
CAFFEINE		2	1.1		1.1	3	1.1
CAMPHOR		1	0.5		0.0	1	0.4
CARBINOXAMINE MALEATE		0	0.0	1	1.1	1	0.4
CARBOCISTEINE		2	1.1	0	0.0	2	0.7
CETIRIZINE HYDROCHLORIDE		2	1.1	0	0.0	2	0.7
CHERRY-LAUREL		1	0.5		0.0	1	0.4
CHLORPHENAMINE MALEATE		3	1.6	2	1.1 0.0 0.0 0.0 2.2	5	1.8
CINCHONA EXTRACT		1	0.5		() . ()		0.4
CINNARIZINE		1	0.5	0		1	0.4
CODEINE		0	0.0	1	1.1	1	0.4
CODEINE PHOSPHATE		3	1.6		0.0	3	1.1
CYCLIZINE HYDROCHLORIDE		4	2.2		1.1		1.8
CYPROHEPTADINE HYDROCHLORIDE		1	0.5	1	1.1	2	0.7
DEXCHLORPHENIRAMINE MALEATE		2	1.1	0	0.0	2	0.7
DEXTROMETHORPHAN HYDROBROMIDE		3	1.6	0	0.0	3	1.1
DICHLOROBENZYL ALCOHOL		0	0.0	1	1.1	1	0.4
DIMENHYDRINATE		3	1.6	1	1.1	4	1.5

Table 13.12b

# Summary of Concomitant Medication Initiated During the Study

TREATMENT GROUP		PAROXET	INE 	PLACE	30	TOTA	Ĺ 
TOTAL NUMBER OF PATIENTS PATIENTS WITH MEDICATIONS	:	182 78	100.0% 42.9%	93 39	100.0% 41.9%	275 117	100.0
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	~~~~~~ 왕	N	 % 	N	 %
DIMETINDENE MALEATE		1	0.5	0	0.0	1	0.4
DIPHENHYDRAMINE		2	1.1	1	1.1	3	1.1
DIPHENHYDRAMINE HYDROCHLORIDE		2	1.1	2	2.2	4	1.5
DIPHENYLPYRALINE HYDROCHLORIDE		0	0.0	1	2.2 1.1 0.0 0.0	1	0.4
DOMPERIDONE		1	0.5	0	0.0	1	0.4
EPHEDRINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4
ETHANOL		1	0.5	0	0.0	1	0.4
ETOPHYLLINE		0	0.0	1	1.1	1	().4
FLUTICASONE PROPIONATE		1	0.5	0	1.1 0.0 0.0 0.0	1	0.4
FUSAFUNGINE		1	0.5	0	0.0	1	() 4
GUAIFENESIN		3	1.6	0	0.0	3	1.1
HONEY		1	0.5	0	0.0	1	0.4
HYDROXYETHYL THEOPHYLLINE		1	0.5	0	0.0	1	0.4
LETTUCE EXTRACT		1	0.5	0	0.0	1	0.4
LORATADINE		1	0.5	1	1.1	2	0.7
MEBHYDROLIN		1	0.5	0	1.1 0.0 1.1	1	0.4
MEPYRAMINE MALEATE		2	1.1	1	1.1	3	1.1
OXITROPIUM BROMIDE		1	0.5	0	0.0	1	0.4
PARACETAMOL		3	1.6	1	1.1	4	1.5
PHENIRAMINE MALEATE		0	0.0	1	1.1	1	0 4
PHENYLEPHRINE HYDROCHLORIDE		5	2.7	4	4.3	9	3.3
PHENYLPROPANOLAMINE HYDROCHLORIDE		1	0.5	2	2.2	3	1.1
PREDNISONE		1	0.5	0	0.0	1	0.4
PROMETHAZINE HYDROCHLORIDE		1	0.5	0	0.0	1	0.4
PSEUDOEPHEDRINE HYDROCHLORIDE		6	3.3	1	1.1	7	2.5
SALICYLAMIDE		1	0.5	1	1.1	2	0.7
SENEGA EXTRACT		1	0.5	0	1.1 0.0 1.1 0.0 1.1 1.1 4.3 2.2 0.0 0.0 1.1 1.1 0.0 0.0 2.2	1	0.4
SODIUM BENZOATE			0.5	Ō	0.0	1	0.4
SODIUM CITRATE		1	0.5	2	2.2	3	1.1
SOUILL EXTRACT		ī	0.5	2 0 1	0.0	1	0.4
THEOPHYLLINE		ī	0.5	1	1.1	2	0.7
TOLO SYRUP		1	0.5	0	0.0	1	0.4

Table 13.12b

# Summary of Concomitant Medication Initiated During the Study

TREATMENT GROUP		PAROXET	INE	PLACE	30	TOTA	<u> </u>
TOTAL NUMBER OF PATIENTS PATIENTS WITH MEDICATIONS	:	182 78	100.0% 42.9%	93 39	100.0% 41.9%	275 117	100.0% 42.5%
ATC CLASSIFICATION LEVEL 1 : GENERIC TERM		N	*	N	%	N	%
TRIPROLIDINE HYDROCHLORIDE		3			1.1		
SENSORY ORGANS:		7	3.8	1	1.1	8	2.9
DICLOFENAC SODIUM		2	1.1	0	0.0	2	0.7
ERYTHROMYCIN		1	0.5	0	0.0	1	0.4
HEXAMIDINE ISETHIONATE		1	0.5	0	0.0	1	0.4
HYOSCINE HYDROBROMIDE		0	0.0	1	1.1	1	0.4
LEVOCABASTINE HYDROCHLORIDE		1 1	0.5	0	0.0	1	0.4
METHYLPREDNISOLONE TETRACYCLINE		1	0.5	0	1.1 0.0 0.0 0.0 1.1 0.0 0.0	1	0.4 0.4
SYSTEMIC HORMONAL:		2			1.1 1.1 0.0 0.0		1.1
BETAMETHASONE SODIUM PHOSPHATE		0	0.0	1	1.1	1	0.4
METHYLPREDNISOLONE		1	0.5	0	0.0	1	0.4
PREDNISONE		1					0.4
VARIOUS:		5	2.7	0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	5	1.8
AMINO ACIDS NOS		1	0.5	0	0.0	1	0.4
ANTIINFLAMMATORY NOS		1	0.5	0	0.0	1	0.4
CARBOHYDRATES NOS		1	0.5	0	0.0	1	0.4
ELECTROLYTES NOS		1	0.5	0	0.0	1	0.4
FIBER		1	0.5	0	0.0	1	0.4
MINERALS NOS		1	0.5	0	0.0	1	0.4
NUTRITIONAL SUPPLEMENT NOS		1	0.5	0	0.0	1	
SERTRALINE		2	1.1	Ü	0.0	2	0.7
VITAMINS NOS		1	0.5	0	0.0	1	0.4

Table 13.13b

### Patient Withdrawals

## Intention to Treat Population

Treatment Group: Paroxetine

	  Week 1	Week 2	Week 3	Week 4	Week 6	  Week 8	Week 12	TOTAL
Number of Patients	182	176	166	164	155	149	136	127
REASON								
Adverse Experience	3	5	1	5		2	4	20
Lack of Efficacy	1	1		1	2	4		9
Protocol Violation, including non compliance	1	1		1		2	2	7
Lost to Follow-up	1	2	1	2	3	2	2	13
Other Reason	ļ	1			1	3	1	6
Number of Withdrawals	6	10	2	9	6	13	9	55

### Table 13.13b

#### Patient Withdrawals

## Intention to Treat Population

## Treatment Group: Placebo

	  Week 1	Week 2	  Week 3	  Week 4	Week 6	  Week 8	Week 12	TOTAL
Number of Patients	93	91	88	84	81	78	73	69
REASON	 	 	<u></u>			<u>+</u>	 	
Adverse Experience	1	1		1		2	1	6
Lack of Efficacy		1	1	1	1	2		6
Protocol Violation, including non compliance	1		1	1	1		1	5
Lost to Follow-up		1	2			1	2	6
Other Reason					1			1
Number of Withdrawals	2	3	4	3	3	5	4	24

#### Table 13.14b

### Maximum Daily Amount of Investigational Drug

## Intention To Treat Population

	 	Paroxe	etine		Placebo					
	Number of	Maximum Dose Level				Maximum Dose Level				
	Patients	20 mg	30 mg	40 mg	Number of  Patients	1	2	3		
Number	181	103	46	32	93	52	18	23		
8	100	56	25	17	100	55	19	24		

i = Intention to Treat Population, e = Per Protocol Population

Patient 377.023.00170 is omitted from the Paroxetine Group due to lack of CRF data ( ie. no dose level recorded )

Placebo Dose recorded as Dose Level

#### Table 13.15b

### Summary Statistics of Maximum Daily Amount of Investigational Drug

### Intention To Treat Population

Paroxetine							Placebo						
Mean	Median	Std Dev	Minimum	   Maximum	NO OF PATIENTS IN GROUP	Mean	Median	Std Dev	Minimum	Maximum	NO OF PATIENTS IN GROUP		
26.1	20.0	†   7.7	20	40	181	1.7	1.0	0.8	1	3	93		

i = Intention to Treat Population, e = Per Protocol Population

Patient 377.023.00170 is omitted from the Paroxetine Group due to lack of CRF data ( ie. no dose level recorded )

Placebo Dose recorded as Dose Level

#### Table 13.16b

### Summary of Dose Level at Endpoint

### Intention To Treat Population

		Paroxe	etine		Placebo					
	Number of		Dose Level		  Number of	Dose Level				
	Patients	20 mg	30 mg	40 mg	Patients	1	2	3		
Number	181	107	43	31	93	56	17	20		
%	100	59	23	17	100	60	18	21		

i = Intention to Treat Population, e = Per Protocol Population

Patient 377.023.00170 is omitted from the Paroxetine Group due to lack of CRF data ( ie. no dose level recorded )

Placebo Dose recorded as Dose Level

#### Table 13.17b

### Summary Statistics of Dose Level at Endpoint

### Intention To Treat Population

	Paroxetine							Placebo						
Mean	Median	Std Dev	Minimum	Maximum	NO OF PATIENTS IN GROUP	Mean	Median	Std Dev	Minimum	Maximum	NO OF PATIENTS IN GROUP			
25.8	20.0	7.7	20	40	181	1.6	1.0	0.8	1	3	93			

i = Intention to Treat Population, e = Per Protocol Population

Patient 377.023.00170 is omitted from the Paroxetine Group due to lack of CRF data ( ie. no dose level recorded )

Placebo Dose recorded as Dose Level

#### Table 13.18b

#### Summary Statistics of Mean Dose on Active Treatment

#### Intention To Treat Population

	Paroxetine								Placebo		
Mean	Median	Std Dev	Minimum	Maximum	NO OF PATIENTS IN GROUP	Mean	Median	Std Dev	Minimum	Maximum	NO OF PATIENTS IN GROUP
23.9	20.0	5.2	20	37	181	1.4	1.0	0.6	1	2	93

i = Intention to Treat Population, e = Per Protocol Population

Patient 377.023.00170 is omitted from the Paroxetine Group due to lack of CRF data ( ie. no dose level recorded )

Placebo Dose recorded as Dose Level

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]JOTEST6.SAS (04AUG98 10:28)

Paroxetine - Protocol: 377

Table 13.2b

Summary of Demographic Data

		Paroxetine	Placebo
NUMBER OF PAT	IENTS IN GROUP	182	93
AGE (years)	Mean	15.5	15.8
	Std dev	1.6	1.6
	Minimum	12	13
	Maximum	182   15.5   1.6   12   19   182   163.6	18
	N	15.5   1.6   1.6   1.7   1.6   1.7	93
	Missing		
HEIGHT (cm)	Mean	163.6	164.5
	Std dev	9.1	8.5
	Minimum	140	131
	Maximum	185	184
	N	180	93
	Missing	2	

Paroxetine - Protocol: 377

Table 13.2b

#### Summary of Demographic Data

	Parox	etine	Placebo		
	Number	Percent	Number	Percent	
SEX					
Female	122	67.0	61	65.6	
Male	60	33.0	32	34.4	
TOTAL	182	100.0	93	100.0	
RACE					
Black	2	1.1	4	4.3	
Caucasian	126	69.2	61	65.6	
Oriental	2	1.1			
Other	52	28.6	28	30.1	
TOTAL	182	100.0	93	100.0	

Paroxetine - Protocol: 377

Table 13.2c

#### Summary of Demographic Data

#### Per Protocol Population

		Paroxetine	Placebo
NUMBER OF PAT	IENTS IN GROUP	130	68
AGE (years)	Mean	15.5	15.7
	Std dev	1.6	1.5
	Minimum	13	13
	Maximum	18	18
	N	15.5  1.6  13   18   130   162.7  8.7  142   185	68
	Missing	<u> </u>	
HEIGHT (cm)	Mean	162.7	164.2
	Std dev	8.7	9.0
	Minimum	142	131
	Maximum	185	184
	N	128	68
	Missing	2	

Paroxetine - Protocol: 377

Table 13.2c

#### Summary of Demographic Data

#### Per Protocol Population

	Parox	etine	Placebo		
	Number	Percent	Number	Percent	
SEX					
Female	92	70.8	43	63.2	
Male	38	29.2	25	36.8	
TOTAL	130	100.0	68	100.0	
RACE					
Black	2	1.5	4	5.9	
Caucasian	88	67.7	41	60.3	
Oriental	2	1.5			
Other	38	29.2	23	33.8	
TOTAL	130	100.0	68	100.0	

Paroxetine - Protocol: 377

Table 13.20

#### Number (%) of Patients by Protocol Violation

#### Randomised Patients

		]	reatmer	nt Group	)	
	Paroxetine   Placebo			Total		
	N	%	N	%	N	%
Long term,individualised formal psychotherapy scheduled during study period	18	9.6	8	8.1	26	9.1
Patient has received psychotropic	3	1.6			3	1.0
Duration of active treatment < 6 weeks (36 days)	32	17.1	17	17.2	49	17.1
Concomitant use of prohibited medications	9	4.8	5	5.1	14	4.9
Not compliant with study medication on two consecutive visits	3	1.6	3	3.0	6	2.1
Did not fulfil inclusion criteria	5	2.7			5	1.7
Out of range screening lab values	2	1.1	1	1.0	3	1.0
Total Number of Patients with at least one Major Protocol Violation	57	30.5	31	31.3	88	30.8
Total Number of Patients with no Major Protocol Violations	130	69.5	68	68.7	198	69.2
Total Number of Patients	187	100.0	99	100.0	286	100.0

Paroxetine - Protocol: 377

Table 13.21b

#### Study Medication Compliance

	Treatment Group				
	PAROXETINE   PLACEBO				
Compliant	179	90			
Non Compliant	3	3			

BRL-029060/RSD-100TNP/2/CPMS-377

#### Paroxetine - Protocol: 377

Table 13.3b

#### Significant Medical/Surgical History and Physical Examination Number and % of Patients With Ongoing Conditions Intention to Treat Population

	=====	======	=======	======		======	=====
TREATMENT GROUP			INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH CONDITIONS	:	182 45	100.0% 24.7%	93 27	100.0% 29.0%	275 72	100.0% 26.2%
DISEASE CODE LEVEL 1 : PREFERRED TERM		N	%	N	%	N	용
BLOOD/BLOOD FORMING ORGAN DIS: ANEMIA, HEMOLYT, HERED ANEMIA, OTHER LEUKOPENIA		3 1 2 0	1.6 0.5 1.1 0.0	1 0 0 1	1.1 0.0 0.0	4 1 2 1	1.5 0.4 0.7 0.4
CIRCULATORY SYST: CONDUCTION DISORD HYPERTENSION HYPOTENSION, OTHER		2 1 1 0	1.1 0.5 0.5 0.0	0	1.1 0.0 0.0 1.1	1	1.1 0.4 0.4 0.4
DIGESTIVE SYST:  CONSTIPATION  DYSPEPSIA  ENTERITIS/COLITIS  GASTRITIS/DUODENITIS  TEETH DISORD		2 0 0 1 0 1	0.0	1	3.2 1.1 1.1 0.0 1.1 0.0	1	1.8 0.4 0.4 0.4 0.4
ENDOCR/METAB/IMMUNITY DISORD: CARBOHYDRATE DISORD DIABETES MELLITUS OBESITY		1 0 0 1	0.5 0.0 0.0 0.5	2 1 1 0	2.2 1.1 1.1 0.0	3 1 1 1	1.1 0.4 0.4 0.4
EXT CAUSES OF INJURY/POISONING: ADVERSE EFF/ANTIBIOTIC		1 1	0.5 0.5		0.0	1 1	$0.4 \\ 0.4$
GENITOURINARY SYST DIS: BREAST DISORD GENITAL FEMALE DISORD, OTHER KIDNEY DISORD		5 1 4 0	2.7 0.5 2.2 0.0	0 2	3.2 0.0 2.2 1.1	1 6	2.9 0.4 2.2 0.4
INJURY/POISONING: ALLERGY, NEC		0	0.0	1 1	1.1 1.1	1 1	0.4 0.4

Table 13.3b

#### Significant Medical/Surgical History and Physical Examination Number and % of Patients With Ongoing Conditions Intention to Treat Population

		======	=======	:=====:	======	=====	=====
TREATMENT GROUP		PAROXET	INE	PLACE	30 	TOTA	С
TOTAL NUMBER OF PATIENTS	:	182 45	100.0% 24.7%	93 27	100.0% 29.0%	275 72	100.09 26.29
DISEASE CODE LEVEL 1 : PREFERRED TERM							
MENTAL DISORD: ALCOHOL ABUSE ANXIETY CONDUCT DISORD DRUG ABUSE NEUROSES		4	2.2	1	1.1 0.0 1.1 0.0 0.0	5 1	1.8
MUSCULOSKEL/CONNECT TISSUE DIS: ARTHRITIS, RHEUMATOID BACK PAIN DEFORMITY, ACQUIRED		5 1 3 1	2.7 0.5 1.6 0.5	1 0 1 1	1.1 0.0 1.1 1.1	1	2.2 0.4 1.5 0.7
NERVOUS SYST/SENSE ORGAN DIS: CATARACT EYE DISORD, OTHER MIGRAINE		1 0 1 0	0.5 0.0 0.5 0.0	Ω	1.1	1	1.1 0.4 0.4 0.4
OPERATIONS: OPERATION, EYE OPERATION, OTHER MUSCULOSKEL		1 0 1	0.0	1 1 0	1.1 1.1 0.0	1	0.7 0.4 0.4
RESPIRATORY SYST DIS: ASTHMA RHINITIS, ALLERGIC SINUSITIS, OTHER SINUSITIS,NOS		14 9 3 1 2		4	3.2 4.3 0.0	12 7	
SIGNS,SYMPTOMS,ILL-DEFINED CON: CARDIAC MURMURS DIZZINESS AND GIDDINESS FLATULENCE GASTROINTEST PROB, NEC		15 1 2 0 1	8.2 0.5 1.1 0.0 0.5	8 0 0 1 0	0.0	1	8.4 0.4 0.7 0.4

## Paroxetine - Protocol: 377 Table 13.3b

#### Significant Medical/Surgical History and Physical Examination Number and % of Patients With Ongoing Conditions Intention to Treat Population

	=====	======	=======	======	=======	=====:	======
TREATMENT GROUP		PAROXET	INE	PLACE	30	TOTA	Ĺ
TOTAL NUMBER OF PATIENTS PATIENTS WITH CONDITIONS	:		100.0% 24.7%		100.0%		100.0% 26.2%
DISEASE CODE LEVEL 1 : PREFERRED TERM		N	%	N	%	N	%
HEADACHE INSOMNIA MENTAL STATUS, IMPAIRED NAUSEA PAIN, ABDOMINO-PELVIC PALPITATIONS		8 3 1 2 2 0	4.4 1.6 0.5 1.1 1.1	5 2 0 0 0		13 5 1 2 2	4.7 1.8 0.4 0.7 0.7
SKIN/SUBCUTANEOUS TISSUE DIS: SKIN/SUBCUT DISORD, OTHER		4 4	2.2	4 4	4.3 4.3	8 8	2.9 2.9

 ${\bf Table~13.31}$  Number (%) of Patients with Clinically Significant Abnormalities in ECG at Screening

SIGNIFICANT ABNORMALITY	PAROXI	ETINE	PLAC	CEBO	NO THERAPY DISPENSED			
	N	%	N	   %	N	%		
YES	1	0.53	0	0	2	6.45		
NO	186	99.47	99	100.00	29	93.55		
NUMBER OF PATIENTS WITH ASSESSMENT	187	100.00	99	100.00	31	100.00		
MISSING	0	0	0	0	7	100.00		

All Patients

Table 13.4b

#### Psychiatric History

	Paroxetine						Placebo						
	Nι	Number of Patients in Group						Number of Patients in Group					
		182						93					
	No   Suspected			Υe	es	No	)	Suspe	ected   Yes		es		
	N	%	N	%	N	   %	N	%	N	%	N	%	
Major episode of depression	129	70.9	14	7.7	39	21.4	64	68.8	10	10.8	19	20.4	
Schizophrenia	182	100.0	0	0	0	0	93	100.0	0	0	0	0	
Alcoholism/drug abuse/medication abuse	178	97.8	0	0	4	2.2	89	95.7	1	1.1	3	3.2	
Anxiety/obsessional disorders	163	89.6	6	3.3	13	7.1	82	88.2	2	2.2	9	9.7	
Personality disorder	177	97.3	3	1.6	2	1.1	93	100.0	0	0	0	0	

BRL-029060/RSD-100TNP/2/CPMS-377

Paroxetine - Protocol: 377

Table 13.3.2b

Significant Medical/Surgical History and Physical Examination Number and % of Patients With Past, Ongoing or Past and Ongoing Conditions Intention to Treat Population

TREATMENT GROUP		PAROXET	INE	PLACEI	30	TOTA	L		
	:	182 64	100.0% 35.2%	93 37	100.0% 39.8%	275 101	100.0% 36.7%		
DISEASE CODE LEVEL 1 : PREFERRED TERM					%				
ANOMALIES: CONG ANOM, GU		0	0.0	1 1	1.1 1.1	1	0.4		
BLOOD/BLOOD FORMING ORGAN DIS: ANEMIA, HEMOLYT, HERED ANEMIA, IRON DEFIC ANEMIA, OTHER LEUKOPENIA		4 1 1 2 0	2.2 0.5 0.5 1.1 0.0	0	1.1 0.0 0.0 0.0 1.1	1	0.4		
CIRCULATORY SYST: CONDUCTION DISORD HYPERTENSION HYPOTENSION, OTHER		2 1 1 0	1.1 0.5 0.5 0.0	0	1.1 0.0 0.0 1.1	1	0.4		
COMPLIC OF PREGNANCY/BIRTH: PREGNANCY, COMPLICATIONS		0 0	0.0	1 1	1.1 1.1	1	0.4 0.4		
DIGESTIVE SYST: APPENDICITIS CONSTIPATION DYSPEPSIA ENTERITIS/COLITIS GASTRITIS/DUODENITIS HEPATITIS HERNIA, ABDOMINAL TEETH DISORD		6 1 0 0 1 0 1 2	0.5	0 1 1 0 2 0	4.3 0.0 1.1 1.1 0.0 2.2 0.0 0.0	1 1 1 2 1 2	0.4 0.4 0.4 0.7 0.4		
ENDOCR/METAB/IMMUNITY DISORD: CARBOHYDRATE DISORD DIABETES MELLITUS OBESITY		1 0 0 1	0.5 0.0 0.0 0.5		2.2 1.1 1.1 0.0	3 1 1 1	1.1 0.4 0.4 0.4		

Table 13.3.2b

Significant Medical/Surgical History and Physical Examination Number and % of Patients With Past, Ongoing or Past and Ongoing Conditions Intention to Treat Population

TREATMENT GROUP		INE	PLACE	30	TOTAL					
TOTAL NUMBER OF PATIENTS PATIENTS WITH CONDITIONS	: 182 : 64	100.0% 35.2%	93 37	100.0% 39.8%	275 101	100.0% 36.7%				
DISEASE CODE LEVEL 1 : PREFERRED TERM				%						
EXT CAUSES OF INJURY/POISONING: ACCIDENT/MOTOR VEHICLE ADVERSE EFF/ANTIBIOTIC SUICIDE	1 0 1 0	0.5 0.0 0.5 0.0	2 1 0 1	2.2 1.1 0.0 1.1	3 1 1 1	1.1 0.4 0.4 0.4				
GENITOURINARY SYST DIS: BREAST DISORD GENITAL FEMALE DISORD, OTHER KIDNEY DISORD	6 1 5 0	3.3 0.5 2.7 0.0	2	3.2 0.0 2.2 1.1	7	3.3 0.4 2.5 0.4				
INFECTIOUS/PARASITIC DIS: VIRAL DIS/EXANTHEM VIRUS/CHLAMYD DIS, OTHER	3 1 3	1.6 0.5 1.6		0.0 0.0 0.0	3 1 3	1.1 0.4 1.1				
INJURY/POISONING: ALLERGY, NEC CONTUSION FRACTURE, LOWER LIMB FRACTURE, UPPER LIMB SPRAINS/STRAINS TRAUMA/INJURIES, UNSPEC	3 0 0 1 1 1 0	1.6 0.0 0.0 0.5 0.5 0.5	1	1.1 1.1 1.1 0.0	1 2 1	0.4 0.7				
MENTAL DISORD: ALCOHOL ABUSE ANXIETY CONDUCT DISORD DRUG ABUSE NEUROSES PSYCHOGENIC PHYSIOL DYSFUNC	5 1 1 1 2 0	2.7 0.5 0.5 0.5 0.5 1.1	0	2.2 0.0 1.1 0.0 0.0	7 1 2 1 1 2					
MUSCULOSKEL/CONNECT TISSUE DIS: ARTHRITIS, RHEUMATOID	6 1	3.3 0.5		1.1	7 1	2.5 0.4				

BRL-029060/RSD-100TNP/2/CPMS-377

Paroxetine - Protocol: 377

Table 13.3.2b

Significant Medical/Surgical History and Physical Examination Number and % of Patients With Past, Ongoing or Past and Ongoing Conditions Intention to Treat Population

TREATMENT GROUP		PAROXET	INE	PLACE	30	TOTAL		
					100.0% 39.8%			
DISEASE CODE LEVEL 1 : PREFERRED TERM		N	%	N	%	N	%	
BACK PAIN DEFORMITY, ACQUIRED PAIN, JOINT				1 1 0	1.1 1.1 0.0	4 2 1	1.5 0.7 0.4	
NERVOUS SYST/SENSE ORGAN DIS: CATARACT EPILEPSY EYE DISORD, OTHER MENINGITIS MIGRAINE		4 0 2 1 2 0	2.2 0.0 1.1 0.5 1.1	3 1 1 0 0	3.2 1.1 1.1 0.0 0.0	7 1 3 1 2 1	2.5 0.4 1.1 0.4 0.7 0.4	
OPERATIONS: OPERATION, APPENDIX OPERATION, BONE/JOINT OPERATION, EAR OPERATION, EYE OPERATION, FEM GENITAL OPERATION, NOSE/MOUTH OPERATION, OTHER MUSCULOSKEL OPERATION, OTHER URINARY OPERATION, SKIN/SUBCUT PROCEDURE, SURGERY UNSP		13 4 3 0 0 0 6 1 0	7.1 2.2 1.6 0.0 0.0 0.0 3.3 0.5 0.0	2 0 1 1 5 0 1	9.7 2.2 0.0 1.1 1.1 5.4 0.0 1.1 0.0	6 3 1 1 1 11 1 1	2.2 1.1 0.4 0.4 0.4 4.0 0.4 0.4 0.4	
PROCEDURES: EVALUATION, DX EXAM		1 1	0.5 0.5	0 0	0.0	1 1	0.4 0.4	
RESPIRATORY SYST DIS: ASTHMA BRONCHITIS, OTHER PNEUMONIA, OTHER RESP DIS, OTHER RHINITIS, ALLERGIC		17 10 2 0 1 3	9.3 5.5 1.1 0.0 0.5 1.6	3 0	8.6 3.2 0.0 2.2 0.0 4.3	13 2	4.7 0.7	

Table 13.3.2b

Significant Medical/Surgical History and Physical Examination Number and % of Patients With Past, Ongoing or Past and Ongoing Conditions Intention to Treat Population

TREATMENT GROUP	:=====: :	PAROXET:	====== INE	PLACEI	30	TOTAL		
TOTAL NUMBER OF PATIENTS PATIENTS WITH CONDITIONS	:	182	 100.0%	93	100.0%	275	100.0%	
DISEASE CODE LEVEL 1 : PREFERRED TERM		N	*	N	%	N	%	
SINUSITIS, OTHER SINUSITIS,NOS		1 2	0.5 1.1	0	0.0	1 2	0.4	
SIGNS,SYMPTOMS,ILL-DEFINED CON: ANOREXIA CARDIAC MURMURS CONVULSIONS DIZZINESS AND GIDDINESS EPISTAXIS FLATULENCE GASTROINTEST PROB, NEC HEADACHE		21 0 1 1 3 1 0 1	11.5 0.0 0.5 0.5 1.6 0.5 0.0 0.5	0 0	9.7 1.1 0.0 0.0 0.0 0.0 1.1 0.0 5.4 1.1 2.2	1 1 3	0.4 0.4 1.1	
HYPERVENTILATION INSOMNIA MENTAL STATUS, IMPAIRED NAUSEA PAIN, ABDOMINO-PELVIC PALPITATIONS SWELLING, MASS, LOCALIZED		0 4 1 2 3 0	0.0 2.2 0.5 1.1 1.6 0.0	0 0	1.1 2.2 0.0 0.0 0.0 1.1	2 3	0.4 0.7 1.1	
SKIN/SUBCUTANEOUS TISSUE DIS: INFLAM SKIN/SUBCUT SKIN/SUBCUT DISORD, OTHER		5 1 4	2.7 0.5 2.2	4 0 4	4.3 0.0 4.3			

Table 13.5b

### Personal History - Current Situation Family Composition

	Paroxe	tine	Placebo		
	N	%	N	%	
2 parent home	92	50.5	48	51.6	
Single parent alone	34	18.7	16	17.2	
1 parent & 1 step- parent	11	6.0	4	4.3	
1 parent & 1 common- law parent	3	1.6	3	3.2	
Other relative(s) is (are) caregiver(s)	6	3.3	2	2.2	
Parent & other relative(s) are caregiver(s)	3	1.6	3	3.2	
Other	33	18.1	17	18.3	
Number of patients in group	182	100.0	93	100.0	

Table 13.6b

#### Personal History - Current Situation Adoptive Status

	Paroxe	etine	Placebo		
	N	%   %	N	· 왕	
Adopted	+   5	2.7	0	0	
Natural offspring	172	94.5	91	97.8	
Other	5	2.7	2	2.2	
Number of patients in group	182	100.0	93	100.0	

Table 13.7b

### Personal History - Current Situation Education

 	Paroxe	tine	Placebo		
	N	%	N	%	
Regular education	168	92.3	85	91.4	
Special education	11	6.0	7	7.5	
Number of patients in group	182	100.0	93	100.0	
Missing	3	0	1	0	

### 11 Source Tables: Efficacy Results

and Change from Baseline in Depression Subscale Total Scores by Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline. Excluding Centre 007 (ITT)	000168
Table 14.010d K-SADS-L (Using Last 2 Weeks Rating Score) Baseline and Change from Baseline in Depression Subscale Total Scores by Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline. Excluding Centre 007 (ITT LOCF)	
Table 14.01b MADRS Response Rates (Total Score Reduced by at Least 50% from Baseline) Excluding Centre 007 (ITT)	000172
Table 14.01c MADRS Response Rates (Total Score Reduced by at Least 50% from Baseline) Excluding Centre 007 (PP)	000173
Table 14.01d MADRS Response Rates (Total Score Reduced by at Least 50% from Baseline) Excluding Centre 007 (ITT LOCF)	000174
Table 14.01e MADRS Response Rates (Total Score Reduced by at Least 50% from Baseline) Excluding Centre 007 (PP LOCF)	000175
Table 14.02b MADRS Response Rates by Dose at Endpoint Excluding Centre 007 (ITT)	000176
Table 14.02c MADRS Response Rates by Dose at Endpoint Excluding Centre 007 (PP)	000179
Table 14.02d MADRS Response Rates by Dose at Endpoint Excluding Centre 007 (ITT LOCF)	000182
Table 14.02e MADRS Response Rates by Dose at Endpoint Excluding Centre 007 (PP LOCF)	000185
Table 14.03b MADRS Baseline and Change from Baseline in Total Scores Excluding Centre 007 (ITT)	000188
Table 14.03d MADRS Baseline and Change from Baseline in Total Scores Excluding Centre 007 (ITT LOCF)	
Table 14.04b K-SADS-L (Using Last 2 Weeks Rating Score) Baseline and Change from Baseline in Depression Subscale Total Scores Excluding Centre 007 (ITT)	000190
Table 14.04c K-SADS-L (Using Last 2 Weeks Rating Score) Baseline and Change from Baseline in Depression Subscale Total Scores Excluding Centre 007 (PP)	
Table 14.04d K-SADS-L (Using Last 2 Weeks Rating Score) Baseline and change from Baseline in Depression Subscale Total Scores Excluding Centre 007 (ITT LOCF)	000192
Table 14.04e K-SADS-L (Using Last 2 Weeks Rating Score) Baseline and Change from Baseline in Depression Subscale Total Scores Excluding Centre 007 (PP LOCF)	

Table 14.05b Montgomery-Asberg Depression Rating Scale. Response rates (Total Score Reduced by at Least 50% from Baseline) by Age Group Excluding Centre 007 (ITT)	00194
Table 14.05d Montgomery-Asberg Depression Rating Scale. Response rates (Total Score Reduced by at Least 50% from Baseline) by Age Group Excluding Centre 007 (ITT LOCF)	00196
Table 14.06b Montgomery-Asberg Depression Rating Scale. Response rates (Total Score Reduced by at Least 50% from Baseline) by Presence of Comorbid Conduct Disorder at Baseline Excluding Centre 007 (ITT)	00198
Table 14.06d Montgomery-Asberg Depression Rating Scale. Response rates (Total Score Reduced by at Least 50% from Baseline) by Presence of Comorbid Conduct Disorder at Baseline Excluding Centre 007 (ITT LOCF)	00199
Table 14.07b Montgomery-Asberg Depression Rating Scale. Response rates (Total Score Reduced by at Least 50% from Baseline) by Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline Excluding Centre 007 (ITT)	00200
Table 14.07d Montgomery-Asberg Depression Rating Scale. Response rates (Total Score Reduced by at Least 50% from Baseline) by Comorbid Social Phobia/OCD/GAD/Panic Disorder Excluding Centre 007 (ITT LOCF)	00202
Table 14.08b K-SADS-L (Using Last 2 Weeks Rating Score) Baseline and Change from Baseline in Depression Subscale Total Scores. By Age Group. Excluding Centre 007 (ITT)	00204
Table 14.08d K-SADS-L (Using Last 2 Weeks Rating Score) Baseline and Change from Baseline in Depression Subscale Total Scores. By Age Group. Excluding Centre 007 (ITT LOCF)	00206
Table 14.09b K-SADS-L (Using Last 2 Weeks Rating Score) Baseline and Change from Baseline in Depression Subscale Total Scores by presence of Baseline Comorbid Conduct Disorder at Baseline.  Excluding Centre 007 (ITT)	00208
Table 14.09d K-SADS-L (Using Last 2 Weeks Rating Score) Baseline and Change from Baseline in Depression Subscale Total Scores by Presence of Baseline Comorbid Conduct Disorder at Baseline.  Excluding Centre 007 (ITT LOCF)	00209
Table 14.10b Number and Percentage of Patients in Each Category of CGI Severity of Illness Scores Excluding Centre 007 (ITT) 00	00210
Table 14.10d Number and Percentage of Patients in Each Category of CGI Severity of Illness Scores Excluding Centre 007 (ITT LOCF)00	00216
Table 14.11b Baseline and Change from Baseline in CGI Severity of Illness Score Excluding Centre 007 (ITT)	00222
Table 14.11d Baseline and Change from Baseline in CGI Severity of Illness Score Excluding Centre 007 (ITT LOCF)	00223

Table 14.12b Number of Patients in Each Category of Change from Baseline in CGI Severity of Illness Score Excluding Centre 007 (ITT)	000224
Table 14.12d Number of Patients in Each Category of Change from Baseline in CGI Severity of Illness Score Excluding Centre 007 (ITT LOCF)	
Table 14.13b Number and Percentage of Patients in Each Category of CGI Global Improvement Score Excluding Centre 007 (ITT)	000230
Table 14.13d Number and Percentage of Patients in Each Category of CGI Blobal Improvement Score Excluding Centre 007 (ITT LOCF)	000235
Table 14.20b BDI Baseline and Change from Baseline in Total Score Excluding Centre 007 (ITT)	000240
Table 14.20d BDI Baseline and Change from Baseline in Total Score Excluding Centre 007 (ITT LOCF)	000241
Table 14.30b MFQ Baseline and Change from Baseline in Total Scores (ITT)	000242
Table 14.30d MFQ Baseline and Change from Baseline in Total Scores (ITT LOCF)	
Table 14.50b NHP Baseline and Change From Baseline in Total Scores - Every Domain (ITT)	
Table 14.50d Nottingham Health Profile (NHP) Baseline and Change From Baseline in Total Scores - Every Domain (ITT LOCF)	000245
Table 14.51b NHP Baseline and Change From Baseline in Total Scores - Energy Domain (ITT)	000246
Table 14.51d NHP Baseline and Change From Baseline in Total Scores - Energy Domain (ITT LOCF)	000247
Table 14.52b NHP Baseline and Change From Baseline in Total Scores - Emotional Reaction Domain (ITT)	000248
Table 14.52d NHP Baseline and Change From Baseline in Total Scores - Emotional Reaction Domain (ITT LOCF)	000249
Table 14.53b NHP Baseline and Change From Baseline in Total Scores - Pain Domian (ITT)	000250
Table 14.53d NHP Baseline and Change From Baseline in Total Scores - Pain Domian (ITT LOCF)	000251
Table 14.54b NHP Baseline and Change From Baseline in Total Scores - Physical Mobility Domian (ITT)	000252
Table 14.54d NHP Baseline and Change From Baseline in Total Scores - Physical Mobility Domian (ITT LOCF)	000253
Table 14.55b NHP Baseline and Change From Baseline in Total Scores - Sleep Domian (ITT)	000254
Table 14.55d NHP Baseline and Change From Baseline in Total Scores - Sleep Domian (ITT LOCF)	000255
Table 14.56b NHP Baseline and Change from From Baseline in Total Scores - Social Isolation Domian (ITT)	000256

Table 14.56d NHP Baseline and Change From Baseline in Total Scores	
- Social Isolation Domian (ITT LOCF)	
Table 14.60b Euroqol Summary Scores (ITT)	3
Table 14.61b Euroqol Baseline and Change from Baseline in Score (ITT)	9
Table 14.70b Socio-Economic Questionnaire - Living Arrangements At Baseline Assessment Excluding Centre 007 (ITT)000260	$\mathbf{c}$
Table 14.71b Socio-Economic Questionnaire - Current Employment Status Excluding Centre 007 (ITT)00026	1
Table 14.72b Socio-Economic Questionnaire - Patients with problems with Employment Status Excluding Centre 007 (ITT)000265	5
Table 14.73b Socio-Economic Questionnaire - Summary of Patients Missing Days from School/College/Work Excluding Centre 007 (ITT) 000266	5
Table 14.74b Socio-Economic Questionnaire - Summary of Days Missed from School/College/Work Excluding Centre 007 (ITT) 000269	9
Table 14.75b Socio-Economic Questionnaire - Patients with Problems with Specified Activities Excluding Centre 007 (ITT)	1
Table 14.76b Socio-Economic Questionnaire - Change in Problems with Specified Activities Excluding Centre 007 (ITT)	5
Table 14.81b Summary of Psychotherapy Evaluation Profession Involvement Excluding Centre 007 (ITT)	3
Table 14.82b Summary of Psychotherapy Evaluation: Therapy Received Excluding Centre 007 (ITT)	5
Table 14.90b Child-Global Assessment Scale. Screening and Change from Screening in Total Scores Excluding Centre 007 (ITT)00028	7

Table 14.010b

Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score)
Baseline and Change from Baseline in Depression Subscale Total Scores By Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline Excluding Centre 007

Intention to Treat Population

Presence of Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline: No

	Paroxetine						Placebo					
	Mean	Median	S.E	Minimum		Number of Patients in Group	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group
Baseline	24.3	24.0	0.4	11.0	36.0	155	24.7	24.0	0.6	13.0	36.0	81
Week 2	-4.1	-4.0	0.4	-19.0	7.0	153	-4.0	-4.0	0.5	-20.0	6.0	81
Week 4	-6.5	-7.0	0.5	-25.0	15.0	141	-6.3	-6.0	0.6	-20.0	7.0	73
Week 6	-8.1	-9.0	0.6	-26.0	12.0	131	-7.3	-7.0	0.7	-21.0	7.0	71
Week 8	-9.6	-10.0	0.5	-25.0	9.0	129	-8.7	-9.0	0.7	-22.0	7.0	+   67
  Week 12	-10.6	-11.0	0.6	-26.0	6.0	112	-9.9	-9.0	0.7	-22.0	2.0	+   61

#### Table 14.010b

Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score)
Baseline and Change from Baseline in Depression Subscale Total Scores By Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline

Excluding Centre 007

Intention to Treat Population

Presence of Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline: Yes

 			Par	oxetine			Placebo					
	Mean	Median	S.E	Minimum		Number of Patients in Group		Median	S.E	Minimum		Number of  Patients  in Group
Baseline	26.9	26.5	1.2	20.0	37.0	16	25.7	27.0	1.7	16.0	29.0	7
Week 2	-4.4	-3.5	1.2	-12.0	2.0	14	-9.9	-10.0	2.4	-18.0	0.0	7
Week 4	-6.6	-7.0	1.3	-15.0	1.0	14	-10.7	-13.5	3.1	-18.0	2.0	6
Week 6		-9.0	1.7	-21.0	2.0	15	-12.0	-14.5	2.8	-18.0	0.0	6
Week 8	-12.8	-12.5	1.3	-20.0	-4.0	14	-11.6	-15.0	3.3	-18.0	0.0	5
Week 12	-13.4	-13.5	1.8	-23.0	-1.0	14	-10.2	-14.0	4.5	-19.0	1.3	5

### Table 14.010d

Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score)
Baseline and Change from Baseline in Depression Subscale Total Scores By Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline Excluding Centre 007

Intention to Treat Population (LOCF)

#### Presence of Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline: No

			Paro	oxetine			Placebo					
	Mean	Median	S.E	Minimum		Number of Patients in Group	Mean	  Median	S.E	Minimum	Maximum	Number of Patients in Group
Baseline	24.3	24.0	0.4	11.0	36.0	155	24.7	24.0	0.6	13.0	36.0	81
Week 2	-4.1	-4.0	0.4	-19.0	7.0	153	-4.0	-4.0	0.5	-20.0	6.0	81
Week 4	-6.3	-6.0	0.5	-25.0	15.0	155	-6.2	-6.0	0.6	-20.0	7.0	81
Week 6	-7.4	-7.0	0.5	-26.0	12.0	155	-7.1	-7.0	0.6	-21.0	7.0	81
Week 8	-8.4	-8.0	0.5	-25.0	9.0	155	-7.9	-8.0	0.7	-22.0	7.0	81
Week 12	-8.9	-9.0   -9.0	0.5	-26.0	6.0	155	-8.7	-8.0	0.7	-22.0	7.0	81

#### Table 14.010d

Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score)
Baseline and Change from Baseline in Depression Subscale Total Scores By Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline

Excluding Centre 007

Intention to Treat Population (LOCF)

Presence of Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline: Yes

 		Paroxetine					Placebo					
	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group	Mean	Median	S.E	Minimum		Number of  Patients  in Group
Baseline	26.9	26.5	1.2	20.0	37.0	16	25.7	27.0	1.7	16.0	29.0	+   7
Week 2	-4.4	-3.5	1.2	-12.0	2.0	14	-9.9	-10.0	2.4	-18.0	0.0	†   7
Week 4	-7.0	-8.0	1.3	-15.0	1.0	15	-10.6	-12.0	2.7	-18.0	2.0	+   7
Week 6	-9.3	-10.5	1.6	-21.0	2.0	16	-11.7	-14.0	2.4	-18.0	0.0	+   7
Week 8	-11.3	-11.6	1.6	-20.0	2.0	16	-12.1	-15.0	2.4	-18.0	0.0	+   7
Week 12	-11.8	-13.0	1.9	-23.0	2.0	16	-11.1	-14.0	3.3	-19.0	1.3	+   7

Table 14.01b

## Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) Excluding Centre 007 Intention to Treat Population

 	   Pa	aroxetine		Placebo			
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent	
Week 1	176	8	4.5	89	2	2.2	
Week 2	165	22	13.3	86	11	12.8	
Week 3	153	32	20.9	84	24	28.6	
Week 4	155	57	36.8	77	22	28.6	
Week 6	146	69	47.3	77	32	41.6	
Week 8	144	94	65.3	72	43	59.7	
Week 12	126	94	74.6	66	+   47	71.2	

Table 14.01c

## Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) Excluding Centre 007 Per Protocol Population

	P:	aroxetine		Placebo			
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent	
Week 1	130	4	3.1	66	2	3.0	
Week 2	126	18	14.3	66	10	15.2	
Week 3	123	30	24.4	68	20	29.4	
Week 4	127	51	40.2	63	18	28.6	
Week 6	123	59	48.0	66	27	40.9	
Week 8	123	82	66.7	61	36	59.0	
Week 12	108	82	75.9	56	40	71.4	

Paroxetine - Protocol: 377

Table 14.01d

# Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) Excluding Centre 007 Intention to Treat Population LOCF

 	   Pa	aroxetine			Placebo	
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	176	8	4.5	89	2	2.2
Week 2	+   177	23	13.0	91	12	13.2
Week 3	177	35	19.8	91	24	26.4
Week 4	177	60	33.9	91	25	27.5
Week 6	+   177	+	41.2	91	33	36.3
Week 8	+   177	+   97 :	54.8	91	+   45	49.5
Week 12	177	107	60.5	91	+   53	58.2

Table 14.01e

## Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) Excluding Centre 007 Per Protocol Population LOCF

 	   Pa	aroxetine		Placebo			
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent	
Week 1	130		3.1	66	2	3.0	
Week 2	130	18	13.8	68	11	16.2	
Week 3	130	31	23.8	68	20	29.4	
Week 4	130	52	40.0	68	21	30.9	
Week 6	130	61	46.9	68	28	41.2	
Week 8	130	83	63.8	68	38	55.9	
Week 12	130	91	70.0	68	+   45	66.2	

Table 14.02b

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Intention to Treat Population
Dose Level = 1

 	Pa	aroxetine		 	Placebo	 
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	102	5	4.9	53	1	1.9
Week 2	93	14	15.1	51	7	13.7
Week 3	82	21	25.6	49	19	38.8
Week 4	83	37	44.6	46	18	39.1
Week 6	78	40	51.3	46	23	50.0
Week 8	79	61	77.2	43	29	67.4
  Week 12	   71	   58	81.7	39	31	79.5

Active treatment dose levels: 1 = 20mg, 2 = 30mg, 3 = 40mg

#### Table 14.02b

Montgomery-Asberg Depression Rating Scale Response Rates by Dose at Endpoint Excluding Centre 007 Intention to Treat Population Dose Level = 2

 	   Pa	aroxetine		 	Placebo	 
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	43	3	7.0	17		[
Week 2	41	8	19.5	17	2	11.8
Week 3	40	9	22.5	16	3	18.8
Week 4	42	15	35.7	14	2	14.3
Week 6	42	25	59.5	15	6	40.0
Week 8	41	27	65.9	14	9	64.3
Week 12	39	29	74.4	13	11	84.6

Active treatment dose levels: 1 = 20mg, 2 = 30mg, 3 = 40mg

#### Table 14.02b

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Intention to Treat Population
Dose Level = 3

 	Pa	aroxetine		   	Placebo	
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	31			19	1	5.3
Week 2	31		ļ	18	2	11.1
Week 3	31	2	6.5	19	2	10.5
Week 4	30	5	16.7	17	2	11.8
Week 6	26	4	15.4	16	3	18.8
Week 8	24	6	25.0	15	5	33.3
Week 12	16	+   7	43.8	14	5 5	35.7

Active treatment dose levels: 1 = 20mg, 2 = 30mg, 3 = 40mg

Table 14.02c

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Per Protocol Population
Dose Level = 1

 	   Pa	aroxetine		 	Placebo	
	Number of Patients	Number   with 50%  Reduction	Percent	Number of Patients	Number   with 50%  Reduction	Percent
Week 1	76	1	1.3	39	1	2.6
Week 2	73	11	15.1	40	7	17.5
Week 3	71	20	28.2	41	16	39.0
Week 4	73	33	45.2	38	15	39.5
Week 6	70	37	52.9	39	19	48.7
Week 8	71		77.5	37	24	64.9
Week 12	64	53	82.8	32	26	81.3

Active treatment dose levels: 1 = 20mg, 2 = 30mg, 3 = 40mg

#### Table 14.02c

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Per Protocol Population
Dose Level = 2

 	Pa	aroxetine			Placebo	
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	32	3	9.4	13	+	[
Week 2	31	7	22.6	13	1	7.7
Week 3	30	8	26.7	13	2	15.4
Week 4	32	14	43.8	12	1	8.3
Week 6	32	19	59.4	13	5	38.5
Week 8	31	22	71.0	12	7	58.3
Week 12	29	22	75.9	12	10	83.3

Active treatment dose levels: 1 = 20mg, 2 = 30mg, 3 = 40mg

### Table 14.02c

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Per Protocol Population
Dose Level = 3

 	   Pa	aroxetine		Placebo				
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent		
Week 1	22	<u></u>	 	14	1	7.1		
Week 2	22			13	2	15.4		
Week 3	22	2	9.1	14	2	14.3		
Week 4	22	+	18.2	13	2	15.4		
Week 6	21	3	14.3	14	3	21.4		
Week 8	21	5 5	23.8	12	5	41.7		
Week 12	15	+   7	46.7	12	4	33.3		

Active treatment dose levels: 1 = 20mg, 2 = 30mg, 3 = 40mg

Paroxetine - Protocol: 377

Table 14.02d

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Intention to Treat Population LOCF
Dose Level = 1

 	   Pa	aroxetine		Placebo				
	Number of Patients	Number   with 50%  Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent		
Week 1	102	5	4.9	53	1	1.9		
Week 2	103	15	14.6	55	7	12.7		
Week 3	103	24	23.3	55	19	34.5		
Week 4	103	40	38.8	55	20	36.4		
Week 6	103	+   44	42.7	55	24	43.6		
Week 8	103	+	62.1	55	30	54.5		
  Week 12	103	+   68	66.0	55	35	63.6		

Active treatment dose levels: 1 = 20mg, 2 = 30mg, 3 = 40mg

### Table 14.02d

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Intention to Treat Population LOCF
Dose Level = 2

 	Pa	aroxetine		Placebo				
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent		
Week 1	43	3	7.0	17	+	[		
Week 2	43	8	18.6	17	2	11.8		
Week 3	43	9	20.9	17	3	17.6		
Week 4	43	15	34.9	17	3	17.6		
Week 6	43	25	58.1	17	6	35.3		
Week 8	43	27	62.8	17	9	52.9		
Week 12	43	30	69.8	17	12	70.6		

Active treatment dose levels: 1 = 20 mg, 2 = 30 mg, 3 = 40 mg

### Table 14.02d

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Intention to Treat Population LOCF
Dose Level = 3

 	Pa	aroxetine			Placebo	
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	31			19	1	5.3
Week 2	31			19	3	15.8
Week 3	31	2	6.5	19	2	10.5
Week 4	31	5	16.1	19	2	10.5
Week 6	31	4	12.9	19	3	15.8
Week 8	31	6	19.4	19	6	31.6
Week 12	31	9	29.0	19	6	31.6

Active treatment dose levels: 1 = 20 mg, 2 = 30 mg, 3 = 40 mg

Table 14.02e

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Per Protocol Population LOCF
Dose Level = 1

 	   Pa	aroxetine		 	Placebo	 
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	76	1	1.3	39	1	2.6
Week 2	   76	11	14.5	41	7	17.1
Week 3	   76	21	27.6	41	16	39.0
Week 4	   76	34	44.7	41	17	41.5
Week 6	   76	39	51.3	41	20	48.8
Week 8	+   76	56	73.7	41	25	61.0
  Week 12	+   76	60	78.9	41	30	73.2

Active treatment dose levels: 1 = 20mg, 2 = 30mg, 3 = 40mg

### Table 14.02e

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Per Protocol Population LOCF
Dose Level = 2

 	Pa	aroxetine		   	Placebo	
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	32	3	9.4	13		[
Week 2	32	7	21.9	13	1	7.7
Week 3	32	8	25.0	13	2	15.4
Week 4	32	14	43.8	13	2	15.4
Week 6	32	19	59.4	13	5	38.5
Week 8	32	22	68.8	13	7	53.8
Week 12	32	23	†   71.9	13	10	76.9

Active treatment dose levels: 1 = 20mg, 2 = 30mg, 3 = 40mg

### Table 14.02e

Montgomery-Asberg Depression Rating Scale
Response Rates by Dose at Endpoint
Excluding Centre 007
Per Protocol Population LOCF
Dose Level = 3

 	Pa	aroxetine		Placebo				
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent		
Week 1	22	<u></u>	 	14	1	7.1		
Week 2	22	<u></u>	 	14	3	21.4		
Week 3	22	2	9.1	14	2	14.3		
Week 4	22	+	18.2	14	2	14.3		
Week 6	22	3	13.6	14	3	21.4		
Week 8	22	5 5	22.7	14	6	42.9		
Week 12	22	8	36.4	14	5 5	35.7		

Active treatment dose levels: 1 = 20 mg, 2 = 30 mg, 3 = 40 mg

1

Paroxetine - Protocol: 377

Table 14.03b

## Montgomery-Asberg Depression Rating Scale Baseline and Change from Baseline in Total Scores Excluding Centre 007 Intention to Treat Population

	 			Paroxetine			Placebo							
	Mean	Median	s.e	Minimum	   Maximum	Number of   Patients   in Group	   Mean	  Median	s.e	Minimum	   Maximum	Number of   Patients   in Group		
Baseline	25.9	25.0	0.5	16	+   40	177	25.9	25.0	0.6	16	+   39	91		
Week 1	-3.3	-2.5	0.4	-23	11	176	-3.4	-3.0	0.5	-16	11	89		
Week 2	-5.4	-5.0	0.5	-29	12	165	-5.7	-5.0   -5.0	0.7	-22	10	86		
Week 3	-7.9	-7.0	0.6	-32	+   9	153	-7.5	+   -6.5	0.8	-29	10	84		
Week 4	-9.8	-10.0	0.7	-36	+   11	155	-9.0	-8.0	0.7	-25	+   6	-+   77		
Week 6	-11.7	-12.0	0.7	-35	12	146	-11.0	-11.0	1.0	-27	18	77		
Week 8	-14.2	-14.0	0.7	-37	+   12	144	-12.9	-12.5	1.0	-32	+   13	72		
Week 12	+   -16.2	   -17.0	18.0	-39	+   11	126	+   -15.2	++   -16.0	1.0	-31	+   5	-+   66		

1

Paroxetine - Protocol: 377

Table 14.03d

## Montgomery-Asberg Depression Rating Scale Baseline and Change from Baseline in Total Scores Excluding Centre 007 Intention to Treat Population LOCF

 	 			Paroxetine			Placebo						
	Mean	Median	s.e	Minimum	   Maximum	Number of   Patients   in Group	Mean	Median	s.e	Minimum	   Maximum	Number of Patients in Group	
Baseline	25.9	25.0	0.5	16	40	177	25.9	25.0	0.6	16	39	91	
Week 1	-3.3	-2.5	0.4	-23	+   11	176	-3.4	-3.0	0.5	-16	11	89	
Week 2	-5.4	-5.0	0.5	-29	12	177	-5.8	-5.0	0.6	-22	10	91	
Week 3	-7.5	-7.0	0.5	-32	9	177	-7.2	-6.0	0.8	-29	10	91	
Week 4	-9.2	-9.0	0.6	-36	+   11	177	-8.5	-8.0	0.7	-25	10	91	
Week 6	-10.5	-11.0	0.7	-35	12	177	-10.1	-9.0	0.9	-27	18	91	
Week 8	-12.2	-13.0	0.7	-37	12	177	-10.9	-11.0	1.0	-32	18	91	
  Week 12	-13.2	   -14.0	0.7	-39	+   12	+   177	-12.5	++   -13.0	1.0	-31	+   18	91	

Table 14.04b

# Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score) Baseline and Change from Baseline in Depression Subscale Total Scores Excluding Centre 007 Intention to Treat Population

 			Par	oxetine			Placebo					
	Mean	Median	S.E	Minimum		Number of  Patients  in Group	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group
Baseline	24.6	24.0	0.4	11.0	37.0	171	24.8	24.0	0.5	13.0	36.0	88
Week 2	-4.1	-4.0	0.4	-19.0	7.0	167	-4.4	-4.0	0.5	-20.0	6.0	88
Week 4	-6.5	-7.0	0.5	-25.0	15.0	155	-6.6	-6.0	0.6	-20.0	7.0	+   79
Week 6	-8.2	-9.0	0.5	-26.0	12.0	146	-7.7	-7.1	0.7	-21.0	7.0	+   77
Week 8	-9.9	-10.0	0.5	-25.0	9.0	143	-8.9	-9.0	0.7	-22.0	7.0	+   72
Week 12	-10.9	+   -11.0	0.6	-26.0	6.0	+   126	-9.9	++   -9.5	0.7	-22.0	2.0	+   66

Table 14.04c

Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score)
Baseline and Change from Baseline in Depression Subscale Total Scores
Excluding Centre 007
Per Protocol Population

		Paroxetine						Placebo					
	Mean	Median	S.E	Minimum		Number of  Patients  in Group	Mean	Median	S.E	Minimum		Number of  Patients  in Group	
Baseline	24.4	24.0	0.4	11.0	37.0	130	24.1	24.0	0.6	14.0	36.0	68	
Week 2	-4.5	-4.0	0.5	-19.0	7.0	126	-4.4	-4.0	0.6	-20.0	6.0	68	
Week 4	-7.2	-7.0	0.5	-25.0	15.0	127	-6.8	-6.0	0.7	-18.0	4.0	65	
Week 6	-8.5	-9.0	0.6	-26.0	12.0	123	-8.0	-7.6	0.7	-21.0	4.0	66	
Week 8	-10.1	-10.0	0.5	-25.0	9.0	123	-9.2	-9.0	0.7	-22.0	4.0	61	
Week 12	-10.9	-11.0	0.6	-26.0	6.0	108	-10.1	-9.5 -9.5	0.7	-21.0	0.0	56	

Table 14.04d

# Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score) Baseline and Change from Baseline in Depression Subscale Total Scores Excluding Centre 007 Intention to Treat Population (LOCF)

			Paro	exetine			Placebo					
	     Mean	Median	S.E	Minimum		Number of  Patients  in Group	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group
Baseline	24.6	24.0	0.4	11.0	37.0	171	24.8	24.0	0.5	13.0	36.0	88
Week 2	-4.1	-4.0	0.4	-19.0	7.0	167	-4.4	-4.0	0.5	-20.0	6.0	88
Week 4	-6.3	-6.0	0.5	-25.0	15.0	170	-6.5	-6.0	0.6	-20.0	7.0	88
Week 6	-7.6	-7.0	0.5	-26.0	12.0	171	-7.5	-8.0	0.6	-21.0	7.0	88
Week 8	-8.7	-9.0	0.5	-25.0	9.0	171   171	-8.2	-8.0	0.7	-22.0	7.0	88
Week 12	-9.2	-9.0   -9.0	0.5	-26.0	6.0	+   171	-8.9	-8.5 -8.5	0.7	-22.0	7.0	88

## Table 14.04e

# Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score) Baseline and Change from Baseline in Depression Subscale Total Scores Excluding Centre 007 Per Protocol Population (LOCF)

	Paroxetine							Placebo					
	Mean	Median	S.E	Minimum		Number of  Patients  in Group	Mean	Median	S.E	Minimum		Number of  Patients  in Group	
Baseline	24.4	24.0	0.4	11.0	37.0	130	24.1	24.0	0.6	14.0	36.0	68	
Week 2	-4.5	-4.0	0.5	-19.0	7.0	126	-4.4	-4.0	0.6	-20.0	6.0	68	
Week 4	-7.2	-7.0	0.5	-25.0	15.0	129	-6.9	-6.0	0.7	-20.0	4.0	68	
Week 6	-8.4	-9.0	0.5	-26.0	12.0	130	-8.0	-8.0	0.7	-21.0	4.0	68	
Week 8	-9.7	-10.0	0.5	-25.0	9.0	130	-8.7	-9.0	0.7	-22.0	4.0	68	
Week 12	-10.0	-10.0	0.6	-26.0	6.0	130	-9.5	-9.0   -9.0	0.7	-21.0	4.0	68	

Paroxetine - Protocol: 377

Table 14.05b

# Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) By Age Group Excluding Centre 007 Intention to Treat Population

Age Group: <= 16 Years

 	Pa	aroxetine			Placebo	
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	117	3	2.6	55	2	3.6
Week 2	108	11	10.2	54	4	7.4
Week 3	100	15	15.0	55	14	25.5
Week 4	103	37	35.9	51	15	29.4
Week 6	+   97	41	42.3	51	21	41.2
Week 8	93		58.1	49	30	61.2
  Week 12	80	   56	70.0	45	33	73.3

### Table 14.05b

# Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) By Age Group Excluding Centre 007 Intention to Treat Population

Age Group: > 16 Years

	   Pa	aroxetine		   	Placebo	 
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	59	5	8.5	34	0	0
Week 2	   57	11	19.3	32	7	21.9
Week 3	53	17	32.1	29	10	34.5
Week 4	52	20	38.5	26	†   7	26.9
Week 6	+   49	28	57.1	26	11	42.3
Week 8	   51	40	78.4	23	13	56.5
Week 12	+   46	38	82.6	21	14	66.7

Table 14.05d

# Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) By Age Group Excluding Centre 007 Intention to Treat Population LOCF

Age Group: <= 16 Years

	Pa	aroxetine		Placebo				
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent		
Week 1	117	3	2.6	55	2	3.6		
Week 2	118	12	10.2	57	5	8.8		
Week 3	118	17	14.4	57	14	24.6		
Week 4	118	38	32.2	57	17	29.8		
Week 6	118	43	36.4	57	22	38.6		
Week 8	118	56	47.5	57	32	56.1		
Week 12	118	65	55.1	57	37	64.9		

### Table 14.05d

# Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) By Age Group Excluding Centre 007 Intention to Treat Population LOCF

Age Group: > 16 Years

	Pa	aroxetine			Placebo	
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	59	5	8.5	34	0	0
Week 2	59   59	11	18.6	34	†   7	20.6
Week 3	59	18	30.5	34	10	29.4
Week 4	59	22	37.3	34	8	23.5
Week 6	59	30	50.8	34	11	32.4
Week 8	59	41	69.5	34	13	38.2
Week 12	59	42	71.2	34	16	47.1

Table 14.06b

## Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) By Presence of Comorbid Conduct Disorder at Baseline Excluding Centre 007 Intention to Treat Population

### Presence of Comorbid Conduct Disorder at Baseline: No

	I	Paroxetine		Placebo				
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent		
Week 1	176	8	4.5	*   89	2	2.2		
Week 2	165	22	13.3	86	11	12.8		
Week 3	153	32	20.9	84	24	28.6		
Week 4	155	57	36.8	+   77	22	28.6		
Week 6	146	69	47.3	+   77	32	41.6		
Week 8	144	94	65.3	72	43	59.7		
Week 12	126	-+   94	74.6	+   66	+   47	71.2		

Table 14.06d

## Montgomery-Asberg Depression Rating Scale Response Rates (Total Score Reduced by at Least 50% from Baseline) By Presence of Comorbid Conduct Disorder at Baseline Excluding Centre 007 Intention to Treat Population LOCF

Presence of Comorbid Conduct Disorder at Baseline: No

 	P	aroxetine		 	Placebo	
	Number of Patients	Number with 50% Reduction	Percent	Number of Patients	Number with 50% Reduction	Percent
Week 1	176	8	4.5	89	2	2.2
Week 2	177	23	13.0	91	12	13.2
Week 3	177	35	19.8	91	24	26.4
Week 4	177	60	33.9	91	25	27.5
Week 6	177	73	41.2	91	33	36.3
Week 8	177	97	54.8	91   91	+   45	49.5
Week 12	177	107	60.5	91	+   53	58.2

Table 14.07b

Montgomery-Asberg Depression Rating Scale
Response Rates (Total Score Reduced by at Least 50% from Baseline) By Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline
Excluding Centre 007
Intention to Treat Population

Presence of Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline: No

	P	aroxetine		Placebo			
	Number of Patients	Number with 50% Reduction		Number of Patients	Number with 50% Reduction	Percent	
Week 1	159	8	5.0	81	†   1	1.2	
Week 2	151	21	13.9	80	10	12.5	
Week 3	139	31	22.3	78	21	26.9	
Week 4	140	54	38.6	71	+   19	26.8	
Week 6	131	65	49.6	71	29	40.8	
Week 8	130	85	65.4	67	40	59.7	
Week 12	112	84	75.0	   61	+   44	72.1	

Table 14.07b

Montgomery-Asberg Depression Rating Scale
Response Rates (Total Score Reduced by at Least 50% from Baseline) By Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline
Excluding Centre 007
Intention to Treat Population

Presence of Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline: Yes

	   Pa	aroxetine		Placebo				
	Number of Patients	Number with 50% Reduction		Number of Patients	Number with 50% Reduction	Percent		
Week 1	17	0	0	8	1	12.5		
Week 2	14	1	7.1	6	1	16.7		
Week 3	14	1	7.1	6	3	50.0		
Week 4	15	3	20.0	6	3	50.0		
Week 6	15	4	26.7	6	3	50.0		
Week 8	14	9	64.3	5	3	60.0		
Week 12	14	10	71.4	5	3	60.0		

Table 14.07d

Montgomery-Asberg Depression Rating Scale
Response Rates (Total Score Reduced by at Least 50% from Baseline) By Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline
Excluding Centre 007
Intention to Treat Population LOCF

Presence of Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline: No

	P	aroxetine		Placebo			
	Number of Patients	Number with 50% Reduction		Number of Patients	Number with 50% Reduction	Percent	
Week 1	159	8	5.0	81	1	1.2	
Week 2	160	22	13.8	83	10	12.0	
Week 3	160	34	21.3	83	21	25.3	
Week 4	160	+   56	35.0	83	22	26.5	
Week 6	160	68	42.5	83	30	36.1	
Week 8	160	88	55.0	83	+   41	49.4	
Week 12	+   160	+   97	+   60.6	+   83	+   49	59.0	

Table 14.07d

Montgomery-Asberg Depression Rating Scale
Response Rates (Total Score Reduced by at Least 50% from Baseline) By Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline
Excluding Centre 007
Intention to Treat Population LOCF

Presence of Comorbid Social Phobia/OCD/GAD/Panic Disorder at Baseline: Yes

	Pa	aroxetine			Placebo	
	Number of Patients			Number of Patients	Number with 50% Reduction	Percent
Week 1	17	0	0	8	1	12.5
Week 2	17	1	5.9	8	2	25.0
Week 3	17	1	5.9	8	3	37.5
Week 4	17	4	23.5	8	3	37.5
Week 6	17	+	29.4	8	3	37.5
Week 8	17	9	52.9	8	4	50.0
Week 12	17	10	58.8	8	4 4	50.0

### Table 14.08b

# Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score) Baseline and Change from Baseline in Depression Subscale Total Scores By Age Group Excluding Centre 007 Intention to Treat Population

Age Group: <= 16 Years

	 	Paroxetine						Placebo					
	Mean	Median	S.E	Minimum		Number of Patients in Group	Mean	Median	S.E	Minimum	Maximum	Number of Patients in Group	
Baseline	24.2	24.0	0.5	11.0	37.0	113	24.4	24.0	0.6	14.0	35.0	55	
Week 2	-3.6	-3.0	0.4	-19.0	7.0	109	-4.5	-4.0	0.6	-20.0	6.0	55	
Week 4	-5.7	-5.5	0.6	-19.0	15.0	102	-6.7	-6.0	0.8	-20.0	3.0	52	
Week 6	-7.3	-7.0	0.6	-21.0	9.0	97	-7.8	-7.0	0.8	-21.0	3.0	51	
Week 8	-8.9	-8.5	0.6	-23.0	5.0	93	-8.9	-8.0	0.8	-22.0	2.0	49	
Week 12	-10.2	-10.0	0.7	-24.0	3.0	80	-9.7	-10.0	0.8	-21.0	2.0	45	

## Table 14.08b

## Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score) Baseline and Change from Baseline in Depression Subscale Total Scores By Age Group Excluding Centre 007 Intention to Treat Population

Age Group: > 16 Years

	 		Paro	exetine		 !	Placebo					
	Mean	Median	S.E	Minimum		Number of Patients in Group	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group
Baseline	25.3	26.0	0.6	13.0	35.0	58	25.4	25.0	1.0	13.0	36.0	33
Week 2	-5.1	-5.0	0.8	-15.0	5.0	58	-4.3	-3.0	0.9	-18.0	3.0	33
Week 4	-8.0	-8.0	0.9	-25.0	6.0	53	-6.5	-7.0	1.2	-18.0	7.0	27
Week 6	-10.1	-11.0	1.0	-26.0	12.0	49	-7.5	-8.0	1.2	-18.0	7.0	26
Week 8	-11.8	-13.0	0.9	-25.0	9.0	50	-9.0	-10.0	1.3	-20.0	7.0	23
Week 12	-12.3	-13.0	0.9	-26.0	6.0	46	-10.5	-8.0	1.2	-22.0	0.0	21

### Table 14.08d

# Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score) Baseline and Change from Baseline in Depression Subscale Total Scores By Age Group Excluding Centre 007 Intention to Treat Population (LOCF)

Age Group: <= 16 Years

			Paro	exetine			Placebo					
	Mean	Median	S.E	Minimum		Number of Patients in Group	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group
Baseline	24.2	24.0	0.5	11.0	37.0	113	24.4	24.0	0.6	14.0	35.0	55
Week 2	-3.6	-3.0	0.4	-19.0	7.0	109	-4.5	-4.0	0.6	-20.0	6.0	55
Week 4	-5.5	-5.0	0.6	-19.0	15.0	112	-6.8	-6.0	0.8	-20.0	3.0	55
Week 6	-6.6	-6.0	0.6	-21.0	9.0	113	-7.7	-7.1	0.7	-21.0	3.0	55
Week 8	-7.7	-7.0	0.6	-23.0	6.0	113	-8.7	-8.0	0.8	-22.0	2.0	55
Week 12	-8.2	-8.0	0.6	-24.0	6.0	113	-9.2	-9.0   -9.0	0.8	-21.0	2.0	+   55

## Table 14.08d

## Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score) Baseline and Change from Baseline in Depression Subscale Total Scores By Age Group Excluding Centre 007 Intention to Treat Population (LOCF)

Age Group: > 16 Years

			Paro	exetine			Placebo					
	Mean	Median	S.E	Minimum		Number of Patients in Group	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group
Baseline	25.3	26.0	0.6	13.0	35.0	58	25.4	25.0	1.0	13.0	36.0	33
Week 2	-5.1	-5.0	0.8	-15.0	5.0	58	-4.3	-3.0	0.9	-18.0	3.0	33
Week 4	-7.9	-7.5	0.9	-25.0	6.0	58	-6.0	-7.0	1.1	-18.0	7.0	33
Week 6	-9.5	-10.5	0.9	-26.0	12.0	58	-7.0	-8.0	1.1	-18.0	7.0	33
Week 8	-10.5	-11.0	0.9	-25.0	9.0	58	-7.3	-9.0	1.2	-20.0	7.0	33
Week 12	-11.0	-11.5	0.9	-26.0	6.0	58	-8.4	-8.0	1.2	-22.0	7.0	33

## Table 14.09b

Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score)
Baseline and Change from Baseline in Depression Subscale Total Scores By Presence of Comorbid Conduct Disorder at Baseline Excluding Centre 007

Intention to Treat Population

Presence of Comorbid Conduct Disorder at Baseline: No

 			Par	oxetine		 !	Placebo					
	Mean	Median	S.E	Minimum	Maximum	Number of Patients in Group	Mean	Median	S.E	Minimum		Number of  Patients  in Group
Baseline	24.6	24.0	0.4	11.0	37.0	171	24.8	24.0	0.5	13.0	36.0	88
Week 2	-4.1	-4.0	0.4	-19.0	7.0	167	-4.4	-4.0	0.5	-20.0	6.0	88
Week 4	-6.5	-7.0	0.5	-25.0	15.0	155	-6.6	-6.0	0.6	-20.0	7.0	†   79
Week 6	-8.2	-9.0	0.5	-26.0	12.0	146	-7.7	-7.1	0.7	-21.0	7.0	+   77
Week 8	-9.9	-10.0	0.5	-25.0	9.0	143	-8.9	-9.0	0.7	-22.0	7.0	72
  Week 12	-10.9	-11.0	0.6	-26.0	6.0	126	-9.9	-9.5	0.7	-22.0	2.0	+   66

### -------

### Table 14.09d

Kiddie-SADS-Lifetime (Using Last 2 Weeks rating score)
Baseline and Change from Baseline in Depression Subscale Total Scores By Presence of Comorbid Conduct Disorder at Baseline
Excluding Centre 007

Intention to Treat Population (LOCF)

## Presence of Comorbid Conduct Disorder at Baseline: No

 			Par	oxetine		 !	Placebo					
	Mean	Median	S.E	Minimum	Maximum	Number of Patients in Group	Mean	Median	S.E	Minimum		Number of  Patients  in Group
Baseline	24.6	24.0	0.4	11.0	37.0	171	24.8	24.0	0.5	13.0	36.0	88
Week 2	-4.1	-4.0	0.4	-19.0	7.0	167	-4.4	-4.0	0.5	-20.0	6.0	88
Week 4	-6.3	-6.0	0.5	-25.0	15.0	170	-6.5	-6.0	0.6	-20.0	7.0	88
Week 6	-7.6	-7.0	0.5	-26.0	12.0	171	-7.5	-8.0	0.6	-21.0	7.0	88
Week 8	-8.7	-9.0	0.5	-25.0	9.0	171	-8.2	-8.0	0.7	-22.0	7.0	88
Week 12	-9.2	-9.0	0.5	-26.0	6.0	171	-8.9	-8.5	0.7	-22.0	7.0	88

Paroxetine - Protocol: 377

Table 14.10b

Number and Percentage of Patients in Each Category of CGI Severity of Illness Score  ${\tt Excluding~Centre~007}$ 

			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	%	N N	%
WEEK	CGI Severity				
Baseline	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	1	1.12
	Normal, not at all	0	0.00	0	0.00
	Borderline mentally	5	2.91	3	3.37
	Mildly ill	25	14.53	17	19.10
	Moderately ill	84	48.84	33	37.08
	Markedly ill	48	27.91	26	29.21
	Severely ill	10	5.81	9	10.11
	Among the most extremely ill patients	0	0.00	0	0.00
	Number of Patients in Group	172	100.00	89	100.00

## Table 14.10b

Number and Percentage of Patients in Each Category of CGI Severity of Illness Score

Excluding Centre 007

 			Treat	ment	
		Parox	etine	Plac	cebo
		N	%	N	%
WEEK	CGI Severity				
Week 2	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	0	0.00
	Normal, not at all   ill	4	2.38	2	2.25
	Borderline mentally	16	9.52	14	15.73
	Mildly ill	47	27.98	26	29.21
	Moderately ill	71	42.26	23	25.84
	Markedly ill	24	14.29	17	19.10
	Severely ill	6	3.57	7	7.87
	Among the most extremely ill patients	0	0.00	0	0.00
	Number of Patients   in Group	168	100.00	89	100.00

Table 14.10b

Number and Percentage of Patients in Each Category of CGI Severity of Illness Score

Excluding Centre 007

			Treat	ment	
		Paroxe	etine	Plac	cebo
		N N	%	N N	%
WEEK	CGI Severity				
Week 4	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	0	0.00
	Normal, not at all	17	10.97	6	7.59
	Borderline mentally		22.58	26	32.91
	Mildly ill	52	33.55	25	31.65
	Moderately ill	40	25.81	13	16.46
	Markedly ill	7	4.52	8	10.13
	Severely ill	4	2.58	1	1.27
	Among the most extremely ill patients	0	0.00	0	0.00
	Number of Patients in Group	155	100.00	79	100.00

Paroxetine - Protocol: 377

Table 14.10b

Number and Percentage of Patients in Each Category of CGI Severity of Illness Score

Excluding Centre 007

		Treatment					
		Paroxe	etine	Plac	cebo		
		N	%	N	%		
WEEK	CGI Severity						
Week 6	Missing	0	0.00	0	0.00		
	Not assessed	0	0.00	0	0.00		
	Normal, not at all	28	19.18	12	15.58		
	Borderline mentally		28.08	25	32.47		
	Mildly ill	42	28.77	16	20.78		
	Moderately ill	26	17.81	15	19.48		
	Markedly ill	6	4.11	8	10.39		
	Severely ill	3	2.05	1	1.30		
	Among the most extremely ill patients	0	0.00	0	0.00		
	Number of Patients in Group	146	    100.00	77	100.00		

## Table 14.10b

Number and Percentage of Patients in Each Category of CGI Severity of Illness Score

Excluding Centre 007

 			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	%	N	%
WEEK	CGI Severity				
Week 8	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	0	0.00
	Normal, not at all	44	30.56	19	26.39
	Borderline mentally	47	32.64	22	30.56
	Mildly ill	28	19.44	17	23.61
	Moderately ill	17	11.81	10	13.89
	Markedly ill	6	4.17	4	5.56
	Severely ill	1	0.69	0	0.00
	Among the most extremely ill patients	1	0.69	0	0.00
	Number of Patients in Group	144	100.00	72	100.00

Paroxetine - Protocol: 377

Table 14.10b

Number and Percentage of Patients in Each Category of CGI Severity of Illness Score

Excluding Centre 007

		   	Treat	ment	
		Parox	etine	Plac	cebo
		N	%	N N	%
WEEK	CGI Severity				
Week 12	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	0	0.00
	Normal, not at all	59	46.83	33	50.00
	Borderline mentally	42	33.33	14	21.21
	Mildly ill	14	11.11	10	15.15
	Moderately ill	7	5.56	7	10.61
	Markedly ill	3	2.38	2	3.03
	Severely ill	1	0.79	0	0.00
	Among the most extremely ill patients	0	0.00	0	0.00
	Number of Patients in Group	126	100.00	66	100.00

Paroxetine - Protocol: 377

Table 14.10d

Number and Percentage of Patients in Each Category of CGI Severity of Illness Score  ${\tt Excluding~Centre~007}$ 

Intention to Treat Population (LOCF)

 			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	8	N	%
WEEK	CGI Severity				
Baseline	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	1	1.12
	Normal, not at all	0	0.00	0	0.00
	Borderline mentally	5	2.91	3	3.37
	Mildly ill	25	14.53	17	19.10
	Moderately ill	84	48.84	33	37.08
	Markedly ill	48	27.91	26	29.21
	Severely ill	10	5.81	9	10.11
	Among the most extremely ill patients	0	0.00	0	0.00
	Number of Patients in Group	172	100.00	89	100.00

Paroxetine - Protocol: 377

Table 14.10d

			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	%	N	%
WEEK	CGI Severity				
Week 2	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	0	0.00
	Normal, not at all ill	4	2.38	2	2.25
	Borderline mentally	16	9.52	14	15.73
	Mildly ill	47	27.98	26	29.21
	Moderately ill	71	42.26	23	25.84
	Markedly ill	24	14.29	17	19.10
	Severely ill	6	3.57	7	7.87
	Among the most extremely ill patients	0	0.00	0	0.00
	Number of Patients    in Group	168	100.00	89	100.00

Paroxetine - Protocol: 377

Table 14.10d

			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	%	N N	%
WEEK	CGI Severity				
Week 4	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	0	0.00
	Normal, not at all	18	10.53	6	6.74
	Borderline mentally	37	21.64	28	31.46
	Mildly ill	57	33.33	26	29.21
	Moderately ill	45	26.32	16	17.98
	Markedly ill	8	4.68	11	12.36
	Severely ill	6	3.51	2	2.25
	Among the most extremely ill patients	0	0.00	0	0.00
	Number of Patients in Group	171	100.00	89	100.00

Paroxetine - Protocol: 377

Table 14.10d

			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	8	N	8
WEEK	CGI Severity				
Week 6	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	0	0.00
	Normal, not at all ill	29	16.86	13	14.61
	Borderline mentally	44	25.58	26	29.21
	Mildly ill	53	30.81	19	21.35
	Moderately ill	34	19.77	19	21.35
	Markedly ill	6	3.49	11	12.36
	Severely ill	6	3.49	1	1.12
	Among the most extremely ill patients	0	0.00	0	0.00
	Number of Patients   in Group	172	100.00	89	100.00

Paroxetine - Protocol: 377

Table 14.10d

 			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	%	N N	%
WEEK	CGI Severity				
Week 8	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	0	0.00
	Normal, not at all	46	26.74	19	21.35
	Borderline mentally	49	28.49	24	26.97
	Mildly ill	35	20.35	20	22.47
	Moderately ill	28	16.28	15	16.85
	Markedly ill	8	4.65	10	11.24
	Severely ill	5	2.91	1	1.12
	Among the most extremely ill patients	1	0.58	0	0.00
	Number of Patients in Group	172	100.00	89	100.00

Paroxetine - Protocol: 377

Table 14.10d

 			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	%	N N	8
WEEK	CGI Severity				
Week 12	Missing	0	0.00	0	0.00
	Not assessed	0	0.00	0	0.00
	Normal, not at all	65	37.79	37	41.57
	Borderline mentally	47	27.33	16	17.98
	Mildly ill	24	13.95	13	14.61
	Moderately ill	24	13.95	13	14.61
	Markedly ill	6	3.49	9	10.11
	Severely ill	6	3.49	1	1.12
	Among the most extremely ill patients	0	0.00	0	0.00
	Number of Patients in Group	172	100.00	89	100.00

1

#### Paroxetine - Protocol: 377

#### Table 14.11b

### Baseline and Change from Baseline in CGI Severity of Illness Score

### Excluding Centre 007

			I	aroxetine						Placebo		
	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group
Baseline	4.2	4.0	0.1	2	6	172	4.2	4.0	0.1	2	6	88
Week 2	-0.5	0.0	0.1	-3	2	168	-0.5	0.0	0.1	-3	3	89
Week 4	-1.2	-1.0	0.1	-5	1	155	-1.2	-1.0	0.1	-3	2	†    79
Week 6	-1.6	-2.0	0.1	-5	2	146	-1.3	-1.0	0.2	-4	2	†    77
Week 8	-1.9	-2.0	0.1	-5	1	144	-1.7	-1.5	0.2	-4	2	72
Week 12	-2.4	-3.0	0.1	-5	   1	126	-2.1	-2.0	0.2	-4	3	+    66

1

### Paroxetine - Protocol: 377

Table 14.11d

### Baseline and Change from Baseline in CGI Severity of Illness Score

### Excluding Centre 007

 			I	Paroxetine						Placebo		
	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group	Mean	Median	S.E	Minimum	Maximum	Number of  Patients  in Group
Baseline	4.2	4.0	0.1	2	6	172	4.2	4.0	0.1	2	+   6	88
Week 2	-0.5	0.0	0.1	-3	2	168	-0.5	0.0	0.1	-3	3	89
Week 4	-1.2	-1.0	0.1	-5	2	+   171	-1.1	-1.0	0.1	-3	2	89
Week 6	-1.4	-1.0	0.1	-5	2	172	-1.3	-1.0	0.1	-4	2	89
Week 8	-1.6	-2.0	0.1	-5	2	172	-1.5	-1.0	0.1	-4	2	89
  Week 12	-1.9	+   -2.0	0.1	-5	2	+   172	-1.8	-2.0	0.2	-4	+   3	+   89

#### Table 14.12b

## Number of Patients in Each Catagory of Change from Baseline in CGI Severity of Illness Score Excluding Centre 007

Week 2

	 	No. of Patients										
	-3	-2	-1	0	1	2	3	Total No.				
Paroxetine	3	20	57	70	17	1	0	168				
Placebo	3	11	27	40	5	2	1	89				

Week 4

		No. of Patients											
	-5	-4	-3	-2	-1	0	1	2	Total No.				
Paroxetine	1	2	19	34	55	38	   6	0	155				
Placebo	0	0	12	16	30	18	2	†   1	79				

#### Table 14.12b

## Number of Patients in Each Catagory of Change from Baseline in CGI Severity of Illness Score

### Excluding Centre 007

## Intention to Treat Population

#### Week 6

		No. of Patients										
	-5	-5   -4   -3   -2   -1   0   1   2   of Patic										
Paroxetine	1	3	29	43	44	20	5	1	146			
Placebo	0	3	+   15	13	26	+   16	+   1	3	+    77			

#### Week 8

		No. of Patients										
	-5	-4	-3	-2	-1	0	1	2	Total No. of Patients			
Paroxetine	1	9	35	51	26	18	4	0	144			
Placebo	0	5	18	13	25	+   6	4	1	72			

Table 14.12b

## Number of Patients in Each Catagory of Change from Baseline in CGI Severity of Illness Score

### Excluding Centre 007

Week 12

		No. of Patients											
	-5	-4	-3	-2	-1	0	1	3	Total No.				
Paroxetine	3	10	53	35	14	10	1	0	126				
Placebo	0	+   7	   21	+   19	+   12	+   5	   1	+   1	66				

#### raroncome froctor s.

#### Table 14.12d

## Number of Patients in Each Catagory of Change from Baseline in CGI Severity of Illness Score Excluding Centre 007

Intention to Treat Population (LOCF)

#### Week 2

		No. of Patients							
	-3	-2	-1	0	1	2	3	Total No. of Patients	
Paroxetine	3	20	57	70	17	1	0	168	
Placebo	3	11	27	40	5	2	1	89	

#### Week 4

	No. of Patients								
	-5	-4	-3	-2	-1	0	1	2	Total No. of Patients
Paroxetine	1	2	20	+   35	62	+   44	+6	+   1	171
Placebo	0	0	14	+   17	32	22	2	+   2	89

#### Table 14.12d

## Number of Patients in Each Catagory of Change from Baseline in CGI Severity of Illness Score

### Excluding Centre 007

## Intention to Treat Population (LOCF)

#### Week 6

		No. of Patients							
	-5	-4	-3	-2	-1	0	1	2	Total No.
Paroxetine	1	3	30	+   45	56   56	29	   6	2	172
Placebo	0	3	+   16	+   15	31	20	+   1	3	89

#### Week 8

		No. of Patients							
	-5	-4	-3	-2	-1	0	1	2	Total No.
Paroxetine	1	10	36	51	37	29	†   7	1	172
Placebo	0	   5	20	14	32	11	+   4	3	89

#### Table 14.12d

## Number of Patients in Each Catagory of Change from Baseline in CGI Severity of Illness Score

### Excluding Centre 007

## Intention to Treat Population (LOCF)

#### Week 12

		No. of Patients							
	-5	-4	   -3	   -2	-1	0	1	2	3
Paroxetine	3	11	+   54	42	30	26	5	1	0
Placebo	0	9	+   25	20	20	10	2	2	1

(CONTINUED)

	No. of Patients
	Total No. of Patients
	+
Paroxetine	172
Placebo	89   89

Paroxetine - Protocol: 377

Table 14.13b

Number and Percentage of Patients in Each Category of CGI Global Improvement Score  ${\tt Excluding~Centre~007}$ 

		 	Treat	ment	
		Paroxe	etine	Plac	cebo
		N	%	N N	%
WEEK	CGI Improvement	   			
Week 2	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	10	5.95	3	3.37
	Much Improved	34	20.24	18	20.22
	Minimally improved	65	38.69	41	46.07
	No change	46	27.38	23	25.84
	Minimally worse	9	5.36	4	4.49
	Much worse	4	2.38	0	0.00
	Very much worse	0	0.00	0	0.00
	Total No. of Patients	168	100.00	89	100.00

#### Table 14.13b

## Number and Percentage of Patients in Each Category of CGI Global Improvement Score Excluding Centre 007

		Treatment			
		Paroxe	etine	Plac	cebo
		N N	%	N N	8
WEEK	CGI Improvement				
Week 4	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	20	12.90	11	13.92
	Much Improved	54	34.84	25	31.65
	Minimally improved	54	34.84	30	37.97
	No change	15	9.68	11	13.92
	Minimally worse	9	5.81	1	1.27
	Much worse	3	1.94	1	1.27
	Very much worse	0	0.00	0	0.00
	Total No. of Patients	155	100.00	79	100.00

#### Table 14.13b

Number and Percentage of Patients in Each Category of CGI Global Improvement Score

Excluding Centre 007

		   	Treat	ment	
		Paroxe	etine	Plac	cebo
		N N	%	N	%
WEEK	CGI Improvement				
Week 6	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	33	22.60	14	18.18
	Much Improved	58	39.73	27	35.06
	Minimally improved	30	20.55	22	28.57
	No change	16	10.96	7	9.09
	Minimally worse	3	2.05	6	7.79
	Much worse	6	4.11	1	1.30
	Very much worse	0	0.00	0	0.00
	Total No. of Patients	146	100.00	77	100.00

#### Table 14.13b

Number and Percentage of Patients in Each Category of CGI Global Improvement Score

Excluding Centre 007

 		   	Treat	ment	
		Paroxe	etine	Plac	cebo
		N N	%	N N	%
WEEK	CGI Improvement				
Week 8	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	49	34.03	21	29.17
	Much Improved	49	34.03	24	33.33
	Minimally improved	26	18.06	15	20.83
	No change	11	7.64	6	8.33
	Minimally worse	4	2.78	5	6.94
	Much worse	4	2.78	1	1.39
	Very much worse	1	0.69	0	0.00
	Total No. of Patients	144	100.00	72	100.00

#### Table 14.13b

Number and Percentage of Patients in Each Category of CGI Global Improvement Score

Excluding Centre 007

			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	%	N	%
WEEK	CGI Improvement				
Week 12	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	63	50.00	28	42.42
	Much Improved	42	33.33	16	24.24
	Minimally improved	9	7.14	12	18.18
	No change	5	3.97	7	10.61
	Minimally worse	7	5.56	3	4.55
	Much worse	0	0.00	0	0.00
	Very much worse	0	0.00	0	0.00
	Total No. of Patients	126	100.00	66	100.00

Paroxetine - Protocol: 377

Table 14.13d

Number and Percentage of Patients in Each Category of CGI Global Improvement Score  ${\tt Excluding\ Centre\ 007}$ 

			Treat	ment	
		Paroxe	etine	Plac	cebo
		N	%	N N	%
WEEK	CGI Improvement	   			
Week 2	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	10	5.95	3	3.37
	Much Improved	34	20.24	18	20.22
	Minimally improved	65	38.69	41	46.07
	No change	46	27.38	23	25.84
	Minimally worse	9	5.36	4	4.49
	Much worse	4	2.38	0	0.00
	Very much worse	0	0.00	0	0.00
	Total No. of Patients	168	100.00	89	100.00

Paroxetine - Protocol: 377

Table 14.13d

Number and Percentage of Patients in Each Category of CGI Global Improvement Score

Excluding Centre 007

			Treat	ment	
		Parox	etine	Plac	cebo
		N	%	N	%
WEEK	CGI Improvement	   			
Week 4	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	22	12.87	11	12.36
	Much Improved	56	32.75	27	30.34
	Minimally improved	59	34.50	32	35.96
	No change	19	11.11	16	17.98
	Minimally worse	10	5.85	2	2.25
	Much worse	5	2.92	1	1.12
	Very much worse	0	0.00	0	0.00
	Total No. of Patients	171	100.00	89	100.00

Table 14.13d

Number and Percentage of Patients in Each Category of CGI Global Improvement Score

Excluding Centre 007

 		   	Treat	ment	
		Paroxe	etine	Plac	cebo
		N N	%	N	%
WEEK	CGI Improvement				
Week 6	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	35	20.35	15	16.85
	Much Improved	63	36.63	29	32.58
	Minimally improved	38	22.09	25	28.09
	No change	22	12.79	13	14.61
	Minimally worse	   5	2.91	6	6.74
	Much worse	9	5.23	1	1.12
	Very much worse	0	0.00	0	0.00
	Total No. of Patients	172	100.00	89	100.00

Table 14.13d

Number and Percentage of Patients in Each Category of CGI Global Improvement Score

Excluding Centre 007

			Treat	ment	
		Parox	etine	Plac	cebo
		N	%	N N	%
WEEK	CGI Improvement	   			
Week 8	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	52	30.23	22	24.72
	Much Improved	53	30.81	27	30.34
	Minimally improved	32	18.60	18	20.22
	No change	20	11.63	13	14.61
	Minimally worse	5	2.91	7	7.87
	Much worse	9	5.23	2	2.25
	Very much worse	1	0.58	0	0.00
	Total No. of Patients	172	100.00	89	100.00

Table 14.13d

Number and Percentage of Patients in Each Category of CGI Global Improvement Score

Excluding Centre 007

			Treat	ment	
		Paroxe	etine	Plac	cebo
		N N	%	N N	8
WEEK	CGI Improvement				
Week 12	Missing	0	0.00	0	0.00
	Not evaluated	0	0.00	0	0.00
	Very much improved	71	41.28	32	35.96
	Much Improved	48	27.91	19	21.35
	Minimally improved	20	11.63	15	16.85
	No change	18	10.47	16	17.98
	Minimally worse	8	4.65	6	6.74
	Much worse	6	3.49	1	1.12
	Very much worse	1	0.58	0	0.00
	Total No. of Patients	172	100.00	89	100.00

#### Table 14.20b

# Beck Depression Inventory Baseline and Change from Baseline in Total Score Excluding Centre 007

### Intention to Treat Population

				Paroxetine			Placebo							
	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group		
Baseline	23.0	22.0	0.8	1	+   57	174	22.4	20.0	1.2	5	+   50	90		
Week 1	-4.1	-3.0	0.5	-28	   11	174	-2.7	-2.0	0.7	-29	15	88		
Week 2	-6.0	-5.0	0.5	-25	13	161	-5.1	-5.0	0.7	-24	9	85		
Week 3	-7.7	-7.0	0.8	-34	+   27	152	-6.9	-7.0	1.0	-32	21	83		
Week 4	-9.0	-9.0	0.8	-39	   27	155	-8.3	-8.5	1.0	-32	24	76		
Week 6	-10.0	-8.2	0.9	-55	25	144	-10.3	-9.0	1.1	-40	18	77		
Week 8	-12.0	-11.0	0.9	-43	26	141	-12.2	-11.0	1.1	-37	+   7	72		
Week 12	-13.1	-12.5	1.1	-54	+   36	124	-13.0	-12.0	1.1	-41	+   5	66		

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]LT1420.SAS (24JUL98 11:39)

#### Table 14.20d

# Beck Depression Inventory Baseline and Change from Baseline in Total Score Excluding Centre 007

	 			Paroxetine			   !			Placebo		
	Mean	Median	Std Err	Minimum	   Maximum	Number of   Patients   in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group
Baseline	23.0	22.0	0.8	1	+   57	174	22.4	20.0	1.2	5	+   50	90
Week 1	-4.1	-3.0	0.5	-28	+   11	174	-2.7	-2.0	0.7	-29	15	88
Week 2	-5.8	-5.0	0.5	-25	13	174	-5.0	-4.5	0.6	-24	9	90
Week 3	-7.5	-7.0	0.7	-34	+   27	174	-6.7	-7.0	0.9	-32	21	90
Week 4	-8.9	-8.5	0.7	-39	   27	174	-8.1	-8.0	0.9	-32	24	90
Week 6	-9.8	-8.0	0.8	-55	25	174	-9.6	-7.0	1.0	-40	18	90
Week 8	-11.0	-10.0	0.8	-43	+   26	174	-10.4	-9.0	1.0	-37	18	90
Week 12	-11.9	-11.0	0.9	-54	+   36	174	-11.2	-10.0	1.0	-41	18	90

#### Table 14.30b

#### Moods and Feelings Questionnaire Baseline and Change from Baseline in Total Scores Excluding Centre 007

				Paroxetine			Placebo						
	Mean	Median	Std Err	Minimum	Maximum	NUMBER OF PATIENTS IN GROUP	Mean	Median	Std Err	Minimum	Maximum	NUMBER OF PATIENTS IN GROUP	
Baseline	33.4	34.0	0.9	3	60	169	33.6	33.0	1.5	8	62	88	
Week 2	-5.7	-5.0	0.8	-42	20	165	-5.0	-5.0	1.2	-37	22	88	
Week 4	-9.0	-7.0	1.0	-41	18	154	-9.1	-8.0	1.5	-38	23	78	
Week 6	-12.4	-10.0	1.1	-46	16	145	-12.3	-10.0	1.6	-48	24	77	
Week 8	-15.2	-15.0	1.3	-52	25	142	-16.8	-15.0	1.6	-53	17	72	
  Week 12	-16.7	-16.0	1.3	-53	22	125	-17.2	-14.0	1.6	-52	+   8	66	

#### 14101101110 11000001 57

#### Table 14.30d

#### Moods and Feelings Questionnaire Baseline and Change from Baseline in Total Scores Excluding Centre 007

 				Paroxetine			Placebo						
	Mean	Median	Std Err	Minimum	Maximum	NUMBER OF PATIENTS IN GROUP	Mean	Median	Std Err	Minimum	Maximum	NUMBER OF PATIENTS IN GROUP	
Baseline	33.4	34.0	0.9	3	60	169	33.6	33.0	1.5	8	62	88	
Week 2	-5.7	-5.0	0.8	-42	20	165	-5.0	-5.0	1.2	-37	22	88	
Week 4	-8.9	-6.0	0.9	-42	18	168	-8.3	-7.5	1.4	-38	23	88	
Week 6	-11.7	-9.9	1.0	-46	18	169	-11.2	-10.0	1.4	-48	24	88	
Week 8	-14.0	-12.4	1.1	-52	25	169	-14.1	-11.0	1.5	-53	24	88	
Week 12	-15.0	-13.1	1.1	-53	+   22	+   169	-14.3	-11.0	1.5	-52	+   24	+   88	

## Table 14.50b

# Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Every Domain Excluding Centre 007

	 		Placebo									
	Mean	Median	Std Err	Minimum		Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group
Baseline	0.37	0.39	0.01	0.00	0.95	162	0.39	0.39	0.02	0.05	0.95	81
Week 4	-0.10	-0.08	0.01	-0.79	0.29	160	-0.11	-0.11	0.02	-0.60	0.32	79
Week 8	-0.17	-0.13	0.02	-0.84	0.32	140	-0.20	-0.16	0.02	-0.71	0.18	72
Week 12	-0.18	-0.16	0.02	-0.95	0.34	125	-0.21	-0.20	0.02	-0.71	0.18	+   66

#### Table 14.50d

# Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Every Domain Excluding Centre 007

	 		Paro	ketine			Placebo					
	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group
Baseline	0.37	0.39	0.01	0.00	0.95	162	0.39	0.39	0.02	0.05	0.95	81
Week 4	-0.10	-0.08	0.01	-0.79	0.29	160	-0.11	-0.11	0.02	-0.60	0.32	79
Week 8	-0.16	-0.13	0.02	-0.84	0.32	162	-0.18	-0.16	0.02	-0.71	0.18	81
Week 12	-0.17	-0.14	0.02	-0.95	0.34	162	-0.19	-0.16	0.02	-0.71	0.18	81

## Table 14.51b

# Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Energy Domain Excluding Centre 007

	 		Parox	ketine			Placebo					
	Mean	Median	Std Err	Minimum		Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group
Baseline	0.55	0.67	0.03	0.00	1.00	162	0.57	0.67	0.04	0.00	1.00	81
Week 4	-0.12	0.00	0.03	-1.00	0.67	160	-0.15	0.00	0.04	-1.00	0.67	79
Week 8	-0.24	-0.17	0.04	-1.00	0.67	140	-0.29	-0.33	0.05	-1.00	0.67	72
Week 12	-0.27	-0.33	0.04	-1.00	1.00	125	-0.32	-0.33	0.05	-1.00	0.67	+   66

## Table 14.51d

# Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Energy Domain Excluding Centre 007

	 		Placebo									
	Mean	Median	Std Err	Minimum		Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group
Baseline	0.55	0.67	0.03	0.00	1.00	162	0.57	0.67	0.04	0.00	1.00	81
Week 4	-0.12	0.00	0.03	-1.00	0.67	160	-0.15	0.00	0.04	-1.00	0.67	79
Week 8	-0.23	0.00	0.04	-1.00	0.67	162	-0.27	-0.33	0.04	-1.00	0.67	81
Week 12	-0.25	0.00	0.03	-1.00	1.00	162	-0.30   -0.30	-0.33	0.05	-1.00	0.67	81

#### Table 14.52b

# Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Emotional Reaction Domain Excluding Centre 007

			Paroz	ketine		Placebo							
	Mean	Median	Std Err	Minimum		Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	
Baseline	0.59	0.67	0.02	0.00	1.00	162	0.63	0.67	0.03	0.11	1.00	81	
Week 4	-0.19	-0.11	0.02	-0.89	0.56	160	-0.19	-0.11	0.03	-0.89	0.56	79	
Week 8	-0.29	-0.33	0.03	-1.00	0.78	140	-0.34	-0.33	0.04	-1.00	0.44	72	
Week 12	-0.31	-0.33	0.03	-1.00	0.54	125	-0.35	-0.33	0.04	-1.00	0.33	+   66	

## Table 14.52d

# Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Emotional Reaction Domain Excluding Centre 007

 			Parox	ketine		Placebo							
	Mean	Median	Std Err	Minimum		Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	
Baseline	0.59	0.67	0.02	0.00	1.00	162	0.63	0.67	0.03	0.11	1.00	+   81	
Week 4	-0.19	-0.11	0.02	-0.89	0.56	160	-0.19	-0.11	0.03	-0.89	0.56	+   79	
Week 8	-0.27	-0.22	0.03	-1.00	0.78	162	-0.31   -0.31	-0.33	0.04	-1.00	0.44	+   81	
Week 12	+   -0.29	-0.28	0.03	-1.00	0.54	162	-0.33	-0.22	0.04	-1.00	0.33	+   81	

## Table 14.53b

# Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Pain Domain Excluding Centre 007

	 		Paro	ketine		Placebo							
	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	
Baseline	0.14	0.00	0.02	0.00	1.00	162	0.14	0.00	0.03	0.00	1.00	81	
Week 4	-0.04	0.00	0.01	-0.75	0.63	160	-0.03	0.00	0.02	-0.63	0.50	79	
Week 8	-0.04	0.00	0.02	-0.88	0.75	140	-0.07	0.00	0.02	-0.75	0.38	72	
Week 12	-0.05	0.00	0.02	-0.88	0.63	125	-0.07	0.00	0.02	-0.63	0.25	+   66	

## Table 14.53d

# Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Pain Domain Excluding Centre 007

	Paroxetine							Placebo							
	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group			
Baseline	0.14	0.00	0.02	0.00	1.00	162	0.14	0.00	0.03	0.00	1.00	81			
Week 4	-0.04	0.00	0.01	-0.75	0.63	160	-0.03	0.00	0.02	-0.63	0.50	79			
Week 8	-0.04	0.00	0.02	-0.88	0.75	162	-0.06	0.00	0.02	-0.75	0.38	81			
Week 12	-0.06	0.00	0.02	-0.88	0.63	162	-0.06	0.00	0.02	-0.63	0.25	81			

#### Table 14.54b

# Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Physical Mobility Domain Excluding Centre 007

	 		Paro	ketine			Placebo							
	Mean	Median	Std Err	Minimum		Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group		
Baseline	0.16	0.13	0.02	0.00	1.00	162	0.17	0.13	0.02	0.00	1.00	81		
Week 4	-0.03	0.00	0.01	-0.75	0.88	160	-0.04	0.00	0.02	-0.50	0.63	79		
Week 8	-0.07	0.00	0.02	-0.88	0.63	140	-0.09	0.00	0.02	-0.63	0.25	72		
Week 12	-0.08	0.00	0.02	-0.88	0.25	125	-0.11	-0.13	0.02	-0.63	0.13	+   66		

#### Table 14.54d

## Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Physical Mobility Domain Excluding Centre 007

Intention to Treat Population (LOCF)

	 	Paroxetine						Placebo						
	Mean	Median	Std Err	Minimum		Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group		
Baseline	0.16	0.13	0.02	0.00	1.00	162	0.17	0.13	0.02	0.00	1.00	81		
Week 4	-0.03	0.00	0.01	-0.75	0.88	160	-0.04	0.00	0.02	-0.50	0.63	79		
Week 8	-0.06	0.00	0.01	-0.88	0.63	162	-0.08	0.00	0.02	-0.63	0.25	81		
Week 12	-0.08	0.00	0.01	-0.88	0.50	162	-0.10   -0.10	-0.13	0.02	-0.63	0.13	81		

### Table 14.55b

## Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Sleep Domain Excluding Centre 007

	 		Paro	ketine			Placebo						
	Mean	Median	Std Err	Minimum		Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	
Baseline	0.40	0.40	0.02	0.00	1.00	162	0.42	0.40	0.03	0.00	1.00	81	
Week 4	-0.12	0.00	0.02	-0.80	0.80	160	-0.14	0.00	0.03	-0.80	0.40	79	
Week 8	-0.18	-0.20	0.03	-1.00	1.00	140	-0.20	-0.20	0.03	-0.80	0.40	72	
Week 12	-0.19	-0.20	0.03	-1.00	0.80	125	-0.21	-0.20	0.04	-0.80	0.40	+   66	

### Table 14.55d

## Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Sleep Domain Excluding Centre 007

Intention to Treat Population (LOCF)

	 		Paro	ketine			Placebo						
	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	
Baseline	0.40	0.40	0.02	0.00	1.00	162	0.42	0.40	0.03	0.00	1.00	81	
Week 4	-0.12	0.00	0.02	-0.80	0.80	160	-0.14	0.00	0.03	-0.80	0.40	79	
Week 8	-0.17	-0.20	0.03	-1.00	1.00	162	-0.18	-0.20	0.03	-0.80	0.40	81	
Week 12	-0.18	-0.20	0.02	-1.00	0.80	162	-0.19	-0.20	0.04	-0.80	0.40	81	

#### Table 14.56b

## Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Social Isolation Domain Excluding Centre 007

	 		Paro	ketine			Placebo						
	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group	
Baseline	0.50	0.40	0.03	0.00	1.00	162	0.58	0.60	0.04	0.00	1.00	81	
Week 4	-0.13	0.00	0.03	-1.00	0.60	160	-0.15	0.00	0.03	-1.00	0.40	79	
Week 8	-0.23	-0.20	0.03	-1.00	0.60	140	-0.26	-0.20	0.04	-1.00	0.40	72	
Week 12	-0.26	-0.20	0.03	-1.00	0.60	125	++   -0.29	-0.20	0.04	-1.00	0.40	+   66	

#### Table 14.56d

## Nottingham Health Profile (NHP) Baseline and Change from Baseline in Total Scores - Social Isolation Domain Excluding Centre 007

Intention to Treat Population (LOCF)

			Paroz	ketine			Placebo					
	Mean	Median	Std Err	Minimum		Number of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	Number of Patients in Group
Baseline	0.50	0.40	0.03	0.00	1.00	162	0.58	0.60	0.04	0.00	1.00	81
Week 4	-0.13	0.00	0.03	-1.00	0.60	160	-0.15	0.00	0.03	-1.00	0.40	79
Week 8	-0.21	-0.20	0.03	-1.00	0.60	162	-0.23	-0.20	0.04	-1.00	0.40	81
Week 12	-0.23	-0.20	0.03	-1.00	0.60	162	-0.26	-0.20	0.04	-1.00	0.40	81

#### Table 14.60b

#### Euroqol Summary Scores Excluding Centre 007

Ī				Paroz	ketine			Placebo						
		Number of					Median	Std			Maxim-	Number of Patients in Group		
	Baseline	49.8	50.0	1.8	0.0	95.0	130	49.3	50.0		2.5	9.0	90.0	68
	Week 12	71.6	76.0	2.0	8.5	100.0	120	72.1	80.0		2.7	20.0	100.0	64

#### Table 14.61b

### Euroqol Baseline and Change from Baseline in Scores Excluding Centre 007

-				Paro	oxetine			 		Pla	acebo		
		Mean	Median		Minim- um	Maxim-	Number of Patients in Group		Median	Std Err	Minim- um		Number of Patients in Group
	Baseline	49.8	50.0	1.8	0.0	95.0	130	49.3	50.0	2.5	9.0	90.0	68
	Week 12	22.1	20.0	2.3	-55.0	75.0	120	24.0	20.0	2.9	-20.0	90.0	64

Table 14.70b

### Socio-Economic Questionnaire - Living Arrangements at Baseline Assessment Excluding Centre 007

	 	Paroxe	etine	Plac	ebo
		Number	Percent	Number	Percent
Baseline	Total no. of patients in group	177	100.0	91	100.0
	At home with parents	123	69.5	68	74.7
	At home with grandparents	3	1.7	2	2.2
	At home with sisters/brothers	18	10.2	9	9.9
	At home with other relatives	8	4.5	3	3.3
	In rented accomodation	1	0.6		
	In a hostel	12	6.8	3	3.3
	In residential care	12	6.8	6	6.6

Table 14.71b

#### Socio-Economic Questionnaire - Current Employment Status Excluding Centre 007

#### Intention to Treat Population

 		Paroxe	etine	Plac	ebo
		Number	Percent	Number	Percent
Baseline	Total no. of patients in group	177	100.0	91	100.0
	Attending school	151	85.3	72	79.1
	Attending college or further education	5	2.8	8	8.8
	Job training scheme	2	1.1	1	1.1
	Full time employed	2	1.1	1	1.1
	Part time employed	4	2.3	1	1.1
	Casual labour	2	1.1	1	1.1
	Unemployed	11	6.2	7	7.7
Week 4	Total no. of patients in group	169	100.0	82	100.0
	Attending school	141	83.4	 65	79.3

(CONTINUED)

#### Table 14.71b

#### Socio-Economic Questionnaire - Current Employment Status Excluding Centre 007

#### Intention to Treat Population

		Paroxe	etine	Plac	ebo
		Number	Percent	Number	Percent
Week 4	Attending college or further education	8	4.7	4	4.9
	Job training scheme	1	0.6	2	2.4
	Full time employed	2	1.2	1	1.2
	Part time employed	4	2.4	3	3.7
	Casual labour	1	0.6	1	1.2
	Unemployed	12	7.1	6	7.3
Week 8	Total no. of patients in group	142	100.0	73	100.0
	Attending school	116	81.7	 57	78.1
	Attending college or further education	5	3.5	5	6.8
	Job training   scheme				

(CONTINUED)

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]LT1470.SAS (05AUG98 12:55)

#### Table 14.71b

#### Socio-Economic Questionnaire - Current Employment Status Excluding Centre 007

#### Intention to Treat Population

		Paroxe	etine	Plac	ebo
		Number	Percent	Number	Percent
Week 8	Full time  employed	3	2.1	1	1.4
	Part time   employed	3	2.1	3	4.1
	Casual labour	2	1.4	1	1.4
	Unemployed	13	9.2	6	8.2
Week 12	Total no. of patients in group	129	100.0	66	100.0
	Attending school	103	79.8	52	78.8
	Attending college or further education	6	4.7	5	7.6
	Job training scheme	1	0.8	1	1.5
	Full time   employed	4	3.1		
	Part time   employed	3	2.3	3	4.5
	Casual labour	2	1.6	1	1.5
	Unemployed	10	7.8	 4	6.1

(CONTINUED)

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]LT1470.SAS (05AUG98 12:55)

#### Table 14.71b

#### Socio-Economic Questionnaire - Current Employment Status Excluding Centre 007

		Paroxe	etine	Plac	ebo
		Number	Percent	Number	Percent
>Week 12	Total no. of patients in group	7	100.0	4	100.0
	Attending school	7	100.0	1	25.0
	Attending college or further education				
	Job training   scheme			1	25.0
	Full time employed			1	25.0
	Part time employed		 	1	25.0
	Casual labour				
	Unemployed	+	+ 	+ 	

Table 14.72b

### Socio-Economic Questionnaire - Patients with Problems with Employment Status Excluding Centre 007 $\,$

 		Paroxetine	 	Placebo				
	Number in group	Number with   problem	Percent with problem	Number in group	Number with   problem	Percent with problem		
Baseline	175	89	50.9	91	50	54.9		
Week 4	167	65	38.9	81	27	33.3		
Week 8	142	32	22.5	72	16	22.2		
Week 12	126	25	19.8	66	14	21.2		

#### Table 14.73b

### Socio-Economic Questionnaire - Summary of Patients Missing Days from School/College/Work Excluding Centre 007

#### Intention to Treat Population

#### School

		Paroxetine		Placebo				
	Number in group	Number with   problem	Percent with problem	Number in group	Number with   problem	Percent with problem		
Baseline	175	54	30.9	91	26	28.6		
Week 4	161	38	23.6	 79	17	21.5		
Week 8	137	25	18.2	72	12	16.7		
Week 12	122	24	19.7	66	9	13.6		

#### Table 14.73b

Socio-Economic Questionnaire - Summary of Patients Missing Days from School/College/Work Excluding Centre 007

#### Intention to Treat Population

#### College or further education

		Paroxetine		Placebo			
	Number in Number with group problem		Percent with   problem	Number in group	Number with   problem	Percent with problem	
Baseline	175	4	2.3	91	6	6.6	
Week 4	161	<u></u>		79	2	2.5	
Week 8	137	+		72	+   !		
Week 12	122	+ 	 	66	2	3.0	

#### Table 14.73b

Socio-Economic Questionnaire - Summary of Patients Missing Days from School/College/Work Excluding Centre 007

#### Intention to Treat Population

#### Work

		Paroxetine		Placebo			
	Number in   Number with   I group   problem		Percent with problem	Number in group	Number with problem	Percent with   problem	
Baseline	175	4	2.3	91	2	2.2	
Week 4	161	2	1.2	79		ļ	
Week 8	137	3	2.2	72	+	[	
Week 12	122	1	0.8	66	 		

Table 14.74b

### Socio-Economic Questionnaire - Summary of Days Missed from School/College/Work Excluding Centre 007

 			Paroxe	etine		
	Mean	Median	Std Err	Minimum	Maximum	Number of patients
Baseline	3.2	0.0	0.6	0.0	60.0	181
Week 4	1.5	0.0	0.4	0.0	60.0	172
Week 8	3.0	0.0	1.0	0.0	90.0	144
Week 12	3.8	0.0	1.3	0.0	90.0	130
  >Week 12	3.4	0.0	3.4	0.0	24.0	7

#### Table 14.74b

## Socio-Economic Questionnaire - Summary of Days Missed from School/College/Work Excluding Centre 007

		Placebo								
	Mean	Median	Std Err	Minimum	Maximum	Number of patients				
Baseline	2.0	0.0	0.4	0.0	20.0	93				
Week 4	1.5	0.0	0.6	0.0	35.0	83				
Week 8	1.0	0.0	0.5	0.0	30.0	75				
  Week 12	2.0	0.0	1.1	0.0	70.0	69				
>Week 12	28.5	4.0	25.9	0.0	106.0	4				

#### Table 14.75b

## Socio-Economic Questionnaire Patients with Problems with Specified Activities Excluding Centre 007

#### Intention to Treat Population

#### Home activities

		Paroxetine		Placebo			
	Number in group	Number with problem	Percent with problem	Number in group	Number with   problem	Percent with problem	
Baseline	176	166	94.3	91	87	95.6	
Week 4	166	155	93.4	81	74	91.4	
Week 8	140	126	90.0	72	66	91.7	
Week 12	123	113	91.9	66	   60	90.9	

#### Table 14.75b

# Socio-Economic Questionnaire Patients with Problems with Specified Activities Excluding Centre 007

#### Intention to Treat Population

#### Social life

	 	Paroxetine	 	Placebo			
	Number in group	Number with problem	Percent with   problem	Number in group	Number with problem	Percent with problem	
Baseline	176	166	94.3	91	87	95.6	
Week 4	166	155	93.4	81	78	96.3	
Week 8	140	129	92.1	72	67	93.1	
Week 12	123	115	93.5	66	61	92.4	

#### Table 14.75b

# Socio-Economic Questionnaire Patients with Problems with Specified Activities Excluding Centre 007

#### Intention to Treat Population

#### Home life

		Paroxetine		Placebo			
	Number in group	Number with problem	Percent with problem	Number in group	Number with problem	Percent with problem	
Baseline	176	165	93.8	91	88	96.7	
Week 4	166	154	92.8	81	77	95.1	
Week 8	140	127	90.7	72	69	95.8	
Week 12	123	112	91.1	66	61	92.4	

#### Table 14.75b

# Socio-Economic Questionnaire Patients with Problems with Specified Activities Excluding Centre 007

#### Intention to Treat Population

#### Personal relationships

		Paroxetine		Placebo			
	Number in group	Number with problem	Percent with   problem	Number in group	Number with   problem	Percent with problem	
Baseline	176	163	92.6	91	84	92.3	
Week 4	166	153	92.2	81	†75	92.6	
Week 8	140	125	89.3	72	66	91.7	
Week 12	123	112	91.1	66	61	92.4	

#### Table 14.76b

#### Socio-Economic Questionnaire Change in Problems with Specified Activites Excluding Centre 007

#### Intention to Treat Population

#### Home activities

	   	Paroxetine											
	Total No. Experiencing   Problem		Wor	Worse		Same		Better					
	Number	Percent	Number	Percent	Number	Percent	Number	Percent					
Baseline	166	93.8	31	18.7	122	73.5	13	7.8					
Week 4	155	92.8	11	7.1	76	49.0	68	43.9					
Week 8	126	88.7	8	6.3	56	44.4	62	49.2					
Week 12	113	89.7	9	8.0	41	36.3	63	55.8					

#### Table 14.76b

#### Socio-Economic Questionnaire Change in Problems with Specified Activites Excluding Centre 007

#### Intention to Treat Population

#### Home activities

				Plac	cebo			
		Total No. Experiencing Problem		Worse   Sam		ne	Better	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Baseline	87	95.6	15	17.2	66	75.9	6	6.9
Week 4	74	91.4	7	9.5	40	54.1	27	36.5
Week 8	66	91.7	4	6.1	30	45.5	32	48.5
Week 12	60	90.9	3	5.0	30	50.0	27	45.0

#### Table 14.76b

#### Socio-Economic Questionnaire Change in Problems with Specified Activites Excluding Centre 007

#### Intention to Treat Population

#### Social life

 				Paroxe	tine				
	Total No. Experiencing   Problem		Worse		Sam	ne	Better		
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	
Baseline	166	93.8	44	26.5	105	63.3	17	10.	
Week 4	155	92.8	12	7.7	65	41.9	78	50.3	
Week 8	129	90.8	7	5.4	41	31.8	81	62.	
Week 12	115	91.3	9	7.8	35	30.4	71	61.	

#### Table 14.76b

#### Socio-Economic Questionnaire Change in Problems with Specified Activites Excluding Centre 007

#### Intention to Treat Population

#### Social life

	 			Plac	cebo			
	Total No. Experiencing Problem		Wor	Worse		ne	Better	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Baseline	87	95.6	19	21.8	61	70.1	7	8.0
Week 4	78	96.3	5	6.4	36	46.2	37	47.4
Week 8	67	93.1	4	6.0	26	38.8	37	55.2
Week 12	61	92.4	3	4.9	24	39.3	34	55.7

#### Table 14.76b

#### Socio-Economic Questionnaire Change in Problems with Specified Activites Excluding Centre 007

#### Intention to Treat Population

#### Home life

 				Paroxe	etine				
	Total No. Experiencing   Problem		Worse		San	ne	Better		
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	
Baseline	165	93.2	41	24.8	113	68.5	11	6.7	
Week 4	154	92.2	19	12.3	69	44.8	66	42.9	
Week 8	127	89.4	16	12.6	52	40.9	59	46.5	
Week 12	112	88.9	13	11.6	38	33.9	61	54.5	

#### Table 14.76b

#### Socio-Economic Questionnaire Change in Problems with Specified Activites Excluding Centre 007

#### Intention to Treat Population

#### Home life

 	 	Placebo											
	Total No. Experiencing Problem		Wor	Worse		ne	Better						
	Number	Percent	Number	Percent	Number	Percent	Number	Percent					
Baseline	88	96.7	20	22.7	59	67.0	9	10.2					
Week 4	77	95.1	8	10.4	39	50.6	30	39.0					
Week 8	69	95.8	7	10.1	32	46.4	30	43.5					
Week 12	61	92.4	4	6.6	24	39.3	33	54.1					

#### Table 14.76b

#### Socio-Economic Questionnaire Change in Problems with Specified Activites Excluding Centre 007

#### Intention to Treat Population

#### Personal relationships

	 			Paroxe	etine			
	Total No. Experiencing Problem Number Percent		Worse		Same		Better	
			Number	Percent	Number	Percent	Number	Percent
Baseline	163	92.1	33	20.2	118	72.4	12	7.4
Week 4	153	91.6	17	11.1	65	42.5	71	46.4
Week 8	125	88.0	6	4.8	54	43.2	65	52.0
Week 12	112	88.9	8	7.1	34	30.4	70	62.5

#### Table 14.76b

#### Socio-Economic Questionnaire Change in Problems with Specified Activites Excluding Centre 007

#### Intention to Treat Population

#### Personal relationships

				Plac	cebo				
	Total No. Experiencing   Problem   Number   Percent		Worse		San	ie	Better		
			Number	Percent	Number	Percent	Number	Percent	
Baseline	84	92.3	21	25.0	57	67.9	6	7.1	
Week 4	75	92.6	5	6.7	38	50.7	32	42.7	
Week 8	66	91.7	8	12.1	23	34.8	35	53.0	
Week 12	61	92.4	1	1.6	29	47.5	31	50.8	

Table 14.81b

### Summary of Psychotherapy Evaluation Professional Involvement Excluding Centre 007

#### Intention to Treat Population

Treatment Group: Paroxetine

 	Soc	ial worke	r	Occupati	ional ther	apist	Ps>	chologist		 !	Other	
	Number of Patients in Group	N		Number of Patients in Group	N		Number of Patients in Group	N		Number of  Patients  in Group	N	Percent
Screening	178	19	10.7	ļ		ļ	178	14	7.9			ļ
Baseline	178	6	3.4	ļ		ļ	178	8	4.5			ļ
Week 1	176	3	1.7	176	2	1.1	176	9	5.1	ļ		ļ
Week 2	168	5	3.0	168	2	1.2	168	7	4.2			ļ
Week 3	157	4	2.5	157	2	1.3	157	7	4.5			ļ
Week 4	159	2	1.3	159	2	1.3	159	8	5.0			
Week 6	150	1	0.7	150	2	1.3	150	7	4.7	150	1	0.7
Week 8	145	4	2.8	145	1	0.7	145	9	6.2	   		Ī
Week 12	131	2	1.5	131	2	1.5	131	9	6.9			

Table 14.81b

## Summary of Psychotherapy Evaluation Professional Involvement Excluding Centre 007

#### Intention to Treat Population

Treatment Group: Placebo

	Soc	cial worke	r	Psy	chologist	
	Number of Patients in Group	N	Percent	Number of Patients in Group	N	Percent
Screening	91	7	7.7	91	12	13.2
Baseline	90	2	2.2	90	6	6.7
Week 1	91	1	1.1	91	5	5.5
Week 2	ļ		<u>+</u>	86	6	7.0
Week 3	85	1	1.2	85	6	7.1
Week 4	ļ		! !	81	5	6.2
Week 6	81	1	1.2	81	7	8.6
Week 8	74	1	1.4	74	5	6.8
Week 12	+   68	1	+   1.5	68	5	+    7.4

Table 14.82b

### Summary of Psychotherapy Evaluation Therapy Received Excluding Centre 007

Intention to Treat Population

Treatment Group: Paroxetine

 	Fami	lly Therap	 !	Supportiv	re Psychot	herapy	Formal	Psychothe	rapy
	Number of Patients in Group	N	Percent	Number of Patients in Group	N	Percent	Number of  Patients  in Group	N	Percent
Screening	178	2	1.1	178	21	11.8	178	1	0.6
Baseline			 	178	14	7.9	<u>+</u>	 	ļ
Week 1				176	15	8.5			ļ
Week 2				168	13	7.7			ļ
Week 3				157	13	8.3			ļ
Week 4				159	16	10.1			ļ
Week 6				150	14	9.3			ļ
Week 8	145	2	1.4	145	13	9.0	   		ļ
Week 12	131	2	1.5	131	17	13.0	<u></u>	 	ļ
>Week 14	7	1	14.3	7	1	14.3			

#### Table 14.82b

## Summary of Psychotherapy Evaluation Therapy Received Excluding Centre 007

#### Intention to Treat Population

Treatment Group: Placebo

	Fami	ily Therapy	Y	Supportiv	re Psychotl	herapy
	Number of Patients in Group	N	Percent	Number of Patients in Group	N	Percent
Screening				91	8	8.8
Baseline	90	1	1.1	90	8	8.9
Week 1				91	7	7.7
Week 2				86	6	7.0
Week 3				85	7	8.2
Week 4				81	7	8.6
Week 6				81	10	12.3
Week 8				74	8	10.8
Week 12	68	1	1.5	68	8	11.8

#### Table 14.90b

#### Child-Global Assessment Scale Screening and Change from Screening in Total Scores Excluding Centre 007

	Paroxetine					Placebo						
	Mean	Median	Std Err	Minimum	Maximum	No of Patients in Group	Mean	Median	Std Err	Minimum	Maximum	No of Patients in Group
Screening	51.1	51.0	0.6	25	68	178	50.6	51.0	0.9	23	65	91
Week 12	24.5	23.0	1.2	-11	55	127	22.9	22.5	1.7	-3	55	66

## 12 Source Tables: Safety Results

Table 15.011B Number (%) of Patients with Emergent AE's During Active Treatment Phase. Non-gender specific AE's only (ITT)	. 000291
Table 15.012B Number (%) of Patients with Emergent AE's During Active Treatment Phase. Male specific AE's only (ITT)	. 000294
Table 15.013B Number (%) of Patients with Emergent AE's During Active Treatment Phase. Female specific AE's only (ITT)	. 000295
Table 15.01B Number (%) of Patients with Emergent AE's During Active Treatment Phase Displayed by Body System (ITT)	. 000296
Table 15.041B Number (%) of Patients with Emergent AE's Classed by the Investigator as severe During Active Treatment Phase Non-gender specific AE's only (ITT)	•
Table 15.042B Number (%) of Patients with Emergent AE's Classed by the Investigator as severe During Active Treatment Phase Male specific AE's only (ITT)	. 000298
Table 15.043B Number (%) of Patients with Emergent AE's Classed by the Investigator as severe During Active Treatment Phase Female specific AE's only (ITT)	
Table 15.04B Number (%) of Patients with Emergent AE's Classed by the Investigator as severe During Active Treatment Phase Displayed by Body System (ITT)	. 000300
Table 15.051B Number (%) of Patients with Emergent AE's Considered to be related to the Study Medication During Active Treatment Phase Non-gender specific AE's only	. 000301
Table 15.052B Number (%) of Patients with Emergent AE's Considered to be related to the Study Medication During Active Treatment Phase: Male specific AE's only	
Table 15.053B Number (%) of Patients with Emergent AE's Considered to be related to the Study Medication During Active Treatment Phase:	
Female specific AE's only	
Table 15.061B Number (%) of Patients with Emergent AE's Leading to Withdrawal During Active Treatment Phase Non-gender specific AE's only (ITT)	) S
Table 15.062B Number (%) of Patients with Emergent AE's Leading to Withdrawal During Active Treatment Phase Male specific AE's only (ITT)	
Table 15.063B Number (%) of Patients with Emergent AE's Leading to Withdrawal During Active Treatment Phase Female specific AE's only (ITT)	y y

Table 15.06B Number (%) of Patients with Emergent AE's Leading to Withdrawal During Active Treatment Phase Displayed by Body System (ITT)	. 000308	8
Table 15.071B Number (%) of Patients with AE's Classed by Investigator as Serious During Active Treatment Phase Non-gender specific AE's only (ITT)	. 000309	9
Table 15.072B Number (%) of Patients with AE's Classed by Investigator as Serious During Active Treatment Phase Male specific AE's only (ITT)	. 000310	0
Table 15.073B Number (%) of Patients with AE's Classed by Investigator as Serious During Active Treatment Phase Female specific AE's only (ITT)	. 000311	1
Table 15.07B Number (%) of Patients with AE's Classed by Investigate as Serious During Active Treatment Phase Displayed by Body System (ITT)	n	2
Table 15.081B Number (%) of Patients with Emergent AE's During the First Two Weeks of Active Treatment Non-gender specific AE's only (ITT)	,	3
Table 15.082B Number (%) of Patients with Emergent AE's During the First Two Weeks of Active Treatment Male specific AE's only (ITT)	e	
Table 15.083B Number (%) of Patients with Emergent AE's During the First Two Weeks of Active Treatment Female specific AE's only (ITT		7
Table 15.08B Number (%) of Patients with Emergent AE's During the First Two Weeks of Active Treatment Displayed by Body System (ITT)	. 000318	8
Table 15.091B Number (%) of Patients with Emergent AE's During the First Two Weeks of Active Treatment By Baseline Body Weight (< 50 Kg, 50-70 Kg, >= 70 Kg) Non-gender specific AE's only (ITT)		9
Table 15.092B Number (%) of Patients with Emergent AE's During the First Two Weeks of Active Treatment By Baseline Body Weight. (< 50 Kg, 50-70 Kg, >= 70 Kg) Male specific AE's only (ITT)	e	
Table 15.093B Number (%) of Patients with Emergent AE's During the First Two Weeks of Active Treatment By Baseline Body Weight( < 5 Kg, 50-70 Kg, >= 70 Kg) Female specific AE's only (ITT)	e 50	
Table 15.09B Number (%) of Patients with Emergent AE's During the First Two Weeks of Active Treatment By Baseline Body Weight (< 50 Kg, 50-70 Kg, >= 70 Kg) Displayed by Body System (ITT)		
Table 15.101B Number (%) of Patients with Emergent AE's by Baselin Body Weight (< 50kg, 50-70kg, >70kg). Non-Gender Specific AEs only (ITT)	ne	
Table 15.102B Number (%) of Patients with Emergent AE's by Baselin Body Weight (< 50kg, 50-70kg, >70kg). Male Specific AEs only (ITT)		

Table 15.103B Number (%) of Patients with Emergent AE's by Baseline	
Body Weight (< 50kg, 50-70kg, >70kg). Female Specific Aes only (ITT)	0
	9
Table 15.10B Number (%) of Patients with Emergent AE's by BaselineBody Weight (< 50kg, 50-70kg, >70kg). Displayed by Body	
System (ITT)	3
Table 15.111B Number (%) of Patients with Emergent AE's During Down Titration Phase. Non-gender specific AE's only (ITT)	7
Table 15.112B Number (%) of Patients with Emergent AE's During  Down Titaration Phase. Male specific AE's only (ITT)	
Table 15.113B Number (%) of Patients with Emergent AE's During  Down Titaration Phase. Female specific AE's only (ITT)	0
Table 15.11B Number (%) of Patients with Emergent AE's During Down Titration Phase. Displayed by Body System (ITT)	1
Table 15.12B Number (%) of Deaths During Active Treatment (ITT) 000362	
Table 15.21b Summary of Flagged Vital Signs by Parameter (ITT) 00036	3
Table 15.22b Summary of Group Vital Signs (ITT)000370	0
Table 15.23b Summary of Group Vital Signs Changes from Baseline	
(ITT)	
Table 15.34b Summary of Qualitative Laboratory Values (ITT) 000402	2
Table 15.3b Number of Patients with Quantitive Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB	
Lab Units (ITT)	6

#### TABLE 15.011B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING ACTIVE TREATMENT PHASE NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

FREATMENT GROUPS				PLACEBO			Ĺ
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 119	100.0% 65.4%	93 55	100.0% 59.1%	275 174	100.09
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		61	33.5	34	36.6 9.7 1.1 0.0 0.0	95	34.5
ABDOMINAL PAIN		6	3.3	9	9.7	15	5.5
ABSCESS		2	1.1	1	1.1	3	1.1
ACCIDENTAL OVERDOSE ALLERGIC REACTION		1	0.5	0	0.0	1	0.4
ASTHENIA		1 2	0.5	0	0.0	21	7.6
BACK PAIN		7.7	1.6	9 1	9.7	4	1.5
CHEST PAIN		5	2 7	0	0.0	5	1.8
FEVER		1	0.5	0	9.7 1.1 0.0 0.0	1	0.4
FLU SYNDROME		1	0.5	1	1.1	2	0.7
HEADACHE		34	18.7	21	22.6 6.5 1.1 1.1 2.2	55	20.0
INFECTION		14	7.7	6	6.5	20	7.3
MALAISE		0	0.0	1	1.1	1	0.4
NEOPLASM		0	0.0	1	1.1	1	0.4
PAIN		1	0.5	2	2.2	3	1.1
TRAUMA		5	2.7	0	0.0	5	1.8
Cardiovascular System		12	6.6	1	1.1 0.0 0.0	13	4.7
HYPERTENSION		2	1.1	0	0.0	2	0.7
HYPOTENSION		3	1.6	0	0.0	3	1.1
PALPITATION		2	1.1	0	0.0	2	0.7
POSTURAL HYPOTENSION		3	1.6	1	1.1	4	1.5
SYNCOPE		1	0.5	0	0.0	1	0.4
VASODILATATION		1			0.0 1.1 0.0 0.0		0.4
Digestive System		64	35.2	21	22.6 1.1	85	30.9
BILIARY PAIN		0	0.0	1	1.1	1	0.4
CONSTIPATION		3	1.6	1	1.1	4	1.5
DECREASED APPETITE			7.7	3	3.2	17	6.2
DIARRHEA		4	2.2	3	3.2	7	2.5
DRY MOUTH		4	2.2	0	0.0	4	1.5
DYSPEPSIA		1 2	0.5	U	0.0	1	0.4
GASTROENTERITIS GINGIVITIS		2	1 · 1	Ţ	1.1	2	1.1
INCREASED APPETITE		2	1.1	0	0.0	2	0.7
NAUSEA		44	24.2	1.4	0.0 15.1	5.8	21.1
TOOTH DISORDER		1	0.5	0		1	0.4

### TABLE 15.011B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING ACTIVE TREATMENT PHASE NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS					BO 	TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 119	100.0% 65.4%	93 55	100.0% 59.1%	275 174	100.0
ADECS BODY SYSTEM : PREFERRED TERM  VOMITING		N	%	N	%	N	%
VOMITING		7	3.8	3	3.2	10	3.6
Hemic and Lymphatic System ANEMIA EOSINOPHILIA LEUKOCYTOSIS THROMBOCYTOPENIA		3 1 1 0	1.6 0.5 0.5 0.0	2 0 1 1 0	2.2 0.0 1.1 1.1 0.0	5 1 2 1 1	1.8 0.4 0.7 0.4 0.4
Metabolic and Nutritional Disorders HYPOGLYCEMIC REACTION WEIGHT GAIN WEIGHT LOSS		3 1 1 1	1.6 0.5 0.5	0		3 1 1 1	
Musculoskeletal System ARTHRALGIA MYALGIA TENDINOUS DISORDER		2 1 0 1	1.1 0.5 0.0 0.5	3 2 1 0	3.2 2.2 1.1 0.0	5 3 1 1	1.8 1.1 0.4 0.4
Nervous System ABNORMAL DREAMS AGITATION ANXIETY CONFUSION CONVULSION DEPERSONALIZATION DEPRESSION DIZZINESS EMOTIONAL LABILITY HOSTILITY HYPESTHESIA HYPOKINESIA HYSTERIA INSOMNIA MYOCLONUS NERVOUSNESS NEUROSIS PARESTHESIA		64 2 4 3 1 1 2 2 19 8 1 1 1 1 9 4 2	35.2 1.1 2.2 1.6 0.5 0.5 1.1 1.1 10.4 4.4 0.5 0.5 0.5 0.5 0.5	0 0 0 0 0 7 3 0 0	0.0 0.0 0.0 7.5 3.2 0.0 0.0 0.0 0.0	3 4 3 1 1 2 2 26 11 1 1 1 1 1 2 5	0.4 0.7 0.7 9.5 4.0 0.4 0.4 0.4

# Paroxetine - Protocol: 377 TABLE 15.011B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING ACTIVE TREATMENT PHASE NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS		PAROXETINE		PLACEBO		TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 119	100.0% 65.4%	93 55	100.0% 59.1%	275 174	100.09
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
SOMNOLENCE		17	9.3	6	6.5 1.1	23	8.4
TREMOR		6	3.3	1	1.1	7	2.5
Respiratory System		22	12.1	13	14.0		12.7
BRONCHITIS		1	0.5	3	3.2	4	1.5
COUGH INCREASED		5	2.7	1	1.1	6	2.2
DYSPNEA		3	1.6	0	1.1 0.0 0.0	3	1.1
EPISTAXIS		1	0.5	0	0.0	1	0.4
PHARYNGITIS		2	1.1	5	5.4	7	2.5
RESPIRATORY DISORDER		5	2.7	3	3.2 3.2 1.1	8	
RHINITIS		3	1.6	3	3.2	6	2.2
SINUSITIS		4	2.2	3 1 0	1.1	5	1.8
YAWN		1	0.5	0	0.0	1	0.4
Skin and Appendages		12	6.6	2	2.2	14	5.1
ACNE		2	1.1	0 0	0.0	2.	0.7
ALOPECIA		1					0.4
HERPES ZOSTER		1		0			0.4
PHOTOSENSITIVITY		1	0.5	0	0.0	1	0.4
RASH		2	1.1	1	1.1	3	1.1
SWEATING		4	2.2			5	1.8
SWEATING DECREASED		1	0.5	0	0.0	1	0.4
Special Senses		6	3.3	1	1.1	7	2.5
ABNORMAL VISION		3	1.6	1	1.1	4	1.5
MYDRIASIS		1	0.5	0	0.0	1	0.4
OTITIS MEDIA		2	1.1	0	0.0	2	0.7
Urogenital System		5	2.7	3	3.2 3.2	8	2.9
CYSTITIS		1	0.5	3	3.2	4	1.5
PYURIA		1	0.5	0	0.0	1	0.4
URINARY TRACT INFECTION		3	1.6	0	0.0	3	1.1

#### PAROXETINE - PROTOCOL: 377

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING ACTIVE TREATMENT PHASE MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.012B

------

TREATMENT GROUPS	PAROXETINE			PLACE	30	TOTAL	ı
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	60 1	100.0% 1.7%	32	100.0% 0.0%	92 1	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	 왕	N	e 8	N	%
Urogenital System ABNORMAL EJACULATION IMPOTENCE		1 1 1	1.7 1.7 1.7	0 0 0	0.0 0.0 0.0	1 1 1	1.1 1.1 1.1

#### PAROXETINE - PROTOCOL: 377

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING ACTIVE TREATMENT PHASE FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.013B

------

TREATMENT GROUPS	PAROXETINE			PLACE	30	TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	122 2	100.0% 1.6%	61 0	100.0%	183 2	100.0% 1.1%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	ૄ	N	%
Urogenital System DYSMENORRHEA MENSTRUAL DISORDER		2 1 1	1.6 0.8 0.8	0 0 0	0.0 0.0 0.0	2 1 1	1.1 0.5 0.5

Paroxetine - Protocol: 377

TABLE 15.01B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING ACTIVE TREATMENT PHASE DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

	======	======	=======	======	=======	======	======
TREATMENT GROUPS	I	PAROXETINE			30	TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:				100.0% 59.1%		100.0% 63.6%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		61	33.5	34	36.6	95	34.5
Cardiovascular System		12	6.6	1	1.1	13	4.7
Digestive System		64	35.2	21	22.6	85	30.9
Hemic and Lymphatic System		3	1.6	2	2.2	5	1.8
Metabolic and Nutritional Disorders		3	1.6	0	0.0	3	1.1
Musculoskeletal System		2	1.1	3	3.2	5	1.8
Nervous System		64	35.2	22	23.7	86	31.3
Respiratory System		22	12.1	13	14.0	35	12.7
Skin and Appendages		12	6.6	2	2.2	14	5.1
Special Senses		6	3.3	1	1.1	7	2.5
Urogenital System		8	4.4	3	3.2	11	4.0

Paroxetine - Protocol: 377

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES CLASSED BY INVESTIGATOR AS SEVERE DURING ACTIVE TREATMENT PHASE NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.041B

		======	=======		=======	======	=====
TREATMENT GROUPS		PAROXET	AROXETINE		PLACEBO		С
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182	100.0%	93	100.0%	275	100.0%
PATIENTS WITH ADVERSE EXPERIENCES	:	20	11.0%	6	6.5% 	26	9.5%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		5	2.7	3	3.2	8	2.9
ASTHENIA		0	0.0	2	2.2	2	0.7
HEADACHE		3	1.6	0	0.0	3	1.1
INFECTION		1	0.5		0.0		
PAIN		0	0.0		1.1		
TRAUMA		1	0.5	0	0.0	1	0.4
Digestive System		4	2.2	0	0.0	4	1.5
DECREASED APPETITE		1	0.5	0	0.0	1	0.4
GINGIVITIS		1	0.5	0	0.0	1	0.4
NAUSEA		3	1.6	0	0.0	3	1.1
VOMITING		1	0.5	0	0.0	1	0.4
Nervous System		10	5.5	3	3.2	13	4.7
AGITATION		2	1.1	0	0.0	2	0.7
ANXIETY		1	0.5	0	0.0	1	0.4
DEPRESSION		1	0.5	0	0.0	1	0.4
EMOTIONAL LABILITY		2	1.1	2	2.2	4	1.5
HOSTILITY		1	0.5	0	0.0	1	0.4
HYSTERIA		1	0.5	0	0.0	1	0.4
INSOMNIA		2	1.1	0	0.0	2	0.7
NERVOUSNESS		1	0.5	1	1.1	2	0.7
SOMNOLENCE		2	1.1	0	0.0	2	0.7
Respiratory System		1	0.5	0	0.0	1	0.4
SINUSITIS		1	0.5	0	0.0	1	0.4
Skin and Appendages		1	0.5	0	0.0	1	0.4
ACNE		1	0.5	0	0.0	1	0.4

000298

TABLE 15.042B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES CLASSED BY INVESTIGATOR AS SEVERE DURING ACTIVE TREATMENT PHASE
MALE SPECIFIC ADVERSE EXPERIENCES ONLY
INTENTION TO TREAT POPULATION

000299

TABLE 15.043B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES CLASSED BY INVESTIGATOR AS SEVERE DURING ACTIVE TREATMENT PHASE FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

04B/11304B/1000L1990.17.30/NELSOB01/DEV32/UNPA1/SBBRL29000/377
Paroxetine - Protocol: 377

TABLE 15.04B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES CLASSED BY INVESTIGATOR AS SEVERE DURING ACTIVE TREATMENT PHASE DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

=======================================		======	=======	======	=======		
TREATMENT GROUPS	PAROXETINE		PLACEBO		TOTAL		
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	182 20	100.0% 11.0%	93 6	100.0% 6.5%	275 26	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		5	2.7	3	3.2	8	2.9
Digestive System		4	2.2	0	0.0	4	1.5
Nervous System		10	5.5	3	3.2	13	4.7
Respiratory System		1	0.5	0	0.0	1	0.4
Skin and Appendages		1	0.5	0	0.0	1	0.4

Paroxetine - Protocol: 377

#### TABLE 15.051B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES CONSIDERED TO BE RELATED TO THE STUDY MEDICATION DURING ACTIVE TREATMENT PHASE NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY

		======	=======		=======	======	======	
TREATMENT GROUPS		PAROXET	INE	NE PLACEBO		TOTAL		
	:				100.0% 4.3%			
ADECS BODY SYSTEM : PREFERRED TERM					* 8		%	
Body as a Whole ASTHENIA HEADACHE INFECTION			3.8	2 1 0	2.2 1.1 0.0 1.1	9 4 4	3.3 1.5	
Cardiovascular System HYPERTENSION		1 1	0.5 0.5	0 0	0.0	1 1	0.4 0.4	
Digestive System DECREASED APPETITE DRY MOUTH DYSPEPSIA NAUSEA VOMITING		20 4 2 1 16 3	11.0 2.2 1.1 0.5 8.8 1.6	1	1.1 1.1 0.0 0.0 1.1	5 2	1.8	
Metabolic and Nutritional Disorders WEIGHT LOSS		1 1	0.5 0.5	0 0	0.0	1 1	0.4 0.4	
Nervous System AGITATION ANXIETY DIZZINESS EMOTIONAL LABILITY INSOMNIA		14 3 1 3 1 4	7.7 1.6 0.5 1.6 0.5 2.2	0 0 0 0	0.0 0.0 0.0 0.0	1 3 1 4	1.1 0.4 1.1 0.4 1.5	
SOMNOLENCE TREMOR		6 1	3.3			8 1		

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES CONSIDERED TO BE RELATED TO THE STUDY MEDICATION DURING ACTIVE TREATMENT PHASE MALE SPECIFIC ADVERSE EXPERIENCES ONLY

NO DATA AVAILABLE FOR THIS REPORT

BRL-029060/RSD-100TNP/2/CPMS-377

### EVT001/T15053B/T15053B/16JUL1998:17:45/NELSOB01/DEV32/UKPAT/SBBRL29060/377 PAROXETINE - PROTOCOL: 377

TABLE 15.053B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES CONSIDERED TO BE RELATED TO THE STUDY MEDICATION DURING ACTIVE TREATMENT PHASE FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY

Paroxetine - Protocol: 377

#### TABLE 15.05B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES CONSIDERED TO BE RELATED TO THE STUDY MEDICATION DURING ACTIVE TREATMENT PHASE DISPLAYED BY BODY SYSTEM

	=====	======	=======	======	=======	======	=====
TREATMENT GROUPS	PAROXETINE		PLACEBO		TOTAL		
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	182 31	100.0% 17.0%	93 4	100.0% 4.3%	275 35	100.0% 12.7%
ADECS BODY SYSTEM : PREFERRED TERM		N	 %	N	8	N	%
Body as a Whole		7	3.8	2	2.2	9	3.3
Cardiovascular System		1	0.5	0	0.0	1	0.4
Digestive System		20	11.0	1	1.1	21	7.6
Metabolic and Nutritional Disorders		1	0.5	0	0.0	1	0.4
Nervous System		14	7.7	2	2.2	16	5.8

#### tille - Flotocol: 37

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES LEADING TO WITHDRAWAL DURING ACTIVE TREATMENT PHASE NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.061B

TREATMENT GROUPS			INE			IATOT	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 19	100.0%	93 7	100.0% 7.5%	275 26	100.0% 9.5%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		2	1.1	2	2.2	4	1.5
ABSCESS		0	0.0	1	1.1	1	0.4
ASTHENIA		0	0.0	1	1.1 1.1 0.0	1	0.4
HEADACHE		2	1.1	0	0.0	2	0.7
Cardiovascular System		2	1.1		0.0	2	0.7
PALPITATION		1	0.5	0	0.0	1	0.4
POSTURAL HYPOTENSION		1	0.5	0	0.0	1	0.4
Digestive System		8	4.4	1	1.1	9	3.3
DECREASED APPETITE		1	0.5	0	0.0	1	0.4
DIARRHEA		1	0.5	0	0.0	1	0.4
DRY MOUTH		1	0.5	0	0.0	1	0.4
DYSPEPSIA		1	0.5	0	0.0	1	0.4
NAUSEA		6	3.3	1	1.1	7	2.5
VOMITING		2	1.1	0	0.0	2	0.7
Nervous System		15	8.2	5	5.4	20	7.3
AGITATION		3	1.6	0	0.0	3	1.1
ANXIETY		2	1.1	0	0.0	2	0.7
CONVULSION		1	0.5	0	0.0	1	0.4
DEPRESSION		1	0.5	0	0.0	1	0.4
DIZZINESS		1	0.5	0	0.0	1	
EMOTIONAL LABILITY		5	2.7	3	3.2	8	2.9
HYSTERIA		1	0.5	0	0.0	1	0.4
INSOMNIA		1	0.5	0	0.0	1	0.4
MYOCLONUS		1	0.5	0	0.0	1	0.4
NERVOUSNESS		1	0.5	1	1.1	2	0.7
SOMNOLENCE		4	2.2	1	1.1	5	1.8
TREMOR		1	0.5	0	0.0	1	0.4
Respiratory System		1	0.5	0	0.0	1	0.4
DYSPNEA		1	0.5	0	0.0	1	0.4
Special Senses		1	0.5	0	0.0	1	0.4
ABNORMAL VISION		1	0.5	0	0.0	1	0.4

TABLE 15.062B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES LEADING TO WITHDRAWAL DURING ACTIVE TREATMENT PHASE

MALE SPECIFIC ADVERSE EXPERIENCES ONLY

INTENTION TO TREAT POPULATION

TABLE 15.063B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES LEADING TO WITHDRAWAL DURING ACTIVE TREATMENT PHASE FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

Paroxetine - Protocol: 377

TABLE 15.06B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES LEADING TO WITHDRAWAL DURING ACTIVE TREATMENT PHASE DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

=======================================	=====	======	=======	======	=======	======	=====
TREATMENT GROUPS		PAROXET	INE	PLACE	30	TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 19	100.0% 10.4%	93 7	100.0%	275 26	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	e %	N	8	N	%
Body as a Whole		2	1.1	2	2.2	4	1.5
Cardiovascular System		2	1.1	0	0.0	2	0.7
Digestive System		8	4.4	1	1.1	9	3.3
Nervous System		15	8.2	5	5.4	20	7.3
Respiratory System		1	0.5	0	0.0	1	0.4
Special Senses		1	0.5	0	0.0	1	0.4

Oxecine - Prococor: 377

NUMBER (%) OF PATIENTS WITH ADVERSE EXPERIENCES CLASSED BY INVESTIGATOR AS SERIOUS DURING ACTIVE TREATMENT PHASE NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.071B

TREATMENT GROUPS	PAROXET			30 		
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES		100.0%	93	100.0%	275	100.0%
ADECS BODY SYSTEM : PREFERRED TERM	N	%	N	%	N	%
Body as a Whole	 2	1.1	0	0.0	2	0.7
ACCIDENTAL OVERDOSE		0.5	-		1	
INFECTION	1	0.5	0	0.0	1	0.4
Cardiovascular System	1	0.5	0	0.0	1	0.4
POSTURAL HYPOTENSION	1	0.5	0	0.0	1	0.4
Digestive System	2	1.1	0	0.0	2	0.7
DECREASED APPETITE	1	0.5	0	0.0	1	0.4
DRY MOUTH	1	0.5	0	0.0	1	0.4
NAUSEA	2	1.1	0	0.0	2	0.7
VOMITING	1	0.5	0	0.0	1	0.4
Nervous System	14	7.7	4	4.3	18	6.5
AGITATION	3	1.6	0	0.0	3	
ANXIETY	1	0.5	0	0.0	1	0.4
CONVULSION	1	0.5	0	0.0	1	0.4
DEPRESSION	2	1.1	0	0.0	2	0.7
DIZZINESS	1	0.5	0	0.0	1	0.4
EMOTIONAL LABILITY	6	3.3	3	3.2	9	3.3
HYSTERIA	1	0.5	0	0.0	1	0.4
INSOMNIA	1	0.5	0	0.0	1	
MYOCLONUS	1	0.5	0	0.0 0.0 0.0 1.1 0.0	1	
NERVOUSNESS	1	0.5	1	1.1	2	0.7
NEUROSIS	1	0.5	0	0.0	1	
TREMOR	1	0.5	0	0.0	1	0.4
Special Senses	1	0.5	0	0.0	1	
ABNORMAL VISION	1	0.5	0	0.0	1	0.4

TABLE 15.072B

NUMBER (%) OF PATIENTS WITH ADVERSE EXPERIENCES CLASSED BY INVESTIGATOR AS SERIOUS DURING ACTIVE TREATMENT PHASE MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

00031

TABLE 15.073B

NUMBER (%) OF PATIENTS WITH ADVERSE EXPERIENCES CLASSED BY INVESTIGATOR AS SERIOUS DURING ACTIVE TREATMENT PHASE FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

#### Paroxetine - Protocol: 377

TABLE 15.07B

# NUMBER (%) OF PATIENTS WITH ADVERSE EXPERIENCES CLASSED BY INVESTIGATOR AS SERIOUS DURING ACTIVE TREATMENT PHASE DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

=======================================	======	======	=======	:=====	=======	======	=====
TREATMENT GROUPS		PAROXET	INE	PLACE	30	TOTAI	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 15	100.0% 8.2%	93 4	100.0% 4.3%	275 19	100.0% 6.9%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		2	1.1	0	0.0	2	0.7
Cardiovascular System		1	0.5	0	0.0	1	0.4
Digestive System		2	1.1	0	0.0	2	0.7
Nervous System		14	7.7	4	4.3	18	6.5
Special Senses		1	0.5	0	0.0	1	0.4

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

	======	======	=======	======	=======	======	=====
TREATMENT GROUPS		PAROXET	INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 90	100.0% 49.5%	93 35	100.0% 37.6%	275 125	100.0% 45.5%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole ABDOMINAL PAIN ASTHENIA BACK PAIN CHEST PAIN FEVER HEADACHE INFECTION NEOPLASM		33 1 9 1 4 1 15 3 0	18.1 0.5 4.9 0.5 2.2 0.5 8.2	20 2 4 1 0 0	21.5 2.2 4.3 1.1 0.0 0.0 14.0 3.2 1.1 0.0	53 3 13 2 4 1 28	19.3 1.1 4.7 0.7 1.5 0.4
TRAUMA  Cardiovascular System HYPOTENSION PALPITATION POSTURAL HYPOTENSION VASODILATATION		3 6 2 1 2	1.6 3.3 1.1 0.5 1.1 0.5		0.0 0.0 0.0 0.0 0.0		
Digestive System BILIARY PAIN CONSTIPATION DECREASED APPETITE DIARRHEA DRY MOUTH DYSPEPSIA NAUSEA TOOTH DISORDER VOMITING		45 0 2 11 3 3 1 32 1 3	24.7 0.0 1.1 6.0 1.6 1.6 0.5 17.6 0.5	12 1 0 3 1 0 0 8 0	12.9 1.1 0.0 3.2 1.1 0.0 0.0 8.6 0.0	14 4 3 1 40	5.1 1.5 1.1 0.4 14.5
Metabolic and Nutritional Disorders WEIGHT LOSS		1 1	0.5 0.5	0	0.0	1 1	0.4
Musculoskeletal System ARTHRALGIA TENDINOUS DISORDER		2 1 1	1.1 0.5 0.5		0.0 0.0 0.0	2 1 1	0.7 0.4 0.4
Nervous System ABNORMAL DREAMS		48 0	26.4 0.0	9 1	9.7 1.1	57 1	20.7 0.4

# Paroxetine - Protocol: 377 TABLE 15.081B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS		PAROXET	INE 	PLACE	B0 	TOTA	L 
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 90	100.0% 49.5%	93 35	100.0% 37.6%	275 125	100.0% 45.5%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	8	N	%
AGITATION		4	2.2	0	0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0	4	1.5
ANXIETY		3	1.6	0	0.0	3	1.1
DEPERSONALIZATION		1	0.5	0	0.0	1	0.4
DEPRESSION		1	0.5	0	0.0	1	0.4
DIZZINESS		11	6.0	3	3.2	14	5.1
EMOTIONAL LABILITY		1	0.5	0	0.0	1	0.4
HOSTILITY		1	0.5	0	0.0	1	0.4
HYPESTHESIA		1	0.5	0	0.0	1	0.4
HYPOKINESIA		1	0.5	0	0.0	1	0.4
HYSTERIA		1	0.5	0	0.0	1	0.4
INSOMNIA			4.9	3	3.2	12	4.4
MYOCLONUS		3	1.6	0	0.0	3	1.1
NERVOUSNESS		1	0.5	2	2.2	3	1.1
SOMNOLENCE		16	8.8	2	2.2	18	6.5
TREMOR		6	3.3	0	3.2 0.0 2.2 2.2 0.0	6	2.2
Respiratory System		9	4.9	4	4.3	13	4.7
COUGH INCREASED		1	0.5	0	0.0	1	0.4
DYSPNEA		3	1.6	0	0.0	3	1.1
PHARYNGITIS		0	0.0	1	1.1	1	0.4
RESPIRATORY DISORDER		2	1.1	1	1.1	3	1.1
RHINITIS		1	0.5	2	2.2	3	1.1
SINUSITIS		2	1.1	0	0.0	2	0.7
YAWN		1	0.5	0	4.3 0.0 0.0 1.1 1.1 2.2 0.0	1	0.4
Skin and Appendages		4	2.2 0.5		1.1 0.0 0.0 1.1		
HERPES ZOSTER		1	0.5	0	0.0	1	0.4
RASH		2	1.1	0	0.0	2	0.7
SWEATING		1	0.5	1	1.1	2	0.7
Special Senses		4	2.2 1.1	1	1.1 1.1	5	1.8
ABNORMAL VISION		2	1.1	1	1.1	3	1.1
MYDRIASIS		1	0.5	0	0.0	1	
OTITIS MEDIA		1	0.5	0	0.0	1	0.4
Urogenital System		1	0.5 0.0	1	1.1 1.1	2	0.7
CYSTITIS		0	0.0	1	1.1	1	0.4

#### Paroxetine - Protocol: 377

TABLE 15.081B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

	======	=====	=======	======	=======	=====	======
TREATMENT GROUPS	]	PAROXET	INE	PLACE	30	TOTA	Ĺ
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 90	100.0% 49.5%	93 35	100.0% 37.6%	275 125	100.0% 45.5%
ADECS BODY SYSTEM : PREFERRED TERM		N	*	N	%	N	%
URINARY TRACT INFECTION		1	0.5	0	0.0	1	0.4

TABLE 15.082B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT
MALE SPECIFIC ADVERSE EXPERIENCES ONLY
INTENTION TO TREAT POPULATION

#### TABLE 15.083B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

Paroxetine - Protocol: 377

TABLE 15.08B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

	:=====::			.======:	=======		
TREATMENT GROUPS		PAROXET	LNE 	PLACE	30 	TOTA	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	182 90			100.0% 37.6%		100.0% 45.5%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		33	18.1	20	21.5	53	19.3
Cardiovascular System		6	3.3	0	0.0	6	2.2
Digestive System		45	24.7	12	12.9	57	20.7
Metabolic and Nutritional Disorders		1	0.5	0	0.0	1	0.4
Musculoskeletal System		2	1.1	0	0.0	2	0.7
Nervous System		48	26.4	9	9.7	57	20.7
Respiratory System		9	4.9	4	4.3	13	4.7
Skin and Appendages		4	2.2	1	1.1	5	1.8
Special Senses		4	2.2	1	1.1	5	1.8
Urogenital System		1	0.5	1	1.1	2	0.7

#### Paroxetine - Protocol: 377

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.091B

WEIGHT: < 50 KG

TREATMENT GROUPS		PAROXET	INE	PLACE	30	TOTA	L 
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	47 25	100.0% 53.2%	23	100.0% 34.8%	70 33	100.09 47.19
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		6	12.8	4	17.4 0.0 4.3 13.0 0.0	10	14.3
CHEST PAIN		1	2.1	0	0.0	1	1.4
HEADACHE		4	8.5	1	4.3	5	7.1
INFECTION		1	2.1	3	13.0	4	5.7
TRAUMA		1	2.1	0	0.0	1	1.4
Cardiovascular System		1	2.1 2.1	0	0.0	1	1.4
HYPOTENSION		1	2.1	0	0.0	1	1.4
Digestive System		14	29.8	3	13.0	17	24.3
DECREASED APPETITE		2	4.3	0	0.0	2	2.9
DIARRHEA		1	2.1	0	0.0	1	1.4
DYSPEPSIA		1	2.1	0	0.0	1	1.4
NAUSEA		12	25.5	3	13.0	15	21.4
VOMITING		1	2.1	0	0.0 13.0 0.0 0.0 0.0 13.0 0.0	1	1.4
Musculoskeletal System		1	2.1 2.1	0	0.0	1	1.4
ARTHRALGIA		1	2.1	0	0.0	1	1.4
Nervous System		13	27.7 2.1	1	4.3	14	20.0
AGITATION		1	2.1	0	0.0	1	1.4
ANXIETY		1		0	0.0	1	1.4
DIZZINESS		2	4.3	0	0.0	2	2.9
HYSTERIA		1	2.1	0	0.0	1	1.4
INSOMNIA		1	2.1	1	4.3	2	2.9
NERVOUSNESS		1	2.1	0	0.0	1	1.4
SOMNOLENCE		7	14.9	0	0.0	7	10.0
TREMOR		1	2.1	0	4.3 0.0 0.0 0.0 0.0 4.3 0.0 0.0	1	1.4
Respiratory System		2	4.3 2.1 2.1	2		4 1 1	
COUGH INCREASED		1	2.1	2	0.0	1	1.4
DYSPNEA		1	2.1	0	0.0	1	1.4
RESPIRATORY DISORDER		1	2.1	1	4.3	2	2.9
RHINITIS		0	2.1	1	4.3 4.3	1	1.4
Skin and Appendages		1	2.1	0	0.0	1	1.4
HERPES ZOSTER		1	2.1	0	0 0	1	1.4

Paroxetine - Protocol: 377

#### TABLE 15.091B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: < 50 KG

TREATMENT GROUPS	F	PAROXET	INE	PLACE	30	TOTA	С
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	47 25	100.0% 53.2%	23 8	100.0%	70 33	100.0% 47.1%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Urogenital System CYSTITIS		0	0.0	1 1	4.3 4.3	1 1	1.4 1.4

Paroxetine - Protocol: 377

TABLE 15.091B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: 50 - 70 KG

TREATMENT GROUPS		PAROXET	INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	111 53	100.0% 47.7%	58 20	100.0% 34.5%	169 73	100.09 43.29
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	용
Body as a Whole ABDOMINAL PAIN ASTHENIA BACK PAIN CHEST PAIN HEADACHE INFECTION NEOPLASM		23 1 8 1 3 10 1	20.7 0.9 7.2 0.9 2.7	14 2 4 1 0	24.1 3.4 6.9 1.7 0.0 17.2 0.0 1.7 0.0	37 3 12 2 3	21.9 1.8 7.1 1.2 1.8
TRAUMA		2	1.8	0	0.0	2	1.2
Cardiovascular System PALPITATION POSTURAL HYPOTENSION		3 1 2	2.7 0.9 1.8	0 0 0	0.0	3 1 2	1.8 0.6 1.2
Digestive System CONSTIPATION DECREASED APPETITE DIARRHEA DRY MOUTH NAUSEA TOOTH DISORDER VOMITING		28 2 8 2 3 18 1 2	7.2 1.8 2.7	3 1 0	12.1 0.0 5.2 1.7 0.0 6.9 0.0	11 3 3	20.7 1.2 6.5 1.8 1.8 13.0 0.6
Metabolic and Nutritional Disorders WEIGHT LOSS		1 1	0.9	0		1 1	0.6 0.6
Nervous System ABNORMAL DREAMS AGITATION ANXIETY DEPRESSION DIZZINESS EMOTIONAL LABILITY HOSTILITY HYPESTHESIA HYPOKINESIA INSOMNIA		28 0 3 2 1 9 1 1 1 1	0.9 8.1 0.9 0.9	0 1 0 0	1.7 0.0 0.0	1 3 2 1 10 1 1	0.6 5.9 0.6 0.6 0.6

### TABLE 15.091B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: 50 - 70 KG

TREATMENT GROUPS		PAROXET	INE	PLACE	во	TOTAL	<u></u>
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:				100.0% 34.5%		
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
MYOCLONUS		3	2.7	0	0.0	3	1.8
NERVOUSNESS		0	0.0	2 2	3.4	2	1.2
SOMNOLENCE		6	5.4		3.4	8	4.7
TREMOR		4	3.6	0	0.0	4	2.4
Respiratory System		6	5.4	1	1.7	7	4.1
DYSPNEA		2	1.8	0	0.0	2	1.2
PHARYNGITIS		0	0.0	1	1.7	1	0.6
RESPIRATORY DISORDER		1	0.9	0	0.0	1	0.6
RHINITIS		1	0.9	0	0.0	1	0.6
SINUSITIS		1	0.9	0	0.0	1	0.6
YAWN		1	0.9	0	0.0	1	0.6
Skin and Appendages		2	1.8	0	0.0	2	1.2
RASH		2	1.8	0	0.0	2	1.2
Special Senses		4	3.6	1	1.7	5	3.0
ABNORMAL VISION		2	1.8	1	1.7	3	1.8
MYDRIASIS		1	0.9	0	0.0	1	0.6
OTITIS MEDIA		1	0.9	0	0.0	1	0.6

# Paroxetine - Protocol: 377 TABLE 15.091B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: > 70 KG

TREATMENT GROUPS		PAROXETINE		PLACEBO		TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	22 11	100.0% 50.0%	11 6	100.0% 54.5%	33 17	100.0% 51.5%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		4	18.2	1	9.1 0.0 0.0 9.1 0.0	5	15.2
ASTHENIA		1	4.5	0	0.0	1	3.0
FEVER		1	4.5	0	0.0	1	3.0
HEADACHE		1	4.5	1	9.1	2	6.1
INFECTION		1	4.5	0	0.0	1	3.0
Cardiovascular System		2	9.1 4.5	0	0.0 0.0 0.0	2	6.1
HYPOTENSION		1	4.5	0	0.0	1	3.0
VASODILATATION		1	4.5	0	0.0	1	3.0
Digestive System		3	13.6 0.0 4.5	2	18.2 9.1 0.0 9.1	5	15.2
BILIARY PAIN		0	0.0	1	9.1	1	3.0
DECREASED APPETITE		1	4.5	0	0.0	1	3.0
NAUSEA		2	9.1	1	9.1	3	9.1
Musculoskeletal System			4.5	0	0.0	1	3.0
TENDINOUS DISORDER		1					
Nervous System		6	27.3	2	18.2 0.0 18.2 0.0 0.0	8	24.2
DEPERSONALIZATION		1	4.5	0	0.0	1	3.0
DIZZINESS			0.0	2	18.2	2	6.1
INSOMNIA		1	4.5	0	0.0	1	3.0
SOMNOLENCE		3	13.6	0	0.0	3	9.1
TREMOR		1	4.5	0	0.0	1	3.0
Respiratory System		0	0.0	1	9.1 9.1	1	3.0
RHINITIS		0	0.0	1	9.1	1	3.0
Skin and Appendages		1	4.5	1	9.1 9.1	2	6.1
SWEATING		1	4.5	1	9.1	2	6.1
Urogenital System		1	4.5	0	0.0	1 1	3.0
URINARY TRACT INFECTION		1	4.5	0	0.0	1	3.0

Paroxetine - Protocol: 377

TABLE 15.091B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: MISSING

TREATMENT GROUPS		PAROXETINE			PLACEBO		TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	2 1	100.0% 50.0%	1 1		3 2	100.0% 66.7%	
ADECS BODY SYSTEM : PREFERRED TERM		N	 왕	N	%	N	%	
Body as a Whole HEADACHE		0 0	0.0	1 1	100.0	1 1	33.3	
Nervous System INSOMNIA		1 1	50.0 50.0	0 0	0.0	1 1	33.3 33.3	
Respiratory System SINUSITIS		1 1	50.0 50.0	0 0	0.0	1 1	33.3 33.3	

## TABLE 15.092B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

	======	=====		======			=====
TREATMENT GROUPS	P	AROXET	INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS	:	11	100.0%	6	100.0%	17	100.0%
PATIENTS WITH ADVERSE EXPERIENCES	: 	0	0.0% 	0	0.0%	0 	0.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	용	N	용

# PAROXETINE - PROTOCOL: 377 TABLE 15.092B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

		=====		======		======	=====
TREATMENT GROUPS	P	AROXET	INE	PLACE	30	TOTA	Ĺ
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	41	100.0% 0.0%	21	100.0%	62 0	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	 %	N	%	N	 %

## PAROXETINE - PROTOCOL: 377

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.092B

WEIGHT: > 70 KG

	=======	=====	=======		=======	======	======
TREATMENT GROUPS	P.	AROXET	INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS	:	7	100.0%	5	100.0%	12	100.0%
PATIENTS WITH ADVERSE EXPERIENCES	: 	0	0.0%	0	0.0%	0 	0.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	용

## TABLE 15.092B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: MISSING

TREATMENT GROUPS	P.	PAROXETINE			0	TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	1 0	100.0% 0.0%	0	0.0%	1 0	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		 N	 %	N	%	N	 %

## TABLE 15.093B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS	F	PAROXET	INE	PLACE	BO TOTAL		
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	36 0	100.0%	17 0	100.0%	53 0	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	 %	N	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	N	 ଖ

# PAROXETINE - PROTOCOL: 377 TABLE 15.093B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg). FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

=======================================		=====	=======	======	=======	=====	=====
TREATMENT GROUPS	P	AROXET	INE	PLACE	во	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	70 0	100.0% 0.0%	37 0	100.0%	107	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	 %	N	 %	N	~ %

# 0033

## TABLE 15.093B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg). FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: > 70 KG

	=======		=======		=======	======	======
TREATMENT GROUPS	F	AROXET	INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	15 0	100.0% 0.0%	6 0	100.0% 0.0%	21	100.0%
ADECS BODY SYSTEM : PREFERRED TERM	·	 N	 %	  N	 %	 N	

## TABLE 15.093B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg). FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: MISSING

	========		=======			======	
TREATMENT GROUPS	P.	AROXET	INE	PLACE	во	TOTA	L
TOTAL NUMBER OF PATIENTS	:	1	100.0%	1	100.0%	2	100.0%
PATIENTS WITH ADVERSE EXPERIENCES	·		0.0% 		0.0%		0.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	ક	N	ક	N	용

## Paroxetine - Protocol: 377

TABLE 15.09B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

=======================================		======	=======	======		======	
TREATMENT GROUPS	1	PAROXET:	INE	PLACEBO		TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	47 25	100.0% 53.2%		100.0% 34.8%		100.0% 47.1%
ADECS BODY SYSTEM : PREFERRED TERM		N	* *	N	%	N	%
Body as a Whole		6	12.8	4	17.4	10	14.3
Cardiovascular System		1	2.1	0	0.0	1	1.4
Digestive System		14	29.8	3	13.0	17	24.3
Musculoskeletal System		1	2.1	0	0.0	1	1.4
Nervous System		13	27.7	1	4.3	14	20.0
Respiratory System		2	4.3	2	8.7	4	5.7
Skin and Appendages		1	2.1	0	0.0	1	1.4
Urogenital System		0	0.0	1	4.3	1	1.4

## Paroxetine - Protocol: 377

TABLE 15.09B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

TREATMENT GROUPS		PAROXETINE			PLACEBO		Ĺ
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	111 53	100.0% 47.7%		100.0% 34.5%		100.0% 43.2%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		23	20.7	14	24.1	37	21.9
Cardiovascular System		3	2.7	0	0.0	3	1.8
Digestive System		28	25.2	7	12.1	35	20.7
Metabolic and Nutritional Disorders		1	0.9	0	0.0	1	0.6
Nervous System		28	25.2	6	10.3	34	20.1
Respiratory System		6	5.4	1	1.7	7	4.1
Skin and Appendages		2	1.8	0	0.0	2	1.2
Special Senses		4	3.6	1	1.7	5	3.0

## Paroxetine - Protocol: 377

TABLE 15.09B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

WEIGHT: > 70 KG

TREATMENT GROUPS	I	PAROXETINE		PLACEBO		TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	22 11	100.0% 50.0%		100.0% 54.5%		
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole		4	18.2	1	9.1	5	15.2
Cardiovascular System		2	9.1	0	0.0	2	6.1
Digestive System		3	13.6	2	18.2	5	15.2
Musculoskeletal System		1	4.5	0	0.0	1	3.0
Nervous System		6	27.3	2	18.2	8	24.2
Respiratory System		0	0.0	1	9.1	1	3.0
Skin and Appendages		1	4.5	1	9.1	2	6.1
Urogenital System		1	4.5	0	0.0	1	3.0

# Paroxetine - Protocol: 377 TABLE 15.09B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE FIRST TWO WEEKS OF ACTIVE TREATMENT BY BASELINE BODY WEIGHT (<50kg, 50-70kg, >70kg). DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

WEIGHT: MISSING

	=======	:====:	=======	======	=======	=====	======
TREATMENT GROUPS	I	PAROXETINE		PLACEBO		TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	2 1	100.0% 50.0%	1 1	100.0% 100.0%	3 2	100.0% 66.7%
ADECS BODY SYSTEM : PREFERRED TERM		N	* *	N	%	N	%
Body as a Whole		0	0.0	1	100.0	1	33.3
Nervous System		1	50.0	0	0.0	1	33.3
Respiratory System		1	50.0	0	0.0	1	33.3

## TABLE 15.101B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS		PAROXET	INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	47 32	100.0% 68.1%	23 13	100.0% 56.5%	70 45	100.0% 64.3%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole ABDOMINAL PAIN ASTHENIA BACK PAIN CHEST PAIN FLU SYNDROME HEADACHE INFECTION		14 2 1 1 2 1 11 5	29.8 4.3 2.1 2.1 4.3 2.1 23.4 10.6	10 2 3 0 0 0 6 4	43.5 8.7 13.0 0.0 0.0 0.0 26.1 17.4	24 4 4 1 2 1 17 9	34.3 5.7 5.7 1.4 2.9 1.4 24.3 12.9
PAIN TRAUMA		1 2	2.1 4.3	0	0.0	1 2	1.4 2.9
Cardiovascular System HYPERTENSION HYPOTENSION PALPITATION		3 1 1	6.4 2.1 2.1 2.1		0.0 0.0 0.0 0.0	3 1 1 1	4.3 1.4 1.4 1.4
Digestive System DECREASED APPETITE DIARRHEA DRY MOUTH DYSPEPSIA GINGIVITIS NAUSEA VOMITING		18 3 2 1 1 2 13	38.3 6.4 4.3 2.1 2.1 4.3 27.7 6.4	1 0 0	0.0 0.0 17.4	3 1 1 2 17	1.4 1.4 2.9
Hemic and Lymphatic System EOSINOPHILIA		0 0	0.0		4.3 4.3		1.4 1.4
Metabolic and Nutritional Disorders HYPOGLYCEMIC REACTION		1 1	2.1 2.1	0	0.0	1 1	1.4 1.4
Musculoskeletal System ARTHRALGIA MYALGIA		1 1 0	2.1 2.1 0.0	2 1 1	8.7 4.3 4.3	3 2 1	4.3 2.9 1.4
Nervous System AGITATION		18 1	38.3 2.1	3 0	13.0 0.0	21 1	30.0 1.4

# Paroxetine - Protocol: 377 TABLE 15.101B

## NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES

BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS		PAROXETINE					Ĺ
	:	47	100.0%	23	100.0%	70	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	8	N	%
ANXIETY		1	2.1	0	0.0	1	1.4
CONFUSION		1	2.1	0	0.0 0.0 4.3 0.0	1	
CONVULSION		1	2.1	0	0.0	1	1.4
DIZZINESS		3	6.4	1	4.3	4	
EMOTIONAL LABILITY		3	6.4	0	0.0	3	4.3
HYSTERIA		1	2.1	U	U.U	1	
INSOMNIA		1	2.1	1	4.3	2	
NERVOUSNESS		1	2.1	0	0.0	1	1.4
PARESTHESIA		0	0.0	1	4.3	1	1.4
SOMNOLENCE		7	14.9	0	0.0	7	10.0
TREMOR		1	2.1	0	0.0	1	1.4
Respiratory System		4	8.5	3	13.0	7	10.0
COUGH INCREASED		3	6.4	0	0.0	3	4.3
DYSPNEA		1	2.1	0		1	1.4
PHARYNGITIS		0	0.0	1	4.3	1	1.4
RESPIRATORY DISORDER		1	2.1	1	4.3	2	2.9
RHINITIS		0	0.0	2	8.7	2	2.9
Skin and Appendages		5	10.6	0	0.0	5	7.1
ACNE		1	2.1	0	0.0	1	1.4
ALOPECIA		1	2.1	0	0.0	1	1.4
HERPES ZOSTER		1	2.1	0	0.0	1	1.4
SWEATING		1	2.1	0	0.0	1	1.4
SWEATING DECREASED		1	2.1	0	0.0	1	1.4
Urogenital System		0	0.0	1	4.3	1	1.4
CYSTITIS		0	0.0	1	4.3	1	1.4

# Paroxetine - Protocol: 377 TABLE 15.101B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 Kg, 50-70 Kg, >70 Kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS		PAROXET	INE	PLACE	30	TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	111 68	100.0% 61.3%	58 35	100.0% 60.3%	169 103	100.0% 60.9%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	ક
ABDOMINAL PAIN ABSCESS ACCIDENTAL OVERDOSE ALLERGIC REACTION ASTHENIA BACK PAIN CHEST PAIN FLU SYNDROME HEADACHE INFECTION MALAISE NEOPLASM		39 4 1 1 1 9 2 3 0 19 8 0 0	35.1 3.6 0.9 0.9 0.9 8.1 1.8 2.7 0.0 17.1 7.2	19 5 0 0 6 1 1 12	32.8 8.6 0.0 0.0 10.3 1.7 0.0 1.7 20.7	58 9 1 1 15 3 3 1 31 9	34.3 5.3 0.6 0.6 0.6 8.9 1.8 0.6 18.3 5.3 0.6
PAIN TRAUMA		0	0.0 2.7	1 0	1.7 1.7 0.0	1 3	0.6 1.8
Cardiovascular System HYPERTENSION HYPOTENSION PALPITATION POSTURAL HYPOTENSION		6 1 1 1 3	5.4 0.9 0.9 0.9 2.7	1 0 0 0	1.7 0.0 0.0 0.0	7 1 1 1 4	4.1 0.6 0.6 0.6 2.4
Digestive System CONSTIPATION DECREASED APPETITE DIARRHEA DRY MOUTH GASTROENTERITIS NAUSEA TOOTH DISORDER VOMITING		36 3 9 2 3 1 25 1 3	32.4 2.7 8.1 1.8 2.7 0.9 22.5 0.9 2.7	1 3 2 0 0	19.0 1.7 5.2 3.4 0.0 0.0 13.8 0.0 0.0	4 12 4 3 1 33	27.8 2.4 7.1 2.4 1.8 0.6 19.5 0.6
Hemic and Lymphatic System EOSINOPHILIA LEUKOCYTOSIS THROMBOCYTOPENIA		2 1 0 1	1.8 0.9 0.0 0.9	1 0 1 0	1.7 0.0 1.7 0.0	3 1 1	1.8 0.6 0.6 0.6

Paroxetine - Protocol: 377

TABLE 15.101B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 Kg, 50-70 Kg, >70 Kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS		PAROXET	INE	PLACE	BO 	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	111 68	100.0% 61.3%	58 35	100.0% 60.3%	169 103	100.0% 60.9%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Metabolic and Nutritional Disorders WEIGHT LOSS		1	0.9 0.9	0	0.0	1 1	0.6
Musculoskeletal System ARTHRALGIA		0	0.0	1 1	1.7 1.7	1 1	0.6 0.6
Nervous System ABNORMAL DREAMS AGITATION ANXIETY DEPRESSION DIZZINESS EMOTIONAL LABILITY HOSTILITY HYPESTHESIA HYPOKINESIA INSOMNIA MYOCLONUS NERVOUSNESS NEUROSIS SOMNOLENCE TREMOR		36 2 3 2 2 16 4 1 1 1 6 4 0 1	1.8 1.8 14.4 3.6	1 0 0 0 4 3	27.6 1.7 0.0 0.0 0.0 6.9 5.2 0.0 0.0 3.4 1.7 5.2 0.0 6.9	3 3 2 2 20 7	1.2 1.2 11.8 4.1
Respiratory System BRONCHITIS COUGH INCREASED DYSPNEA EPISTAXIS PHARYNGITIS RESPIRATORY DISORDER RHINITIS SINUSITIS YAWN		14 1 2 2 1 2 3 2 2 1	12.6 0.9 1.8 1.8 0.9 1.8 2.7 1.8 1.8	8 2 1 0 0 3 2 0	13.8 3.4 1.7 0.0 0.0	22 3 3 2 1 5	13.0 1.8 1.8 1.2 0.6 3.0 3.0 1.2 1.8 0.6
Skin and Appendages ACNE PHOTOSENSITIVITY		6 1 1	5.4 0.9 0.9	1 0 0	1.7 0.0 0.0	7 1 1	4.1 0.6 0.6

## TABLE 15.101B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS		PAROXET	INE	PLACE	====== BO	TOTA	 L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	111 68	100.0% 61.3%		100.0% 60.3%		100.0% 60.9%
ADECS BODY SYSTEM : PREFERRED TERM		N	~~~~~~ 왕	N	~~~~~~ 왕	N	*
RASH SWEATING		2 2 2	1.8 1.8	1 0	1.7 0.0	3 2	1.8 1.2
Special Senses ABNORMAL VISION MYDRIASIS OTITIS MEDIA		5 3 1 1	4.5 2.7 0.9 0.9	1 1 0 0	1.7 1.7 0.0 0.0	6 4 1 1	3.6 2.4 0.6 0.6
Urogenital System CYSTITIS PYURIA URINARY TRACT INFECTION		4 1 1 2	3.6 0.9 0.9 1.8	2 2 0 0	3.4 3.4 0.0 0.0	6 3 1 2	3.6 1.8 0.6 1.2

Paroxetine - Protocol: 377

TABLE 15.101B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: > 70 KG

TREATMENT GROUPS							
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	22 17	100.0% 77.3%	11 6	100.0% 54.5%	33 23	100.0% 69.7%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
Body as a Whole ABDOMINAL PAIN ABSCESS ASTHENIA FEVER HEADACHE INFECTION		8 0 1 2 1 4	36.4 0.0 4.5 9.1 4.5 18.2 4.5	4 1 1 0 0 2 0	36.4 9.1 9.1 0.0 0.0 18.2 0.0	12 1 2 2 1 6	36.4 3.0 6.1 6.1 3.0 18.2 3.0
Cardiovascular System HYPOTENSION SYNCOPE VASODILATATION				0 0 0	0.0 0.0 0.0	3 1 1	9.1 3.0 3.0
Digestive System BILIARY PAIN DECREASED APPETITE GASTROENTERITIS INCREASED APPETITE NAUSEA VOMITING		10 0 2 1 2 6	45.5 0.0 9.1 4.5 9.1 27.3 4.5	3 1 0 1 0 2	27.3 9.1 0.0 9.1 0.0 18.2 0.0	13 1 2 2 2 2 8 1	39.4 3.0 6.1 6.1 24.2 3.0
Hemic and Lymphatic System ANEMIA		1 1	4.5 4.5		0.0	1 1	3.0 3.0
Metabolic and Nutritional Disorders WEIGHT GAIN		1 1	4.5 4.5	0 0	0.0	1 1	3.0 3.0
Musculoskeletal System TENDINOUS DISORDER		1 1	4.5 4.5	0 0		1	
Nervous System DEPERSONALIZATION DIZZINESS EMOTIONAL LABILITY INSOMNIA NERVOUSNESS SOMNOLENCE		9 2 0 1 1 1 4	40.9 9.1 0.0 4.5 4.5 4.5	2 0 2 0 0 0	18.2 0.0 18.2 0.0 0.0 0.0 9.1	11 2 2 1 1 1 5	33.3 6.1 6.1 3.0 3.0 3.0

## NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 Kg, 50-70 Kg, >70 Kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: > 70 KG \_\_\_\_\_\_\_

TREATMENT GROUPS	Ι	PAROXET	INE	PLACE	во	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	: :	22 17	100.0% 77.3%	11 6	100.0% 54.5%		100.0% 69.7%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
TREMOR		1	4.5	0	0.0	1	3.0
Respiratory System RESPIRATORY DISORDER RHINITIS SINUSITIS		3 1 1 1	13.6 4.5 4.5 4.5	1 0 1 0	9.1 0.0 9.1 0.0	4 1 2 1	12.1 3.0 6.1 3.0
Skin and Appendages SWEATING		1 1	4.5 4.5	1 1	9.1 9.1	2 2	6.1 6.1
Urogenital System URINARY TRACT INFECTION		1	4.5 4.5	0	0.0	1 1	3.0 3.0

BRL-029060/RSD-100TNP/2/CPMS-377

000344

## TABLE 15.101B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: MISSING

TREATMENT GROUPS		PAROXET	INE	PLACEBO		TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	2 2	100.0%	1	100.0% 100.0%	3	100.0% 100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	*	N	%
Body as a Whole ABDOMINAL PAIN HEADACHE INFECTION PAIN		0 0 0 0 0	0.0 0.0 0.0 0.0	1 1 1 1 1	100.0 100.0 100.0 100.0 100.0	1 1 1 1 1	33.3 33.3
Nervous System INSOMNIA SOMNOLENCE		1 1 0	50.0 50.0 0.0		100.0 0.0 100.0	2 1 1	66.7 33.3 33.3
Respiratory System BRONCHITIS PHARYNGITIS SINUSITIS		1 0 0 1	50.0 0.0 0.0 50.0	1 1 1 0		2 1 1 1	66.7 33.3 33.3 33.3
Special Senses OTITIS MEDIA		1 1	50.0 50.0	0	0.0	1	33.3 33.3

## EVT001/T15102B/T15102B/16JUL1998:18:10/NELSOB01/DEV32/UKPAT/SBBRL29060/377 PAROXETINE - PROTOCOL: 377

TABLE 15.102B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (< $50~\rm Kg$ , $50-70~\rm Kg$ , >70 Kg). MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS	1	PAROXET	INE	PLACE	во	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	11 0	100.0% 0.0%	6 0	100.0%	17 0	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	 ક	N	8 8	N	~~~~~ %

## PAROXETINE - PROTOCOL: 377

TABLE 15.102B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (< 50 Kg, 50-70 Kg, >70 Kg). MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

		=====	=======		=======	======	
TREATMENT GROUPS	P	PAROXETINE		PLACEBO		TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	41	100.0% 2.4%	21	100.0%	62 1	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	* *
Urogenital System ABNORMAL EJACULATION IMPOTENCE		1 1 1	2.4 2.4 2.4 2.4	0 0 0	0.0 0.0 0.0	1 1 1	1.6 1.6 1.6

# 0034

## TABLE 15.102B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (< 50 Kg, 50-70 Kg, >70 Kg). MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: > 70 KG

TREATMENT GROUPS	P	AROXET	INE	PLACE	во	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	7 0	100.0% 0.0%	5 0	100.0%	12 0	100.0% 0.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	 %	N	*	 N	 %

## RETINE TROTOCOL. 577

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (< 50 Kg, 50-70 Kg, >70 Kg). MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.102B

WEIGHT: MISSING

	=======	=====	=======		======	======	======
TREATMENT GROUPS	P.	AROXET	INE	PLACEBO	)	TOTA	L
TOTAL NUMBER OF PATIENTS	:	1	100.0%	0	0.0%	1	100.0%
PATIENTS WITH ADVERSE EXPERIENCES	:	0	0.0%	0	0.0%	0	0.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	8	N	ે	N	ક

## EVT001/T15103B/T15103B/16JUL1998:18:11/NELSOB01/DEV32/UKPAT/SBBRL29060/377 PAROXETINE - PROTOCOL: 377

TABLE 15.103B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 Kg, 50-70 Kg, >70 Kg). FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TREATMENT GROUPS	I	PAROXET	INE	PLACE	во	TOTA	<u></u>
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	36 0	100.0% 0.0%	17 0	100.0% 0.0%	53 0	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	 %	N	%

## PAROXETINE - PROTOCOL: 377

TABLE 15.103B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

		=====						
TREATMENT GROUPS	F	AROXET	INE	PLACEBO		TOTA	_	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	70 2	100.0% 2.9%	37 0	100.0% 0.0%	107 2	100.0%	
ADECS BODY SYSTEM : PREFERRED TERM		N	*	N	%	N	* *	
Urogenital System DYSMENORRHEA MENSTRUAL DISORDER		2 1 1	2.9 1.4 1.4	0 0 0	0.0 0.0 0.0	2 1 1	1.9 0.9 0.9	

## AETINE IROTOCOL' 377

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.103B

WEIGHT: > 70 KG

		=====	=======		=======	======	======
TREATMENT GROUPS TOTAL NUMBER OF PATIENTS	PAROXETINE			PLACEBO		TOTAL	
	:	15 0	100.0% 0.0%	6 0	100.0% 0.0%	21	100.0%
PATIENTS WITH ADVERSE EXPERIENCESADECS BODY SYSTEM : PREFERRED TERM			 %		 %	 N	

# 000352

## TABLE 15.103B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

WEIGHT: MISSING

	=======	=====	=======		=======	======	======	
TREATMENT GROUPS	PAROXETIN		INE PLACEBO		30	TOTAL		
TOTAL NUMBER OF PATIENTS	:	1	100.0%	1	100.0%	2	100.0%	
PATIENTS WITH ADVERSE EXPERIENCES	:	0	0.0%	0	0.0%	0	0.0%	
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	용	

## TABLE 15.10B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

	=======	======	=======	======	=======	======	======	
TREATMENT GROUPS		PAROXETINE			PLACEBO		TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	47 32		23 13	100.0% 56.5%			
ADECS BODY SYSTEM : PREFERRED TERM			%	N	%	N	%	
Body as a Whole		14	29.8	10	43.5	24	34.3	
Cardiovascular System		3	6.4	0	0.0	3	4.3	
Digestive System		18	38.3	7	30.4	25	35.7	
Hemic and Lymphatic System		0	0.0	1	4.3	1	1.4	
Metabolic and Nutritional Disorders		1	2.1	0	0.0	1	1.4	
Musculoskeletal System		1	2.1	2	8.7	3	4.3	
Nervous System		18	38.3	3	13.0	21	30.0	
Respiratory System		4	8.5	3	13.0	7	10.0	
Skin and Appendages		5	10.6	0	0.0	5	7.1	
Urogenital System		0	0.0	1	4.3	1	1.4	

# 000354

## TABLE 15.10B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

	======								
TREATMENT GROUPS		PAROXETINE		PLACEBO		TOTAL			
	:				100.0% 60.3%		100.0% 61.5%		
ADECS BODY SYSTEM : PREFERRED TERM		N	*	N	*	N	%		
Body as a Whole		39	35.1	19	32.8	58	34.3		
Cardiovascular System		6	5.4	1	1.7	7	4.1		
Digestive System		36	32.4	11	19.0	47	27.8		
Hemic and Lymphatic System		2	1.8	1	1.7	3	1.8		
Metabolic and Nutritional Disorders		1	0.9	0	0.0	1	0.6		
Musculoskeletal System		0	0.0	1	1.7	1	0.6		
Nervous System		36	32.4	16	27.6	52	30.8		
Respiratory System		14	12.6	8	13.8	22	13.0		
Skin and Appendages		6	5.4	1	1.7	7	4.1		
Special Senses		5	4.5	1	1.7	6	3.6		
Urogenital System		7	6.3	2	3.4	9	5.3		

Paroxetine - Protocol: 377

## TABLE 15.10B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

WEIGHT: > 70 KG

TREATMENT GROUPS		PAROXETINE			во	TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:		100.0% 77.3%		100.0% 54.5%		100.0% 69.7%
ADECS BODY SYSTEM : PREFERRED TERM		N	*	N	%	N	%
Body as a Whole		8	36.4	4	36.4	12	36.4
Cardiovascular System		3	13.6	0	0.0	3	9.1
Digestive System		10	45.5	3	27.3	13	39.4
Hemic and Lymphatic System		1	4.5	0	0.0	1	3.0
Metabolic and Nutritional Disorders		1	4.5	0	0.0	1	3.0
Musculoskeletal System		1	4.5	0	0.0	1	3.0
Nervous System		9	40.9	2	18.2	11	33.3
Respiratory System		3	13.6	1	9.1	4	12.1
Skin and Appendages		1	4.5	1	9.1	2	6.1
Urogenital System		1	4.5	0	0.0	1	3.0

Paroxetine - Protocol: 377

## TABLE 15.10B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES BY BASELINE BODY WEIGHT (<50 kg, 50-70 kg, >70 kg). DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

WEIGHT: MISSING

TREATMENT GROUPS	PAROX		ROXETINE		30	TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	2 2	100.0% 100.0%	1 1	100.0% 100.0%	3 3	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	*	N	%	N	%
Body as a Whole		0	0.0	1	100.0	1	33.3
Nervous System		1	50.0	1	100.0	2	66.7
Respiratory System		1	50.0	1	100.0	2	66.7
Special Senses		1	50.0	0	0.0	1	33.3

## oxetine - Protocol: 3//

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE DOWN TITRATION PHASE NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.111B

		======	=======	======	=======	======	=====
TREATMENT GROUPS		PAROXETINE		PLACE	PLACEBO		L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	133 19	100.0% 14.3%	72 6	100.0% 8.3%	205 25	100.0% 12.2%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	 % 	N	%
Body as a Whole ABDOMINAL PAIN BACK PAIN HEADACHE INFECTION TRAUMA		4 2 0 2 2 2	3.0	4 1 1 2 0	5.6 1.4 1.4 2.8 0.0	8	3.9 1.5 0.5 2.0 1.0
Digestive System DIARRHEA INCREASED APPETITE NAUSEA VOMITING		1 0 0 0 1	0.8 0.0 0.0 0.0		2.8 1.4 1.4 1.4 0.0	I .	1.5 0.5 0.5 0.5
Hemic and Lymphatic System ANEMIA LEUKOPENIA LYMPHOCYTOSIS		4 1 1 2		0 0 0 0	0.0	1	
Nervous System AGITATION ANXIETY DEPRESSION DIZZINESS EMOTIONAL LABILITY NERVOUSNESS THINKING ABNORMAL TREMOR		6 1 2 1 2 0 1 1	1.5	2 0 0 0 0 1 1 0	0.0 0.0 0.0 1.4 1.4	1 2 1 2 1 2	1.0
Respiratory System ASTHMA BRONCHITIS COUGH INCREASED PHARYNGITIS RESPIRATORY DISORDER		5 1 1 1 1	3.8 0.8 0.8 0.8 0.8	1 0 0 0 1		1 1 1	2.9 0.5 0.5 0.5 1.0
Urogenital System KIDNEY PAIN		2 1	1.5 0.8	0 0	0.0	2 1	1.0 0.5

## DAECTHE - FIOCOCOT: 37

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE DOWN TITRATION PHASE NON-GENDER SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.111B

			=======		=======		======
TREATMENT GROUPS	I	PAROXET	INE	PLACE	30	TOTA	L
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	133 19	100.0% 14.3%	72 6	100.0%	205 25	100.0% 12.2%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	%	N	%
URINARY INCONTINENCE		1	0.8	0	0.0	1	0.5

TABLE 15.112B

NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE DOWN TITRATION PHASE MALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

NO DATA AVAILABLE FOR THIS REPORT

## \_\_\_\_\_

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE DOWN TITRATION PHASE FEMALE SPECIFIC ADVERSE EXPERIENCES ONLY INTENTION TO TREAT POPULATION

TABLE 15.113B

=======================================		=====	=======			======	======
TREATMENT GROUPS	F	AROXET	INE	PLACEBO		TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	91 1	100.0% 1.1%	45 0	100.0% 0.0%	136 1	100.0% 0.7%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	용	N	%
Urogenital System DYSMENORRHEA		1 1	1.1 1.1	0	0.0 0.0	1 1	0.7 0.7

BRL-029060/RSD-100TNP/2/CPMS-377

# Paroxetine - Protocol: 377 TABLE 15.11B

# NUMBER (%) OF PATIENTS WITH EMERGENT ADVERSE EXPERIENCES DURING THE DOWN TITRATION PHASE DISPLAYED BY BODY SYSTEM INTENTION TO TREAT POPULATION

=======================================	====	======	=======	======	=======	======	=====
TREATMENT GROUPS		PAROXET	INE	PLACE	30	TOTAL	
TOTAL NUMBER OF PATIENTS PATIENTS WITH ADVERSE EXPERIENCES	:	133 19	100.0% 14.3%	72 6	100.0%	205 25	100.0%
ADECS BODY SYSTEM : PREFERRED TERM		N	%	N	ૄ	N	%
Body as a Whole		4	3.0	4	5.6	8	3.9
Digestive System		1	0.8	2	2.8	3	1.5
Hemic and Lymphatic System		4	3.0	0	0.0	4	2.0
Nervous System		6	4.5	2	2.8	8	3.9
Respiratory System		5	3.8	1	1.4	6	2.9
Urogenital System		3	2.3	0	0.0	3	1.5

BRL-029060/RSD-100TNP/2/CPMS-377

Paroxetine - Protocol: 377

TABLE 15.12b

NUMBER (%) OF DEATHS DURING ACTIVE TREATMENT INTENTION TO TREAT POPULATION

NO DATA AVAILABLE FOR THIS REPORT

#### Table 15.21b Summary of Flagged Vital Signs by Parameter Intention to Treat Population

Sitting Diastolic BP (mmHg)

Treatment Groups	Paroxetine		Placebo		
	N	%	N	%	
High	1	0.5	0	0.0	
Low	7	3.8	3	3.2	
Significant Increase	8	4.5	5	5.4	
Significant Decrease	25	14.1	15	16.1	
Number with Assessment	182	100.0	93	100.0	
Number with Base and Post-base Assessment	177	97.3	93	100.0	

Key
High - greater than 105mmHg
Low - less than 50mmHg
Significant Increase - increase of 30mmHg or more from baseline
Significant Decrease - decrease of 20mmHg or more from baseline
Number with Assessment - number of patients who had a sitting diastolic blood pressure measurement at any time

#### Table 15.21b Summary of Flagged Vital Signs by Parameter Intention to Treat Population

Standing Diastolic BP (mmHg)

Treatment Groups	Paroxe	etine	Placebo		
	N	\   %	N	%	
High	1	0.5	1	1.1	
Low	4	2.2	4	4.3	
Significant Increase	8	4.5	3	3.2	
Significant Decrease	22	12.4	15	16.1	
Number with Assessment	182	100.0	93	100.0	
Number with Base and Post-base Assessment	177	97.3	93	100.0	

Key
High - greater than 105mmHg
Low - less than 50mmHg
Significant Increase - increase of 30mmHg or more from baseline
Significant Decrease - decrease of 20mmHg or more from baseline
Number with Assessment - number of patients who had a sitting diastolic blood pressure measurement at any time

#### Table 15.21b Summary of Flagged Vital Signs by Parameter Intention to Treat Population

Sitting Systolic BP (mmHg)

Treatment Groups		etine	Placebo		
	N	%	N	%	
High	0	0.0	0	0.0	
Low	18	9.9	12	12.9	
Significant Increase	0	0.0	0	0.0	
Significant Decrease	11	6.2	7	7.5	
Number with Assessment	182	100.0	93	100.0	
Number with Base and Post-base Assessment	+   177	97.3	93	100.0	

Key
High - greater than 180mmHg
Low - less than 90mmHg
Significant Increase - increase of 40mmHg or more from baseline
Significant Decrease - decrease of 30mmHg or more from baseline
Number with Assessment - number of patients who had a sitting systolic blood pressure measurement at any time

#### Table 15.21b Summary of Flagged Vital Signs by Parameter Intention to Treat Population

Standing Systolic BP (mmHg)

Treatment Groups	Paroxe	etine	Placebo		
	N		N	%	
High	0	0.0	0	0.0	
Low	24	13.2	12	12.9	
Significant Increase	0	0.0	2	2.2	
Significant Decrease	12	6.8	5	5.4	
Number with Assessment	182	100.0	93	100.0	
Number with Base and Post-base Assessment	177	97.3	93	100.0	

Key
High - greater than 180mmHg
Low - less than 90mmHg
Significant Increase - increase of 40mmHg or more from baseline
Significant Decrease - decrease of 30mmHg or more from baseline
Number with Assessment - number of patients who had a sitting systolic blood pressure measurement at any time

#### Table 15.21b Summary of Flagged Vital Signs by Parameter Intention to Treat Population

Sitting Pulse (beats per min)

Treatment Groups	Paroxe	etine	Placebo		
	N	%	N	8	
High	1	0.5	1	1.1	
Low	1	0.5	1	1.1	
Significant Increase	11	6.2	4	4.3	
Significant Decrease	7	4.0	0	0.0	
Number with Assessment	182	100.0	93	100.0	
Number with Base and Post-base Assessment	177	97.3	93	100.0	

Key
High - greater than 120 BPM
Low - less than 50 BPM
Significant Increase - increase of 30 BPM or more from baseline
Significant Decrease - decrease of 30 BPM or more from baseline
Number with Assessment - number of patients who had a sitting pulse rate measurement at any time

#### Table 15.21b Summary of Flagged Vital Signs by Parameter Intention to Treat Population

Standing Pulse (beats per min)

Treatment Groups	Paroxe	tine	Placebo		
	N	%	N	%	
High	6	3.3	3	3.2	
Low	0	0.0	0	0.0	
Significant Increase	16	9.0	9	9.7	
Significant Decrease	9	5.1	4	4.3	
Number with Assessment	182	100.0	93	100.0	
Number with Base and Post-base Assessment	   177	97.3	93	100.0	

Key
High - greater than 120 BPM
Low - less than 50 BPM
Significant Increase - increase of 30 BPM or more from baseline
Significant Decrease - decrease of 30 BPM or more from baseline
Number with Assessment - number of patients who had a sitting pulse rate measurement at any time

## Table 15.21b Summary of Flagged Vital Signs by Parameter Intention to Treat Population

Weight (Kg)

Treatment Groups	Paroxe	etine	Placebo		
	N	%   %	N	%	
High	0	0.0	0	0.0	
Low	0	0.0	0	0.0	
Significant Increase	12	8.2	5	6.8	
Significant Decrease	5	3.4	4	5.5	
Number with Assessment	181	99.5	93	100.0	
Number with Base and Post-base Assessment	146	80.7	73	78.5	

Key
High - not relevant
Low - not relevant
Significant Increase - increase of 7% or more from baseline
Significant Decrease - decrease of 7% or more from baseline
Number with Assessment - number of patients who had their weight measured at any time

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Sitting Diastolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	70.2	70.0	9.12	50.0	90.0	179
Week 1	69.9	70.0	9.69	40.0	95.0	170
Week 2	70.5	70.0	10.00	40.0	98.0	165
Week 3	70.2	70.0	9.30	40.0	96.0	158
Week 4	69.2	70.0	9.76	41.0	98.0	158
Week 6	69.2	70.0	9.38	32.0	97.0	149
Week 8	69.7	70.0	10.12	40.0	92.0	147
Week 12	69.6	70.0	10.15	30.0	100.0	130
>Week 12	70.3	70.0	10.47	40.0	110.0	121

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Placebo

Parameter: Sitting Diastolic BP (mmHg)

Interv	val	Mean	Median	Std Dev	Minimum	Maximum	N
Baseli	ine	69.3	70.0	9.27	50.0	90.0	92
Week	1	68.4	70.0	8.58	40.0	90.0	84
Week	2	67.8	70.0	9.15	40.0	85.0	85
Week	3	69.5	70.0	9.11	50.0	90.0	85
Week	4	69.2	70.0	9.75	50.0	95.0	80
Week	6	68.9	70.0	9.16	50.0	90.0	79
Week	8	69.9	70.0	9.32	50.0	95.0	73
Week	12	67.2	70.0	8.39	45.0	80.0	69
>Week	12	68.9	70.0	10.45	50.0	100.0	67

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Standing Diastolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	71.6	70.0	9.91	50.0	97.0	178
Week 1	71.5	70.0	9.88	50.0	100.0	170
Week 2	72.0	70.0	10.57	50.0	100.0	164
Week 3	72.4	70.0	10.28	50.0	101.0	158
Week 4	71.7	70.0	10.72	45.0	100.0	157
Week 6	70.8	70.0	9.95	50.0	100.0	149
Week 8	71.3	70.0	10.39	42.0	100.0	146
Week 12	70.6	70.0	9.69	50.0	100.0	129
>Week 12	71.6	70.0	10.45	40.0	110.0	122

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Placebo

Parameter: Standing Diastolic BP (mmHg)

Interv	al	Mean	Median	Std Dev	Minimum	Maximum	N
Baseli	ine	70.9	70.0	9.21	50.0	85.0	92
Week	1	70.8	70.0	9.02	50.0	95.0	84
Week	2	70.9	70.0	9.84	45.0	95.0	85
Week	3	71.3	70.0	9.57	55.0	90.0	85
Week	4	70.9	70.0	10.02	50.0	90.0	80
Week	6	71.9	70.0	9.29	54.0	94.0	79
Week	8	72.3	70.0	10.32	55.0	95.0	74
Week	12	69.6	70.0	8.64	40.0	90.0	69
>Week	12	69.6	70.0	8.73	50.0	90.0	67

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Sitting Systolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	110.7	110.0	11.52	75.0	142.0	179
Week 1	109.1	110.0	11.47	75.0	145.0	170
Week 2	109.1	110.0	12.08	80.0	150.0	165
Week 3	108.8	110.0	11.95	80.0	140.0	158
Week 4	108.6	110.0	11.96	80.0	150.0	158
Week 6	108.3	110.0	13.50	75.0	150.0	149
Week 8	109.1	110.0	11.64	80.0	150.0	147
Week 12	109.1	110.0	12.67	60.0	140.0	130
>Week 12	108.1	110.0	11.57	70.0	130.0	121

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Placebo

Parameter: Sitting Systolic BP (mmHg)

Interv	7al	Mean	Median	Std Dev	Minimum	Maximum	N
Baseli	ine	108.5	110.0	11.43	80.0	150.0	92
Week	1	108.5	110.0	12.28	80.0	150.0	84
Week	2	107.3	110.0	13.93	80.0	155.0	85
Week	3	108.2	110.0	13.17	80.0	150.0	85
Week	4	108.0	110.0	13.91	80.0	150.0	80
Week	6	108.9	110.0	12.85	80.0	145.0	79
Week	8	108.5	110.0	11.75	90.0	140.0	73
Week	12	107.1	110.0	11.77	85.0	130.0	69
>Week	12	107.6	110.0	13.43	80.0	140.0	67

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Standing Systolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	109.8	110.0	12.41	80.0	142.0	178
Week 1	109.2	110.0	12.97	75.0	140.0	170
Week 2	109.1	110.0	12.62	80.0	140.0	164
Week 3	109.3	110.0	12.73	80.0	149.0	158
Week 4	109.0	110.0	13.22	80.0	150.0	158
Week 6	108.2	110.0	12.59	80.0	148.0	149
Week 8	108.1	110.0	11.71	80.0	145.0	146
Week 12	108.5	110.0	12.39	80.0	145.0	129
>Week 12	107.3	110.0	12.16	72.0	140.0	122

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Placebo

Parameter: Standing Systolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	108.7	110.0	13.21	80.0	150.0	92
Week 1	108.4	110.0	12.95	80.0	150.0	84
Week 2	107.4	110.0	12.56	80.0	150.0	85
Week 3	109.1	110.0	13.27	80.0	150.0	85
Week 4	108.2	110.0	13.14	80.0	150.0	80
Week 6	108.4	110.0	12.76	80.0	140.0	79
Week 8	109.3	110.0	12.65	90.0	140.0	74
Week 12	107.2	110.0	11.33	80.0	140.0	69
>Week 12	108.1	110.0	11.23	85.0	130.0	67

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Sitting Pulse (beats per min)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	76.6	76.0	10.57	58.0	128.0	178
Week 1	75.2	76.0	9.60	44.0	100.0	172
Week 2	76.4	76.5	9.46	52.0	115.0	164
Week 3	76.2	76.0	9.40	52.0	120.0	158
Week 4	78.3	78.0	10.31	52.0	120.0	158
Week 6	77.6	78.0	10.91	52.0	120.0	149
Week 8	77.7	76.0	9.53	60.0	104.0	147
Week 12	77.1	76.0	9.96	56.0	107.0	129
  >Week 12	78.4	78.0	10.55	56.0	118.0	121

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Placebo

Parameter: Sitting Pulse (beats per min)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	75.5	76.0	9.30	56.0	99.0	91
Week 1	77.2	78.0	9.46	59.0	96.0	87
Week 2	76.5	76.0	10.25	56.0	110.0	85
Week 3	77.6	76.0	11.86	52.0	126.0	85
Week 4	77.9	78.0	8.73	60.0	100.0	80
Week 6	77.6	79.5	10.47	55.0	100.0	80
Week 8	75.5	76.0	9.23	52.0	92.0	76
Week 12	76.4	76.0	9.68	58.0	96.0	69
>Week 12	76.8	76.5	10.01	47.0	104.0	66

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Standing Pulse (beats per min)

Interv	al	Mean	Median	Std Dev	Minimum	Maximum	N
Baseli	ine	82.2	80.0	12.01	56.0	122.0	177
Week	1	80.6	80.0	10.58	52.0	114.0	172
Week	2	82.4	82.0	11.55	60.0	137.0	163
Week	3	81.3	80.0	11.61	52.0	125.0	158
Week	4	84.5	83.0	11.72	56.0	130.0	158
Week	6	82.7	80.0	11.11	52.0	125.0	149
Week	8	82.9	80.0	11.33	60.0	120.0	147
Week	12	81.8	82.0	10.31	52.0	112.0	129
>Week	12	82.7	80.0	11.02	60.0	131.0	122

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Placebo

Parameter: Standing Pulse (beats per min)

Interv	/al	Mean	Median	Std Dev	Minimum	Maximum	N
Baseli	ine	80.4	80.0	10.98	60.0	120.0	91
Week	1	82.7	80.0	11.39	62.0	125.0	87
Week	2	82.1	80.0	11.71	52.0	120.0	85
Week	3	83.3	80.0	11.49	64.0	125.0	84
Week	4	84.9	83.0	12.54	60.0	132.0	80
Week	6	83.4	81.5	13.64	56.0	120.0	80
Week	8	80.5	80.0	10.07	59.0	110.0	77
Week	12	81.7	82.0	9.87	64.0	104.0	69
>Week	12	82.4	80.0	10.36	56.0	120.0	66

Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Weight (Kg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	57.6	56.0	13.51	34.0	118.0	180
Week 1	52.0	52.0		52.0	52.0	1
Week 2	54.9	58.5	9.29	42.0	66.0	7
Week 3	57.6	61.3	10.80	45.4	66.0	3
Week 4	75.0	75.0	29.70	54.0	96.0	2
Week 6	50.3	50.0	5.56	45.0	56.0	4
Week 8	59.5	59.5	4.95	56.0	63.0	2
Week 12	57.8	56.0	14.01	34.0	117.0	118
>Week 12	59.3	54.3	12.56	46.0	79.0	6

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Placebo

Parameter: Weight (Kg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	58.2	57.2	11.53	36.0	105.0	92
Week 1	57.0	57.0		57.0	57.0	1
Week 4	43.5	43.5		43.5	43.5	1
Week 6	52.0	54.5	10.34	37.6	61.4	4
Week 8	60.1	63.2	12.79	46.0	71.0	3
Week 12	57.6	56.8	11.13	36.5	96.0	62
>Week 12	71.1	61.7	29.50	47.5	104.2	3

Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Height (cm)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	163.6	163.3	9.08	140.0	185.0	180

## Table 15.22b Summary of Group Vital Signs Intention to Treat Population

Treatment Group: Placebo

Parameter: Height (cm)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	164.5	165.0	8.52	131.0	184.0	93

# Table 15.23b Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Sitting Diastolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	70.3	70.0	9.13	50.0	90.0	177
Week 1	-0.2	0.0	8.44	-27.0	25.0	168
Week 2	0.2	0.0	9.09	-31.0	20.0	162
Week 3	0.2	0.0	8.55	-22.0	25.0	155
Week 4	-1.1	0.0	9.80	-39.0	30.0	156
Week 6	-1.1	0.0	9.76	-38.0	30.0	148
Week 8	-0.4	0.0	10.41	-35.0	30.0	146
Week 12	-0.4	0.0	10.49	-30.0	26.0	129
>Week 12	0.7	0.0	11.81	-30.0	30.0	120

# Table 15.23b

Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Placebo

Parameter: Sitting Diastolic BP (mmHg)

Interv	<i>r</i> al	Mean	Median	Std Dev	Minimum	Maximum	N
Baseli	ine	69.3	70.0	9.27	50.0	90.0	92
Week	1	-0.7	0.0	9.56	-20.0	20.0	83
Week	2	-1.0	0.0	9.87	-20.0	20.0	84
Week	3	0.4	0.0	9.84	-30.0	24.0	84
Week	4	0.4	0.0	10.14	-21.0	35.0	79
Week	6	-0.2	0.0	10.28	-24.0	25.0	78
Week	8	1.7	0.0	10.98	-30.0	35.0	72
Week	12	-0.2	0.0	9.81	-30.0	30.0	68
>Week	12	0.6	0.0	12.54	-25.0	50.0	66

# Table 15.23b Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Standing Diastolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	71.7	70.0	9.92	50.0	97.0	176
Week 1	-0.0	0.0	8.45	-20.0	21.0	167
Week 2	0.4	0.0	9.70	-32.0	30.0	161
Week 3	0.8	0.0	8.98	-15.0	40.0	154
Week 4	-0.0	0.0	10.25	-45.0	32.0	154
Week 6	-0.5	0.0	9.94	-40.0	30.0	147
Week 8	0.2	0.0	9.73	-25.0	30.0	144
Week 12	-0.7	0.0	10.41	-30.0	28.0	128
>Week 12	0.8	0.0	11.48	-30.0	30.0	120

# Table 15.23b

# Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Placebo

Parameter: Standing Diastolic BP (mmHg)

Interv	7al	Mean	Median	Std Dev	Minimum	Maximum	N
Basel	ine	70.9	70.0	9.21	50.0	85.0	92
Week	1	0.4	0.0	9.03	-25.0	30.0	83
Week	2	0.4	0.0	9.81	-25.0	25.0	84
Week	3	0.6	0.0	9.12	-20.0	30.0	84
Week	4	0.2	0.0	9.48	-25.0	25.0	79
Week	6	0.7	0.0	9.82	-25.0	26.0	78
Week	8	2.0	0.0	11.34	-25.0	30.0	73
Week	12	-0.0	0.0	9.75	-20.0	25.0	68
>Week	12	-1.0	0.0	9.99	-25.0	24.0	66

# Table 15.23b Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Sitting Systolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	110.8	110.0	11.46	75.0	142.0	177
Week 1	-1.4	0.0	10.13	-30.0	30.0	168
Week 2	-1.9	0.0	11.39	-35.0	30.0	162
Week 3	-1.7	0.0	10.84	-40.0	20.0	155
Week 4	-2.2	0.0	10.61	-30.0	30.0	156
Week 6	-2.3	0.0	13.35	-62.0	30.0	148
Week 8	-1.5	0.0	11.53	-35.0	30.0	146
Week 12	-1.5	0.0	12.03	-40.0	25.0	129
>Week 12	-2.1	0.0	11.83	-30.0	25.0	120

# Table 15.23b

Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Placebo

Parameter: Sitting Systolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	108.5	110.0	11.43	80.0	150.0	92
Week 1	0.6	0.0	10.73	-28.0	30.0	83
Week 2	-0.8	0.0	10.91	-30.0	30.0	84
Week 3	-0.0	0.0	11.10	-30.0	30.0	84
Week 4	0.0	0.0	11.13	-35.0	30.0	79
Week 6	0.8	0.0	10.51	-30.0	30.0	78
Week 8	1.0	0.0	10.93	-30.0	30.0	72
Week 12	0.1	0.0	9.53	-30.0	20.0	68
>Week 12	-0.2	0.0	12.96	-34.0	30.0	66

# Table 15.23b

Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Standing Systolic BP (mmHg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	109.9	110.0	12.38	80.0	142.0	176
Week 1	-0.7	0.0	11.33	-50.0	30.0	167
Week 2	-0.7	0.0	10.32	-30.0	25.0	161
Week 3	0.1	0.0	11.19	-40.0	28.0	154
Week 4	-1.0	0.0	11.06	-35.0	26.0	155
Week 6	-1.3	0.0	11.38	-40.0	30.0	147
Week 8	-1.5	0.0	11.57	-35.0	30.0	144
Week 12	-0.7	0.0	11.19	-35.0	31.0	128
>Week 12	-1.7	0.0	12.02	-30.0	30.0	120

# Table 15.23b

# Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Placebo

Parameter: Standing Systolic BP (mmHg)

Interv	7al	Mean	Median	Std Dev	Minimum	Maximum	N
Baseli	ine	108.7	110.0	13.21	80.0	150.0	92
Week	1	0.1	0.0	11.41	-30.0	30.0	83
Week	2	-1.2	0.0	10.21	-25.0	30.0	84
Week	3	0.4	0.0	10.93	-38.0	30.0	84
Week	4	-0.4	0.0	10.45	-30.0	20.0	79
Week	6	-0.6	0.0	10.85	-25.0	30.0	78
Week	8	1.3	0.0	13.39	-30.0	40.0	73
Week	12	-0.2	0.0	12.53	-32.0	40.0	68
>Week	12	-0.2	0.0	13.85	-35.0	31.0	66

# Table 15.23b Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Sitting Pulse (beats per min)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	76.8	76.0	10.51	58.0	128.0	176
Week 1	-2.0	0.0	12.61	-64.0	32.0	169
Week 2	-0.5	0.0	12.26	-64.0	48.0	160
Week 3	-1.0	0.0	12.42	-60.0	52.0	154
Week 4	1.4	0.0	12.51	-50.0	32.0	155
Week 6	0.2	0.0	13.72	-60.0	48.0	147
Week 8	0.6	0.0	12.21	-60.0	24.0	145
Week 12	-0.0	0.0	12.60	-64.0	36.0	127
  >Week 12	1.0	2.0	13.46	-64.0	35.0	119

# Table 15.23b

# Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Placebo

Parameter: Sitting Pulse (beats per min)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	75.5	76.0	9.30	56.0	99.0	91
Week 1	1.6	2.0	7.71	-20.0	28.0	85
Week 2	1.2	0.0	9.42	-20.0	36.0	83
Week 3	2.1	0.0	12.54	-26.0	54.0	83
Week 4	2.5	0.0	9.61	-20.0	28.0	78
Week 6	1.7	1.0	9.95	-23.0	32.0	78
Week 8	-0.1	0.0	9.21	-23.0	28.0	74
Week 12	0.8	0.0	9.82	-24.0	19.0	67
  ->Week 12	0.7	0.0	11.34	-25.0	24.0	64

# Table 15.23b Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Standing Pulse (beats per min)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	82.3	80.0	11.97	56.0	122.0	175
Week 1	-1.8	0.0	12.17	-56.0	30.0	168
Week 2	0.3	2.0	11.99	-40.0	48.0	159
Week 3	-0.6	0.0	12.78	-48.0	45.0	153
Week 4	2.8	2.0	12.42	-52.0	33.0	154
Week 6	0.0	0.0	13.66	-32.0	46.0	146
Week 8	0.6	0.0	12.52	-48.0	34.0	144
Week 12	0.4	0.0	11.59	-36.0	24.0	127
>Week 12	0.9	0.0	13.14	-37.0	36.0	119

#### Table 15.23b

## Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Placebo

Parameter: Standing Pulse (beats per min)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	80.4	80.0	10.98	60.0	120.0	91
Week 1	2.2	0.0	10.78	-48.0	30.0	85
Week 2	1.8	0.0	11.76	-40.0	40.0	83
Week 3	2.8	4.0	13.75	-48.0	45.0	82
Week 4	4.9	2.0	12.81	-48.0	42.0	78
Week 6	2.6	2.0	11.95	-28.0	44.0	78
Week 8	-0.1	0.0	13.01	-32.0	24.0	75
Week 12	1.1	0.0	11.69	-40.0	24.0	67
>Week 12	1.1	0.0	12.17	-41.0	32.0	64

# Table 15.23b Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Weight (Kg)

Interv	7al	Mean	Median	Std Dev	Minimum	Maximum	N
Baseli	ine	57.6	56.0	13.58	34.0	118.0	178
Week	1	0.0	0.0		0.0	0.0	1
Week	2	0.0	0.0	1.17	-1.4	2.0	7
Week	3	0.9	0.4	1.23	0.0	2.3	3
Week	4	-2.0	-2.0	2.83	-4.0	0.0	2
Week	6	-0.3	0.5	2.50	-3.9	1.7	4
Week	8	-1.1	-1.1	2.97	-3.2	1.0	2
Week	12	0.3	0.0	3.14	-12.0	10.0	117
>Week	12	0.1	-1.0	4.63	-3.8	9.1	6

#### Table 15.23b

## Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Placebo

Parameter: Weight (Kg)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	58.2	57.2	11.53	36.0	105.0	92
Week 1	-0.5	-0.5		-0.5	-0.5	1
Week 4	1.8	1.8		1.8	1.8	1
Week 6	-0.3	1.2	3.18	-5.0	1.6	4
Week 8	-2.5	-2.0	3.28	-6.0	0.5	3
Week 12	0.5	0.0	3.12	-13.0	11.0	62
  >Week 12	0.4	0.4	1.77	-0.8	1.7	2

#### Table 15.23b

## Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Paroxetine

Parameter: Height (cm)

Interval	Mean	Median	Std Dev	Minimum	Maximum	N
Baseline	163.5	163.3	9.08	140.0	185.0	178

#### Table 15.23b

Summary of Group Vital Signs Changes from Baseline Intention to Treat Population

Treatment Group: Placebo

Parameter: Height (cm)

-	Interval				-
	Baseline		131.0		

# Table 15.34B Summary of Qualitative Laboratory Values Intention to Treat Population

Parameter = Serum BHCG pregnancy test (dipst)

		Treatment					
	Parox	etine	Placebo				
	N	   %	N	%			
Number of Patients	182	<u>+</u>	93				
Number of Patients with Assessment	99	54.4	49 	52.7			
Negative	99	100.0	49	100.0			
Positive	1	1.0	0	0.0			
Trace	0	0.0	   0	0.0			

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T1534B.SAS (31JUL98 17:00)

# Table 15.34B Summary of Qualitative Laboratory Values Intention to Treat Population

Parameter = Urine Blood - Dipstick

 		Treatment				
	Paroxe	etine	Placebo			
	N	   %	N	%		
Number of Patients	182		93			
Number of Patients with Assessment	83	45.6	47	50.5		
Negative	75	90.4	39	83.0		
Positive	16	19.3	12	25.5		
Trace	4	4.8	2	4.3		

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T1534B.SAS (31JUL98 17:00)

# Table 15.34B Summary of Qualitative Laboratory Values Intention to Treat Population

Parameter = Urine Glucose - Dipstick

		Treatment					
	Parox	etine	Placebo				
	N	N   %		%			
Number of Patients	182		93				
Number of Patients with Assessment		45.6		50.5			
Negative	83	100.0	•	100.0			
Positive	0	0.0	1	2.1			
Trace	1	1.2	0	0.0			

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T1534B.SAS (31JUL98 17:00)

# Table 15.34B Summary of Qualitative Laboratory Values Intention to Treat Population

Parameter = Urine Protein - Dipstick

 	 	Treatment				
	Paroxe	etine	Placebo			
	N	   %	N	8		
Number of Patients	182		93			
Number of Patients with Assessment	83	45.6	47	50.5		
Negative	71	85.5	40	85.1		
Positive	11	13.3	7	14.9		
Trace	10	12.0	3	6.4		

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T1534B.SAS (31JUL98 17:00)

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Alanine Aminotransferase (iu/l)

 	Treatment				
	Paroxe	etine	Placebo		
	N	%	N	%	
Number of Patients	182		93		
Number of Patients with Assessment	182	100.0	93	100.0	
L	5	2.7	1	1.1	
н	5	2.7	0	0.0	
+	0	0.0	0	0.0	
	0	0.0	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN
L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Albumin (g/1)

 I							
		Treatment					
	Paroxe	etine	Placebo				
	N	%	N	%			
Number of Patients	182		93				
Number of Patients with Assessment	181	99.5	93	100.0			
L	1	0.6	0	0.0			
н	0	0.0	0	0.0			
+	0	0.0	0	0.0			
	0	0.0	0	0.0			

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN

L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Alkaline Phosphatase (iu/l)

		Treatment				
	Paroxe	etine	Placebo			
	N	   %	N	%		
Number of Patients	182		93			
Number of Patients with Assessment	180	98.9	93	100.0		
L	2	1.1	0	0.0		
н	14	7.8	3	3.2		
+	11	6.1	2	2.2		
-	0	0.0	0	0.0		

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units
Intention to Treat Population

Parameter = Aspartate Aminotransferase (iu/l)

 	Treatment				
	Paroxe	etine	Placebo		
	N   %		N N	%	
Number of Patients	182		93		
Number of Patients with Assessment	182	100.0	93	100.0	
L	0	0.0	0	0.0	
н	2	1.1	2	2.2	
+	0	0.0	0	0.0	
_	0	0.0	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Basophils (10^9/1)

 		Treatment			
	Parox	etine	Plac	cebo	
	N	   %	N	%	
Number of Patients	182	ļ	93		
Number of Patients with Assessment	179	98.4	92	98.9	
L	0	0.0	0	0.0	
н	0	0.0	1	1.1	
+	0	0.0	0	0.0	
-	0	0.0	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN

L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

NB. Any Visit dates > 14 days after last dose of study medication are omitted from this table

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T153B.SAS (31JUL98 14:53)

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Blood Urea Nitrogen (mmol/l)

	Treatment			
	Paroxetine		Placebo	
	N	   %	N	%
Number of Patients	182	ļ	93	
Number of Patients with Assessment	182	100.0	93	100.0
L	+7	3.8	2	2.2
н	1	0.5	1	1.1
+	0	0.0	0	0.0
  -	0	0.0	0	0.0

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN

L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Calcium (mmol/1)

 		Treatment			
	Paroxe	etine	Placebo		
	N	%	N N	8	
Number of Patients	182		93		
Number of Patients with Assessment	181	99.5	93	100.0	
L	3	1.7	2	2.2	
н	53	29.3	21	22.6	
+	. 0	0.0	0	0.0	
-	1	0.6	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Creatinine (umol/1)

		Treatment			
	Parox	etine	Placebo		
	N	   %	N	%	
Number of Patients	182	ļ	93		
Number of Patients with Assessment	182	100.0	93	100.0	
ь	47	25.8	22	23.7	
Н	0	0.0	0	0.0	
+	0	0.0	0	0.0	
-	0	0.0	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Eosinophils (10^9/1)

 		Treatment			
	Parox	etine	Placebo		
	N	%	N	8	
Number of Patients	182	ļ	93		
Number of Patients with Assessment	179	98.4	92	98.9	
ь		0.0	0	0.0	
н	49	27.4	23	25.0	
  +	9	5.0	4	4.3	
	0	0.0	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

NB. Any Visit dates > 14 days after last dose of study medication are omitted from this table

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T153B.SAS (31JUL98 14:53)

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Globulin (g/1)

 	 	Treatment				
	Parox	etine	Plac	cebo		
	N	N   %		   %		
Number of Patients	182		93			
Number of Patients with Assessment	182	100.0	93	100.0		
ь	   6	3.3	   5	5.4		
Н	5	2.7	3	3.2		
+	. 0	0.0	0	0.0		
-	0	0.0	0	0.0		

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

#### Parameter = Hematocrit (%)

	Trantmont						
	Treatment						
	Paroxetine		Plac	cebo			
	N	N   %		   % +			
Number of Patients	182		93				
Number of Patients with Assessment	177	97.3	92	98.9			
L	17	9.6	11	12.0			
н	3	1.7	2	2.2			
+	0	0.0	0	0.0			
	3	1.7	2	2.2			

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

NB. Any Visit dates > 14 days after last dose of study medication are omitted from this table

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T153B.SAS (31JUL98 14:53)

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Hemoglobin (g/1)

 		Treatment				
	Parox	etine	Placebo			
	N	%	N	%		
Number of Patients	182		93			
Number of Patients with Assessment	179	98.4	93	100.0		
L	18	10.1	11	11.8		
н	7	3.9	6	6.5		
+	0	0.0	0	0.0		
-	0	0.0	0	0.0		

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Lymphocytes (10^9/1)

 		Treatment			
	Paroxe	etine	Placebo		
	N	   %	N	8	
Number of Patients	182	ļ	93		
Number of Patients with Assessment	179	98.4	92	98.9	
L	18	10.1	9	9.8	
н	18	10.1	15	16.3	
+	0	0.0	0	0.0	
-	0	0.0	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Monocytes (10^9/1)

 		Treatment			
	Parox	etine	Placebo		
	N			%	
Number of Patients	182		93		
Number of Patients with Assessment	179	98.4	92	98.9	
L	6	3.4	4	4.3	
н	11	6.1	8	8.7	
+	0	0.0	1	1.1	
-  -	0	0.0	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN

L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

NB. Any Visit dates > 14 days after last dose of study medication are omitted from this table

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T153B.SAS (31JUL98 14:53)

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Neutrophil Bands (10^9/1)

		Treatment			
	Parox	Paroxetine		cebo	
	N	   %	N	%	
Number of Patients	182		93		
Number of Patients with Assessment	5	2.7	2	2.2	
ь	4	80.0	2	100.0	
Н	0	0.0	0	0.0	
+	0	0.0	0	0.0	
-	0	0.0	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN

L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Platelets (10^9/1)

	Treatment			
	Paroxetine		Placebo	
	N	%	N	%
Number of Patients	182		93	
Number of Patients with Assessment	179	98.4	93	100.0
L	1	0.6	3	3.2
н	3	1.7	2	2.2
+	0	0.0	0	0.0
  -	0	0.0	0	0.0

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN

L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

NB. Any Visit dates > 14 days after last dose of study medication are omitted from this table

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T153B.SAS (31JUL98 14:53)

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Segmented Neutrophils (10^9/1)

 	Treatment			
	Paroxetine   P		Plac	cebo
	N	%   %	N	ુ
Number of Patients	182		93	
Number of Patients with Assessment	155	85.2	81	87.1
L	2	1.3	1	1.2
н	25	16.1	11	13.6
	0	0.0	0	0.0
  -	0	0.0	1	1.2

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Total Bilirubin (umol/l)

	Treatment			
	Paroxetine		Placebo	
	N	   %	N	%
Number of Patients	182		93	
Number of Patients with Assessment	182	100.0	93	100.0
L	4	2.2	2	2.2
н	8	4.4	6	6.5
+	0	0.0	1	1.1
-	0	0.0	0	0.0

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Total Neutrophils (10^9/1)

 	Treatment			
	Paroxetine		Placebo	
	N	%	N	%
Number of Patients	182		93	
Number of Patients with Assessment	26	14.3	13	14.0
L	8	30.8	3	23.1
н	2	7.7	1	7.7
+	0	0.0	0	0.0
  -	0	0.0	0	0.0

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Total Protein (g/l)

 	Treatment			
	Paroxetine		Placebo	
	N	% 	N	%
Number of Patients	182		93	
Number of Patients with Assessment	182	100.0	93	100.0
L	3	1.6	1	1.1
н	2	1.1	0	0.0
+	0	0.0	0	0.0
-	0	0.0	0	0.0

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Urine Red Blood Cells/HPF (alpha)

	Treatment			
	Paroxetine		Plac	ebo
	N	%   %	N	용 8
Number of Patients	182		93	
Number of Patients with Assessment	22	12.1	11	11.8
L	0	0.0	0	0.0
н	2	9.1	3	27.3
+	0	0.0	0	0.0
-	0	0.0	0	0.0

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN

L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

NB. Any Visit dates > 14 days after last dose of study medication are omitted from this table

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = Urine White Blood Cells/HPF (alpha)

 		Treatment			
	Parox	Paroxetine		cebo	
	N	%	N	%	
Number of Patients	182		93		
Number of Patients with Assessment	22	12.1	11	11.8	
L	0	0.0	0	0.0	
н	3	13.6	1	9.1	
+	0	0.0	0	0.0	
-	0	0.0	0	0.0	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN

L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

NB. Any Visit dates > 14 days after last dose of study medication are omitted from this table

DISK\$STATS4:[STATS\_GROUP.SBBRL29060.377.CODE]T153B.SAS

Table 15.3b

Number (%) of Patients with Quantitative Laboratory Values Flagged as outside Normal and Clinical Concern Ranges Using SB Lab Units Intention to Treat Population

Parameter = White Blood Cell Count (10^9/1)

 		Treatment			
	Parox	Paroxetine		cebo	
	N	   %	N	%	
Number of Patients	182	ļ	93		
Number of Patients with Assessment	179	98.4	93	100.0	
ь	24	13.4	   9	9.7	
н	5	2.8	2	2.2	
+	1	0.6	0	0.0	
	1	0.6	   1	1.1	

H: HIGHER THAN REFERENCE RANGE, +: HIGH CLINICAL CONCERN L: LOWER THAN REFERENCE RANGE, -: LOW CLINICAL CONCERN

## 13 Source Tables: Safety Narratives

Table 16 Safety Narratives for patients who experienced non-fatal SAEs 000430

Confidential



### **Paroxetine**

### **BRL-029060**

### **Patient Narratives for Serious Non-fatal Adverse Experiences**

377

Table No. 16

Safety Narratives

SB Document Number: BRL-029060/RSD-100VJ4/1

### PID 377.005.00231

Primary Adverse Experience: Emotional Lability/Suicide Attempt (Overdose on Study

Medication and Tranxene {Intentional}

Other Adverse Experience: Sedation

Appendicitis

Demography: Age-14 years Date of Birth-02-Jan-81 Sex-Female

Height-168.0 cm Weight-57.0 kgRace - Race-White

Country: Belgium

Medical History: Pain {Post-Operative}

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo

Start Date: 14-Oct-95

Stop Date: 13 Nov 95

AE Remarks:

Case, reference number 1995012407-1 is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 14.

On 14 October 1995, the patient received her first treatment with study medication for unipolar major depression. Approximately thirty one days later, on 13 November 1995, the patient attempted suicide by taking an overdose of study medication with Tranxene (clorazepate) (28 x 20mg study medication and 7 capsules clorazepate, dose not specified). The patient was withdrawn from the study the same day due to protocol violation. The next day, 14 November 1995, the patient felt sedated. She was not hospitalised and was reported to have recovered from the sedation the same day.

Approximately fourteen days post therapy, on 27 November 1995, the patient was diagnosed to be suffering from appendicitis. Appendectomy was performed on 4 December 1995. She was treated with Efferalgan (paracetamol) for two days for post operative pain. The patient was reported to have recovered on 4 December 1995.

The patient subsequently changed address and was lost to follow up.

The investigator considers that the suicide attempt is possibly related and the sedation and appendiditis are unrelated to treatment with study medication.

Concomitant Drugs: Start End

Tranxene 13-Nov-1995 13-Nov-1995

Seroxat 15-Nov-1995

Treatment Drugs: Start End

Efferalgan (Paracetamol) 05-Dec-1995 06-Dec-1995

#### Lab Remarks:

The serum received was on clot. Therefore, the results for calcium, LDH, alkaline phophatase and creatinine may be falsely elevated. Results for ASAT (SGOT) and ALAT (SGPT) may be questionable.

Lab Test Code/Name	Date	Lab Value	Units	Normal Range
Alat	27-Nov-1995	3	U/L	0 - 48 U/L
Alkaline Phosphatase	27-Nov-1995	76	U/L	44 - 280 U/L
				(FEMA)
Asat	27-Nov-1995	13	U/L	0 - 41 U/L
Basophils	27-Nov-1995	.3	%	0 - 2.0 %
Lab Test Code/Name	Date	Lab Value	Units	Normal Range
Calcium	27-Nov-1995	2.34	MMOL/L	2.08 - 2.52
				MMOL/L
Creatinine	27-Nov-1995	80	UMOL/L	70 - 130 UMOL/L
Eosinophils	27-Nov-1995	2.2	%	0 - 10.0 %
Hematocrit	27-Nov-1995	.37	UNK	0.36 - 0.49
Hemoglobin	27-Nov-1995	7.9	MMOL/L	7.45 - 9.95
Lymphocytes	27-Nov-1995	28.6	%	21.0 - 51.0 %
Monocytes	27-Nov-1995	5	%	0.0 - 10.0
Platelets	27-Nov-1995	319	UNK	130 - 400
Total Albumin	27-Nov-1995	42	G/L	31 - 53 G/L
Total Bilirubin	27-Nov-1995	18	UMOL/L	70 - 130 UMOL/L
Total Globulin	27-Nov-1995	33	G/L	23 -41 G/L
Total Neutrophils	27-Nov-1995	63.9	%	30.0 - 70.0 %
Total Protein	27-Nov-1995	75	G/L	62 - 88 G/L
White Blood Cell Count	27-Nov-1995	6.3	UNK	4.5 - 13.0

Medical History Remarks:

Reporter Attribution for Primary AE: Possibly Related/Suspected

Reason for Seriousness: Overdose

#### PID 377.005.00232

Primary Adverse Experience: Myoclonus/Repetitive Involuntary Muscle Contraction

{Neck and Arms}

Demography: Age-15 years Date of Birth-31-Jul-1980 Sex-Male

**Height-**170.0 cm **Weight-**57.0 kg **Race-**White

Country: Belgium

Medical History: Asthma

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine
Start Date: 07-Dec-95
Stop Date: 24-Feb-96

AE Remarks:

Case, reference number 1996003240-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a male aged 15. At the time of the event, the patient had asthma and was taking Ventolin (salbutamol) starting in May 1985.

On 7 December 1995, the patient received his first treatment with study medication for major depression. Approximately 78 days later, on 22 February 1996, the patient developed repetitive involuntary muscle contractions in the neck and arms. The patient was hospitalized for observation. The events resolved the following day without treatment. The patient elected to discontinue study medication on 24 February 1996 due to the events of 22 February.

The investigator considers that the event is possibly related to treatment with study medication.

Concomitant Drugs: Start End

Ventolin (Salbutamol) -May-1985

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Possibly Related/Suspected

Reason for Seriousness: Hospitalization Required

### PID 377.005.00234

Primary Adverse Experience: Depression/Worsening Depression

Demog Age-15 Date of Birth-09-Jul-raphy: 9ears 1980 Femal

**Height-** Weight-57.0 kg Race-162.0 cm White

Country: Belgium

Study Depression/Affective Disorders

Diagnosis:

Study Drug: Paroxetine

 Start Date
 Stop Date

 04-Apr-1996
 18-Apr-1996

 19-Apr-1996
 24-Apr-1996

 25-Apr-1996
 03-May-1996

#### AE Remarks:

Case, reference number 1996006421-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 15.On 4 April 1996, the patient received her first treatment with study medication for depression. Approximately thirty days later, on 3 May 1996, the patient developed worsening depression. Study medication was discontinued and the patient was treated with Floxyfral (fluvoxamine). The patient was hospitalised three days later on 6 May 1998.

The patient was reported to have recovered on 16 May 1996.

The investigator considers that the event is unrelated to treatment with study medication.

Concomitant Drugs:	Start	End
Treatment Drugs:	Start	End
Floxyfral (Fluvoxamine)	03-May- 1996	03-May- 1996
Floxyfral (Fluvoxamine)	04-May- 1996	05-May- 1996
Floxyfral (Fluvoxamine)	06-May- 1996	06-May- 1996
Floxyfral (Fluvoxamine)	07-May- 1996	14-Jul- 1996
Floxyfral (Fluvoxamine	15-Jul-1996	13-Aug- 1996
Floxyfral (Fluvoxamine)	14-Aug- 1996	26-Feb- 1997

Lab Remarks:

Lab TestDatLabUnNormalCode/NameeValueitsRange

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason for Seriousness: Disabling, Incapacitating,

Hospitalization Required

### PID 377.005.09286

Primary Adverse Experience: Depression/Worsening of Depression

Demography: Age-13 years Date of Birth-02-Jun-1983 Sex-Female

**Height-**166.0 cm **Weight-**48.0 kg **Race-**White

Country: Belgium

Medical History: Anorexia Nervosa

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo Run-In
Start Date 26-Nov-1996
Stop Date 09-Dec-1996

AE Remarks:

Case, reference number 1997001355-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 13. At the time of the event, the patient had anorexia nervosa.

On 26 November 1996, this patient with major depression received her first treatment with placebo run-in. Approximately fourteen days later, on 9 December 1996, the patient developed worsening depression and was hospitalised. The patient was treated for the event with Seroxat (paroxetine) and placebo run-in was discontinued on 9 December 1996. The patient was reported to have recovered on 20 December 1996.

The investigator considers that the event is unrelated to treatment with placebo run-in and is possibly associated with the patient's anorexia nervosa.

Concomitant Drugs: Start End

Treatment Drugs: Start End

Seroxat 10-Dec-1996

Lab Remarks:

Lab Test Date Lab Value Units Normal Range

Code/Name

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason for Seriousness: Disabling, Incapacitating, Hospitalization

Required

### PID 377.009.00225

Primary Adverse Experience: Emotional Lability/Suicide Attempt

Demography: Age-18 years Date of Birth-02-Jun-1979 Sex-Female

Height- Weight- Race-

Country: Belgium

Medical History: Asthma, Contraception, Suicide Attempt (Overdose)

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine
Study Start: 07-Mar-1997
Study Stop: 25-May-1997

AE Remarks:

Case, reference number 1997013173-1,is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 18. The patient's past medical history included suicide attempt by overdose two years prior to entry in study, and at the time of the event, the patient had asthma and was taking Becotide (beclomethasone) starting January 1991 and Femodene (gestodene) starting in July 1996.

On 7 March 1997, the patient received her first treatment with study medication for depression. Approximately eighty days later, on 25 May 1997, the patient attempted suicide using an overdose of study medication. The patient was hospitalised but was given no treatment medication as there were no signs or symptoms associated with the overdose.

Study medication was discontinued on 25 May 1997. The patient was reported to have recovered on 25 May 1997.

The investigator considers that the event is unrelated to treatment with study medication.

Concomitant Drugs: Start End

Becotide (Beclomethasone) 01-Jan-1991 Femodene (Gestodene) 01-Jul-1996

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason for Seriousness: Hospitalization Required, Overdose

#### PID 377.010.00068

Primary Adverse Experience: Emotional Lability/Overdose of Alprazolam

{Deliberate/Asymptomatic}

Demography: Age-15 years Date of Birth-05-Nov-1981 Sex-Female

Height- Weight-52.0 kg Race-White

Country: Italy

Medical History: Insomnia

Study Diagnosis: Depression/Affective Disorders Study Drug: Invest.Broke Blind-Placebo

 Start Date:
 Stop Date:

 25-Apr-1996
 21-May-1996

 29-Feb-1996
 13-Mar-1996

 14-Mar-1996
 24-Apr-1996

AE Remarks:

Case, reference number 1996007005-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 15.

On 29 February 1996, the patient received her first treatment with study medication for unipolar major depression. Approximately eighty three days later on 21 May 1996, the patient took an intentional overdose of the benzodiazipine, Xanax (alprazolam) (21 tablets). The following day she appeared more tired than usual and, after telling her mother what she had done, was taken to hospital. No treatment was required and the patient was discharged the same day. The investigator broke the blind and it was revealed that the patient was receiving placebo. Study medication was discontinued on 21 May 1996. The patient was reported to have recovered on 22 May 1996. The patient was admitted to the psychiatric unit of another hospital on 24 May 1996.

The investigator considers that the event is unrelated to treatment with study medication.

Concomitant Drugs: Start End

Xanax (Alprazolam) 21-May-1996 21-May-1996

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Hospitalization Required, Potentially Life

Threatening

#### PID 377.011.00061

Primary Adverse Experience: Emotional Lability/Overdose (Intentional)

Demography: Age-17 years Date of Birth-01-May-1978 Sex-Female

**Height-**150.0 cm **Weight-**43.0 kg **Race-**White

Country: Italy

Medical History: Proctitis

Study Diagnosis: Depression/Affective Disorders

Study Drug: Nvest.Broke Blind-29060: 40 mg

 Start Date:
 Stop Date:

 07-Nov-1995
 13-Nov-1995

 13-Nov-1995
 20-Nov-1995

 20-Nov-1995
 20-Jan-1996

AE Remarks:

Case, reference number 1996000694-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 17. The following drugs are known to have been taken by the patient prior to the event: Dipentum (olsalazina) from 10 October 1995 to 21 November 1995 for proctitis.

On 7 November 1995, the patient received her first treatment with study medication for depression. Approximately seventy five days later, on 20 January 1996, the patient took an intentional overdose of 28 tablets of study medication. The patient stated that she took the overdose because she felt nervous and was not attempting suicide. The investigator broke the blind and it was revealed that the patient was receiving paroxetine. The patient was hospitalised and a gastrolavage was performed. She was treated for the event with magnesium sulphate and activated charcoal and study medication was discontinued on 20 January 1996. The only sign of the overdose was a mild tremor of the upper extremities. The patient was reported to have recovered on 21 January 1996

The investigator considers that the event is possibly related to treatment with study medication.

Concomitant Drugs: Start End

Dipentum (Olsalazina Sod.) 10-Oct-1995 21-Nov-1995

Treatment Drugs: Start End

Mgso4 (Magnesium Sulphate) 20-Jan-1996 21-Jan-1996 Activated Charcoal 20-Jan-1996 21-Jan-1996

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range ALAT 21-Jan-1996 39 Ui/L 7-56

ALAT 01-Feb-1996 12 U/L

Alkaline Phosphatase	21-Jan-1996	63	Ui/L	38-126
Alkaline Phosphatase	01-Feb-1996	45	U/L	22 - 130
ASAT	21-Jan-1996	30	Ui/L	5-46
ASAT	01-Feb-1996	14	U/L	
Creatinine	21-Jan-	7	Mg/Dl	.7-1.5
Creatinine	01-Feb-1996	70	Umol/L	70 - 130
Glucose	21-Jan-1996	74	Mg/Dl	65-110
Hematocrit	21-Jan-1996	6.49	10^3/U1	4-10
Hematocrit	01-Feb-1996	.4	U	
Total Bilirubin	21-Jan-1996	.74	Mg/Dl	.2-1.3
Total Bilirubin	01-Feb-1996	12	Umol/L	6 - 22

Medical History Remarks:

Reporter Attribution For Primary AE: Possibly Related/Suspected

Reason For Seriousness: Hospitalization Required, Overdose

Treatment Drugs:

# PID 377.023.00170

Primary Adverse Ex	perience:	Alcohol Abuse/Alcohol Abuse		
Other Adverse Expe	rience:	Aggression, Amnesia		
Demography:	<b>Age-</b> 16 years <b>Height-</b> 176.0 cm	Date of Birth-19-Dec-1979 <b>Weight-</b> 55.0 kg	Sex-Male Race-White	
Country:		Netherlands		
Medical History:		Aggressive Reaction, Alc Amnesia	ohol Abuse,	
Study Diagnosis:		Depression/Affective Dis	orders	
Study Drug:		Paroxetine		
Start Date:		20-Mar-1996		
Stop Date:		27-Apr-1996		
AE Remarks:				
	udy, referring to a m	s a clinical trial report from study numale aged 16. The patient's past medication and amnesia.		
On 20 March 1996, the patient received his first treatment with study medication for adolescent major depression. Approximately forty one days later, on 29 April 1996 and two days following the last dose, the patient had an aggressive outburst following alcohol abuse, in which he attacked his mother and ruined furniture. His mother called for the police, who put him in a cell for one night. After psychiatric evaluation the patient was released the next morning. The patient and hi mother requested that he be hospitalised voluntarily for a "time-out", because they were both anxious that more aggressive assaults would follow. He was admitted to hospital on 2 May 1996 He was discharged after a week on 8 May 1996, whereafter further out-patient treatment was offered. Study medication was discontinued on 27 April 1996. The patient was reported to have recovered on 30 April 1996				
The investigator con	siders that the event	is unrelated to treatment with study m	edication.	
		ndy he did not report any episodes of a that minor events have occurred in the		
Concomitant Drugs:		Start End		

Start

End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

When the patient was screened for this study he did not report any episodes of alcohol abuse with accompanied aggression. It is estimated that minor events of this type have occurred in the past, but this was the most severe event.

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Hospitalization Required

#### PID 377.029.00006

Primary Adverse Experience: Infection/Tick Bite Fever

Other Adverse Experience: Pharyngitis, Fever

Demography: Age-14 years Date of Birth-22-Oct-1981 Sex-Male

**Height-**167.0 cm Weight- **Race-**White

Country: South Africa

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine
Start Date: 25-Aug-1995
Stop Date: 01-Dec-1995

AE Remarks:

Case, reference number 1996001022-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a male aged 14. On 25 August 1995, the patient received his first treatment with study medication for depression. Approximately sixty eight days later, on 31 October 1995, the patient developed pharyngitis and fever. He was treated with Petercillin (ampicillin) and Disprin (aspirin). On 2 November 1995, he was diagnosed to be suffering from tick bite fever and was hospitalised. He was treated for the event with Keflex (cephalexin). Study medication was not discontinued. The patient was reported to have recovered on 9 November 1995.

He was discharged from hospital with continuing treatment of cephalexin and Difenac (diclofenac).

The investigator considers that the event is unrelated to treatment with study medication

Concomitant Drugs: Start End

Treatment Drugs: Start End

 Petercillin (Ampicillin)
 31-Oct-1995
 02-Nov-1995

 Keflex (Cephalexin)
 03-Nov-1995
 09-Nov-1995

 Difenac (Diclofenac)
 06-Nov-1995
 08-Nov-1995

 Disprin (Aspirin)
 31-Oct-1995
 02-Nov-1995

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Hospitalization Required

#### PID 377.029.00015

Primary Adverse Experience: Convulsion/Tonic Clonic Convulsion

Demography: Age-13 years Date of Birth-09-Jan-1983 Sex-Male

**Height-**154.0 cm **Weight-**43.0 kg **Race-**White

Country: South Africa

Medical History: Headache

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

**Start Date:** 21-Feb-1996

**Stop Date:** 27-Apr-1996

AE Remarks:

Case, reference number 1996005745-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a male aged 13.

On 21 February 1996, the patient received his first treatment with study medication for depression. Approximately sixty seven days later on 27 April 1996, the patient experienced an episode of loss of consciousness associated with tonic clonic convulsions. This episode lasted approximately 5 minutes. The patient was taken to hospital casualty where a diagnosis of a drug side effect was made. Study medication was discontinued on 27 April 1996. The patient was given Voltaren (diclofenac) for headache. Another episode occurred on 29 April 1996, two days after receiving the last dose of study medication, and lasted approximately 10 minutes. The event resolved spontaneously without medication. The patient's consciousness was clear with no confusion or neurological signs present. On 30 April 1996, two further convulsive episodes occurred. The patient was admitted to the neurology department for observation and further investigations. Atypical clonic convulsions were observed while he was in the ward. Corneal reflexes were present during the attack. Immediately after the attack his consciousness was clear. No urinary incontinence was noted. Electrocardiogram and CT brain scans were performed. No abnormalities were noted. The investigator made a final diagnosis of pseudoseizures. The patient was reported to have recovered.

The investigator now considers that these events are unrelated to treatment with study medication.

The following facts are also relevant in this case : the patient's father suffers from epilepsy following removal of a brain tumour.

Concomitant Drugs: Start End

Voltaren 27-Apr-1996 27-Apr-1996

Paracetamol 29-Apr-1996

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

The patient's father suffers from epilepsy following removal of a brain tumour.

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason for Seriousness: Disabling, Incapacitating, Serious per SmithKline Beecham

Policy

### PID 377.029.00024

Primary Adverse Experience: Emotional Lability/Suicide Attempt

Other Adverse Experience: Self-Damaging Acts, Upper Respiratory Tract Infection,

Headache, Nausea, Tiredness, Diarrhoea

Demography: Age-17 years Date of Birth-15-Mar-1979 Sex-Female

**Height-**164.5 cm **Weight-**60.0 kg **Race-**White

Country: South Africa

Medical History: Cold, Decongestant, Diarrhoea, Headache, Kidney Problem,

Knee Problem Due to Sport, Non-Steroidal Anti-Inflammatory,

Sinusitus

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo

Start Date: 06-Mar-1996

Stop Date: 01-May-1996

AE Remarks:

Case, reference number 1996005251-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 17. The patient's past medical history included a kidney problem (not specified) and knee problem due to sport, and at the time of the event, the patient had sinusitus, headache and diarrhoea and was taking clarityne, mefanamic acid and Kantrexil (kanamycin; dimevamide; pectin; bismuth; attapulgite). The following drugs are also known to have been taken by the patient prior to the event: paracetamol and aspirin.

On 6 March 1996, the patient received her first treatment with study medication for depression. Approximately thirty days later, on 4 April 1996, the patient attempted suicide using a pair of scissors, after visiting her mother and being molested by her brother. She stopped when her mother came into the room. The wound was not serious. She has also tried to burn herself with a cigarette lighter. These self-damaging acts were ongoing at the time of reporting. Study medication was discontinued on 1 May 1996. The patient was withdrawn from the study and referred for psychotherapy.

The investigator considers that these events are unrelated to treatment with study medication. In their opinion, other possible etiological factors include molestation by her brother.

Concomitant Drugs	Start	End
Clarityne	29-Mar-1996	03-Apr-1996
Mefalgic (Mefanamic Acid)	02-Apr-1996	07-Apr-1996
Kantrexil (Kanamycin, Dimevamide, Pectin,	02-Apr-1996	03-Apr-1996
Bismuth, Attapulgite)		
Feldene (Piroxicam)	16-Apr-1996	24-Apr-1996

Solphyllex (Theiphylline, Etophylline,	16-Apr-1996	24-Apr-1996
Diphenylpyraline, Citrate)		
Panadol (Paracetamol)	11-Mar-1996	11-Mar-1996
Panadol (Paracetamol)	23-Mar-1996	23-Mar-1996
Disprin (Aspirin)	23-Mar-1996	23-Mar-1996
Treatment Drugs:	Start	End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

The patient has a medical history of a kidney problem and a knee problem due to sport.

Reporter Attribution For Primary AE: Unrelated/Not Related

Reason For Seriousness: Disabling, Incapacitating, Significant Hazard

#### PID 377.030.00181

Primary Adverse Experience: Emotional Lability/Suicidal Risk

Other Adverse Experience: Worsening Depression, Hypertension

Date Of Birth-15-Feb-1978 Demography: Age-18 years Sex-Female

> **Height-**165.0 cm Weight-53.8 kg Race-White

Country: Canada

Medical History: Drug Abuse, Headaches, High Blood Pressure, Prophylaxis Against

Measles

Study Diagnosis: Depression/Affective Disorders

Paroxetine Study Drug:

Start Date Stop Date 13-Feb-1996 27-Feb-1996 28-Feb-1996 04-Mar-1996 05-Mar-1996 09-Apr-1996

AE Remarks:

Case, Reference Number 1996005329-1, is a clinical trial report from Study Number 29060 377, which is a blinded study, referring to a female aged 18. The patient's medical history included drug abuse, high blood pressure and headaches. The following drugs are known to have been taken by the patient prior to the event: paracetamol in February 1996 and measles vaccine on 9 April 1996.

On 13 February 1996, the patient received her first treatment with study medication for depression. approximately fifty seven days later, on 9 April 1996, the patient attended the clinic and her condition had worsened. She was noted to be hostile, hopeless and helpless and had written suicide notes. In light of this worsening depression, suicidal risk and possible drug abuse, study medication was discontinued on 9 April 1996 and the patient was hospitalised. The patient was treated for the event with lorazepam, fluvoxamine, sertraline and trazadone. The patient was reported to have recovered on 3 May 1996.

The investigator considers that the event is unrelated to treatment with study medication.

Concomitant Drugs:	Start	End
Measle Vaccine	09-Apr-1996	09-Apr-1996
Tylenol (Paracetamol)	06-Feb-1996	10-Feb-1996
Treatment Drugs:	Start	End
Lorazepam	09-Apr-1996	24-Apr-1996
Fluvoxamine	10-Apr-1996	11-Apr-1996

Sertraline 11-Apr-1996

Trazadone 10-Apr-1996 29-Apr-1996

Lab Remarks:

Blood Pressure (02-Apr-96) 150/100 Supine, 140/95 Standing. Re. Drug Abuse - Results will be provided when available.

Lab Test Code/Name	Date	Lab Value	Units	Normal Range
Hemoglobin	11-Apr-1996	139	G/L	115 - 160
Leucocytes	11-Apr-1996	3.9	10^9/L	4 - 10
Platelets	11-Apr-1996	249	10^9/L	150 - 400
Red Blood Cell Count	11-Apr-1996	4.58	10^121	

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason for Seriousness: Hospitalization Required

#### PID 377.040.00298

Primary Adverse Experience: Depression/Deterioration Depression

Demography: Age-17 years Date of Birth-23-Mar-1979 Sex-Female Race-White

**Height-**171.0 cm Weight-66.0 kg

Country: Belgium

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

Start Date: 03-Dec-1996

Stop Date: 16-Dec-1996

AE Remarks:

Case, reference number 1996018164-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 17.

On 3 December 1996, the patient received her first treatment with study medication for major depression. Approximately fourteen days later, on 16 December 1996, the patient developed deterioration of her depression with suicidal tendency and was hospitalised. The patient was treated for the event with Effexor (venlafaxine hydrochloride) and study medication was discontinued on 16 December 1996. The patient was reported to have recovered on 6 January 1997.

The investigator considers that the event is unrelated to treatment with study medication.

The following facts are also relevant in this case: the patient had a fight with her boyfriend on 14 December 1996, which was thought by the investigator to have possibly caused psychogenic decompensation, resulting in deterioration of her condition.

Concomitant Drugs: Start End

Treatment Drugs: Start End

Effexor (Venlafaxine Hydrochloride) 25-Sep-1997 01-Apr-1998

Lab Remarks:

Lab Test Code/Name	Date	Lab Value	Units	Normal Range
Hemoglobin	17-Dec-1996	8.65	Mmol/L	7.45 - 9.95
Platelets	17-Dec-1996	173	Gi/L	130 - 400
Segmented Neutrophils	17-Dec-1996	70.9	%	30 - 70
White Blood Cell Count	17-Dec-1996	6.9	Gi/L	4.5 - 13

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason for Seriousness: Hospitalization Required

#### PID 377.041.00289

Primary Adverse Experience: Kidney Pain/Renal Colic

Demography: Age-18 years Date of Birth-28-Sep-1978 Sex - Female

Height-164.0 cm Weight-81.0 kg Race-Oriental

Country: Belgium

Medical History: Appendectomy, Cough, Fatigue, Hypotension, Infectious Mononucleosis,

Muscle Pain

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

 Start Date:
 Stop Date:

 17-Oct-1996
 15-Jan-1997

 07-Nov-1996
 13-Nov-1996

 14-Nov-1996
 15-Jan-1997

AE Remarks:

Case, reference number 1997002532-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 18. The patient's past medical history included appendectomy, hypotension, cough, fatigue and muscle pain, and at the time of the event, the patient had infectious mononucleosis and was taking Defatyl (levocarnitine; magnesium aspartate) and Synergum (nutritional supplement). The following drugs are also known to have been taken by the patient prior to the event: Bronchosedal (codeine phosphate; sodium benzoate; aconite tincture; cherry-laurel).

On 17 October 1996, the patient received her first treatment with study medication for depression. Approximately eighty nine days later, on 12 January 1997, the patient developed renal colic and was hospitalised. The patient was not treated for the event but study medication was interrupted. The patient was reported to have recovered on 13 January 1997.

The investigator considers that the event is probably unrelated to treatment with study medication.

Concomitant Drugs	Start	End
Defatyl	29-Oct-1996	
Synergum (Nutritional Supplement)	29-Oct-1996	
Clamoxyl (Amoxicillin)	22-Oct-1996	01-Nov-1996
Regulton (Amezinium Methylsulphate)	21-Oct-1996	30-Oct-1996
Rhinofebral (Paracetamol, Chlorpheniramine Maleate	21-Oct-1996	09-Nov-1996
Ascorbic Acid)		
Bronchosedal	20-Dec-1996	06-Jan-1997
Perdolan	29-Oct-1996	04-Nov-1996

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Probably Unrelated/Unlikely

Reason for Seriousness: Disabling, Incapacitating, Hospitalization Required

#### PID 377.041.00290

Primary Adverse Experience: Anxiety/Hospitalisation Due To Degradation Of Family

Life (Observation) { Unable To Cope }

Demography: Age-15 years Date of Birth-20-Feb-1981 Sex-Female

**Height-**140.0 cm **Weight-**35.0 kg **Race-**White

Country: Belgium

Medical History: Acne, Infectious Mononucleosis, Measles,

Pruritus

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

 Start Date:
 Stop Date:

 17-Oct-1996
 20-Oct-1996

 31-Oct-1996
 20-Jan-1997

AE Remarks:

Case, reference number 1997001337-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 15.

The patient's past medical history included measles and infectious mononucleosis, and at the time of the event, the patient had acne and pruritus and was taking minocycline and doxepin starting in November 1996. On 17 October 1996, the patient received her first treatment with study medication for depression. Approximately seventy four days later, on 8 January 1997, the patient was hospitalised for observation due to degradation of family life. No action was taken with respect to study medication. The patient was reported to have recovered on 23 April 1997.

The investigator considers that the event is unrelated to treatment with study medication.

Concomitant Drugs: Start End

Minocin (Minocycline)26-Nov-1996Sinequan (Doxepin26-Nov-1996

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Measles.

Infectious mononucleosis 1994.

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason for Seriousness: Hospitalization Required

#### PID 377.041.00292

Primary Adverse Experience: Hysteria/Fit of Hysterics

Demography: Age-15 years Date of Birth-03-Apr-1982 Sex-Female Race-White

**Height-**163.0 cm Weight-40.0 kg

Country: Belgium

Medical History: Anxiety

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine Start Date: 01-May-1997 Stop Date: 14-May-1997

AE Remarks:

Case, reference number 1997013996-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 15. The patient's medical history included anxiety. On 1 May 1997, the patient received her first treatment with study medication for depression.

Approximately nine days later, on 9 May 1997, the patient was hospitalised due to a fit of hysterics. Study medication was discontinued on 14 May 1997. The patient was reported to have recovered on 9 May 1997, but was still hospitalised at the time of reporting.

The investigator considers that the event is unrelated to treatment with study medication.

Concomitant Drugs: Start End

12-May-1997 13-May-1997 Temesta (Lorazepam)

Treatment Drugs: Start End

Lab Remarks:

Lab Value Lab Test Code/Name Date Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Hospitalization Required

#### PID 377.041.00294

Primary Adverse Experience: Emotional Lability/Overdose (Tentative Overdose)

Equals Suicide Attempt

Demography: Age-14 years Date of Birth-13-Sep-1983 **Sex-**Female

**Height-**158.0 cm **Weight-**60.0 kg **Race-**White

Country: Belgium

Medical History: Throat Ache

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo

Start Date: 18-Dec-1997

Stop Date: 24-Mar-1998

AE Remarks:

Case, reference number 1998008002-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 14. The patient had taken Panadol (paracetamol) prior to the event, in February 1998, for a sore throat.

On 18 December 1997, the patient received her first treatment with study medication for depression. Approximately eighty seven days later, on 14 March 1998, the patient attempted suicide by the ingestion of paracetamol tablets (20 x 500mg) and was hospitalised. The patient was treated for the event with activated charcoal and study medication was discontinued on 24 March 1998 at visit 10. The patient was reported to have recovered on 14 March 1998, but at the time of reporting, she remained hospitalised.

The investigator considers that the event is possibly related to treatment with study medication. The reason for this causality is that the patient had just started the down titration phase of the study and the investigator considers that the event could have been lack of efficacy due to diminuation of dosage.

Concomitant Drugs: Start End

 Dafalgan (Paracetamol)
 14-Mar-1998
 14-Mar-1998

 Panadol
 16-Feb-1998
 20-Feb-1998

Treatment Drugs: Start End

Carbon (Acivated Charcoal) 14-Mar-1998 14-Mar-1998

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Possibly Related/Suspected

Reason For Seriousness: Hospitalization Required, Overdose

### PID 377.042.00310

Primary Adverse Experience: Emotional Lability/Parasuicide

Demography: Age-15 Date of Birth-31-Mar-1981 Sex-Female

years

**Height- Weight-**96.0 kg **Race-**Other

171.0 cm

Country: South Africa

Medical History: Cyst Removed from Left Side of Neck, Toothache

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo Run-In

Start Date: 12-Nov-1996

Stop Date: 10-Dec-1996

AE Remarks:

Case, reference number 1996017816-1, is a clinical trial report from study number 29060/377, which is a blinded study, referring to a female aged 15.

The patient's past medical history included having a cyst removed from the side of her neck, and at the time of the event, the patient was taking paracetamol for toothache.

On 12 November 1996, the patient started taking 29060 (placebo run-in) for depression. Approximately twenty four days later on 5 December 1996, the patient impulsively slit her wrists following an altercation with her mother. The wounds were superficial and were not stitched.

The patient was withdrawn from the study on 10 December 1996, before any active medication was received, because of the poor response by the patient, the parasuicide and the risk of further attempts.

The investigator considered that the event was possibly related to the treatment medication.

Concomitant Drugs: Start End

Panado (Paracetamol) 25-Oct-1996

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Possibly Related/Suspected

Reason For Seriousness: Suicide Attempt

#### PID 377.042.00315

Primary Adverse Experience: Anxiety/Anxiety

Other Adverse Experience: Agitation Overdose {Intentional Asymptomatic}

Demography: Age-15 years Date Of Birth-27-Feb-1981 Sex - Female

**Height-**154.0 cm **Weight-**61.0 kg **Race-**Other

Country: South Africa

Medical History: Appendicitis {Appendectomy}, Insomnia, Tonsilitis {Tonsillectomy}

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

Start Date: **14-Jan-1997** 

Stop Date: 27-Jan-1997

AE Remarks:

Case, reference number 1997002644-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 15. The patient's past medical history included appendectomy and tonsillectomy, and at the time of the event, the patient was taking flunitrazepam for insomnia.

On 14 January 1997, the patient received her first treatment with study medication for depression. Approximately eight days later, on 21 January 1997, the patient complained of increasing anxiety and agitiation since starting study medication. The patient found it very difficult in the class room situation where she felt uncomfortable and out of control. She maintained that she had never felt this way before and denied any situational component for her anxiety.

The investigator decided to see if the condition would settle spontaneously while on study medication (level 1). Until the 27 January 1997 the patient was seen on an alternative day basis. During this period there was no change in her level of agitation. The patient was incapacitated to the extent that she no longer attended classes. Study medication was discontinued on 27 January 1997. The patient presented on 31 January 1997 in a state of severe agitation and distress and was hospitalised. The patient told the investigator that on the previous night (30 January 1997) she had taken an overdose of 5 Panados, 1 tranquilizer (type unspecified) and 1 herbal hypnotic. No situational precipitant was elicited. The patient was reported to have recovered on 30 January 1997.

The investigator considers that the agitation and anxiety are definitely related and the overdose is possibly related to treatment with study medication.

Concomitant Drugs: Start End

Insom (Flunitrazepam) 15-Jan-1997 15-Jan-1997

Treatment Drugs:StartEnd

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

The patient's past medical history included appendicitis (1989) and tonsillitis (1990).

Reporter Attribution for Primary AE: Definitely Related

Reason For Seriousness: Incapacitating, Hospitalization Required

# PID 377.042.00317

Primary Adverse Experience:		Unintended Pregnancy/Pregnancy		
Demography:	Age-18 years Height- 156.0 cm	Date of Birth- Weigh-61.0 k	05-Sep-1978	Sex-Female  Race-Other
Country:	South Africa			
Study Diagnosis:	Depression/A	ffective Disorders		
Study Drug: Start Date: Stop Date:	Paroxetine <b>26-Feb-1997 11-Mar-1997</b>			
AE Remarks:				
Case, reference number 19 which is a blinded study, r			port from study	number 29060 377,
On 26 February 1997, the Approximately fourteen da carried out a home pregnat laboratories on 12 March 11 March 1997.	ays later on 11 ncy test which	March 1997, at viswas positive. A fu	sit 3, the patient arther test perof	mentioned that she had rmed at the local
The patient gave birth to a and the baby's birth weight was reported to be healthy	t was 3.5kg. T	he patient was con		
The investigator considers	that the event	is unrelated to trea	tment with stud	ly medication.
Concomitant Drugs:			Start	End
Treatment Drugs:			Start	End
Lab Remarks:				
Lab Test Code/Name	Date	Lab Value	Units	Normal Range
Medical History Remarks:				
Reporter Attribution for Pr	rimary AE:	Unrela	ated/Not Relate	d
Reason for Seriousness:				

### PID 377.042.00554

Primary Adverse Experience: Accidental Overdose/Overdose

(Asymptomatic){Accidental}

Other Adverse Experience: Impulsive Act

Demography: Age-16 years Date Of Birth-18-May-1981 Sex-Female

**Height-**152.0 **Weight-**57.0 kg **Race-**Other

cm

Country: South Africa

Medical History: Epilepsy, Influenza, Meningitis, Tonsillectomy, Urinary Tract Infection

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

Start Date: **13-Nov-1997** 

Stop Date: 09-Mar-1998

AE Remarks:

Case, reference number 1998001955-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 16 years. The patient's past medical history included tonsillectomy, epilepsy, meningitis, urinary tract infection and influenza. The patient had received unspecified antibiotics from 10 to 14 January 1998.

On 13 November 1997, the patient received her first treatment with study medication for major unipolar depression. Approximately sixty nine days later, on 19 January 1998 at 16:00 hours, the patient took an overdose of six capsules of study medication. The overdose was considered an "impulsive act" and accidental. The patient was not hospitalised and reported no adverse reactions as a result of the overdose. Study medication was not discontinued. The most recent information received on 20 January 1998 reports that the patient has fully recovered.

The patient received her last dose of study medication on 09 March 1998.

The investigator considers that the event is unrelated to treatment with study medication. In their opinion, other possible etiological factors include the fact that the patient had an argument with her mother.

Concomitant Drugs Start End

Antibiotic 10-Jan-1998 14-Jan-1998 Antibiotic 23-Feb-1998 25-Feb-1998

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Overdose

#### PID 377.042.00555

Primary Adverse Experience: Decreased Appetite/Decreased Appetite

Other Adverse Experience: Agitation, Dizziness, Insomnia, Lability of Mood,

Nausea

Demography: Age-16 years Date Of Birth-12-Aug-1981 **Sex-**Female

**Height-**175.0 cm **Weight-**54.5 kg **Race-**White

Country: South Africa

Medical History: Acne, Panic Attacks, Whiplash

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

Start Date: **13-Nov-1997** 

Stop Date: 11-Dec-1997

AE Remarks:

Case, reference number 1997029491-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 16. The patient's past medical history included whiplash and panic attacks, and at the time of the event, the patient was taking lymecycline for acne and alprazolam for agitation.

On 13 November 1997, the patient received her first treatment with study medication for depression. Approximately thirteen days later, on 26 November 1997, the patient experienced decreased appetite, nausea, agitation, insomnia and dizziness. This was within seven days of study medication being increased to level 2. When study medication was increased to level 3, the conditions became more severe. Study medication was discontinued on 11 December 1997. At the time of reporting the events were all ongoing.

The investigator considers that these events are definitely related to treatment with study medication.

Concomitant Drugs: Start End

Tetralysal (Lymecycline) 01-Jun-1995

Treatment Drugs: Start End

Xanor (Alprazolam) 01-Sep-1995

Lab Remarks:

Lab Test Date Lab Value Units Normal Range

Code/Name

Medical History Remarks:

Panic attacks.

Reporter Attribution For Primary AE: Definitely Related

Reason For Seriousness: Disabling, Incapacitating, Significant Hazard,

Contraindication

#### PID 377.042.00557

Primary Adverse Experience: Angioedema/Severe Facial Angioedema {Allergic}

Demography: Age-17 years Date of Birth-16-Aug-1980 Sex-Female

**Height-**158.0 **Weight-**46.5 kg **Race-**Other

cm

Country: South Africa

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo Run-In

Start Date: **05-Nov-1997** 

Stop Date: 18-Nov-1997

AE Remarks:

Case, reference number 1997027548-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 17.

The patient received her placebo run-in treatment on 5 November 1997 for depression. On 18 November 1997, the patient maintained she was experiencing a pruritic rash following ingestion of the study medication. This concern was highlighted by the patient on 18 November 1997 at a baseline visit. She received her last dose of placebo run-in medication on 18 November 1997.

On 19 November 1997, the patient presented with acute allergic facial angioedema accompanied by swelling of the lips. The investigator diagnosed an 'acute allergic reaction' to the study placebo run-in medication. The patient was treated for the event with Fabahistin anti-histamine therapy. The patient refused to come into clinic on 20 November 1997 due to the swelling. Her mother reported that the swelling was still apparent but was gradually resolving. The patient recovered on 21 November 1997.

The investigator considered the event to be definitely related to treatment with placebo in the runin phase of the study.

The patient did not receive active study medication.

Concomitant Drugs: Start End

Treatment Drugs: Start End

Fabahistin (Mebhydrolin Napadisylate) 19-Nov-1997 21-Nov-1997

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Definitely Related

Reason For Seriousness: Disabling, Incapacitating

#### PID 377.042.00561

Primary Adverse Experience: Vomiting/Vomiting

Other Adverse Experience: Nausea, Agitation, Tremor Blurring of Vision, Dry

Mouth, Postural Hypotension

Demography: Age-14 years Date Of Birth-05-Feb-1983 Sex-Female

**Height-**166.0 cm **Weight-**52.0 kg **Race-**White

Country: South Africa

Medical History: Headache

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

Start Date: **27-Nov-1997** 

Stop Date: 30-Nov-1997

AE Remarks:

Case, reference number 1997028918-1, is a clinical study report from study number 29060 377, which is a blinded study, referring to a female aged 14. On 27 November 1997, the patient received her first treatment with study medication for major depression. Within 24 hours of receiving study medication, the patient experienced nausea, vomiting, agitation and tremor, dry mouth, blurring of vision and postural hypotension. Study medication was discontinued by the patient's parents on the 30 November 1997. The patient was reported to have recovered two days later on 2 December 1997.

The investigator considered that the nausea, vomiting, agitation and tremor were definitely related and the dry mouth, blurring of vision and postural hypotension possibly related to treatment with study medication. The investigator also noted that all events were debilitating, but the decision to discontinue study medication was confounded by the anxiety and concern of the patient's parents.

Concomitant Drugs: Start End

Myprodol (Ibuprofen; Paracetamol; Codeine Phosphate)28- 30-Nov-1997

Nov-1997

Treatment Drugs: Start End

Stementil (Prochlorperazine) 28-Nov-1997 01-Dec-1997

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Definitely Related

Reason for Seriousness: Significant Hazard, Contraindication, Side

Effect or Precaution

#### PID 377.047.00619

Primary Adverse Experience: Emotional Lability/Overdose

{Intentional}{Asymptomatic}

Demography: Age-18 years Date of Birth-05-Nov-1979 Sex-Female

**Height-**160.0 cm **Weight-**55.0 kg Race-White

Country: Belgium

Medical History: Headache, Nausea

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo Run-In

Start Date: **29-Jan-1998** 

Stop Date: 06-May-1998

AE Remarks:

Case, reference number 1998002704-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 18. At the time of the event, the patient was taking Dalfagan and Perdolan for headache (starting 15 January 1998). The following drugs are also known to have been taken by the patient prior to the event :sulpiride for nausea in December 1997.

On 24 January 1997, during the placebo run-in and prior to study medication, the patient took an intentional overdose of bromazepam and valium. It was reported that this was a cry for help from the patient. She experienced no side effects as a result of the overdose. The patient continued in the study and received her first treatment with study medication for major depression on 29 January 1998.

The investigator considers that the event is unrelated to treatment with study medication. In their opinion, other possible etiological factors include the fact that the patient had problems at home and had recently had a fight with her boyfriend.

Concomitant Drugs	Start	End
Bromazepam	24-Jan-1998	24-Jan-1998
Valium (Diazepam)	24-Jan-1998	24-Jan-1998
Dogmatil {Sulpiride}	01-Dec-1997	24-Dec-1997
Dafalgan {Paracetamol}	15-Jan-1998	28-Jan-1998
Perdolan {Acetylsalicylate; Carbromal; Codeine		
Phosphate;		
Paracetamol}	15-Jan-1998	28-Jan-1998
Treatment Drugs:	Start	End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Overdose

#### PID 377.049.00458

Primary Adverse Experience: Nervousness/Irritability

Demography: **Age-**18 years Date of Birth-09-Aug-1978 **Sex-**Female

Height-164.0 cm Weight-59.0 kg Race-Hispanic

Country: Mexico

Medical History: Pharyngitis, Vascular Headache

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo

Start Date: **01-Apr-1997** 

Stop Date: 25-Apr-1997

AE Remarks:

Case, reference number 1997015220-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 18. At the time of the event, the patient was taking ampicillin for pharyngitis. The patient had also taken acetylsalicylic acid for a vascular headache on 29 and 30 March 1997.

On 1 April 1997, the patient received her first treatment with study medication for major depression. Approximately twenty five days later, on 25 April 1997, after a family problem, she had an acute and stormy episode of irritability. She destroyed items at home, and refused to continue medication which she thought was not helping her. She did not return to the site for a visit. Two weeks later, on 9 May 1997, she was hospitalized for another episode of irritability and aggressiveness against family members. As she refused further medication, she remained hospitalised in an intensive psychotherapy program. Study medication was discontinued on 25 April 1997. The patient had not yet recovered at the time of reporting.

The investigator considers that the event is unrelated to treatment with study medication. In their opinion the irritability was associated with the patient's primary condition.

Concomitant Drugs Start End

 Ampicillin
 15-Apr-1997
 25-Apr-1997

 Acetylsalicylic Acid
 29-Mar-1997
 30-Mar-1997

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Hospitalization Required

#### PID 377.049.00479

Primary Adverse Experience: Nervousness/Irritability

Other Adverse Experience: Suicidal Intent, Syncope

Demography: Age-17 years Date of Birth-20-Jan-1980 Sex-Male

**Height-**180.0 cm **Weight-**81.5 kg **Race-**Hispanic

Country: Mexico

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

Start Date: **30-Jul-1997** 

Stop Date: 03-Sep-1997

AE Remarks:

Case, reference number 1997021843-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a male aged 17.

On 30 July 1997, the patient received his first treatment with study medication for major depression. The patient did not experience an improvement while being on study medication. He reported a syncopal episode of three minutes duration on 27 August 1997. An electrocardiogram taken on 27 August 1997 was normal. The investigator reported that this event was non-serious and probably unrelated to the study medication.

Approximately thirty six days after the start of study medication, on 3 September 1997, the patient became very irritable and had an outburst. He was seen by a psychologist who was not involved in the study. The psychologist discontinued study medication on 3 September 1997, without consulting the investigator. No treatment replacement medication was started. The investigator reported that the irritability was the manifestation of the patient not showing any improvement and that this was considered to be "lack of effect".

Without any treatment the patient demonstrated a serious suicidal intent on 5 September 1997 and was hospitalised on 8 September 1997 for both his suicidal intent and his irritability. The patient was started on fluoxetine 20 mg and an unknown benzodiazepine for sedation.

The investigator indicated that the irritability was possibly related to the study medication and the suicidal intent was unrelated to the study medication. The investigator also indicated that the entire episode was associated with the patient's primary condition under study.

Concomitant Drugs: Start End

Treatment Drugs: Start End

Fluoxetine 08-Sep-1997

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Possibly Related/Suspected

Reason for Seriousness: Hospitalization Required

Race-Hispanic

#### PID 377.049.09576

Primary Adverse Experience: Psychosis/Psychosis

Demography: Age-18 years Date of Birth-19-Jan-1979 Sex-Male

**Height-**160.0 Weight-45.3 kg

cm

Country: Mexico

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo Run-In Start Date: **04-Jul-1997**Stop Date: 08-Jul-1997

AE Remarks:

Case, reference number 1997028381-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a male aged 18.

On 4 July 1997, prior to receiving study medication for unipolar major depression, during the placebo run-in phase of the study, the patient developed several complaints which evolved into a severe psychotic episode with mutism, paranoid ideation, confusion and agitation. He was hospitalised from 7 to 25 July 1997. The final diagnosis was schizophreniform disorder. The patient was treated with haloperidol for psychosis and biperiden for Parkinsonism-like symptoms. Study medication was discontinued on 8 July 1997 (the day the patient's mother reported the adverse event) and the patient was withdrawn from the study.

The investigator considers that the psychosis is unrelated to treatment with placebo run-in and associated with schizophreniform disorder.

Concomitant Drugs: Start End

Treatment Drugs: Start End

Haloperidol 11-Jul-1997 Biperiden 17-Jul-1997

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Hospitalization Required

#### PID 377.053.00508

Primary Adverse Experience: Emotional Lability/Suicide Attempt

Date of Birth-28-Mar-1983 Sex-Female Demography: Age-14 years

**Height-**163.0 cm Weight-57.5 kg Race-White

Country: Argentina

Medical History: Headache, Postprandial Abdominal Pain

Study Diagnosis: Depression/Affective Disorders

Study Drug: Paroxetine

Start Date: 17-Dec-1997

Stop Date: 10-Feb-1998

AE Remarks:

Case, reference number 1998004058-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 14. The patient's past medical history included spasmodic bronchitis, contact dermatitis and orthostatic hypotension. At the time of the event, the patient was suffering from postprandial abdominal pain and headache.

On 17 December 1997, the patient received her first treatment with study medication for unipolar major depression. Approximately fifty four days later, on 8 February 1998, the patient attempted suicide after arguing with her mother concerning her decision to marry another man. The patient locked herself in the bathroom and made superficial cuts in her left wrist using a shaving blade. She stated that she did not want to live at the moment, feeling anguish and anger. This episode of crisis lasted approximately two hours, after which the patient calmed and "absorbed" the idea of self destruction.

The investigator considers the suicide attempt unrelated to study medication, associated with the primary condition {unipolar major depression}, and/or maternal relationship conflicts. He described the event as a "low risk attempt". He felt the physical damage was minimal and she was not prone to put her life at stake since she carried out the attempt within a domestic environment where she could be seen and assisted. This action is considered to be an attempt to draw her mother's attention and to rid herself of anger by blaming her. Study medication was not interrupted; it was increased. Both the investigator and SB monitor wished for the patient to continue the study under strict supervision.

On 10 February 1998 the patient was seen by the investigator. During that visit, the investigator decided that the patient would continue in the study because he felt the discontinuation would have been detrimental for the therapeutic relationship, since the patient would have considered it a punishment for her behaviour.

On 13 February 1998, the patient's mother went to a scheduled visit without her daughter. She explained that subsequent to the visit on 10 February 1998, they had argued and the patient had left home afterwards; she stopped taking study medication at that time. As a result, on 13 February 1998, the investigator decided to discontinue the patient from the study for protocol violation.

Concomitant Drugs: Start End

Treatment Drugs: Start End

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Spasmodic bronchitis.

Contact dermatitis.

Orthostatic hypotension in December 1997.

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Life Threatening

#### PID 377.057.00539

Primary Adverse Experience: Gastrointestinal Disorder/Acute Appendicitis

Demography: Age-17 years Date of Birth-27-Sep-1980 Sex-Female

**Height-**165.0 cm **Weight-**60.0 kg **Race-**White

Country: Argentina

Medical History: Headache, Nausea

Study Diagnosis: Depression/Affective Disorders

Study Drug: Placebo Washout 20mg

Start Date: **16-Dec-1997**Stop Date: 24-Mar-1998

AE Remarks:

Case, reference number 1998010967-1, is a clinical trial report from study number 29060 377, which is a blinded study, referring to a female aged 17.

On 16 December 1997, the patient received her first treatment with placebo washout for unipolar major depression. Approximately one hundred days later, on 25 March 1998, one day after completing the placebo wash-out phase of the study, the patient was admitted to hospital with acute appendicitis. The patient had experienced symptoms of nausea and vomiting for one week before a definitive diagnosis was made. An appendectomy was performed. The patient received treatment with metamizole sodium for pain and azithromycin for surgery prophylaxis. The patient was reported to have recovered on 26 March 1998.

The investigator considers the acute appendicitis to be unrelated to study medication and associated with another condition {unspecified}.

Concomitant Drugs:	Start	End

Treatment Drugs: Start End
Dipyrone (Metamizole Sodium) 25-Mar-1998 25-Mar-1998

 Dipyrone (Metamizole Sodium)
 26-Mar-1998
 27-Mar-1998

 Azithromycin
 25-Mar-1998
 27-Mar-1998

Lab Remarks:

Lab Test Code/Name Date Lab Value Units Normal Range

Medical History Remarks:

Reporter Attribution for Primary AE: Unrelated/Not Related

Reason For Seriousness: Life Threatening, Hospitalization Required

# 14 Source Tables: Safety Narratives

Table 17 Safety narratives for patients who where withdrawn due to	
AEs	.000483

Confidential



## **Paroxetine**

### **BRL-029060**

# Patient Narratives for Non-fatal Adverse Experiences Leading to Withdrawal

377

Table No. 17

Safety Narratives

SB Document Number: BRL-029060/RSD-100VJ4/1

PID 377.029.00013				
Reason for Narrative:	Adverse Experience			
	Leading to			
	Withdrawal			
Primary Adverse	Dyspnoea/Worsening			
Experience (Verbatim	severe dyspnoea			
Term):				
Other:	Tiredness, nausea,			
	heartburn, URTI.			
Demography:	Age: 14			
	Sex: Male			
	Race: Caucasian			
Country:	South Africa			
Medical History:	None			
Study Diagnosis:	Adolescent depression			
Study Drug:	Paroxetine			
Start:	15 Feb 96	Stop:	6 Mar 96	
Adverse Experiences	Onset:	Stopped:		
(VerbatimTerm):				
Feels tired oversedation	16 Feb	1 Mar 96		
Heartburn	29 Feb 96	1 Mar 96		
Dyspnoea,	26 Feb 96	26 Feb 96		
nausea,	26 Feb 96	29 Feb 96		
URTI	26 Feb 96	not stated		
Dyspnoea	2 Mar 96	not stated		
AE Remarks:				
On day 1 the patient felt ti	redness which lasted 14	days, followed		
on day 5 by heartburn last		•		
11 for three days and again	= -	-		
had an upper respiratory to	=	_		
the dyspnoea was describe	ed as severe, and the pati	ent was taken		
off study drug.				
Concomitant Drugs:	Onset:	Stopped:		
Diphenhydramine	Day 22	Not stated		
hydrochloride 30ml				

PID 377.029.00016			
Reason for Narrative:	Adverse Experience		
	Leading to Withdrawal		
Primary Adverse	Somnolence/Worsening	g	
Experience (Verbatim	daytime sedation		
Term):			
Other:	None		
Demography:	Age: 15		
	Sex: Female		
	Race: Caucasian		
Country:	South Africa		
Medical History:	None		
Study Diagnosis:	Adolescent depression		
Study Drug:	Paroxetine		
Start:	21 Feb 96	Stop:	19 Mar 96
Adverse Experiences (VerbatimTerm):	Onset:	Stopped:	
Feels sleepy during the day	21 Feb 96	29 Feb 96	
Worsening daytime sedation	29 Feb 96	not stated	
AE Remarks:			
On day 0 the patient felt of	laytime sleepiness which	lasted 8 days,	
By day 8 the daytime sed	_		
severe. As the effect was		y drug the	
patient was taken off stud	<u> </u>		
Concomitant Drugs:	Onset:	Stopped:	
None			

PID 377.029.00035			
Reason for Narrative:	Adverse Experience		
	Leading to		
	Withdrawal		
Primary Adverse	Nausea/Nausea		
Experience (Verbatim			
Term):			
Other:	Flu, sinusitis		
Demography:	Age: 16		
	Sex: Male		
	Race: Caucasian		
Country:	South Africa		
Medical History:	Anxiety/obsessional		
	disorders		
Study Diagnosis:	Adolescent		
	depression		
Study Drug:	Paroxetine		
Start:	26 Apr 96	Stop:	11 May 96
Adverse Experiences	Onset:	Stopped:	
(VerbatimTerm):			
Flu	26 Apr 96	8 May 96	
Nausea	3 May 96	16 May 96	
Sinusitis	7 May 96	not stated	
AE Remarks:			
On day 7 the patient expe	rienced moderate nausea	a which lasted 13	
days and was considered	possibly related to study	y drug.	
Medication was stopped a	after 15 days and the pat	ient withdrawn	
from the study.		1	
Concomitant Drugs:	Onset:	Stopped:	
Ascorbic acid 500mg	8 May 96	Not stated	
Prednisone	8 May 96	Not stated	
brompheniramine			
maleate + phenylephrine			
hydrochoride 5mg			
Phenylpropanolamine	8 May 96	Not stated	
hydrochloride 5 tabs			

PID 377.029.00040			
Reason for Narrative:	Adverse Experience		
	Leading to		
	Withdrawal		
Primary Adverse	Nausea/Nausea		
Experience (Verbatim			
Term):			
Other:	Somnolence		
Demography:	Age: 12		
	Sex: Male		
	Race: Caucasian		
Country:	South Africa		
Medical History:	None		
Study Diagnosis:	Adolescent		
	depression		
Study Drug:	Paroxetine		
Start:	31 Oct 96	Stop:	11 Nov 96
Adverse Experiences (VerbatimTerm):	Onset:	Stopped:	
Nausea	31 Oct 96	not stated	
Somnolence	31 Oct 96	not stated	
AE Remarks:			
On day 0 the patient felt i	noderate nausea and mil	ld somnolence,	
both considered related to	study drug. Medication	was stopped	
after 11 days.			
Concomitant Drugs:	Onset:	Stopped:	
None			

PID 377.029.00047			
Reason for Narrative:	Adverse Experience		
	Leading to		
	Withdrawal		
Primary Adverse	Somnolence/Daytime		
Experience (Verbatim	sedation		
Term):			
Other:	Headache		
Demography:	Age: 16		
	Sex: Female		
	Race: Caucasian		
Country:	South Africa		
Medical History:	None		
Study Diagnosis:	Adolescent		
	depression		
Study Drug:	Paroxetine		
Start:	8 Jan 98	Stop:	4 Feb 98
Adverse Experiences	Onset:	Stopped:	
(VerbatimTerm):			
Daytime sedation	19 Jan 98	11 Feb 98	
Headache	25 Jan 98	26 Jan 98	
Headache	1 Feb 98	no stated	
AE Remarks:			
On day 11 the patient exp	erienced moderately sev	ere daytime	
sedation which lasted 24 of	days and was considered	d possibly	
related to study drug. In a	ddition the patient exper	rienced headache	
on Day 17 which was mile	d and lasted one day, an	d again on Day	
24 which was described a	<u> </u>	•	
was stopped on Day 27, and the patient withdrawn from the study.			
Concomitant Drugs:	Onset:	Stopped:	
Salbutamol	1988	not stated	
Paracetamol 500mg po	26 Jan 98	26 Jan 98	
ASA 600mg po	5 Feb 98	5 Feb 98	
Paracetamol 500mg po	5 Feb 98	5 Feb 98	

PID 377.047.00620			
Reason for Narrative:	Adverse Experience		
	Leading to		
	Withdrawal		
Primary Adverse	Palpitation/		
Experience (Verbatim	Palpitations		
Term):			
Other:	Diarrhoea		
Demography:	Age: 18		
	Sex: Male		
	Race: Caucasian		
Country:	Belgium		
Medical History:	Over anxious		
•	disorder of		
	childhood		
Study Diagnosis:	Adolescent		
	depression		
Study Drug:	Paroxetine		
Start:	6 Feb 96	Stop:	7 Feb 96
Adverse Experiences	Onset:	Stopped:	
(VerbatimTerm):			
Diarrhoea	6 Feb 96	9Feb 96	
Palpitations	6 Feb 96	9Feb 96	
AE Remarks:			
On the first day of treatme	ent the patient experienc	ed moderate	
diarrhoea and palpitations	considered possibly rel	ated to study	
drug. Study drug was stop	pped the next day and th	e patient	
withdrawn from study			
Concomitant Drugs:	Onset:	Stopped:	
None			

PID 377.058.00195				
Reason for Narrative:	Adverse Experience Leading to Withdrawal			
Primary Adverse Experience (Verbatim Term):	Vomiting/Vomiting			
Other:	Diarrhoea			
	Dizziness			
	Nausea			
	Night sweats			
	Laceration of left leg			
Demography:	Age: 17			
	Sex: Female			
	Race: Caucasian			
Country:	Canada			
Medical History:	Low back pain,			
	major episode of			
	depression			
Study Diagnosis:	Adolescent			
-	depression			
Study Drug:	Paroxetine			
Start:	8 Jul 97	Stop:	18 Sep 97	
Adverse Experiences (VerbatimTerm):	Onset:	Stopped:		
Dizziness	16 Jul 97	29 Aug 97		
Nausea	8 Jul 97	16 Jul 97		
Nausea	14 Sep 97	not stated		
Night sweats	16 Aug 97	21 Sept 97		
Laceration of left leg	2 Aug 97	3 Aug 97		
Vomiting	18 Sep 97	not stated		
AE Remarks:				
which was considered pe	perienced moderately se ossibly related to study d	rug. Study drug		
	ient withdrawn from stud			
Concomitant Drugs:	Onset:	Stopped:		
Dimenhydrinate 2 tabs	14 Oct 97	16 Oct 97		

PID 377.005.00263				
Reason for Narrative:	Adverse Experience			
	Leading to			
	Withdrawal			
Primary Adverse	Infection/			
Experience (Verbatim	Mononucleosis			
Term):				
Other:	Cold			
Demography:	Age: 17			
	Sex: Male			
	Race: Caucasian			
Country:	Belgium			
Medical History:	None			
Study Diagnosis:	Adolescent			
	depression			
Study Drug:	Placebo (screening)			
Start:	12 Apr 97	Stop:	25 Apr 97	
Adverse Experiences	Onset:	Stopped:		
(VerbatimTerm):				
Mononucleosis	20 Apr	not stated		
Cold	20 Apr	not stated		
AE Remarks:				
Five days before the patie	ent was due to start treati	ment with		
paroxetine the patient exp	erienced mononucleosis	s and a cold, both		
moderately severe. The pa		•		
none was administered and the patient was withdrawn from study.				
Concomitant Drugs:	Onset:	Stopped:		
Fusafungine 16 puffs	not stated	not stated		
Paracetamol 1000mg	not stated	not stated		

PID 377.009.00227			
Reason for Narrative:	Adverse Experience		
	Leading to		
	Withdrawal		
Primary Adverse	Nervousness/		
Experience (Verbatim	Nervousness		
Term):			
Other:	None		
Demography:	Age: 18		
	Sex: Female		
	Race: Caucasian		
Country:	Belgium		
Medical History:	None		
Study Diagnosis:	Adolescent		
	depression		
Study Drug:	Placebo		
Start:	26 Jun 96	Stop:	28 Jun 96
Adverse Experiences	Onset:	Stopped:	
(VerbatimTerm):			
Nervousness	26 Jun 97	2 Jul 97	
AE Remarks:			
On the day treatment star	ted the patient experience	ced mild	
nervousness lasting six da	ays considered possibly	related to study	
drug, Study drug was stop	pped after two days, and	I the patient	
withdrawn from study.	T	1	
Concomitant Drugs:	Onset:	Stopped:	
Desogestrel +	1987	not stated	
ethinylestradiol 1 tab po			

PID 377.054.00512					
Reason for Narrative:	Adverse Experience				
	Leading to				
	Withdrawal				
Primary Adverse	Abscess/Pharyngeal				
Experience (Verbatim	abscess				
Term):					
Other:	Dizziness				
Demography:	Age: 13				
	Sex: Female				
	Race: Caucasian				
Country:	Argentina				
Medical History:	Pneumonia				
Study Diagnosis:	Adolescent				
	depression				
Study Drug:	Placebo				
Start:	22 Nov 97	Stop:	17 Jan 98		
Adverse Experiences	Onset:	Stopped:			
(VerbatimTerm):					
Pharyngeal abscess	16 Jan 98	8 Feb 98			
Dizziness	26 Nov 97	28 Nov 97			
AE Remarks:					
On day 56 the patient had a pharyngeal abscess considered					
probably unrelated to study drug. Study drug was stopped and					
other corrective therapy given.					
Concomitant Drugs:	Onset:	Stopped:			
Benzathene	21 Jan 98	21 Jan 98			
benzylpenicillin im					
Phenoxymethylpenicilli	21 Jan 98	15 Feb 98			
n po					
Betamethasone sodium	21 Jan 98	21 Jan 98			
phosphate,					
betamethasone acetate					
im					

PID 377.056.00518				
Reason for Narrative:	Adverse Experience			
	Leading to			
	Withdrawal			
Primary Adverse	Asthenia/Asthenia			
Experience (Verbatim				
Term):				
Other:	Drowsiness			
Demography:	Age: 18			
	Sex: Male			
	Race: Caucasian			
Country:	Argentina			
Medical History:	None			
Study Diagnosis:	Adolescent			
	depression			
Study Drug:	Placebo			
Start:	22 Oct 97	Stop:	28 Oct 97	
Adverse Experiences	Onset:	Stopped:		
(VerbatimTerm):				
Asthenia	24 Oct 97	6 Nov 97		
Drowsiness	24 Oct 97	5 Nov 97		
AE Remarks:				
On day 2 the patient expe	erienced mild drowsiness	s lasting six days		
and moderate asthenia las	sting 7 days, followed th	e next day by		
moderate drowsiness and		•		
respectively. As the even		ed to study drug		
the patient withdrawn fro	m study.	T		
Concomitant Drugs:	Onset:	Stopped:		
none				